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Abstract 
The aim of the study was to evaluate a community pharmacy-based 
cardiovascular risk assessment (VRA) service introduced into two pharmacies 
in south Wales. A longitudinal methodology was adopted where participants 
had an initial assessment with a follow-up after 12 months. Body mass index, 
waist circumference, blood pressure and total/HDL cholesterol levels were 
measured and the Framingham 10-year cardiovascular risk was estimated and 
communicated to patients. Demographic details and lifestyle information 
(smoking, alcohol, diet and exercise) were obtained via self-complete 
questionnaires at each consultation. A total of 172 individuals accessed the 
service and had either a brief assessment (n=26) without the calculation of the 
Framingham score or a full VRA (n=146).  Mean age was 60 years (±10.3), 
59% were female and 25% (37/146) were at high risk (>20%) of developing 
cardiovascular disease. High satisfaction with the VRA was obtained via an 
anonymous questionnaire provided immediately after the initial consultation 
(74% response rate). The short-term outcomes of the service (including recall 
of advice, lifestyle improvement and/or making the visit to their GP if they 
were referred) were reported through a semi-structured telephone interview 
two weeks after the initial assessment. In total 105/172 (61%) who attended the 
twelve-month follow-up had results of the two assessments compared using 
paired Student’s t-test. There was a statistically significant increase in mean 
HDL 0.08 mmol/L (95% CI 0.02 to 0.14) and a statically significant reduction 
in mean systolic BP -8.5 mmHg (95% CI -11.0 to -5.9), diastolic BP -7.7 
mmHg (95% CI -10.4 to -5.0) and Framingham score -1.07 (95% CI -1.9 to -
0.2). A comparison between Framingham and QRISK2 algorithms showed the 
importance of using the most accurate tool available in estimating 
cardiovascular risk. This is the first study to investigate short- and longer-term 
outcomes of a community pharmacy-based VRA service in Wales and provides 
a basis for future research. 
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1.1 General Introduction 
This chapter presents background information on the epidemiology of the 
cardiovascular disease (CVD) in Wales, risk factors, primary prevention and 
the risk assessment of CVD. It also presents the literature review identifying 
studies conducted to evaluate the role of the pharmacist in the provision of 
VRA services. 
1.1.1 Cardiovascular disease in Wales 
CVD which includes coronary heart disease (CHD) and cerebrovascular 
disease, is the leading cause of death in Wales, accounting for over 10,400 
deaths in 2009 and a third of all deaths (BHF 2011a). CHD accounts for about 
half of all deaths of CVD whereas stroke accounts for over a quarter of all 
CVD deaths. CVD is also one of the main causes of premature death 
accounting for 32% of premature deaths in men and 23% of premature deaths 
in women. CHD causes over 5,500 deaths a year in Wales or approximately 
one in five deaths in men and one in six deaths in women (Petersen et al. 
2005). Around 28 people die every day from CVD in Wales and an estimated 
312,000 are known to live with the condition (BHF 2011b) 
The UK, of which Wales is part, has one of the highest CVD mortality rates in 
the world. Although mortality rates from CHD have been falling in the UK 
since the late 1970s and death rates from stroke have been falling throughout 
this century, the burden of the disease is still high (Petersen et al. 2005). Ergin 
et al. (2004) suggested that both primary and secondary prevention and 
treatment contributed to the decline in CVD mortality in the United States. The 
Chapter 1: Introduction and Literature Review 
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advances in medical technology and in therapeutics led to the improvement in 
the survival rate following myocardial infarction and for other CVDs. As a 
consequence it has been proposed that more people will be living with CVD as 
a chronic disease and the burden of CVD will continue to rise (McDermott 
2007). To address this there is a need to focus on prevention. The Welsh 
Government (until May 2011 referred to as the Welsh Assembly Government 
or WAG) acknowledged this fact in their National Service Framework (NSF) 
for CHD published in 2001 (WAG 2001). This report highlighted the 
importance of empowering patients to take responsibility for the prevention of 
CHD and to work intensely to decrease the number of people at risk of 
developing CHD. 
1.1.2 Risk factors for cardiovascular disease 
The term ‘cardiovascular risk factor’ is used generally to describe the 
characteristics found in individuals in epidemiological, autopsy, metabolic and 
genetic studies to relate to the consequent occurrence of a CVD (George and 
Johnson 2010). Causes of CVD have been identified as a result of prospective 
observational studies (Kannel 2011). The Framingham Heart Study (Section 
1.1.4.1) which started in 1948 in the town of Framingham, Massachusetts, was 
one of the major cohort studies to identify the common factors or 
characteristics that contribute to CVD (Shindler 2011). 
Risk factors are either modifiable (which can be altered by lifestyle changes or 
other interventions such as pharmacological) or non-modifiable which means 
they cannot be altered. Modifiable risk factors include obesity, weight 
Chapter 1: Introduction and Literature Review 
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distribution, lack of exercise, lack of fruit and vegetable consumption, alcohol 
intake, hypertension, dyslipidaemia and diabetes. The non-modifiable risk 
factors include gender, age, ethnicity and family history of CVD (Yusuf et al. 
2004). Deprivation is also a risk factor and has been incorporated in some 
cardiovascular risk assessment tools (Tunstall-Pedoe and Woodward 2006). 
1.1.2.1 Age 
The prevalence and incidence of CVD increase steeply with age (Table 1-1). 
CVD mainly affects people over the age of 50 years (Cooper et al. 2008). 
There is a consensus that chronologic age is a potent, independent risk for 
increased morbidity and mortality (Maurer 2003). According to Wald et al., 
age is by far the strongest determinant of CVD risk in multiple risk factor 
algorithms (Wald et al. 2011).  
 
Table 1 - 1 incidence rate of cardiovascular diseases in different age groups (Hippisley-Cox 
et al. 2007) 
 Incidence rate per 1000 person years 
Age groups Women Men 
35-44 1.36 2.78 
45-54 4.14 8.06 
55-64 10.43 17.46 
65-74 21.31 29.44 
 
In a recent cost-effectiveness analysis the researchers compared screening for 
future cardiovascular events using age alone with screening using age and 
Chapter 1: Introduction and Literature Review 
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multiple risk factors based on regular Framingham risk assessments.  The 
researchers suggested that prescribing a statin to all people over the age of 50 
years will save more lives and the cost per CVD free year of life gained will be 
the same as the cost of using the universal Framingham assessments, based on 
£200 annual cost of preventive treatment and £150 cost of a Framingham risk 
assessment. If the cut-off age is 55 years, however, the age screening will be 
more cost-effective than Framingham (the cost per CVD free year of life 
gained for age screening is £2,000 versus £2,200 for Framingham) (Wald et al. 
2011). 
1.1.2.2 Gender  
The prevalence of CVD is higher in men than in women. According to the 
British Heart Foundation (BHF) there are about one million men living with 
coronary heart disease in the UK whereas half of that number are women with 
this diagnosis. Data comparing different regions of the UK show the 
prevalence of myocardial infarction is highest in Wales. Also, the mortality 
rate in the UK is higher in men than women, 28% of premature deaths, that is, 
under the age of 75, in men were due to CVD compared with 20% in women 
(BHF 2010). Stroke mortality rate, however, is higher in women (BHF 2011b).  
The most common cause of death in women, however, is CVD and it is even 
more common than all cancers combined (BHF 2010). Due to the protective 
effect of oestrogen, women tend to be older at first presentation with CVD. As 
a consequence they are more likely to suffer poor outcomes of the CVD 
(Schenck-Gustafsson 2009). The awareness of women with regard to heart 
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disease has increased over the years (Mosca et al. 2011). However, in one 
study the majority of the participating women failed to perceive it as a leading 
threat to their health (Mosca et al. 2004). 
1.1.2.3 Family History of CVD 
The hereditary link to CHD and stroke is well established through a number of 
large epidemiological studies (Bensen et al. 1999; Graffagnino et al. 1994; 
Jousilahti et al. 1997). In a small cohort study of ninety patients with CVD and 
ninety control subjects a family history of ischaemic heart disease was present 
in 73% of patients with CVD compared with 53% of the control subjects (P = 
0.019), and a family history of stroke was present in about 47% of the patients 
and 24% of the control subjects (P = 0.014) (Graffagnino et al. 1994). In a 
prospective study of 14,371 middle-aged men and women the risk ratio of 
stroke associated with a positive family history of stroke was 1.89 (P = 0.004) 
in men and 1.80 (P = 0.007) in women and the association was stronger among 
subjects aged 25 to 49 years than among older subjects (Jousilahti et al. 1997). 
Studies usually define positive family history of CVD as fatal or nonfatal 
stroke or myocardial infarction, or as having a diagnosis of angina pectoris 
before the age of 60 years in first degree relatives. Some risk assessment 
algorithms, however, do not take into account the family history of stroke and 
they define family history as angina or heart attack in a first degree relative 
before the age of 60 years (Hippisley-Cox et al. 2007) or the development of 
coronary heart disease in a male first degree relative before the age of 55 years 
and a female first degree relative before the age of 65 years (JBS2 2005). For 
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those who have first degree relatives with CVD, they are considered as affected 
by genetic factors if the age of their relatives was less than 55 years at 
diagnosis. However, diagnosis at a young age (younger than 55 years for men 
and 65 years for women) could be interpreted as a hereditary link but in the 
absence of CVD or a diagnosis at a later stage in family members cannot rule 
out this link completely (Doughty 2003). 
1.1.2.4 Genetic links 
Genetic studies of CVD have been providing evidence of the effects of 
hereditary factors on CHD and stroke (Peden et al. 2011). Also there are a 
number of genetic studies have shown strong links of hereditary factors to the 
conventional risk factors of CVD, such as obesity (Segal and Allison 2002) and 
hypercholesterolemia (Humphries et al. 2010).  
In obesity it is well known that genetic factors play a significant role. Obesity, 
however, is a complex problem caused by the interactions of multiple genes, 
environmental factors and behaviour of the individual. This complexity makes 
the search for obesity genes vary challenging (Comuzzie and Allison 1998). A 
review on the similarity of the body mass index (BMI) and other adiposity 
measures among twins brought up apart and together suggested that genetic 
factors explain 50 to 90% of the causes of obesity (Maes et al. 1997). However, 
there is a possibility that earlier research may have underestimated the effect of 
common environmental factors on obesity because the study design was such 
that lacked the ability to detect them (Segal and Allison 2002). 
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A meta-analysis identified five new genetic variants in addition to the eleven 
common variants associated with coronary artery disease in European 
populations. The authors suggested that many genes have a small effect on the 
CHD risk rather than a few genes having a large effect (Peden et al. 2011). 
Familial hypercholesterolemia is one area in which genetic testing is currently 
feasible and according to one randomised control trial such testing has no 
significant, long-lasting adverse-effect on psychological well-being 
(Humphries et al. 2010). 
Some internet-based commercial companies are offering genetic tests for CHD, 
but researchers believe that this kind of testing is premature and it has little 
value in the prevention of CVD (Humphries et al. 2010). As researchers 
continue to identify more genes associated with CHD the likelihood of 
producing a simple genetic test becomes impossible to be seen in the near 
future.  
In a recent study focusing on metabolic syndrome and obesity, a genetic link 
was identified which could help to explain the prevalent of type II diabetes 
among those who have a healthy BMI, that is, < 25 kg/m
2
. The identified gene 
expression was associated with an impaired metabolic profile, including 
increases in the following: visceral to subcutaneous fat ratio, insulin resistance, 
dyslipidaemia, risk of diabetes and coronary artery disease (Kilpeläinen et al. 
2011).   
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1.1.2.5 Ethnicity 
South Asian populations in the UK are associated with higher morbidity and 
mortality of CVD than Caucasians (Gholap et al. 2011), but the reasons for this 
are still unclear. The prevalence of conventional risk factors, such as 
hypertension and hyperlipidemia among South Asians contribute to this 
increase, but they do not account for the full extent of increased risk. It appears 
that there are variations, among ethnic groupings, in the role and potency of 
risk factors (Astin and Atkin 2010).  
Traditionally, incidence of CVD among South Asians has been studied as one 
ethnic group. Although, South Asians are at increased risk of CVD, this 
underestimates the risk in some subgroups and overestimates it in others (Table 
1-2). The rate of CVD of Pakistani men is almost the double of that of the 
Caucasians compared with about 45% increased risk in Indian men (Hippisley-
Cox et al. 2008). 
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Table 1 - 2 Effect of ethnicity on adjusted hazard ratios (HR) for CVD. Data obtained from 
(Hippisley-Cox et al. 2008) 
 
Ethnic group 
Women 
HR (95% CI) 
Men 
HR (95% CI) 
Caucasians/not 
recorded 
1 1 
Indian 1.43 (1.24 to 1.65)  1.45 (1.29 to 1.63) 
Pakistani 1.80 (1.5 to 2.17)  1.97 (1.70 to 2.29) 
Bangladeshi 1.35 (1.06 to 1.72)  1.67 (1.40 to 2.01) 
Other Asian 1.15 (0.86 to 1.54)  1.37 (1.09 to 1.72) 
Black Caribbean 1.08 (0.94 to 1.24)  0.62 (0.53 to 0.73) 
Black African 0.58 (0.42 to 0.82)  0.63 (0.47 to 0.85) 
Chinese 0.69 (0.44 to 1.10)  0.51 (0.32 to 0.83) 
Other 1.04 (0.85 to 1.28)  0.91 (0.75 to 1.10) 
 
1.1.2.6 Deprivation 
Deprivation indices are a measure of deprivation rather than poverty. The 
difference between the two is that the first describes the situation when there is 
a lack of resources and opportunities including the lack of money, but the 
second one describes the lack of money. A deprivation index is used in the UK 
to compare how well different areas are doing in term of access to resources. 
Not all people living in an area of high deprivation are poor. As it is not a 
measure of poverty, it cannot be used as a measure of wealth. Therefore, when 
using a deprivation index, the least deprived areas should not be considered as 
wealthy areas (CDU 2010; WAG 2008).  
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The Welsh Index of Multiple Deprivation (WIMD) is the official measure of 
deprivation for Wales (WAG 2008). WIMD is based on eight different 
deprivation domains; income, employment, health, education, housing, 
environment, access to services and community safety. Even though each 
domain could affect other domains, for example, poor health may be related to 
unacceptable housing, they all reflect a specific kind of deprivation on their 
own. 
There are 1,896 Lower Layer Super Output Areas (LSOA) in Wales, each 
LSOA having about 1,500 people. The LSOA is a geographical area which is 
designed for analysing small area statistics. All eight domains determine a 
deprivation score for each LSOA. The highest score equates to the area of 
highest deprivation. According to the deprivation sore, all LSOAs are ranked 
from the highest to lowest. The first 10% of LSOAs are the most deprived 
areas, then the second and the third groups each have 10% of LSOAs, the 
fourth group consists of the next 20% and the fifth group (considered the least 
deprived areas) constitute the remaining 50% (WAG 2008).  
The Townsend Deprivation Index (TDI), on the other hand, is based on four 
variables; unemployment (as a percentage of all economically active residents 
aged over 16), overcrowding (households with 1 person per room and over), 
non-car ownership, non-home ownership (CDU 2010). 
The level of deprivation may be associated with some CVD risk factors, such 
as smoking and lack of physical activity. People living in the least deprived 
areas are less likely to have a lifestyle which could adversely affect the risk of 
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CVD and vice versa for those who are from the most deprived areas  (Cubbin 
et al. 2006). Similarly, there are some associations between the level of 
deprivation and the knowledge of the CVD (Cubbin and Winkleby 2005). 
However, even when the variations of risk factors were adjusted for, the people 
living in most deprived areas are at high risk of CVD. Every five unit increase 
in Townsend deprivation score, that is, an increase in deprivation, the adjusted 
hazard ratio for CVD increases 1.13 (95% CI = 1.11 to 1.14) for women and 
1.06 (95% CI = 1.05 to 1.07) for men (Hippisley-Cox et al. 2011). 
1.1.2.7 Hypertension 
Hypertension is a major contributor to cardiovascular morbidity and mortality 
(Appel et al. 2011). Blood pressure measurement, therefore, is one basis for 
cardiovascular disease evaluation and the focus of therapy. Hypertension 
remains a major preventable risk factor for CVD (Aronson and Fontes 2006). 
The prevalence of hypertension among people aged 35–64 years old in western 
countries is between 28% and 55%. There is a continuous increase in age- 
adjusted prevalence of CVD with increasing blood pressure, even in those who 
have high-normal blood pressure (130-139 mmHg) (Pieske and Wachter 2008). 
High blood pressure is the level of blood pressure at which there is evidence 
that blood pressure reduction does more good than harm (JBS2 2005). The 
British Hypertension Society recommend a classification of blood pressure 
levels (Table 1-3) to help clinicians to determine the type of intervention 
necessary (Williams et al. 2004). 
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Table 1 - 3 British Hypertension Society classification of blood pressure levels (JBS2 2005) 
Category  Systolic BP 
 (mmHg) 
Diastolic BP  
(mmHg) 
Optimal blood pressure 
< 120 < 80 
Normal blood pressure < 130 < 85 
High-normal blood pressure 130–139  85–89 
Grade 1 hypertension (mild) 140–159  90–99 
Grade 2 hypertension (moderate) 160–179  100–109 
Grade 3 hypertension (severe) ≥ 180  ≥ 110 
Isolated systolic hypertension (Grade 1) 140–159  < 90 
Isolated systolic hypertension (Grade 2) ≥ 160  < 90 
1.1.2.8 Diabetes 
Morbidity and mortality from CVD are two to five times higher in people with 
diabetes than those who are non-diabetics. The effects of smoking, 
dyslipidaemia, hypertension and/or hyperglycaemia further increase the risk of 
an individual with diabetes developing CVD (Ekinci et al. 2011; Scott et al. 
2011). Two major trials, The Action to Control Cardiovascular Risk in 
Diabetes Study (ACCORD 2008) and the ADVANCE (Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation) (Points 2008), have failed to show significant reduction in 
cardiovascular events in the short term with near-normal glycaemia. However, 
UKPDS (Holman et al. 2008) suggests that optimal glycaemic control have 
long-term benefits on cardiovascular risk. According to Selvin et al. (2004), 
however, there are limitations in studies claiming that uncontrolled glycaemia 
is an independent risk factor for cardiovascular disease. 
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1.1.2.9 Dyslipidaemia 
Dyslipidaemia is defined as “an abnormal plasma lipid status” (Ballantyne 
2009). Common lipid abnormalities which appear to increase the risk of CHD 
include elevated serum concentrations of total cholesterol, low-density 
lipoprotein (LDL) and triglyceride; low levels of high-density lipoprotein 
(HDL) (Walker and Whittlesea 2012). LDL cholesterol, the major atherogenic 
lipoprotein, typically makes up 60-70% of the total serum cholesterol where 
HDL cholesterol, lipoprotein with some evidence that it has protective 
properties against the development of atherosclerosis, makes up 20–30% 
(National Institute of Health 2002). 
In countries where the diet is characterised by high saturated fat, such as 
Western types of diet, most of the population have levels of total cholesterol 
above than the desirable concentration of 5mmol/L, and LDL > 3mmol/L. 
Epidemiological studies have shown that the level of total cholesterol increases 
with age (Wilson et al. 1994). The mean total cholesterol levels among men are 
higher than women up to the age of 54 and then beyond that age the situation is 
reversed. Possible explanation is that men with high level of total cholesterol 
are at increased risk of death before reaching advanced age (Walker and 
Whittlesea 2012). 
In another study 4,849 middle-aged men were followed up for 8 years with the 
primary outcome being CHD events. Individuals with total cholesterol to HDL 
ratio of more than 5.0 had an estimated risk of 19% of experiencing a CHD 
event in the next 8 years, but when this was combined with triglyceride levels 
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of equal to or more than 2.3 mmol/L the risk of CHD increased to about 27%. 
The authors concluded that fasting levels of triglycerides were an independent 
risk factor for CHD events, irrespective of serum levels of HDL or LDL 
(Assmann et al. 1998). It is accepted that raised fasting triglyceride (> 1.7 
mmol/l) increases the risk of CVD (JBS2 2005). However, some researchers 
argued that triglyceride levels which currently considered normal (up to 1.7 
mmol/L) are associated with an increased concentrations of the inflammation 
marker C-reactive protein (CRP) and they recommended that a lower fasting 
triglyceride level of about 1.1 mmol/L used as an optimal cut point in CHD 
risk assessment (Ahmad et al. 2005). Testing for triglycerides is not always 
convenient as fasting is always required which limits its use in the primary 
screening for CVD (Satta et al. 1998). 
The two most common factors linked to elevated levels of serum triglycerides 
are being overweight (including obesity) and physical inactivity. Table 1-4 
shows other factors that can affect the levels of triglyceride and lipoproteins. 
The raised levels of triglycerides are considered as a marker for increased risk 
for CHD, but the first line treatment is usually not more than lifestyle changes 
(National Institute of Health 2002). 
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Table 1 - 4 Factors which could have an effect on dyslipidaemia (National Institute of Health 
2002) 
 Elevated 
Triglycerides 
Low 
HDL 
Overweight and obesity yes yes 
Physical inactivity yes yes 
Smoking yes yes 
High alcohol intake yes no 
Very high-carbohydrate diet yes yes 
Other diseases  
(e.g. type 2 diabetes and chronic renal failure) 
yes yes 
Drugs  
(e.g. corticosteroids, protease inhibitors for HIV, 
beta-adrenergic blocking agents, oestrogens) 
yes yes 
Genetic factors yes yes 
Low concentrations of serum HDL are linked to increased CHD morbidity and 
mortality.  In a community based study 2,489 men and 2,856 women aged 30 
to 74 years were followed up for 12 years. The results showed that the risk of 
CHD was decreased significantly in those with HDL levels of higher than 
1.5mmol/L and a significant increased CHD risk with HDL levels of less than 
0.9 mmol/L (Wilson et al. 1998). Epidemiological data from the Framingham 
Heart Study, showed that a 1 mg/dl (0.026 mmol/L) increase in HDL is 
associated with a 2–3% decrease in CHD risk and 3.7-4.7% decrease in 
mortality rate (Gordon et al. 1989). One of the features of metabolic syndrome, 
in addition to central obesity and fasting triglyceride of more than 1.7mmol/L, 
is the decrease in levels of HDL (less than 1.0mmol/L in men and less than 
1.2mmol/l in women) (JBS2 2005). However, in the management of CVD, 
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HDL levels of less than 1 mmol/L are considered a risk factor for both men and 
women (National Institute of Health 2002). 
An elevated serum LDL level increases the risk of CHD as identified by major 
epidemiological studies (Feinleib 1981; Keys et al. 1984; Wilson et al. 1998). 
However, earlier studies measured only serum total cholesterol, but because 
most of total cholesterol is due to LDL and there is a clear relationship between 
total cholesterol and CHD from these studies, this strongly implies that an 
elevated LDL is an important risk factor (National Institute of Health 2002). 
Particle size of LDL is an important determinant of CHD risk. The presence of 
very low density lipoprotein (VLDL) is highly correlated with the increased 
risk of CHD. 
The importance of apolipoproteins (apo) in studies determining the effects of 
dyslipidaemia on CVD has been increasing in the last decade. There has been 
accumulating clinical evidence that better prediction of CVD risk can be 
achieved by assessing the levels of apo B, a constituent of atherogenic 
lipoproteins such as LDL and VLDL, apo A1, a component of antiatherogenic 
HDL and the apo B/A1 ratio, than measuring serum LDL levels only (Dawar et 
al. 2011; Yusuf et al. 2004). In a study of 593 patients who were treated with a 
statin for secondary prevention of CHD the apo B/A1 ratio was evaluated. It 
was found that the levels of apo B/A1 ratio correlated with clinical outcome 
when corrected for standard risk factors. On the other hand the levels of the 
classic LDL/HDL ratio were not correlated to the CHD events. The authors 
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concluded that their findings add significant prognostic value of apo B/A1 over 
the classic lipid ratio (Liem et al. 2007). 
The use of lipid-lowering medication to achieve determined cholesterol targets 
for primary prevention is not recommended as there is still lack of evidence of 
efficacy, safety and cost-effectiveness of this use (NICE 2008b). However, 
according to the British National Formulary (BNF) individuals with an 
elevated total cholesterol to HDL ratio which exceeds 6.0 will require lipid-
lowering medication, regardless of the presence of other risk factors or the 
estimated CVD risk (BNF 2011). 
For secondary prevention, there are differing guidelines in relation to 
cholesterol targets (Table 1-5). The cost of treatment was a key factor by 
certain guidelines in setting these targets. However, these guidelines are not 
based on a formal cost-effectiveness analysis (NICE 2008b). 
Table 1 - 5 Total cholesterol (TC) and LDL targets for secondary prevention set by different 
guidelines 
 TC 
mmol/L 
LDL 
mmol/L 
The National Service Framework for CHD 
(DOH 2000) 
< 5 < 3 
The Joint European Societies Task Force  
on CVD Prevention (De Backer et al. 2003) 
< 4.5 < 2.5 
the Expert Panel on Detection, Evaluation, and  
Treatment of High Blood Cholesterol in  
Adults (USA) (National Institute of Health 2002) 
 < 1.81 
The Joint British Societies Guideline (JBS2 2005) < 4 < 2 
SIGN guidelines (SIGN 2007) < 5  
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1.1.2.10 Poor diet 
Poor diet is high in salt, saturated and trans fats and low in fibre, fish, fruit and 
vegetables (Bruckert and Rosenbaum 2011). Low fruit and vegetable 
consumption is associated with high prevalence of ischaemic heart disease 
mortality (Crowe et al. 2011). The UK government recommend that individuals 
should have five portions of fruit and vegetables per day and it has been 
considered as a “proxy” for a poor diet if the individual is having low 
consumption of fruit and vegetables (Hotchkiss et al. 2011). In Wales, 
according to a survey conducted in 2009 only 34% of men and 37% of women 
consumed the recommended five portions of fruit and vegetables per day (BHF 
2011b). 
Although salt intake restriction is associated with blood pressure reduction, it is 
still lacking a strong evidence to support the benefits of salt restriction in 
reducing CVD morbidity and mortality (Taylor et al. 2011b). 
According to a body of experts there are clinical and epidemiological studies to 
support the link between a diet high in saturated fats and CVD (Astrup et al. 
2011). In Wales, about 15% of energy consumed is from saturated fat while the 
recommended level is not more than 10% of energy from such fat (BHF 
2011b). Replacing saturated fatty acids with polyunsaturated fatty acids in the 
diet improves the LDL concentration and decreases the CHD incidence (Astrup 
et al. 2011). 
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A review of epidemiological studies concluded that high consumption of red 
meat, processed or non-processed, is associated with an increase in CHD rate, 
with greater risk associated with processed meat (Bernstein and Willett 2010).  
Fish contains long-chain omega-3 polyunsaturated fatty acids, which include 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These 
constituents considered beneficial for the heart as their intake associated with a 
reduction in triglycerides, blood pressure and resting heart rate (Mozaffarian et 
al. 2011). Also oily fish consumption is associated with the reduction of the 
inflammation biomarkers (van Bussel et al. 2011). In an observational study, 
acute coronary syndrome patients tended to live longer if they consumed oily 
fish several times a week than those who consumed rarely or none at all 
(Helmut Gohlke et al. 2011). However, people who consume fish with high salt 
seem to lose the protective effects as they were found at higher risk of 
hemorrhagic stroke (Meng et al. 2011). Similarly, there is no evidence that 
fried fish has CVD benefits (Mozaffarian et al. 2011).  
1.1.2.11 Smoking 
Smoking is a well-established risk factor for CHD and stroke. It is the major 
cause of preventable morbidity and mortality of CVD in the UK. Smoking is 
also associated with different types of cancer, respiratory diseases and stomach 
and duodenal ulcers. It is one of the major causes of inequalities between the 
upper and lower socioeconomic classes (Krska 2010). 
The increase in CHD and stroke associated with smoking is underestimated by 
many studies, particularly earlier ones, as they tended to compare smokers 
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against all non-smokers, that is, they did not exclude people who were exposed 
to environmental tobacco smoke (passive smokers) from the non-smoker 
cohort (Bonita et al. 1999). According to Bonita et al. (1999) active smokers 
had a six-fold increased risk of stroke when compared with people who had 
never smoked or had quit smoking more than 10 years earlier and who were 
not exposed to environmental tobacco smoke. 
The benefit of smoking cessation on the reduction of CHD mortality is 
significantly greater than any other secondary preventive therapies such as 
cholesterol lowering drugs (Erhardt 2009). Smoking cessation is highly cost-
effective to improve cardiovascular health in smokers. The risk of all cause 
mortality among patients with CHD is reduced and this seems to be consistent 
regardless of age or gender (Critchley and Capewell 2003). 
1.1.2.12 Obesity 
Obesity is identified as the accumulation of excess fat or adipose tissue in the 
body. The BMI (Table 1-6) is one of the main measurements to determine the 
effect of weight on health (Maguire and Haslam 2009). Although BMI can 
predict health risk for CVD and cancers, it is not always accurate for two main 
reasons namely firstly, it does not reveal the body shape of the individual. 
Determining the body shape is important as the evidence is strong that central 
obesity is associated with higher risk of metabolic syndrome and CVD 
morbidity and mortality (Czernichow et al. 2011). Also BMI measurement 
cannot discriminate between the adipose tissue and the muscle mass. The 
muscle tissues have a higher density (1g/ml) than fat tissues (0.7g/ml) which 
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means some sportsmen could be considered obese if BMI is used on its own. 
Also those people who start an exercise programme may not see a reduction in 
BMI as they may achieve a reduction in adipose tissue but an increase in 
muscle mass. 
Table 1 - 6 BMI and the prediction of risk to health. Adopted from (Maguire and Haslam 
2009) 
BMI (kg/m
2
) Category Risk to health 
<18.5 Underweight Moderate 
18.5 to < 25 Healthy weight None 
25 to < 30 Overweight Moderate 
30 to < 39 Obese Significant 
≥ 40 Grossly obese Highly significant 
On the other hand, as people with large waist circumferences have excess 
burden of ill health (Lean et al. 1998), when BMI is used in an adjunct to other 
measurements, such as waist-to-hip ratio and waist circumference it becomes 
more accurate in predicting risk (Table 1-7).  
Table 1 - 7 BMI measurements accompanied by wais circumference. Adopted from (NICE 
2006b) 
  Waist circumference 
  
 
Low 
 (men < 94cm; 
women < 80cm) 
High  
(men 94-102cm; 
women 80-88cm) 
Very high  
(men > 102cm; 
women > 88cm) 
B
M
I <30 kg/m
2
 No increased risk Increased risk High risk 
 30-34.9kg/m
2 Increased risk High risk Very high risk 
The abdominal obesity can affect people from different ethnic groups 
differently, for example, the increase of risk of diabetes and CVD is significant 
when waist circumference is more than 102 cm for men or 88 cm for white 
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women compared with an equivalent increase of risk when Asian men have a 
waist circumference of 90 cm in men or more than 80 cm in women (JBS2 
2005). 
Improvement in blood pressure and metabolic syndrome can be seen shortly 
after weight loss is achieved by obese individuals (Maguire and Haslam 2009). 
However, there are relatively little data on the effects of weight loss on the risk 
of diseases, for example, whether weight loss reduces the risk of CVD. The 
lack of data on weight loss is probably because of the fact that only a small 
number of individuals were able to achieve sustained weight loss (Wolin and 
Colditz 2008). 
According to NICE clinical guideline 43 on obesity, weight management is a 
complex problem with no easy solutions (NICE 2006b). Behavioural weight 
loss interventions usually achieve short-term goals and re-gaining weight is a 
common problem in the longer term. Ongoing interaction with the individual 
concerned is recommended in order to sustain weight loss (Svetkey et al. 
2008). 
The recommendation made by NICE is to start with behavioural intervention to 
improve lifestyle which should be delivered with the support of a trained 
professional (NICE 2006b). Pharmacological intervention with orlistat, the 
only licensed agent for weight management in the UK, can be used as a second 
line measure.  
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1.1.2.13 Lack of physical activity 
There is general consensus among researchers that exercise provides 
cardiovascular benefits. Regular exercise alone is linked with health benefits 
and reduction in mortality rate (Archer and Blair 2011). Significant decreases 
in cardiovascular and all-cause mortalities in both men and women are 
associated with an increase in physical activity. The association is clear even 
after adjusting for other relevant risk factors (Nocon et al. 2008).  
1.1.2.14 Alcohol consumption  
The adverse effect of alcohol consumption on health is evident through 
epidemiological studies in all age groups (di Castelnuovo et al. 2009). In fact, 
adverse effects can start before birth when the developing foetus is exposed to 
alcohol consumed by the pregnant woman. Alcohol is associated with a 
number of chronic health diseases including psychiatric, liver, neurological, 
gastrointestinal and cardiovascular conditions and different types of cancer. In 
addition an increased rate of accidents and injuries is also linked to alcohol 
(NICE 2010b).  
Heavy drinking (Table 1-8), episodic drinking patterns or binge drinking is 
linked to all cause mortality including accidents and injuries. There is also a 
strong association of binge drinking of beer with fatal myocardial infarction. 
Binge drinking is associated with marked fluctuations in blood pressure and 
hypertension (Lindschou Hansen et al. 2011). 
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Table 1 - 8 Definitions for Patterns of Alcohol Use (1 unit = 10ml or 8g of pure alcohol) 
 For men For women 
Moderate drinking 
(NHS Choices 2011a) 
3 to 4 units per day on a 
regular basis and < 21 
units per week 
2 to 3 units per day on a 
regular basis and < 14 
units per week 
Heavy drinking (NHS 
Choices 2011a)  
> 4 units per day on a 
regular basis or > 21 
units per week 
> 3 units per day on a 
regular basis or > 14 
units per week 
Binge drinking (Bell 
and Britton 2011) 
> 7 units in a single 
session 
> 5  units in a single 
session 
Other cardiovascular diseases including heart failure and arrhythmias are 
associated with alcohol consumption (World Health Organization 2004). It is 
also a risk factor for hemorrhagic stroke even among moderate drinkers (Zhang 
et al. 2011).  
The overall consumption of alcohol in the UK is similar to other Western 
countries (World Health Organization 2004). The per capita consumption for 
population older than 15 years old in the UK (10.4 litres of pure alcohol) is less 
than France (13.5 litres) and the rate of abstainers (those who drink no alcohol) 
in the UK is 12% compared with 6.7% in France. However, in 2000 the rate of 
heavy drinking was higher in the UK (42% for females and 39% for males) 
compared to 7.8% and 16.6%, respectively, in France. The rate of binge 
drinking is similar in both countries (Shelton and Savell 2011). 
In the UK, the NHS sets guidance for sensible alcohol consumption which is 
not more than 3 to 4 units a day or less for men, and 2 to 3 units a day or less 
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for women (Shelton and Savell 2011). The evidence to suggest that low to 
moderate drinking has some health benefits is strong. The reduced risk of CHD 
is considered as the main health benefit of alcohol (Fuller 2011). However, the 
evidence for this protection, is limited to middle-aged and older individuals  
who are at high risk of CHD (Ellison 2002). 
Moderate consumption of alcohol improves lipid profiles by decreasing LDL 
and increasing HDL. Moderate alcohol consumption is believed to reduce risk 
of CHD by improving the lipid profile and also by changing haemostatic 
factors which reduce platelet aggregation (Stranges and Trevisan 2011). 
In addition to the benefits to CHD, there is evidence that low consumption of 
alcohol is associated with a lower risk of ischaemic stroke. There is also 
evidence to suggest that moderate consumption confers protection against other 
diseases, including diabetes (Stranges and Trevisan 2011). Red wine in 
particular is believed to reduce CHD (Goldberg and Soleas 2011).  
Some experts have recommended that healthcare professionals should 
encourage low to moderate alcohol consumption to reduce the risk of CVD 
unless the patient with previous abuse or with religious, ethical or medical 
reasons for abstinence (Ellison 2002). 
However, the British Heart Foundation’s website advises people to not to start 
drinking in order to reduce CHD risk as there are other ways to risk including 
increasing physical activity, having a healthy diet and quitting smoking. They 
suggested that the benefit of alcohol as a protective against CHD still needs to 
be established in controlled trials (BHF 2010). 
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1.1.2.15 Chronic kidney disease 
Chronic kidney disease, defined as an estimated glomerular filtration rate of 
less than 60 ml/min per 1.73 m
2
 - which means all categories (mild, moderate 
and severe) of chronic kidney disease are included - is an independent risk 
factor for CVD (Weiner et al. 2004). It can increase the risk of myocardial 
infarction, fatal CHD, stroke and death from any cardiovascular event (di 
Angelantonio et al. 2010). The risk of CVD in black individuals with chronic 
kidney disease is increased to about twofold whereas the CVD risk of 
Caucasians with the disease is increased by only 13%. It has been suggested 
that the effect of chronic kidney disease on black people may be due to more 
frequent or more severe subclinical vascular disease secondary to hypertension 
or diabetes (Weiner et al. 2004). 
Whether aggressive lifestyle intervention in patients with chronic kidney 
disease can reduce their substantial CVD risk is unclear (Shlipak et al. 2005). 
1.1.2.16 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease affecting 
approximately 1% of the general population (Van Halm et al. 2009). The high 
mortality rate among patients with this disease appears to be due to CVD. The 
increased CVD risk in patients suffering from RA could be due to an increase 
in prevalence of risk factors such as dyslipidaemia, diabetes, hypertension, 
obesity or impaired physical fitness. Also, RA patients are more likely to be on 
non-steroidal anti-inflammatory drugs (NSAID) which can decreased renal 
blood flow and aggravate hypertension (Boyer et al. 2011). Moreover, it may 
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be due to the fact that in chronic diseases such as RA unrelated conditions such 
as cardiovascular risk factors may be undertreated and/or the chronic 
inflammatory process in the disease may increase the risk of CVD (Van Halm 
et al. 2009).  
According to Gonzalez et al. (2008) the management of CVD risk factors is 
less effective in reducing cardiovascular morbidity and mortality in RA 
patients. Further research is warranted to determine optimal approaches to 
achieve better outcomes (Gonzalez et al. 2008). 
1.1.2.17 Atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the 
UK (NICE 2006a). Unmanaged AF can increase risk of stroke significantly. 
AF mainly increases the risk of stroke caused by embolism formed in the 
atrium rather than atherosclerosis. The risk of stroke is increased four- to five-
fold in patients with AF. AF is associated with about a two-fold increase of 
mortality (Kannel and Benjamin 2008). 
1.1.3 Primary prevention of cardiovascular disease  
Acceptance and implementation of CHD guideline advice by primary care 
physicians, that is, general medical practitioners (GPs) in the UK, was assessed 
in five European countries including the UK (Hobbs and Erhardt 2002). The 
majority of the 754 physicians (150 in the UK) interviewed perceived the 
guidelines as useful. However, it was noted that the figure of UK physicians 
who perceived the guidelines as useful was lowest when compared to the other 
four countries (UK = 85%, France = 90%, Germany = 90%, and Italy = 99%). 
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Only 13% of physicians said that they always use risk calculator charts to 
estimate patients’ risk of CHD. The authors concluded that GPs need more 
information and support on the implementation of CHD and cholesterol 
guideline advice. 
In another study the researchers found that the age of doctors could influence 
their approach to managing the prevention of CVD. Older doctors when 
compared to their younger colleagues tended to recommend lifestyle changes 
over the use of medications (Tocci et al. 2011). 
1.1.3.1 The use of statins in the primary prevention of CVD 
The statins competitively inhibit 3-hydroxy-3-methyl-glutaryl coenzyme A 
(HMG CoA) reductase in the liver. HMG CoA reductase is an enzyme 
involved in cholesterol synthesis. There are five statins licensed in the UK; 
atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin (BNF 2011).  
Reduction in total cholesterol is associated with a reduction in ischaemic heart 
disease mortality (Lewington et al. 2007). By using a statin within therapeutic 
doses, up to 50% reduction can be seen in total body cholesterol levels. 
Lowering LDL cholesterol by about a third can be achieved by standard statin 
regimens and by up to a half when higher doses of atorvastatin or rosuvastatin 
are used (Baigent et al. 2010). Also, there are other effects of statins on the 
cardiovascular system and the arterial walls affecting endothelial function, 
reducing inflammation (measured by CRP), down-regulating of the blood 
coagulation cascade, plaque stabilization and smooth muscle cell migration 
(Yusuf 2010). 
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The benefits of statins in secondary prevention have been well established in 
several landmark trials. The Scandinavian Simvastatin Survival Study (4S) 
included a total of 4,444 patients, suffering from angina or previous myocardial 
infarction, with initial cholesterol levels of 5.5 to 8.0 mmol/L were assigned to 
a control group or an intervention group over a 5.4 year median period. The 4S 
study demonstrated a significant reduction in overall mortality in the 
intervention group (Pedersen et al. 2004). The CARE (Cholesterol and 
Recurrent Events) trial studied 4,159 patients, who had suffered myocardial 
infarction, with a total cholesterol level of 6.2 mmol/L or less. It demonstrated 
a significant reduction in the rate of CHD mortality and nonfatal myocardial 
infarction in the pravastatin group. Also there was a significant reduction in 
stroke rate in the therapeutic group (Sacks et al. 1996). The LIPID (The Long-
Term Intervention with Pravastatin in Ischaemic Disease) study randomised 
9,014 patients with history of myocardial infarction or hospitalisation for 
unstable angina into a pravastatin group or a placebo group over a mean 
follow-up period of 6.1 years. Patients with broad range of total cholesterol 
levels had a reduction in mortality rate from CHD, overall mortality and the 
incidence of all pre-specified cardiovascular events when treated with 
pravastatin 40mg (LIPID 1998). The Heart Protection Study (HPS 2002) 
studied 20,536 patients with CHD, other occlusive arterial disease or diabetes 
which were allocated to receive simvastatin 40mg or placebo. It demonstrated a 
significant reduction in all-cause mortality. To date HPS is the largest study to 
investigate the use of statins in both primary and secondary prevention of CVD 
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and it showed that safety profile is acceptable as side-effects, for example, 
myopathy, were rare in this study. 
The continued emphasis on the use of statins in the secondary prevention of 
CVD is seen as an important intervention in the reduction of cardiovascular 
events. However, it is also important not to overlook the significance of the 
primary prevention as 50% of all myocardial infarctions and strokes occur 
among apparently healthy people with levels of LDL that are below currently 
recommended thresholds for treatment (Ridker et al. 2008). 
The West of Scotland Coronary Prevention Study Group randomly assigned 
6,595 men with no history of myocardial infarction, 45 to 64 years of age, with 
a mean total cholesterol level of 7 mmol/L (SD = ±0.6) to receive pravastatin 
40mg or a placebo over a period of mean 4.9 years. The active therapy group 
had a significantly lower incidence of myocardial infarction and death from 
cardiovascular causes without adversely affecting the risk of death from non-
cardiovascular causes (Shepherd et al. 1995). 
The ASCOT-LLA trial (Sever et al. 2004) assigned 19,342 hypertensive 
patients with at least three other risk factors of CVD and a total cholesterol of 
not more than 6.5 mmol/L to receive atorvastatin 10mg or placebo. It 
demonstrated a significant reduction of 36% in fatal CHD and non-fatal 
myocardial infarction in the statin group compared with placebo. The study 
was stopped after a median follow-up of 3.3 years as it was deemed unethical 
to deprive the control group from the obvious benefit of the statin, hazard ratio 
0.64 [95% CI 0.50 - 0.83] (p = 0.0005). 
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The benefit of statin in the primary prevention of CVD was studied in a cohort 
of participants of 5,608 men and 997 women with a mean total cholesterol 
level was 5.7 mmol/L, mean LDL level was 3.9 mmol/L and below average 
HDL levels, were allocated to receive a statin, lovastat (not available in the 
UK), or a placebo for a period of an average 5.2 years. It resulted in a 37% 
reduction in the risk for first acute major coronary events (Downs et al. 1998).  
On the other hand, no significant reduction was seen either in all-cause 
mortality or CHD in a study compared the use of pravastatin versus usual care 
in 10,355 participants with well-controlled hypertension, moderately elevated 
LDL and with at least 1 additional CHD risk factor. The authors suggested that 
the lack of significant effect could have been due to the unexpected reductions 
of 8% in total cholesterol and 11% in LDL at 4 years in usual care group 
(Furberg et al. 2002).  
In the MEGA study (Nakamura et al. 2006), 7,832 Japanese with 
hypercholesterolemia, total cholesterol 5·7 to 7 mmol/L, but no history of CHD 
or stroke, were allocated in a diet group or diet plus pravastatin 10-20 mg. The 
therapeutic group had a significantly lower incidence of CHD post-study but 
there was no significant reduction in the incidence of stroke rate or total 
mortality when compared to the control group. A major limitation of this study 
is that a placebo was not used in the control group. It could not rule out that the 
benefit of pravastatin was not due to placebo effects. 
In another study, a group of 17,802 men and women were randomly assigned 
to receive a rosuvastatin 20mg or a placebo. Participants were apparently 
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healthy with LDL levels of less than 3.4 mmol/L but with elevated high-
sensitivity C-reactive protein levels. Rosuvastatin significantly reduced the 
incidence of major cardiovascular events and all-cause mortality. However, the 
trial was stopped by the study's independent data and safety monitoring board 
after a median follow-up of 1.9 years with no clear reason for this (Ridker et al. 
2008). 
According to a Cochrane review, when used for primary prevention in people 
at higher risk of CVD, statins can reduce all-cause mortality, combined fatal 
and non-fatal endpoints (CHD, CVD and stroke events) and revascularisation 
rates. Also it is cost-effective to use statins for primary prevention in high risk 
patients. However, the authors recommended a cautious approach when 
considering whether or not to prescribe statins for primary prevention in people 
with low CVD risk (Taylor et al. 2011a). These findings are in line with the 
current NICE guideline recommendations (Cooper et al. 2008). 
1.1.3.2 The use of aspirin for the primary prevention of CVD 
Aspirin at a low dose irreversibly inhibits the enzyme cyclo-oxygenase, which 
is required in the synthesis of thromboxane A2 (Martindale 2011). A complete 
suppression of platelet thromboxane synthesis can be achieved by daily doses 
of 20mg to 50mg over a few days. Larger doses of 150mg to 300mg can 
produce a maximum suppression instantly and no thromboxane A2 can be 
produced for about 24 hours until more platelets are released by the bone 
marrow. Aspirin is indicated for secondary prevention of thrombotic 
cerebrovascular or CVD, and following by-pass surgery (BNF 2011). 
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Aspirin at doses of 75mg to 150mg, according to placebo controlled trials, can 
reduce the risk of all occlusive vascular events, including myocardial 
infarction, ischaemic stroke, unstable or stable angina, peripheral arterial 
disease or atrial fibrillation (Weber 2002). Weber et al. (2002) conducted a 
meta analysis, in which 287 studies were included and involved 135,000 
patients in comparisons of antiplatelet therapy versus control, the overall result 
was a reduction of all vascular events by about one quarter in most of high risk 
patients including those who never had a CVD previously. 
The Joint British Societies guidelines on prevention of CVD in 2005 stated that 
subject to there being no contra-indications people over the age of 50 years 
who are at high risk of CVD, that is, ≥20%, without established CVD (primary 
prevention) should take aspirin 75 mg daily. Those who are hypertensive 
should have their blood pressure controlled to at least the audit standard of 
below 150/90 mmHg diastolic and then prescribed aspirin 75 mg daily (JBS2 
2005). 
The NICE guidelines for the management of type 2 diabetes in primary and 
secondary care, also recommend the use of aspirin 75 mg daily by those who 
are over the age of 50 years if blood pressure is below 145/90 mmHg. Also, the 
guidelines recommend the use of aspirin 75 mg daily by those who are under 
the age of 50 years and have significant other cardiovascular risk factors, such 
as the metabolic syndrome, family history of CVD, smoking, hypertension 
and/or microalbuminuria (NICE 2008a). 
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However, the benefits of aspirin in primary prevention of CVD have been 
questioned more recently (Berger et al. 2011). The evidence for the use of 
aspirin for primary prevention is not as strong as for those who had the disease 
previously. The risk of bleeding cannot always be justified in all of those who 
are at high risk but without extant CVD. The comparison between primary and 
secondary CVD prevention by using long-term aspirin was reported as a result 
of a meta analysis by Collins et al. (2009). The rate of serious vascular events, 
including myocardial infarction, stroke or CVD mortality and major bleeds in 
six primary prevention trials (n = 95,000) and 16 secondary prevention trials (n 
= 17,000) were evaluated in the analysis. Although the effectiveness of aspirin 
in the secondary prevention confirmed previous findings, the primary 
prevention reduction of stroke or mortality in those taking aspirin was not 
significant. It was only significant in non-fatal myocardial infarction 
(0·18% versus 0·23% per year, p < 0·0001) (Collins et al. 2009). This meta 
analysis included data for people at low, moderate and high CHD risk. The 
reduction in mortality rate was modest even in the high risk group. 
Similarly, according to a randomised control trial conducted by Belch et al., 
when compared with placebo, using aspirin for primary prevention in people 
with diabetes, that is, at high CVD risk, was not effective at reducing the CVD 
risk (Belch et al. 2008). 
The Medicines and Healthcare products Regulatory Agency (MHRA) stated 
that the use of aspirin as an antiplatelet drug is licensed for secondary 
prevention only and recommended that if it is used in primary prevention, 
which is an unlicensed use, healthcare professionals should review the benefits, 
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particularly the presence of risk factors for vascular disease (including 
conditions such as diabetes) and the risks, such as gastrointestinal bleeding. 
The balance of the benefits and risks should be considered for each individual 
(MHRA 2009). 
It has been now recommended, in light of the available evidence, that patients 
who are on aspirin for primary prevention should be reviewed. Healthcare 
professionals should engage those patients in the decision about whether to 
continue with the treatment (DTB 2009). Table 1-9 shows the figures acquired 
from a patient decision aid which was produced by the National Prescribing 
Centre (NPC) to assist healthcare professionals in consultations with patients 
with no history of CVD and the treatment with aspirin is being considered 
(NPC 2010). The patient decision aid showed that a modest benefit can be 
gained by taking aspirin 75mg daily for 10 years. The aid interpreted the 
findings of the Collins et al. meta analysis (2009). 
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Table 1 - 9 Benefits and risks of aspirin in three groups of patients (each of n=1,000) who do 
not have existing CVD and take aspirin for the next 10 years (NPC 2010) 
 5% risk 
of CVD 
10% risk  
of CVD 
20% risk  
of CVD 
Number of people who will not die, 
have a non-fatal MI or a stroke 
whether or not they take aspirin 
950 900 800 
Number of people who will be saved 
from dying, having a non-fatal MI or 
a stroke by taking aspirin 
6 12 24 
Number of people who will die or 
have at least one non-fatal MI or 
stroke, whether or not they take 
aspirin 
44 88 176 
Number of people who will not have 
a major bleed whether or not they 
take aspirin 
994 983 972 
Number of people who will have a 
major bleed because they take 
aspirin   
2 6 10 
Number of people who will have a 
major bleed whether or not they take 
aspirin 
4 11 18 
 
1.1.4 Risk assessment for the primary prevention of 
cardiovascular disease 
The cardiovascular risk assessment (VRA) tools in use (see Chapter 7) tend to 
divide people into three groups: those at low risk, that is, with less than 10% 
risk of developing CVD in the next ten years; those at moderate risk with 10-
20% risk of developing CVD in the next ten years; and those at high risk, that 
is, greater than 20% risk of developing CVD in the next ten years. National 
guidelines, such as NICE (NICE 2008b) and SIGN (SIGN 2007), consider a 
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cardiovascular risk score of 20% or more is high risk and only those who are at 
high risk are candidates for preventive pharmacological intervention. 
1.1.4.1 Framingham risk scores 
Most of the risk assessment tools available in the UK are based on the 
American Framingham study although the relevance of this to the current UK 
population is unclear (Hippisley-Cox et al. 2007). The Framingham Heart 
Study was conceived in 1948, at a time when there was insufficient knowledge 
about the causes of CVD. The Framingham Heart Study was set up to identify 
the risk factors that contribute to CVD. More than 14,000 participants over five 
decades and representing three generations have been recruited and monitored 
for the development of CVD. The Framingham Heart Study has successfully 
identified that high blood pressure, high blood cholesterol, smoking, obesity, 
diabetes and physical inactivity are risk factors for CVD (Shindler 2011). As a 
result, the concept of CVD risk factors has become the cornerstone of 
advancing prevention and treatment of CVD (Folsom et al. 2003). Based on the 
Framingham population a risk assessment tool for estimating 10-year CVD risk 
has been developed. 
NICE had followed the recommendation of the Joint British Societies’ 
guidelines in using the modified Framingham equation Until March 2010  
(NICE 2010a). 
1.1.4.2 ASSIGN 
The "ASSessing cardiovascular risk using SIGN" (ASSIGN) is a 
cardiovascular risk score developed in Dundee University, Scotland in 2006 
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(SIGN 2007). The tool was developed by following a cohort of 6,419 men and 
6,618 women aged 30–74 across 25 districts of Scotland and monitoring them 
for cardiovascular mortality and morbidity over a year (Woodward et al. 2007). 
ASSIGN was the first VRA tool to use social deprivation and family history of 
CVD together with the classic risk factors (smoking, blood pressure, total 
cholesterol and HDL) (Tunstall-Pedoe and Woodward 2006). 
1.1.4.3 QRISK and QRISK2 
Researchers from the University of Nottingham have developed QRISK, a 
cardiovascular disease risk algorithm specifically for use in the UK (Hippisley-
Cox et al. 2007). A second, modified version of QRISK, namely QRISK2, was 
launched in 2008 (Hippisley-Cox et al. 2008). In contrast to the US based 
Framingham model, QRISK2 is based on data derived from primary care 
records in the UK. The QRISK2 model is based on data from 531 practices (2.3 
million patients; aged 35-74) studied from 1
st
 Jan 1993 to 31
st
 March 2008. In 
addition to the standard risk factors for CVD taken into account by 
Framingham, QRISK also takes account of variables relating to socioeconomic 
status and ethnicity (Hippisley-Cox et al. 2007). Unlike Framingham, which 
overestimates CVD risk in low risk population and underestimates CVD risk in 
high risk populations, the QRISK2 score is more accurate in predicting CVD 
risk (Jackson 2008). The claimed improved accuracy of QRISK2 at predicting 
CVD risk is due to the increased size of the data base, the type of population 
from which the data were derived and validated, and the inclusion of other 
variables. Furthermore, an independent and external validation of the QRISK2 
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has provided evidence to support the use of QRISK2 in favour of the modified 
Framingham equation (Collins and Altman 2010).  
1.1.4.4 The use of circulating C-reactive protein concentration 
as a CVD risk assessment 
C-reactive protein (CRP) is produced largely by the liver and also produced by 
adipocytes (Vachharajani and Granger 2009). The circulating concentration of 
this protein rises rapidly in response to tissue injury, infection and 
inflammation. It has been thought that the physiological role of CRP is a host 
protective by binding to molecules containing phosphocholine expressed on the 
surface of dead or dying cells and some types of bacteria to active then 
activating the classical complement pathway, which is important to help the 
antibodies and phagocytes to clear pathogens from the system (Thompson et al. 
1999). 
It has been suggested that the concentration level of CRP as a biomarker for 
cardiovascular risk prediction and as a selection marker for initiating statin 
treatment (Shah et al. 2010). There are a number of prospective studies of high 
quality design that have shown a strong and independent correlation between 
concentrations of CRP and future major cardiovascular events (Imhof et al. 
2003). The link between CRP and CVD was used by some researchers to 
confirm the inflammatory nature of the atherosclerosis, that is, it is a marker 
for the inflammation of the vascular cell wall (Bucova et al. 2008). 
Inflammation is involved in atherosclerosis starting in early youth and 
advancing for decades throughout life (Kones 2010). However, it is also 
suggested that as CRP amplifies the pro-inflammatory effects of cytokines, the 
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high levels of CRP could be responsible for the inflammation rather than a 
result of it. In other words, high concentrations of circulating CRP should be 
regarded as a risk for CVD and not only a biomarker to predict the disease 
(Vachharajani and Granger 2009). This view remains controversial and data 
indicate that CRP concentration is unlikely to be a causal factor in CHD 
(Wensley et al. 2011). Most researchers regard CRP as an independent 
predictor of future cardiovascular events without confirming the direct 
involvement in atherosclerosis (Kones 2010). 
There are also laboratory and clinical studies to show the strong association 
between CRP and various features of metabolic syndrome. Metabolic 
syndrome is diagnosed by the presence of any three of the following features; 
central obesity, dyslipidaemia (high triglycerides, low HDL), hypertension or 
impaired fasting glucose. According to Devaraj et al. (2010) the addition of 
CRP to the present definition of the metabolic syndrome may help identify 
patients at high risk of diabetes and CVD (Devaraj et al. 2010). However, as 
most observational studies confirming the association between CRP and CVD 
have been in Caucasians, caution should be exercised in extrapolating to non-
Caucasions. A meta-analysis was conducted to evaluate the influence of the 
ethnicity on CRP concentration and concluded that a single threshold value of 
CRP for cardiovascular risk prediction may not accurately reflect underlying 
levels of cardiovascular risk. The authors were able to show variations in CRP 
concentration in populations of diverse ethnicity were large but only partially 
influenced by differences in variables related to cardiovascular risk (Shah et al. 
2010). According to Khera et al. there are significant variations of mean levels 
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of CRP not only between different ethnic groups but also between genders. It 
was suggested that further research is required to determine whether variations 
in CRP levels among different ethnic groups and genders contribute to 
differences in cardiovascular outcomes, and also to determine whether 
thresholds for a preventative treatment should adjusted for these groups (Khera 
et al. 2005). 
As far as the circulating CRP is concerned, the inflammatory process in 
atherosclerosis is relatively limited. Therefore, high-sensitivity assays have 
been developed and become commercially available for measuring of 
circulating CRP concentrations for risk prediction of CVDs (Imhof et al. 2003). 
The following categories can be determined by using such assays; low risk < 
1mg/L, moderate risk 1-3mg/L and high risk >3mg/L (Longmore et al. 2004). 
The JUPITER trial (Justification for the Use of Statins in Primary Prevention: 
An Intervention Trial Evaluating Rosuvastatin) claimed that patients are better 
managed when both LDL and CRP levels are reduced, when compared with 
reducing only LDL level (Kones 2010). However, an analysis from a large-
scale study showed that regardless of baseline levels of CRP, statin treatment 
was associated with a similar reduction in cardiovascular events (Heart 
Protection Study Collaborative Group 2011). 
The use of CRP concentrations has been suggested to augment other risk 
assessment tools, such as Framingham algorithm. It has been suggested as 
being capable of improving the predictability of Framingham when used to 
determine who of those at moderate risk would benefit from preventative 
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treatment (Dent 2010). The US Food and Drug Administration extended the 
indications for rosuvastatin to include asymptomatic individuals with high CRP 
level plus one additional risk factor. The measurement of the circulating CRP 
is recommended by the American Heart Association to those who are at 
moderate intermediate risk of CVD. The Canadian Cardiovascular Society 
guidelines recommended use of statins in individuals at moderate risk even 
those with low LDL if CRP level is high (Kones 2010). 
A study conducted in Brazil, however, questioned the reliance on CRP or on 
CVD risk assessment tools to predict cardiovascular events as more than half 
of patients presenting with myocardial infarction in the study would not be 
considered as candidates for preventive therapy by the current CVD risk 
algorithms or the current thresholds of CRP concentrations (Sposito et al. 
2011). 
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1.2 Literature Review of Pharmacy Based VRAs 
A search of the literature on pharmacy based VRA services was performed to 
identify studies conducted to evaluate the role of pharmacy and/or the 
pharmacist in the provision of such services. The databases MEDLINE and 
EMBASE were searched from 1996 to the 24
th
 June 2009 to inform the method 
of the study and to prepare for the study protocol. The same search strategy 
was repeated with from 1996 to present (4
th
 November 2011) using appropriate 
subject headings for each database as some subject headings were available for 
one database but not the other. For the Embase database; the following Subject 
Headings were used: ‘cardiovascular disease’, ‘risk assessment’, ‘pharmacy’ 
and then all results were combined with AND. For the Medline database the 
subject headings were ‘cardiovascular diseases’, ‘community pharmacy 
services’ and ‘risk assessment’ and then combined with AND. 
Also the following terms were used in combination to complement the search 
with studies on UK specific services; ‘pharmac$’ and ‘NHS Health Check$’.  
To obtain more comprehensive results, the search was not limited in either of 
the databases to the English Language as it was unknown whether there was 
any study focussing on CVD risk assessment in any of the non-English 
speaking countries. 
Additionally, reference lists and bibliographies of the identified studies and 
government reports produced on the VRA services were reviewed. 
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1.2.1 Results of the search strategy 
The results of the search strategy are summarised in Table 1-10 below. There 
were 14 relevant studies from Embase database which were included in this 
literature review. The reasons for the excluding 22 from the literature review 
were as follows; there were three papers on medicines adherence, three 
reviews, two papers studying screening services for other health problems 
(namely chronic obstructive pulmonary disease and sleep disorders) and two 
papers studying prescribing of COX-2 inhibitors, one paper studying the 
cardiovascular therapy under-treatment in patients with rheumatoid arthritis, 
one paper evaluating the use of gastrointestinal prophylaxis in NSAID patients, 
one paper studying the inappropriate medication use in the elderly, one a 
duplicate record, and 6 were editorial (n = 1), letter (n = 2), view (n = 2) or 
report (n = 1). Two conference abstracts were found relating to this PhD 
(Waheedi et al. 2011; Waheedi et al. 2010) and these were also excluded. 
Table 1 - 10 Results of the search strategy of the literature review as in 4th November 2011 
Embase Medline 
Subject headings Number of 
papers 
Subject headings Number of 
papers 
Pharmacy 30339 Community 
Pharmacy Services 
1665 
Risk assessment 242089 Risk Assessment 127101 
Cardiovascular 
disease 
112838 Cardiovascular 
diseases 
58229 
Combined with AND  36 
Included  14 papers 
Combined with AND  7 
(3 were found by Embase as well) 
Included  Additional 4 papers 
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The search using the Medline database resulted in four additional papers being 
identified. The search using the following terms ‘pharmac$’ and ‘NHS Health 
Check$’ resulted one additional study being identified by Embase database. 
Four papers were excluded for the following reasons; one duplicate, one 
identified through the previous search, one was a review on conference 
abstracts and one was an article on NHS Health Checks.  
Table 1-11 lists the studies which were identified through the search strategy. 
Table 1 - 11 Studies identified using Embase, Medline and manual search 
Embase Medline Manual search 
Amariles et al. 2005 Amariles et al. 2008 Boyle et al. 2004 
Chambers et al. 2005 Carter et al. 2009 Donyai and van den 
Berg 2009 
Crabtree et al. 2010√ Horgan et al. 2010* Horgan et al. 2009 
Didonato and May 
2011 
Liu et al. 2009* Thornley et al. 2009a 
Fernandez-Pinilla and 
Chaves 2008 
Mc Namara et al. 2010*  
Horgan et al. 2010* Simpson et al. 2001  
Kaczorowski et al. 2010 Yamada et al. 2005  
Lalonde et al. 2006   
Liu et al. 2009*   
Loo et al. 2011†   
Mc Namara et al. 2010*   
O’Donovan et al. 2010   
Peterson et al. 2010   
Sancar et al. 2011   
Thornley et al. 2009b   
* Identified by both Medline and Embase, √ Identified using the search terms 
method, † Identified using the search terms method and the subheadings method. 
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1.2.2 Literature overview- pharmacy based VRAs 
A total of 23 studies were identified through the research strategy. Table 1-12 
shows a list of the studies outlining the country in which they were conducted, 
the VRA tool used and the deprivation index used if applicable. Table 1-13 
presents a summary of studies’ aims/objectives, methods and key findings. 
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Table 1 - 12 Studies identified through the research strategy with the country they were 
conducted in, VRA tool and the deprivation index used, if applicable 
Author(s) and year Country VRA tool Deprivation 
index 
Simpson et al. 2001 Canada Framingham  
Boyle et al. 2004 USA Men's Health 
Risk 
Assessment 
 
Amariles et al. 2005 Spain   
Chambers et al. 2005 Canada   
Yamada et al. 2005 Canada Framingham  
Lalonde et al. 2006 Canada   
Amariles et al. 2008 Spain Framingham  
Fernandez-Pinilla and 
Chaves 2008 
Spain SCORE (based 
on Framingham) 
 
Carter et al. 2009 Canada   
Donyai and van den 
Berg 2009 
UK Framingham The Output Area 
Classification 
Horgan et al. 2009 UK Framingham The Index of 
Multiple 
Deprivation 
Liu et al. 2009 USA Individual risk 
factors 
 
Thornley et al. 2009a UK Framingham  
Thornley et al. 2009b UK Framingham The Output Area 
Classification 
Crabtree et al. 2010 UK   
Horgan et al. 2010 UK Framingham The English 
Index of Multiple 
Deprivation 
Kaczorowski et al. 
2010 
Canada   
Mc Namara et al. 2010 Australia Framingham  
O’Donovan et al. 2010 Republic 
of 
Ireland 
Questionnaire  
Peterson et al. 2010 Australia Framingham  
Didonato and May 
2011 
USA   
Loo et al. 2011 UK   
Sancar et al. 2011 Turkey Framingham  
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Table 1 - 13 Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
Author(s) 
and year 
Aim/ objectives Method Key findings 
Simpson et 
al. 2001 
Evaluate economic 
impact of the 
cardiovascular risk 
intervention by 
pharmacists. 
The cost of an earlier study, involved 50 
community pharmacies in a randomised 
control trial, was analyzed to describe the 
economic impact of the programme. The 
change in CVD risk was also reported. 
The CVD risk decreased from 17.3% to 
16.4% (p < 0.0001) during the 4 months. The 
incremental cost appeared, according to the 
authors, minimal from both government and 
pharmacy manager perspectives. 
Boyle et al. 
2004 
Determine whether 
community pharmacists 
could encourage men to 
visit their physician. 
A 12 week prospective cohort study 
recruited men aged 25-74 years with 
potential untreated or uncontrolled health 
risks, who visited any of the 30 participated 
pharmacies in 2002. 
Up to 50% of participants were found to be at 
risk of hypertension, hyperlipidaemia or 
diabetes. 64% made their visit or waiting for 
an appointment. 
Chambers et 
al. 2005 
The introduction of the 
Cardiovascular Health 
Awareness Programme 
(CHAP) 
Description of the implementation of the 
programme. 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Amariles et 
al. 2005 
Investigate the 
relationship between 
knowledge and CVD 
risk. 
A cross sectional survey of patients 
attending 6 community pharmacies in 
Andalucia, Spain was used over a period of 
15 days.  
257 were recruited; mean age was 61 years 
(SD ±10.8), male 36%, current smokers 13%, 
hypertensive 79%, raised cholesterol levels 
42%, type 2 diabetes 20%, and CVD 23%. 
36% of participants were at low CVD risk, 
21% at moderate risk and 43% at high risk. 
According to the survey’s results the degree 
of knowledge was considered as adequate in 
61%. No significant difference in patient's 
knowledge was found between those at low, 
moderate or high CVD risk. 
Yamada et 
al. 2005 
Determine the effect of a 
community pharmacist 
intervention in patients at 
high risk for CHD on 
LDL. 
Patients from another study (Tsuyuki et al. 
1999) were invited to return to their 
community pharmacy 6 months after they 
had an intervention by their pharmacist to 
have a measure of their fasting LDL level. 
162 patients (45%) returned to their 
community pharmacy. There was an increase 
of 0.07 mmol/L in the mean LDL level 
between original and follow up, 95% 
confidence interval = -0.5-0.19. 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Lalonde et 
al. 2006 
Assess the feasibility and 
relevance of providing a 
community pharmacist 
two different decision 
aids to patients on lipid-
lowering or blood 
pressure medicines. 
Patients at 10 community pharmacies were 
randomised to two groups, pharmacists 
helped patients to use a unique decision aid 
for each group. Patients were evaluated at 
baseline, two weeks, and three months after 
a pharmacist consultation. 
26 participated in the study. All patients 
agreed the tools were useful. Only one-third 
of participants estimated their CVD risks 
correctly and this has not improved after the 
intervention. Decision making by patients 
improved significantly (P = 0.02). 
Amariles et 
al. 2008 
A descriptive, 
observational study to 
compare between two 
CVD risk assessment 
systems (both based on 
Framingham). 
Including patients aged 25-74 years from 
six community pharmacies of Andalusia, 
Spain over 15 days in 2004 if they were on 
any medication for CVD prevention. 
Results were compared using the SCORE 
system and the Wilson-Grundy method. 
A total of 257 patients, 92 male (36%), mean 
age was 60.9 (SD = 10.8) years. 22 
participants were assessed as at high risk with 
SCORE system but at low risk when assessed 
with the Wilson-Grundy method. 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Fernandez-
Pinilla and 
Chaves 2008 
Determine the CVD risk, 
based on the SCORE 
(Systematic Coronary 
Risk Evaluation) model, 
in community 
pharmacies. 
An observational study was conducted in 
Spain in 362 community pharmacies. 
Blood pressure, cholesterol and glucose 
were measured. 
5,334 were recruited. The mean age was 57 
years; 67% were women; 67% were 
overweight or obese; 19% smokers; 32% 
hypertensive; 52% hyperlipideamia and 12% 
diabetic. The average mean CVD risk was 
4.2. 30% were at a moderately high to very 
high CVD risk.  
Carter et al. 
2009 
Describe the 
implementation of the 
CHAP (Chambers et al. 
2005a) 
Community pharmacists were recruited to 
deliver a VRA service in 129 pharmacies in 
Canada. Assessment results were sent to 
the GPs (99%) who agreed to receive them. 
The number of participants who had the 
assessment was 15,889. (more results 
published by Kaczorowski et al. 2010, see 
below) 
Donyai and 
van den 
Berg 2009 
To find associations 
between participants' 
demographics and 10-
year CHD risks 
Analysing data from 8,287 records of a free 
VRA service provided by a large UK 
pharmacy chain from August 2004 to April 
2006. 
Pharmacists provided lifestyle advice for the 
participants regardless of their characteristics 
and only less than 3% were sold a product to 
manage the risk of CHD. 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
Chapter 1: Introduction and Literature Review 
53 
 
Author(s) 
and year 
Aim/ objectives Method Key findings 
Horgan et al. 
2009 
A survey of participants 
who accessed the Heart 
MOT, a pilot of a 
community pharmacy 
based VRA service. 
400 were sent a questionnaire 3 months 
after accessing the service in one of the 14 
participated pharmacies in Birmingham, 
England during the period between April 
2007 and June 2008. 
176 responded to this survey. High percentage 
agreed that they were happy with the service 
(98%), consultation room (93), and that they 
would recommend the service (99%). The 
percentage plummeted in response to 
professionalism (77%), cleanliness (76%), 
confidentiality (80%) and the overall 
experience (76%). 
Liu et al. 
2009 
A descriptive study of 
VRA service provided 
by the community 
pharmacy. 
The site of the screening was at work place 
for workers and their dependents. 20 years 
of age or older, were eligible for the 
screening. Risk levels of CVD determined 
by checking BP, total cholesterol, and 
HDL. 
The total number of patients was 452. 137 
were found at high risk because of an SBP ≥ 
140 mmHg (45%), 73 had a DBP ≥ 90 mmHg 
(24%), 81 had high total cholesterol (24%), 
and 55 had  low HDL (16%). 
Thornley et 
al. 2009a 
Analysis of consultation 
times with service users. 
Consultation time were recorded by the 
pharmacy teams in eight Boots pharmacies 
in the UK (see Thornley et al. 2009b) 
The median time was 35 minutes (20 minutes 
of team member time, 10 minutes of 
pharmacist time and 5 minutes of paperwork) 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Thornley et 
al. 2009b 
Analysis the 
demography of VRA 
service users and 
evaluation of the 
findings. 
Analysing data from a private VRA service 
which was provided by eight Boots 
pharmacies in the UK.  
400 used the service, 70% were women and 
72% were 50 years or over. Only 13% were 
from the disadvantaged socioeconomic 
groups.  
Crabtree et 
al. 2010 
Explore why pharmacy 
staff involved in one of 
the pilots held positive 
views about the NHS 
Health Check service. 
32 semi-structured telephone interviews 
were conducted with a member of staff, 
pharmacists (n = 15), support staff (n = 13) 
and pre-registration pharmacists (n = 4), 
who were involved in the service in 
different pharmacies.  
In general pharmacy staffs were positive with 
some negative views being held which might 
be resolved by providing educational and 
training support. 
Horgan et al. 
2010 
Evaluate a VRA pilot Data for 99% (1130 of 1141) of the 
participants were included for the analysis 
of a VRA pilot in 23 UK independent 
community pharmacies targeted at those 
aged 40-70 without known CVD. 
Referral to general practice reached 70% of 
participants. Only 18% were referred because 
they were at high risk of CVD. 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Kaczorowski 
et al. 2010 
Evaluate a community 
pharmacy based 
educational programme 
to reduce the morbidity 
of CVD. 
39 communities in Ontario, Canada were 
randomized, 20 to receive the CHAP 
(Chambers et al. 2005b) and the remaining 
19 were to receive the usual care, i.e. no 
intervention. Those aged ≥ 65 years were 
recruited to attend educational sessions 
over a 10-week period. Information 
collected was shared with their family 
doctor. The primary outcome was the rate 
of hospital admissions for acute myocardial 
infarction, stroke and congestive heart 
failure. Analysis was by intention to treat 
among those aged ≥ 65 years in both 
groups.  
A total of 129 (90%) pharmacies provided the 
CHAP during the 10-week period. A total of 
15,889 participants had their CVD risk 
assessed. CHAP was associated with a 
significant reductions in hospital admissions 
for acute myocardial infarction (rate ratio 
0.87, p = 0.008) and congestive heart failure 
(rate ratio 0.90, p = 0.029), but not for stroke 
(rate ratio 0.99, p = 0.89). 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Mc Namara 
et al. 2010 
Assess the feasibility of 
implementing a primary 
CVD prevention 
programmes into 
community pharmacy (A 
study protocol) 
A longitudinal pre- and post-test pilot study 
with a cohort of up to 100 patients (50-74 
year old) in 10 pharmacies. Community 
pharmacists will provide consultations to 
improve lifestyle, adherence to medicines 
and medicines management. 
This paper only presented the study protocol. 
O’Donovan 
et al. 2010 
Pilot a novel paper-based 
questionnaire that can be 
used as a VRA instead of 
the invasive methods 
available like 
Framingham. 
The questionnaire was developed, using 
European Society of Cardiology guidelines, 
for self-reporting by patients in community 
pharmacies. No measurement took place in 
the pharmacy; lipid testing and blood 
pressure were omitted and weight and 
height were self-reported by patients. Each 
question was assigned a weighting and then 
the weightings for each risk factor were 
added to give a score related to their CVD 
risk; low, moderate or high. Six community 
pharmacies in Northern Ireland participated 
in this pilot. 
204 were recruited, 32% were males, mean 
age was 41 years (SD = ±15). BMI was 25.7 
(SD = ±4.8). 102 (50%) had low risk, 80 
(39%) had a moderate risk and 22 (11%) had 
a high risk. 
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Chapter 1: Introduction and Literature Review 
57 
 
Author(s) 
and year 
Aim/ objectives Method Key findings 
Peterson et 
al. 2010 
Assess the suitability of 
the community 
pharmacy as a place for 
delivering the VRA 
service. 
The service was offered, in 14 community 
pharmacies in Australia to those aged over 
30 years and with no existing CVD. The 
baseline knowledge of participants was 
assessed followed by an educational 
programme. Feedback was received 
through a questionnaire and a phone call.  
655 accessed the VRA service. 71% females, 
aged 30-90 years. 7% were found at high risk, 
30% had BP > 140/90 mmHg, 40% had total 
cholesterol > 5.5 mmol/L and 20% had HDL 
< 1 mmol/L. 97% regarded pharmacy as an 
appropriate place for the service. Knowledge 
improved significantly. 46% of the high risk 
patients indicated that they had lifestyle 
changes or were prescribed a new drug. 
Didonato 
and May 
2011 
Measure impact of 
wellness screening and 
monitoring services 
provided in a community 
pharmacy 
Participants completed a personal health 
assessment, CVD and diabetes risk 
assessments, and screening for cholesterol, 
blood glucose, blood pressure, and body 
mass index. Then those who were 
diagnosed with any abnormality had 
monthly to quarterly follow-up 
appointments.  
95 patients enrolled and 8 were found healthy, 
those included in the programme were: 57 
hypertension, 74 cholesterol, 24 diabetes, and 
60 weight management patients. 
Table 1 – 13 (Continued) Studies on community pharmacy based VRA services identified through the research strategy of this literature review 
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Author(s) 
and year 
Aim/ objectives Method Key findings 
Loo et al. 
2011 
Explore community 
pharmacists' activities 
and their attitudes 
towards the provision of 
the NHS Health Check. 
A validated questionnaire was sent to 1301 
pharmacies in the most deprived areas in 
England in November and a reminder in 
December 2009. The questionnaire was to 
establish whether pharmacists provided a 
VRA service and about their views on 
barriers and training needs.  
The response rate was 34%. Lack of time, 
shortage of staff and lack of reimbursement 
were commonly the perceived barriers 
identified by pharmacists for providing VRA 
services. Training requirements were 
suggested for the use of CVD predictive tools. 
Sancar et al. 
2011 
Assess CVD risk of 
patients with 
hyperlipidaemia 
Patients with hyperlipidemia, who attended 
a community pharmacy for dispensing their 
medications (March-April 2010) were 
included. The demographic, clinical and 
medication history was directly obtained 
from patients and medical records. A tool 
based on Framingham was used to 
calculate CVD risk. 
50 patients were included, The mean age was 
57 (SD ± 9). 76% had no smoking history. 
10% had a family history of hyperlipidaemia. 
58% had comorbid disease. 34% had a CVD 
risk > 20%. 
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1.2.3 Discussion 
1.2.3.1 Prior to the study 
Prior to commencing the present study there were only three papers (Horgan et 
al. 2009; Thornley et al. 2009a, 2009b) found in the literature which were 
conducted in the UK, two of which analysed data obtained from the same 
service. Thornley et al. (2009a) analysed the consultation times with the 
service user while Thornley et al. (2009b) presented the demographic 
characteristics of the service users. The feedback of service users was 
presented by Horgan et al. (2009).  
Of the eight remaining studies, five non-UK based studies evaluating 
interventions, with CVD management as the main element of the programmes 
(Amariles et al. 2005; Boyle et al. 2004; Lalonde et al. 2006; Simpson et al. 
2001; Yamada et al. 2005). Although there were some similarities between 
these programmes none were a screening service like those provided in the 
UK. Chambers et al. (2005) presented a descriptive of a CVD awareness 
programme in Canada. Two Spanish studies evaluated different VRA tools 
(Amariles et al. 2008; Fernandez-Pinilla and Chaves 2008). 
Studies identified in the literature prior to the study in this thesis being 
designed and undertaken are discussed further below (Section 1.2.3.2). 
1.2.3.2 Final literature review 
There were six descriptive studies of the service identified in the literature 
(Carter et al. 2009; Chambers et al. 2005b; Horgan et al. 2010; Kaczorowski et 
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al. 2010; Liu et al. 2009; Peterson et al. 2010). The role of community 
pharmacists in the prevention of CVD was the focus of four studies (Boyle et 
al. 2004; Didonato and May 2011; Lalonde et al. 2006; Yamada et al. 2005). 
Another four studies presented patients’ characteristics (Amariles et al. 2005; 
Donyai and van den Berg 2009; Sancar et al. 2011; Thornley et al. 2009b). 
Three studies focused on the VRA tools (Amariles et al. 2008; Fernandez-
Pinilla and Chaves 2008b; O'Donovan et al. 2010). Views of pharmacists 
and/or pharmacy support staff on the provision of the service were evaluated 
by two studies (Crabtree et al. 2010a; Loo et al. 2011). One study was a survey 
of VRA service users (Horgan et al. 2009). One paper was a protocol for a 
feasibility study yet to commence (Mc Namara et al. 2010). One paper 
evaluated the economic impact of a programme involving pharmacists’ 
interventions (Simpson et al. 2001).  
In addition to the fact that the identified studies being conducted in different 
countries (the UK, Republic of Ireland, Spain, Turkey, Canada and the USA) 
that is, in different health systems, there are also other variations in the way the 
services were provided. For instance, the VRA tools were not the same in all 
studies. One service used the absolute 10-year risk of CHD (Wilson et al. 
1998) rather than the 10-year risk of CVD commonly used and recommended 
by the current guidelines (NICE 2008b). Tools assessing CVD risk and based 
on Framingham study were the most common tools used by the identified 
studies. However, as it was shown in the study conducted by Amariles et al. 
(2008) different tools could yield different results even if both were based on 
Framingham.  
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Although some studies claim they used tools based on Framingham study they 
included patients whose risk could not be assessed accurately by any of the 
tools available. For example, one study included young patients, that is, 
younger than 30 years of age (Amariles et al. 2008). There was a study which 
included patients older than 74 years (Peterson et al. 2010) with a maximum 
age of 90 years. Furthermore, the authors of one study (Donyai and van den 
Berg 2009) combined the figures for those at moderate and high risk without 
explaining the reasons for this. Discriminating between the three categories of 
risk is fundamental for providing the adequate management for each group. 
Other issues concerning the assessment of CVD risk, including the absence of 
any details of the tool being used (Amariles et al. 2005; Carter et al. 2009), the 
nature of the screening was unclear with only mentioning of the use of a risk 
assessment tool (Men’s Health Risk Assessment Tool) (Boyle et al. 2004), or 
using individual risk factors as a method to identify people at high risk (Liu et 
al. 2009). In the latter study not all risk factors were reported as the data on 
smoking status, body weight and family history were missing. Furthermore, 
one study (Amariles et al. 2008) was different from other studies involving 
screening service in that it targeted those who were already diagnosed with 
hypertension, diabetes or a CVD. 
In one study (Horgan et al. 2010), the referral of participants to general practice 
was as high as 70%. Only 18% were referred because they were at high risk of 
CVD. Other subjects were referred because of individual risk factors, such as 
BP > 140/90 mmHg and total cholesterol level > 6 mmol/L. About a quarter 
were referred because of their BMI ≥ 30 kg/m2 or a waist circumference ≥ 88 
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cm (for women) or ≥ 102 cm (for men). The referral rate seemed to be high, as 
the authors agreed, which could affect the cost-effectiveness of the service.  
On the other hand in another study (Liu et al. 2009) no official referral to any 
other healthcare professional was made because of issues regarding the 
contract by the company coordinating the screening; however, at risk patients 
were encouraged to discuss issues with their physicians.  
Whether the pharmacy based screening services would help to reduce health 
inequalities or worsen the gap is not known. Although a pilot (Horgan et al. 
2010) targeted people living in the most deprived areas, most of participants 
were from average and less deprived quintiles. 
The VRA was not always outlined in detail in the studies. The authors of one 
study (Carter et al. 2009) concluded that the programme required “a balance of 
standardization to ensure the integrity of the intervention components and 
flexibility to fit the local context.” without giving specific details of the 
assessment. The role of the community pharmacist in dealing with individuals 
with CVD risk factors was not mentioned by the authors of another study 
(Fernandez-Pinilla and Chaves 2008a, 2008b).  
The main outcome of one study (Boyle et al. 2004) was determining the 
number of men who were seen by a physician, if were referred, by asking them 
via a telephone call. Although self-reporting is not necessarily inaccurate, the 
authors combined the number of those who had actually seen their doctor with 
those who said they were waiting for an appointment which could affect the 
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end results. This is because the telephone call could put pressure on some 
participants to visit the doctor or it could be a reminder to others.  
One small study of 26 participants (Lalonde et al. 2006) had the advantage of 
being a longitudinal study which had two follow-ups, one at two weeks and the 
other at three months. Other studies (total number = 7) which followed 
participants to investigate whether there was any short-term or longer-term 
benefits include; Simpson et al. (2001) who investigated the changes in CVD 
risk four months after having had an intervention from a pharmacist, Yamada 
et al. (2005) who measured the changes in LDL levels 6 months after an 
intervention and Peterson et al. (2010) who assessed knowledge and lifestyle 
changes through a questionnaire and a telephone call. Kaczorowski et al. 
(2010) reported the rate of hospital admissions and compared them with those a 
year prior to the intervention (although the authors did not state how long after 
the intervention, the comparison was made). Horgan et al. (2009) surveyed 
participants three months after they accessed a VRA service and Mc Namara et 
al. (2010) planned in their study protocol a follow up to investigate the average 
change to estimated 5-year risk of CVD between baseline and six months, 
although this study has yet to be concluded. 
Studies indentified through the search strategy in the literature review varied in 
their aims and objectives and their methodology. There were limitations in the 
studies, however not all of these limitations were discussed by the authors. 
There was no study specific in targeting a Welsh population, and those 
conducted in England were mostly observational studies without investigating 
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the benefit of attending the VRA service even on a short term. Of the studies in 
the UK, three of which had been published prior to the design and 
commencement of the present study described in the thesis (Crabtree et al. 
2010b; Horgan et al. 2010; Loo et al. 2011). 
Therefore, the current study was designed and undertaken. 
1.3 Study aim and objectives 
Aim: 
The aim of this study was to establish and evaluate a community pharmacy 
based cardiovascular risk assessment service. 
Objectives: 
1. Examine the feasibility of establishing a VRA service in Welsh 
community pharmacies similar to that available in England, that is free 
of charge. 
2. Determine how different people, including those who may be “hard-to-
engage”, respond to the service.  
3. Examine patients’ acceptance of the community pharmacy based VRA 
service. 
4. Examine the short-term outcomes of those who accessed the VRA 
service. 
5. Examine the longer term outcomes of those who accessed the VRA 
service. 
6. To examine the differences, and the impact these difference could have 
on the service users, between the common tools available in the UK to 
estimate CVD risk. 
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2.1 Introduction 
This chapter examines the feasibility of establishing a community pharmacy 
based VRA service. It provides the details of the method used in establishing 
the service in two Boots pharmacies in South Wales. Also, the chapter outlines 
the method used in the evaluation of the service.  
The demographic profile of service users have been reported as have the results 
of the tests and measurements at the initial assessment and as a result of a 
twelve-month follow-up assessment are included as have been comparisons of 
the results obtained at the initial and follow-up visits. 
Aim 
To establish and evaluate a community pharmacy based cardiovascular risk 
assessment service for a Welsh population. 
Objectives 
 Examine the feasibility of establishing a community pharmacy based 
cardiovascular risk assessment service. 
 Identify the demographic profile of service users. 
 Determine how different people, including those from the most 
deprived communities, respond to the service.  
 Examine at 12 months the outcome of those who accessed the 
community pharmacy based cardiovascular risk assessment service. 
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2.2 Method 
2.2.1 Brief outline 
The cardiovascular risk assessment (VRA) service was provided free of charge 
at two Boots pharmacies in south Wales; Porthcawl from 4
th
 November 2009 
until 4
th
 August 2010, and New Market Walk, Merthyr Tydfil from 29
th
 June 
2010 until 5
th
 August 2010. The elements of the service are outlined in 
Appendix 1 (Participant Journey). The VRA service comprised either a Brief 
Health Check or a VRA depending on inclusion and exclusion criteria. 
Individuals were invited to participate in the study for approximately 12 
months (Figure 2-1) and were provided with participant information sheet 
(Appendix 2a) and consent form (Appendix 2b) in addition to the standard 
Boots service questionnaire and consent form (Appendix 3a).  
 
 
 
 
 
 
Figure 2 - 1 A brief outline of the main stages of the study.  
BHC = Brief Health Check. VRA = cardiovascular risk assessment 
 
Recruitment 
BHC VRA 
Two-week follow-up 
telephone interview 
Twelve-month follow-up 
assessment 
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Those who did not consent to participate in the research study but wanted an 
assessment without follow-up were required to complete and sign the standard 
Boots VRA service questionnaire and consent form before the research 
pharmacist performed the tests and measurements required. Their risk of CVD 
was calculated and appropriate lifestyle advice was provided. Those identified 
at high risk (Section 2.2.1.15) were advised to see their GP, and those who 
might benefit from other services, such as a smoking cessation clinic or weight 
management clinic, were signposted accordingly. Those individuals identified 
with pre-existing CVD were advised to see their GP. User satisfaction was 
assessed by a questionnaire given to all service users (Section 2.2.1.17). 
Those who showed an interest in participating in the research study were asked 
to read the patient information sheet (Appendix 2a) and sign, if they wished to 
participate, the study consent form (Appendix 2b). They received the same 
service as other service users, but were invited to have a follow-up interview at 
two weeks (Section 2.2.2.3) and a follow-up consultation 12 months after the 
VRA service (Section 2.2.2.4). 
2.2.1.1 Preparation 
Although the VRA service was previously established at another Boots 
pharmacy, located in Queen Street, Cardiff, it was recognised that 
implementing it in another venue for research purposes would need different 
and careful steps. Initially, stakeholders for this project were identified and 
they were as follows; patients, general practitioners, local surgeries, local 
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health board, pharmacy staff, pharmacy management, Cardiff University and 
ethics committees. 
After receiving full support from Boots at a higher level for this project, visits 
to the selected Boots stores were made by the research pharmacist to meet with 
the store managers to confirm their agreement to accommodate the study.  
Issues discussed include cost of equipment, time for providing the service, 
recruitment of participants and helping in appointment booking. Consideration 
was given to reduce interference with normal pharmacy activities. 
Bridgend Local Health Board (LHB) was responsible for NHS services in the 
Porthcawl area. The LHB and two local GP surgeries were approached by the 
research pharmacist and by the academic supervisors. A summary of the 
protocol was sent to them and an opportunity was given to answer any 
questions they might have regarding the research. The research pharmacist 
queried whether the local GPs were happy with Boots referral criteria or 
whether they wanted to change it to suit local policies. 
Indemnity issues were clarified with Cardiff University and with Boots. 
Professional indemnity was part of Boots contract, and research activities were 
covered by the university. 
2.2.1.2 Ethics committee approval 
In order to obtain research ethics committee (REC) approval the research 
application form was completed using the Integrated Research Application 
System. The South West Wales REC was then contacted, as the appropriate 
NHS REC for Porthcawl, on the 3rd August 2009 to obtain an REC reference 
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number that was required in order to submit the form online. A summary of not 
more than two A4 pages was requested to be provided to the committee before 
submitting the full protocol. In response to this summary information the 
following reply from the South West Wales REC was received by email: 
“the chairman has considered the information provided as is of the opinion 
that as this is a service already offered by retail pharmacies in England, it does 
not need review by a REC and should therefore be viewed as a Service 
Evaluation.  However, as patients are involved, the chairman suggests you 
email your proposal to the National Research Ethics Service (NRES) to also 
obtain their opinion.  You can email your proposal to 
Queries@nationalres.org.uk.” 
A query was sent to NRES Queries Line to check whether the project needed a 
full REC scrutiny or not. Then they responded with the following: 
“Based on the information you provided, our advice is that the project is not 
considered to be research according to this guidance. Therefore it does not 
require ethical review by a NHS Research Ethics Committee.” 
After it was confirmed that the NHS REC would not review this application 
because they considered it as a service evaluation, the application was 
submitted to the Welsh School of Pharmacy REC (Appendix 4). The WSP 
REC approval was received on 23
rd
 September 2009. 
2.2.1.3 The service 
Brief Health Check 
Inclusion criteria: 
 Over 18 years old. 
 Communicate in English. 
 Able to give informed consent to participate. 
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Exclusion criteria: 
 Under 18 years of age. 
 Pregnant. 
 Suffer from polycythaemia or haemophilia. 
 Taking any of the following drugs: dopamine, methyldopa, warfarin (or 
other anticoagulant.) 
 
Those who had blood disorders or who were on certain medication (Section 
3.3.1.2) which made them unsuitable for taking a blood sample in community 
pharmacy were offered: 
 blood pressure (systolic and diastolic)  
 waist circumference  
 BMI 
Those who were suitable for taking a blood sample but unsuitable for 
calculating VRA (Section 2.2.1.4) were offered the measurement of: 
 blood pressure  
 waist circumference  
 BMI 
 HDL and total cholesterol level 
 blood glucose (for those who were at high risk of diabetes, e.g. the 
obese)* 
Although the Brief Health Check did not allow calculation of the CVD risk 
with the accuracy of the VRA, it provided sufficient information for the 
individual to help the individual to manage a number of CVD risk factors.  
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Participants were offered with healthy lifestyle advice and signposted to other 
services as appropriate (Appendix 5 for Porthcawl). 
2.2.1.4 VRA 
Inclusion criteria: 
  At the age of 40 to 74 years. 
 Communicate in English. 
 Able to give informed consent to participate. 
Exclusion criteria: 
 Under 18 years of age for the Brief Health Check or under 40 or over 
74 years of age for the VRA. 
 Pregnant. 
 Suffer from polycythaemia or haemophilia. 
 Taking any of the following drugs: dopamine, methyldopa, warfarin (or 
other anticoagulant.) 
 Diagnosed with diabetes. 
 Diagnosed with hypertension. 
 History of CVD. 
 
The company’s standard operating procedures for the service have been 
provided as Appendix 6.  
The VRA comprised measurement of:  
 blood pressure  
 waist circumference  
 BMI 
 HDL and total cholesterol level 
 blood glucose (for those who were at high risk of diabetes, e.g. the 
obese)* 
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Participants were provided with healthy lifestyle advice (Appendix 6b) 
and signposted to other services as appropriate (Appendix 5).  
*Participants were asked to attend another appointment to have a fasting 
glucose test measurement if their initial measured glucose level was between 
5.6 and 11 mmol/L (Appendix 6j). Fasting was defined as no caloric intake for 
at least 8 hours (JBS2 2005). Patients were provided with lifestyle advice and 
the necessary recommendations after the fasting glucose test.  
Based on the results of this check, the risk of developing CVD in the following 
10 years was calculated (Section 2.2.1.15) using the modified Framingham risk 
score system (Cooper et al. 2008). Participants received information and advice 
tailored to their needs, or were referred to their GP or other healthcare service 
provider as appropriate (Section 2.2.1.16 and Appendix 5). 
2.2.1.5 Patient Recruitment  
An advert was designed (Appendix 7a) to inform people about the availability 
of a VRA service. The flyer was placed in the pharmacy, in two local GP 
surgeries and a local caravan site. The advert was subsequently altered to 
specify the age groups to attract those who are eligible for the VRA (Appendix 
7b).  
It was distributed as a mail drop to a small number of houses in different streets 
in Porthcawl. To raise awareness of the service an advertisement was placed in 
local newspapers, The GEM on 13
th
 May 2010 (Appendix 7c) and Merthyr 
Tydfil Express (Appendix 7d) on 15
th
 July 2010. 
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A poster with a similar design to the advert was placed in the pharmacy 
window and on a board next to the dispensary where patients handed in and 
collected their prescriptions. 
The research pharmacist checked the eligibility of those who requested an 
assessment when arranging for the appointments and also, for confirmation, 
just before conducting the tests.  
2.2.1.6 Venue 
The VRA service took place in a private consultation room at: 
 Boots, John St, Porthcawl. 
 Boots, New Market Walk, Merthyr Tydfil. 
2.2.1.7 Times 
In Porthcawl, the service was provided on Wednesdays from 10am till 4pm. In 
Merthyr Tydfil, the service was provided on Tuesdays and Thursdays from 
10am till 4pm. 
Participants were required to make an appointment by telephone, or by visiting 
the pharmacy. Walk in appointments were also available at times when there 
were gaps between appointments. 
2.2.1.8 Duration of consultation 
The time allocated for the tests and the consultation was 30 minutes (Thornley 
et al. 2009a). For each participant the time taken was recorded for subsequent 
analysis (Appendix 3b). 
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2.2.1.9 Staff 
The research pharmacist, who was contracted with Boots and covered by 
indemnity, was responsible for service provision and operation. 
Responsibilities included: 
 Ensuring all members of staff involved in the service, e.g. recruiting 
patients, understood the various standard operating procedures 
(Appendix 6a-j) and followed all instructions. 
 Obtaining written consent for the Brief Health Check or the VRA from 
service users (Appendix 3a). 
 Helping (interested) service users to complete the Boots service 
questionnaire (Appendix 3a) (Section 2.2.1.11). 
 Measuring body weight and height to calculate BMI (Appendix 6d). 
 Measuring waist circumference (Appendix 6e). 
 Measuring blood pressure (Appendix 6f). 
 Taking blood samples (Appendix 6c) to use in the validated equipment 
to determine HDL levels, total cholesterol, and glucose levels. 
 Calculating cardiovascular risk using the modified Framingham score 
(Cooper et al. 2008) and discussing the result with service users. 
 Providing counselling and written information (Appendix 5) tailored to 
the needs of the service user. 
 Ensuring accurate documentation, recording of results and maintenance 
of confidentiality (Appendix 6b). 
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There are four measurements normally taken by a healthcare assistant where 
the service is established by Boots; body mass index (obtained from measuring 
height and weight), total cholesterol and HDL, blood pressure, and waist 
circumference. However, in this study only the research pharmacist was 
obtaining all the measurements as no one else had the training to do so as this 
study was based in pharmacies other than those selected by the head office to 
provide the service. 
2.2.1.10 Blood Pressure measurement  
Blood pressure was taken after sitting in the pharmacy and after completing the 
necessary forms in the consultation room. Therefore, a total time of sitting of at 
least 10 minutes was allowed before measuring blood pressure. Service users 
were asked to sit in a relaxed position with their arm resting on the table. 
Service users were asked to leave both feet on the floor as crossing legs can 
raise the blood pressure. 
Blood pressure in both arms was measured and the higher reading was 
recorded. If there was a difference of more than 10 mmHg in either systolic or 
diastolic blood pressure between the two arms the sitting position of the 
concerned service user was checked. Usually it was resolved by correcting the 
position. If the difference between the right and the left arms was not resolved 
by correcting the sitting position the service user was referred to the GP as per 
standard operating procedure as this could be a sign of peripheral vascular 
disease. 
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If the measurement was just over 140 mmHg, that is, up to 149 mmHg and the 
service user had a caffeinated drink within the last hour or was feeling 
uncomfortable, a repeat of the blood pressure measurement in the pharmacy 
within a week was offered. If the service user accepted to have the repeat then 
the second measurement was recorded. If the service user refused to come back 
for a second measurement of BP then he/she was advised to repeat the check at 
GP surgery.  
2.2.1.11 The service questionnaire 
All service users were asked to complete the Boots service questionnaire 
(Appendix 3a) to elicit the following information required for checking 
inclusion and exclusion criteria and also necessary to identify risk factors: 
 Age 
 Gender 
 Smoking status 
 Demographic characteristics to include:  
o Ethnicity (Appendix 3b) based on the ethnic classification 
scheme which included the 16+1 ethnic categories as in 2001 
census for England and Wales. The use of this scheme was 
necessary (Hippisley-Cox et al. 2007) to calculate CVD risk 
using QRISK2 (Chapter 7). 
o alcohol intake  
o smoking status  
o postcode  
 Family history of CVD.  
 Drug history. 
 Medical history of CVD. 
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2.2.1.12 Cost 
This was a service that was free to users. 
2.2.1.13 Equipment 
Equipment was provided and maintained by Boots. Training was provided for 
the research pharmacist to ensure correct use and this included: taking blood 
samples, measuring blood pressure, validation and maintenance of the 
equipment and operation of the quality control process. 
 BMI machine (Appendix 6d): weight and height measured using Davi 
& Cia Scale. BMI was calculated automatically by the machine. 
 Blood Pressure: the validated Omron M7 upper arm BP Monitor 
(Coleman et al. 2008; El Feghali et al. 2007) was used. The blood 
pressure monitor was replaced 12 months after first use as per SOP 
(Appendix 6f) 
 Glucose meter; CardioChek PA was used to determine both lipid profile 
and glucose. The device was calibrated every day (Appendix 6h). 
 Cholesterol meter; CardioChek PA (Panz et al. 2005).  
 A sharps bin and clinical waste bin were used in accordance with the 
SOP (Appendix 6i). 
2.2.1.14 Quality Control 
Internal and external quality control procedures were used for the CardioChek 
PA cholesterol/glucose meter. 
The internal quality control required, as per the Boots SOP, comprised of daily 
check and a monthly quality control. The daily check was performed by using a 
special strip to confirm the sensor functioning well. This was required on every 
day which the service being carried out (Appendix 6h). Also, control solution 
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tests were carried out whenever a new pot of test strips was opened, every 
month or after a failed external quality assessment (EQA). 
An EQA was performed every two months to ensure the device was working to 
the required standard (Appendix 6k). 
The blood pressure monitor was replaced 12 months after first use as per SOP 
(Appendix 6f) 
2.2.1.15 Risk score calculation 
Cardiovascular risk was calculated using the modified Framingham Risk Score 
System (Cooper et al. 2008). The parameters required to calculate 
cardiovascular risk were: 
 Age 
 Gender 
 Ethnicity 
 Family history 
 Smoking status 
 Diabetes status 
 HDL cholesterol 
 Total cholesterol 
 Systolic blood pressure 
After the VRA was determined using the modified Framingham risk score 
system, participants were allocated into one of the three groups; low risk 
(<10% CVD risk in 10 years), moderate risk (10-20% CVD risk in 10 years), 
high risk (>20% CVD risk in 10 years). 
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All tests results were used after the consultation to calculate the CVD risk 
using QRISK2. This was to allow comparison of the Framingham based CVD 
risk assessment with that of QRISK2 (Chapter 7). This was a desk top exercise 
and the results were not communicated to the service user. 
2.2.1.16 Advice and signposting 
All service users received a copy of the assessment results form (Appendix 8) 
which stated the results of the assessment. Those identified at low risk were 
offered lifestyle advice. Individuals at moderate risk with a risk factor that 
could be modified, e.g. smokers, were offered specific advice on how to reduce 
risk and/or signposted (Appendix 5) to other services. Individuals at high risk 
were advised to visit their GP for further investigation (Appendix 9). Service 
users were also referred if their glucose level was more than 11 mmol (or if 
fasting glucose > 5.6 mmol), total cholesterol ≥ 7.5 mmol, systolic blood 
pressure ≥ 140, diastolic blood pressure ≥ 120 or a low glucose level ≤ 2.5 
mmol. In addition, those who had risk factors and might benefit from other 
local services, such as smoking cessation and weight management, were 
signposted and encouraged to attend these services regardless of their 
Framingham score. Participants received the standard Boots literature titled 
‘Looking after your heart’. The pharmacist documented the advice given to the 
service users (Appendix 6b). 
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2.2.1.17 Satisfaction questionnaire 
The level of satisfaction with the service was determined by inviting 
participants to fill in a questionnaire (Appendix 10). Results of the satisfaction 
survey are presented and discussed in Chapter 3.  
2.2.2 Study 
2.2.2.1 Recruitment 
A convenience sample was used (self-selection). Those who showed interest in 
having the VRA (Section 2.2.1.4) were asked to consider participating in the 
study. It was expected that a minimum of four participants would be recruited 
each week and all recruitments would be completed within a six month period. 
2.2.2.2 Participant information sheet and consent form 
When participants attended the pharmacy to make an appointment, they were 
provided with the patient information sheet (Appendix 2a) and consent form 
(Appendix 2b). They were given the opportunity to ask questions about the 
objectives of the study. Participants were asked to fill in the consent form and 
to bring it with them when they were scheduled to have their VRA service.  
Participants making appointments over the telephone were asked to provide a 
postal address or an email address, so the participant information sheet and the 
consent form could be completed prior to their appointment. 
Those who preferred a walk in access to the service or had not completed a 
consent form in advance completed the documentation on the day but prior to 
the assessment. The research pharmacist would check their understanding of 
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the project. Participation in the research study (as distinct to accessing the 
VRA service) started with the first follow-up (an interview with a different 
researcher who did not provide the VRA service), that is, approximately two 
weeks after the service. This meant that even if participants signed the consent 
form they had enough time to change their mind if they wanted to withdraw 
from the study before being contacted for the two week follow-up. By 
participating in the service but not consenting to be part of the research study, 
subjects consented to their anonymised data being used for research purposes 
(Appendix 3a). 
2.2.2.3 Two-week follow-up telephone interview 
The first follow-up (Appendix 11a) was an interview and this was designed to 
take place approximately two weeks after undertaking the VRA. The aim of 
this follow-up interview was to examine participants’ perceptions, commitment 
to the advice given by the research pharmacist and any benefit from the VRA 
service. A researcher (not the research pharmacist) who did not provide the 
VRA service contacted the participants to conduct a semi-structured interview 
over the telephone. The results of this follow-up are presented and discussed in 
Chapter 4.   
2.2.2.4 Twelve month follow-up assessment 
The reminder letter (Appendix 12a) was sent to each participant eleven to 
thirteen months after the initial tests. The aim of the reminder letter was to 
inform participants that the research pharmacist will contact them over the 
telephone to arrange an appointment.  
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A form (Appendix 12b) was also enclosed with the reminder letter for those 
who might prefer not to be contacted again, together with a free-post envelope. 
When completing the form, participants could either indicate if they wanted to 
withdraw from the study or they wanted to contact the research team rather 
than being contacted. If they were content to be telephoned by the researcher 
then they were advised that they did not need to do anything. 
It was made clear that those who chose to withdraw from the study did not 
have to give any reason, but if they wished to share reasons for withdrawal, 
they were given the opportunity to do so. Some indicated on the form that they 
did not want the researcher to contact them but they would prefer to make the 
contact themselves. These records would stay ‘pending’ until the end of the 
study, and if they did not contact the research team by the end of the study they 
would be considered as withdrawn from the study. That is, as requested no 
further attempts were made to contact individuals. 
After about 10 days from sending the reminder letter, the research pharmacist 
contacted by telephone those who did not send back the form assuming they 
were happy to be contacted. A diary with a flexible timing was kept to make 
sure the appointments offered were as convenient as possible to participants.  
Several attempts were made to contact each participant, if there was no answer 
or if there was another reason, such as the telephone number provided by the 
individual was unavailable another letter was sent offering a range of dates and 
times. It was the individual’s decision whether or not to attend at the pharmacy 
as the study neared completion. 
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A Boots colleague volunteered to contact some of the participants when it was 
believed that a local accent may be helpful, for example, when a participant 
seemed to find the foreign accent unclear over the telephone. The dates of the 
telephone calls and the follow-up assessments were recorded. 
All follow-up assessments took place in the same Boots pharmacy where the 
initial assessments occurred.  
During each follow-up appointment, participants were given a form (Appendix 
13) to complete. This form consisted of a question to check whether or not they 
had a similar check between the initial tests and the follow-up, and questions 
about lifestyle. In addition, exactly the same questions they were asked in the 
initial assessment on the Boots service questionnaire (Appendix 3a) were asked 
again. Also, questions were asked to recall any changes to lifestyle. 
Participants were also asked if there were any changes in their medical 
conditions since they had the initial assessments and whether or not they had 
started any new medications. This was to identify whether or not they met the 
necessary inclusion criteria and that they were not tested if any exclusion 
criteria for the service applied. 
The tests undertaken at the initial VRA were repeated and the results relayed to 
the participants during the consultation. Advice was provided and when 
necessary referral to the GP was made. 
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2.2.3 Data analysis 
The socio-economic status was determined by allocating participants’ 
postcodes to a deprivation level. The two deprivation indices used in this thesis 
are the Welsh Index of Multiple Deprivation (WIMD) (WAG 2008) and the 
Townsend Deprivation Index (TDI) (CDU 2010). TDI was also used in the 
analysis to overcome some of the disadvantages associated with WIMD. Panel 
2-1 shows the difference between the two indices. 
Panel 2 - 1 The differences between WIMD and TDI 
WIMD: 
Areas are divided into 5 ranks as the following: 
 Rank 1 (First 10% of areas, i.e. the most deprived areas) 
 Rank 2 (Next 10%) 
 Rank 3 (Next 10%) 
 Rank 4 (Next 20%) 
 Rank 5 (Next 50%, i.e. the least deprived areas) 
TDI: 
Areas are divided into five equal quintiles with Quintile 1 
consists of the least deprived areas and Quintile 5 consists of the 
most deprived areas. 
PASW Statistics 18 (formerly SPSS) was used for analysing the data. Chi-
square test was used when comparing variables with nominal values, for 
example, gender and smoking status, or ordinal values, e.g. deprivation status. 
Mann-Whitney U test was used when comparing variables (two samples) with 
non-parametric continuous data, for example, age, blood pressure, and 
cholesterol levels. The Kruskal Wallis test was used when comparing three or 
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more groups with ranked data for example, comparing age distribution between 
categories of the number of visits. Paired-samples student t-test was used to 
compare the results of continuous data, for example, blood pressure, HDL, 
total cholesterol at the initial assessment and the twelve-month assessment.  
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2.3 Results 
2.3.1 Overview 
A total of 172 patients (Appendix 14) accessed the VRA service at the two 
Boots pharmacies in south Wales; 133 (77%) patients had their tests at Boots, 
Porthcawl between 4
th
 November 2009 and 4
th
 August 2010 and 39 (23%) 
patients had their tests at Boots, New Market Walk, Merthyr Tydfil in the 
period 29
th
 June 2010 to 5
th
 August 2010. Figure 2-2 shows the numbers of 
patients who accessed the VRA service, those who had the two-week follow-up 
and those who had the twelve-month follow-up. 
 
 
 
 
 
 
 
Figure 2 - 2 Number of patients at each phase of the study 
VRA¥ = number of subjects who had a full VRA including the calculation of CVD risk 
 
Initial assessment:                   
172 patients (VRA¥ = 146) 
9 did not consent, 4 could 
not be contacted. 
  Two week follow up 
interview:   159 patients 
(VRA¥ = 136) (Chapter 4) 
Twelve month follow up:     
105 patients (VRA¥ = 90) 
 
23 declined, 14 were 
unable to come during the 
planned period, 17 lost to 
follow-up. 
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2.3.2 Results of initial assessments 
The proportion of females was higher (59%) than males. Almost all 
participants (99%) were white. Demographics are shown in Table 2-1. 
Table 2 - 1 Demographics of all service users in both pharmacies, Porthcawl (n = 133) and 
Merthyr Tydfil (n = 39) 
Demographics Results 
Age Mean = 60 years  
[range 19 to 87, SD = ±10.3]  
 Number of patients (%) 
Females 101 (59) 
Males 71 (41) 
Family history of CVD 54 (31) 
Ethnicity- White 170 (99) 
Pakistani  1 (0.6) 
Indian 1 (0.6) 
Deprivation (missing values = 4)  
1. First 10% (most deprived) 12 (7) 
2. Next 10% 13 (8) 
3. Next 10% 20 (12) 
4. Next 20% 31 (18) 
5. Last 50% (least deprived) 92 (54) 
 
 
The lifestyle characteristics, that is, smoking status, alcohol consumption and 
the level of physical exercise as provided by self completion of the Boots form 
(Appendix 12), are shown in Table 2-2. 
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Table 2 - 2 Lifestyle characteristics of the service users 
Characteristics  Results (%) 
Current smokers 11 (6) 
Quit smoking within the last 5 years 7 (4) 
Alcohol  
None 31 (18) 
Within the weekly 
recommended level 
126 (73) 
Exceeding the weekly 
recommended level 
15 (9) 
Consumption of alcohol by male 
participants 
Mean = 11 units  
[range 0 to 50, SD = ±11] 
Consumption of alcohol by females 
participants 
Mean = 4.5 units  
[range 0 to 20, SD = ±5] 
Exercise  
None 9 (5) 
Some (1 or 2 days a week) 43 (25) 
Moderate (3 or 4 days a week) 55 (32) 
Regular (at least 5 days a week) 65 (38) 
About three quarters (76%) of service users were overweight or obese (Table 
2-3).  
Table 2 - 3 Mean BMI and numbers of service users in each category as per Boots SOPs 
 Results (%) 
BMI mean = 27.9 kg/m
2
 [range 
18.4 to 48.5, SD = ±4.5]  
Less than 25 42 (24) 
25 to 29.9 81 (47) 
30 to 34.9 38 (22) 
35 or above 11 (6) 
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The waist circumference was within acceptable limits in 29% of the 
participants (Table 2-4). 
Table 2 - 4 Mean of waist circumference of each gender and numbers of service users in 
each category as per Boots SOPs 
Waist circumference Results (%) 
Male mean  100.1 cm [range 78 
to 124, SD = ±9.9] 
Female mean 86.9 cm [range 65 to 
116, SD = ±11.5] 
OK† (acceptable size) 48 (29) 
Increased risk‡ 47 (28) 
High risk$ 73 (43) 
† < 94 cm for men and < 80 cm for women 
‡ 94 - 102 cm for men and 80 - 88 cm for women 
$ ≥ 102 cm for men and ≥ 88 cm for women 
 
Categories of participants’ blood pressure and lipid profiles are presented in 
Table 2-5. 
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Table 2 - 5 Results of systolic and diastolic BP and the lipid profile of the service users 
 Mean Category Number (%) 
Systolic BP 136 mmHg  
(range 82-194, SD ±18.7) 
< 120 mmHg 28 (16) 
< 130 mmHg 45 (26) 
130-139 mmHg 31 (18) 
140-199 mmHg 68 (40) 
Diastolic BP 86 mmHg  
(range 49- 121, SD ±10.6) 
< 80 mmHg 43 (25) 
80-84 mmHg 39 (23) 
85-89 mmHg 30 (17) 
90-109 mmHg 57 (33) 
Total 
Cholesterol 
4.83 mmol/L  
(range 2.75 to 7.28, SD 
±0.9) 
≤ 5 mmol/L 100 (61) 
5.1-7.4 mmol/L 63 (39) 
HDL 
Cholesterol 
1.3 mmol/L  
(range 0.62-2.49, SD  ±0.42) 
Low‡ 62 (39) 
Ok 99 (61) 
TC: HDL 
ratio 
4.1  
(range1.7-7.8,  SD ±1.3) 
> 6   12 (7) 
‡ If HDL level < 1 mmol/L for men and < 1.2 mmol/L for women 
 
The Framingham risk of CVD in the next 10 years was calculated for 146 
service users (Table 2-8). The remaining 26 patients could not have their risk 
calculated for the reasons listed in Table 2-6. 
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Table 2 - 6 Reasons for not calculating the CVD risk. Individuals (n = 26) may have had more 
than one reason for being excluded 
Reason Total 
Age < 35 years 1 
Age > 74 years 4 
Medical history of CVD 11 
On BP treatment 13 
Diabetic 4 
On warfarin (no blood taken) 3 
 
The subject’s last visit to the GP for any reason was recorded and the answers 
varied between as recently as the same morning as having the VRA to 14 years 
ago. 
The duration of the consultation, including the assessments, ranged from 15 to 
50 minutes (mean = 30 minutes, SD = ± 6.6). Consultations with male 
participants (mean = 32 minutes, SD = ±7.5) were longer than female 
participants (mean = 28 minutes, SD = ±5.5) (p = 0.003, Mann-Whitney U 
test). No difference was seen in duration between younger (< 65 year old) and 
older participants (p = 0.132, Mann-Whitney U test).  
Almost three-quarters of the participants (n = 128, 74%) had seen their GP 
during the 12 months prior to accessing the VRA service; 48 (28%) of these 
128 had seen their GP in the month prior to having the assessment. The number 
of visits to the GP during the 12 months prior to accessing the service was as 
follows; 21 participants made one visit to their GP, 61 participants made two to 
three visits, 24 participants made four to five visits, 19 participants made 6 or 
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more visits. There was no significant difference between males and females in 
the number of visits to the GP (p = 0.584, Mann-Whitney U test). Also the 
distribution of age was not significantly different across the categories of the 
number of visits (p = 0.207, Kruskal-Wallis test).  
In line with the Boots SOP, a diabetes test was offered to participants with a 
BMI ≥ 30 kg/m2. However, those who were referred (n = 17) to their GP were 
informed that, for their convenience, they should wait until their GP visit 
otherwise they could result in having a fasting glucose test at the pharmacy and 
also at the GP surgery. Twenty participants were tested for diabetes while 12 
participants stated that they wished to have it at GP surgery. The mean fasting 
glucose (n = 20) was 3.6 mmol/L (range from 2.2 to 4.7 mmol/L, SD = ±0.66). 
According to a tool developed by University of Leicester, University Hospitals 
of Leicester and Diabetes UK (Gray et al. 2010), there were 21 participants 
(12%) at high risk of developing diabetes in the next 10 years (Table 2-7). 
Table 2 - 7 Risk of developing Type 2 diabetes in the next 10 years based on a score 
developed by University of Leicester, University Hospitals of Leicester and Diabetes UK 
(Gray et al. 2010) (Appendix 15) 
 Total (%) 
Low risk (1 in 20) 24 (14) 
Increased risk (1 in 10) 64 (37) 
Moderate risk (1 in 7) 63 (37) 
High risk (1 in 3) 21 (12) 
 
The total number of participants who had their CVD risk estimated was 146 
(Table 2-8).  
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Table 2 - 8 Categories of the 10-year CVD risk estimated using Framingham based BNF 
charts (total number = 146) 
 Total (%) 
Low risk (< 10%) 63 (43) 
Moderate risk (10-20%) 46 (32) 
High risk (> 20%) 37 (25) 
 
Three participants could not be allocated a WIMD rank (Table 2-9). 
 
Table 2 - 9 The number of participants (%) in each deprivation rank and their 10-year CVD 
risk. (Total number = 143) 
  10-year CVD risk 
  <10% 10-20% >20% 
WIMD Rank 1 (most deprived) 5 (8) 4 (9) 3 (8) 
Rank 2 6 (10) 5 (11) 0 
Rank 3 6 (10) 6 (13) 2 (5) 
Rank 4 14 (23) 7 (16) 8 (21) 
Rank 5 (Least deprived) 30 (49) 23 (51) 24 (65) 
 
2.3.2.1 Referral to GP 
The total number of participants who were referred to their GP was 57 (33%) 
(Tables 2-10 and 2-11). About half of male participants (n = 37) were referred 
compared to only 20% of females (n = 20) (p < 0.001, Chi-square test). The 
mean age of those who were referred was 63 years (SD = ± 7.6) compared to 
59 years (SD = ± 11.1) for those were not referred (p = 0.01, Mann-Whitney U 
test). However, there was no significant difference among those who were 
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referred or not referred from areas with different levels of deprivation (p > 
0.05, Chi-Squared test). 
Table 2 - 10 Reasons for referral to GP as per Boots SOPs. Some participants were referred 
because of more than one referral criterion 
Reason Total 
High risk of CVD 33 
Systolic BP of ≥ 140 mmHg 44 
Diastolic BP of ≥ 120 mmHg 1 
BP of < 90/60 and patient feels unwell 1 
Total Cholesterol of ≥ 7.5 mmol/L 0 
Glucose level of > 11 mmol/L 0 
Fasting glucose level of > 5.6 mmol/L 0 
Glucose level of < 2.5 mmol/L 1 
 
Table 2 - 11 Referral as per JBS2 recommendations. Some participants were referred 
because of more than one referral criterion 
Reason Total 
Total cholesterol HDL of ≥ 6 mmol/L 8 
Diastolic BP of ≥ 100 mmHg 11 
 
2.3.3 Results of the twelve month follow-up 
This follow-up was planned to occur approximately 12 months after having the 
initial VRA. However, some issues with the external quality control of the 
equipment delayed recruitment for some participants for up to three months. 
The mean duration between the initial assessment and the twelve-month 
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follow-up was 391 days (12.8 months) [range 343 days to 525 days, SD = 
34.9]. 
The total number of participants who had the 12-month follow-up assessment, 
that is, who completed the study, was 105 (61%) (Table 2-12).  
Table 2 - 12 Twelve-month follow-up recruitment 
 Number (%) 
Subjects who had the 12-month follow-up 105 (61) 
Subjects who withdrew from the study 23 (13) 
Subjects said they would contact Boots for an appointment but 
they did not do so by the end of the study. 
14 (8) 
Subjects who could not be contacted 21 (12) 
Subjects who did not consent to have the 12-month follow-up 9 (5) 
Twenty-three participants declined the invitation to have the follow-up. Six of 
them voluntarily provided their reasons for the withdrawal (Table 2-13). They 
were not asked to provide any further explanation. 
Table 2 - 13 Reasons given by participants for withdrawal from the study. 
1. A participant had just moved from England before the initial 
assessment and he believed this study more for the Welsh 
population. 
2. Not feeling well 
3. Panicked last year, was told high BP but GP said it was normal 
(see comment made by Subject 2 in the two-week follow-up, 
Section 4.3.9) 
4. Going on holiday 
5. Taken to the hospital due to illness 
6. Having a kidney infection 
 
Chapter 2: A longitudinal study of a community pharmacy based VRA service 
97 
 
The demographics of those who completed the study were not statistically 
different to those who undertook the initial VRA as shown in Table 2-14.  
Table 2 - 14 Main characteristics at initial assessment and at twelve month follow-up. 
Characteristics  Initial assessment 12 month follow 
up 
p value 
Age Mean = 60 years  
[range 19 to 87, SD = 
±10.3]  
Mean = 61 years  
[range 39 to 88, SD = 
±9.7] 
0.409† 
 Number of patients (%)  
Females 101 (59) 57 (54) 0.275‡ 
Males 71 (41) 48 (46)  
Family history of 
CVD 
54 (31) 33 (31) 0.549‡ 
Medical history of 
CVD 
11 (6) 9 (9) 0.326‡ 
Current smokers 11 (6) 2 (2) 0.073‡ 
Ethnicity- White 170 (99) 103 (98) 0.882‡ 
Pakistani  1 (0.6) 1 (1)  
Indian 1 (0.6) 1 (1)  
Deprivation  (missing values = 4) (missing values = 3) 0.893‡ 
1- First 10%  
(most deprived) 
12 (7) 7 (7)  
2- Next 10% 13 (8) 8 (8)  
3- Next 10% 20 (12) 9 (9)  
4- Next 20% 31 (18) 23 (22)  
5- Last 50%  
(least deprived) 
92 (54) 55 (52)  
† Mann Whitney U test. ‡ Chi-squared test 
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2.3.3.1 Outcome of GP referral (if) made at the initial 
assessment  
Most of participants (n = 35, 61%) who were referred to their GP stated, either 
during the two-week follow-up or the twelve-month follow-up, that they made 
a visit as advised by the pharmacist. Only two participants indicated that they 
had not seen the GP by the end of the study. It was stressed to them during the 
12-month follow-up that they did need to see their GP to discuss ways to 
manage risk factors and to reduce the CVD risk. Eight participants said during 
the two-week follow up they booked or would book an appointment with their 
GP. However, these eight did not attend the twelve-month follow-up to 
confirm whether or not they actually went and discussed their results with their 
GP or any other healthcare professional (Figure 2-3).  
Five participants (four female and one male) who were not referred by the 
pharmacist said they had seen their GP as a result of accessing the VRA 
service. 
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Figure 2 - 3 By the end of the study a total of 35 participants reported that they made a visit 
to their GP after a referral 
 
Four subjects who did not have either of the follow-ups all of whom were male 
and at high risk of CVD, were provided with a referral letter for their GP from 
the pharmacist. Therefore, it could not be determined whether or not they went 
to see their GP. 
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Different participants responded differently to the advice given by the 
pharmacist. Beliefs could have played a role in shaping participants’ responses. 
An example of participants’ beliefs as an obstacle to compliance with referral 
is mentioned in Panel 2-2.   
Panel 2 - 2 Example of patients’ beliefs as an obstacle to compliance 
Case 1 
A 71 year old woman (Subject 109) had a systolic blood pressure reading of 
194 mmHg in the pharmacy (this was the maximum SBP in the study cohort). 
This person stated that she usually had a blood pressure of not more than 
130/80 at home. Although she was advised strongly to see her GP within 2 
weeks, when she was asked whether or not she talked to her GP a month later 
she stated she had not. She did not attend the 12 month follow up and so it was 
not possible to determine the outcome. 
 
Pharmacological intervention is one of the important methods to manage CVD 
risk recommended in the national guidelines (NICE 2008c). Of the 35 
participants who made a visit to the GP only five participants reported a 
pharmacological intervention (Table 2-16 and Panel 2-3). A further participant, 
who was not referred by the pharmacist, stated that she discussed statin 
treatment with her GP. Although she was identified at low risk at the pharmacy 
with all acceptable parameters she stated that she had all the tests repeated 
again at the GP surgery. One doctor suggested that she should start a statin 
because the total cholesterol was 6 mmol/L but another doctor said that there 
was no need because her total cholesterol: HDL ratio was 3.5. This suggests 
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that the focus by at least some GPs is still on the total cholesterol rather than 
the total cholesterol: HDL ratio.   
Table 2 - 15 Pharmacological changes initiated by GP as reported by participants after being 
referred 
Participant Outcome Reason for referral by 
pharmacist 
Subject 17 BP treatment (not stated) BP (See Panel 2 - 3) 
Subject 116 On felodipine 2.5mg Systolic BP 
Subject 131 On statin CVD risk and Systolic BP 
Subject 172 On statin and ramipril CVD risk and Systolic BP 
Subject 95 Orlistat to help in weight loss 
programme  with gym referral  
Low glucose 
 
Panel 2 - 3 A pharmacological intervention was reported during the two week follow up but 
then it was stopped 
Case 2 
A 50 year old male (Subject 17) was referred to GP because of a blood 
pressure measurement of 170/100 mmHg. He went to see the GP who 
prescribed BP treatment as he confirmed it during the two-week follow-up. 
However, he went back to the GP as he was reluctant to take the treatment. 
Consequently, he was provided with a monitor to check BP over a period of 14 
days. The BP was normal after he became accustomed to the measuring. The 
GP suggested it could be white coat syndrome. BP was measured during the 12 
month follow up and it was 139/87 mmHg. 
 
A further participant was on CVD management medication at the twelve-
month follow-up. However, this was not because of the referral but because of 
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having suffered from a myocardial infarction and this was the only known 
CVD event to occur between the initial assessment and the twelve-month 
follow-up (Panel 2-4). 
Panel 2 - 4 A CVD event was reported at the end of the study 
Case 3 
A 65 year old Caucasian male (Subject 47) from Merthyr Tydfil, had quit 
smoking more than five years ago, drank alcohol in moderation (on average 
two units of alcohol every week), had regular exercise, not on any medications 
and with a family history of CVD. He came to the pharmacy to have a VRA in 
August 2010 and his test results were as follows: BMI 25.6 kg/m
2
, waist 92 
cm, BP 128/71 mmHg, total cholesterol 3.08 mmol/L, 0.71 mmol/L, total 
cholesterol to HDL ratio 4.3 and he was identified at high risk of CVD. 
Consequently he was referred to his GP. 
In the two week follow-up he confirmed to the interviewer that he had seen the 
GP the day after the consultation and had all the tests repeated. It was not clear 
what options were discussed with the GP to reduce his risk but he said he had 
started Omega 3 fish oil supplements. 
At the twelve-month follow-up, July 2011, he reported that in April 2011 he 
had a myocardial infarction and he had undergone  bypass surgery. Then he 
was prescribed atorvastatin 40mg tablets OD, bisoprolol 2.5mg tablets OD, 
ramipril 2.5mg capsules OD, aspirin 75mg tablets OD and clopidogrel 75mg 
tablets OD. 
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2.3.3.2 Changes to lifestyle 
Participants were asked to self-complete a questionnaire (Appendix 13) how 
they perceived their diet and other lifestyle factors had changed since the initial 
assessment.  
Reponses to the changes in lifestyle questionnaire are provided in Tables 2-16 
and 2-17. The most common answer was “no change” for the all risk factors. 
Forty-four percent of participants self-reported they improved their diet by 
increasing fruit and vegetable intake, 39% by increasing oily fish in diet, 
approximately one third by reducing salt intake (39%), red meat (37%) and 
dairy products (33%). Ten participants (10%) admitted that their diet had 
worsened in at least one food type. With regard to other lifestyle factors, 38% 
said they had done more exercise than before and 30% had decreased their 
alcohol consumption. Also, there were two participants who reported 
successfully having stopped smoking.   
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Table 2 - 16 Self-reported overall changes in diet between having the initial assessment and the 12 month follow-up 
 Much 
increased 
Increased No change Decreased Much 
decreased 
Unsure Not 
applicable 
Red meat 0 2 60 29 10 1 3 
Dairy products 
1 2 66 30 5 1 0 
Oily fish 6 35 58 2 2 0 2 
Salt 0 1 54 28 16 4 2 
Fruits and vegetables 
14 32 56 1 2 0 0 
 
Table 2 - 17 Self-reported  overall changes in lifestyle factors namely exercise, smoking and alcohol intake, between having the initial assessment and 
the 12 month follow-up 
 Started Increased No change Decreased Stopped Unsure Not 
applicable 
Exercise 2 38 54 9 0 1 1 
Smoking 0 0 2 1 2 0 100 
Alcohol 0 3 54 31 1 2 14 
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However, there were some inconsistencies seen in some participants’ answers 
to the some questions. Four participants claimed they had decreased their 
alcohol consumption but their number of units per week they said they 
consumed had increased when compared with the amount they provided at the 
initial assessment. Also, two people claimed that there was no change in their 
alcohol intake but at the initial assessment they exceeded the recommended 
weekly level where at the twelve-month follow-up the units they said they 
consumed were within the recommended weekly level (from 28 to 12 
units/week and from 25 to 8 units/week). Tables 2-18, 2-19 and 2-20 
summarise self-reported alcohol intake, exercise level and fruit and vegetable 
consumption, respectively.  
Table 2 - 18 Weekly alcohol consumption at initial assessment and at follow-up as reported 
by participants 
  follow up 
  None OK* Exceeding+ 
Initial 
assessment 
None 14 3↑ 0 
OK* 5↓ 73 1↑ 
Exceeding+  0 4↓ 5 
At follow-up ↓ a total of 9 reported less alcohol consumption 
and ↑ a total of 4 reported more alcohol consumption. 
*Not more than 14 units per week for women and 21 units for men 
where + exceeding this weekly level. 
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Table 2 - 19 Exercise levels at initial assessment and at twelve month follow-up as 
reported by participants. Categories as per Boots SOPs 
  follow-up 
  None Some Moderate Regular 
Initial 
assessment 
None 2 1↑ 0 2↑ 
Some 2↓ 11 8↑ 5↑ 
Moderate 0 2↓ 19 8↑ 
Regular 0 5↓ 11↓ 29 
At follow-up ↓ a total of 20 reported less physical exercise  
and ↑ a total of 24 reported more physical exercise 
 
Table 2 - 20 Fruit and vegetable intake at initial assessment and at twelve month follow-up 
Have fruits and 
vegetables every day?* 
follow-up  
No Yes  
Initial 
assessment 
No 10 9  
Yes 7 79  
* The number of portions was not recorded at the initial assessment 
2.3.3.3 Results of tests and measurements 
Participants’ BMIs were categorised into one of four groups (Maguire and 
Haslam 2009). Table 2-21 shows that 13 participants managed to reduce their 
BMI to a lower category, opposed to only two who increased from the < 25 
kg/m
2
 category to the 25-29.9 kg/m
2
 category. 
The mean BMI decreased from 27.5 kg/m
2 
at the initial assessments to 27.0 
kg/m
2 
by the end of the study. Although this was a small change, it was a 
statistically significant (-0.45 kg/m
2
, 95% CI -0.736 to -0.155) (Figure 2-4).  
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Figure 2 - 4 the mean of BMI at initial assessment and twelve month follow-up 
 
Table 2 - 21 The number of participants who at 12 month follow-up changed, or otherwise, 
the category of BMI. Categories as per Boots SOPs 
  Follow-up 
  < 25 
kg/m
2
 
25-29.9 
kg/m
2
 
30-34.9 
kg/m
2
 
≥ 35 
kg/m
2 
Initial 
assessment 
<25 kg/m
2
 24 2↑ 0 0 
25-29.9 kg/m
2
 5↓ 48 0 0 
30-34.9 kg/m
2
 0 7↓ 15 0 
≥ 35 kg/m2 0 1↓ 0 3 
At follow-up ↓ a total of 13 their BMI decreased to a lower category 
and ↑ two increased to a higher category 
 
Figure 2-5 shows a small change, non-statistically significant, in mean waist 
circumference; - 1.1 cm (95% CI -2.3 to 0.1). Table 2-22 shows the numbers of 
participants who reduced or increased their waist circumference to another 
level of risk, as categorised in Boots SOP (Appendix 6e). 
Initial tests: 27.5 
Kg/m
2
 (SD ±3.69) 
Initial tests: 27.0 
Kg/m
2
 (SD ±3.72) 
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Figure 2 - 5 the mean waist circumference at initial assessment and twelve-month follow-up 
 
Table 2 - 22  The number of participants who at 12 month follow-up changed, or otherwise, 
the level of risk determined by the waist circumference. Categories as per Boots SOPs 
  Follow-up 
  OK† Increased 
risk‡ 
High 
risk$ 
Initial 
assessment 
OK† 24 5↑ 0 
Increased risk‡ 1↓ 14 7↑ 
High risk$ 1↓ 14↓ 33 
At follow-up ↓ a total of 16 their circumference decreased to another 
category and ↑ a total of 12 increased 
† < 94 cm for men and < 80 cm for women 
‡ 94 - 102 cm for men and 80 - 88 cm for women 
$ ≥ 102 cm for men and ≥ 88 cm for women 
 
The difference in the mean systolic blood pressure at initial assessment and at 
the twelve month follow-up was statistically significant. There was a reduction 
of 8.5 mmHg (95% CI -11.0 to -5.9). This was similar for the difference in the 
mean diastolic blood pressure; -7.7 mmHg (95% CI -10.4 to -5.0) (Figures 2-6 
and 2-7).  
Initial tests: 93.0 
cm (SD ±11.9) 
Initial tests: 91.9 
cm (SD ±12.4) 
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Figure 2 - 6 the mean systolic blood pressure at initial assessment and at the twelve-month 
follow-up 
About half of the subjects (n = 51) improved their systolic blood pressure 
(Table 2-23), and 57% improved their diastolic blood pressure (Table 2-24) at 
the twelve-month follow-up. 
Table 2 - 23 The numbers of participants at each category of systolic blood pressure 
(mmHg). Categories as per JBS2 (JBS2 2005) 
  Follow-up 
  <120 120 -129 130-139 140-199 
Initial 
assessment 
<120 13 4↑ 0 0 
120-129 21↓ 6 1↑ 1↑ 
130-139 4↓ 8↓ 5 2↑ 
140-199 4↓ 4↓ 10↓ 22 
At follow-up ↓ a total of 51 their systolic BP decreased to another category 
and ↑ a total of 8 increased 
 
Initial tests: 136 
mmHg (SD ±18.3) 
Follow up: 127 
mmHg (SD ±17.9) 
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Figure 2 - 7 the mean diastolic blood pressure at initial assessment and at the twelve-month 
follow-up 
 
Table 2 - 24 The number of participants at each category of diastolic blood pressure 
(mmHg). Categories as per JBS2 (JBS2 2005) 
  Follow-up  
  <80 80-84 85–89 90-109 ≥110 
Initial 
assessment 
<80 20 2↑ 2↑ 1↑ 0 
80-84 16↓ 2 2↑ 0 0 
85–89 10↓ 6↓ 4 1↑ 0 
90-
109 
11↓ 7↓ 9↓ 11 0 
≥110 0 0 0 1↓ 0 
At follow-up ↓ a total of 60 their diastolic BP decreased to another category 
and ↑ a total of 8 increased 
The mean total cholesterol level increased slightly by 0.06 mmol/L (95% CI -
0.11 to 0.23) (Figure 2-8). This increase was not statistically significant. Also 
the mean total cholesterol: HDL ratio did not change significantly; -0.15 (95% 
Initial tests: 87 
mmHg (SD ±10.1) 
Follow-up: 80 
mmHg (SD ±9.3) 
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CI -0.35 to 0.05) (Figure 2-9). The numbers of participants and the changes in 
their total cholesterol and the total cholesterol: HDL ratio are shown in Tables 
2-25 and 2-26, respectively.  
 
Figure 2 - 8 the mean total cholesterol at initial assessment and at the twelve-month follow-
up. 
 
Figure 2 - 9 The mean of total cholesterol: HDL ratio and initial assessment and follow up 
Initial tests: 4.85 
mmol/L (SD ±0.97) 
Follow-up: 4.91 
mmol/L (SD ±1.12) 
Initial tests: 4.03 
(SD ±1.18) 
Follow-up: 3.88 
mmol/L (SD ±1.36) 
Chapter 2: A longitudinal study of a community pharmacy based VRA service 
112 
 
Table 2 - 25 The numbers of participants and their total cholesterol. Categories as per Boots 
SOPs 
  Follow-up 
  ≤  5mmol/L 5.1-7.4 mmol/L  ≥ 7.5 
mmol/L 
Initial 
assessment 
≤ 5mmol/L 46 16↑ 0 
5.1-7.4 
mmol/L 
8↓ 31 1↑ 
≥ 7.5 mmol/L 0 0 0 
At follow-up ↓ 8 their total cholesterol decreased to another category and ↑ a total of 
17 increased 
 
Table 2 - 26 The numbers of participants and their total cholesterol: HDL ratio. > 6 is 
considered high risk (BNF 2011) 
  Follow-up 
  ≤ 6 > 6  
Initial 
assessment 
≤ 6 84 6 
> 6 4 1 
 
There was a small but a statistically significant increase in the mean HDL of 
0.08 mmol/L (95% CI 0.02 to 0.14) at the twelve month follow-up (Figure 2-
10). Fourteen participants improved their level of HDL compared to seven 
participants where there was a decrease in their HDL level at the twelve month 
follow-up (Table 2-27) 
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Table 2 - 27 The numbers of participants and their HDL level. Categories as per JBS2 (2005) 
  Follow-up  
  OK* Low‡  
Initial 
assessment 
OK* 58 7  
Low‡ 14 20  
* HDL level considered OK if it is ≥ 1 mmol/L for men and ≥ 1.2 
mmol/L for women,  
‡ if HDL level < 1 mmol/L for men and < 1.2 mmol/L for women 
 
 
Figure 2 - 10 The mean HDL at initial assessment and at the twelve-month follow-up 
 
2.3.3.4 Calculating Framingham risk at the twelve-month 
follow-up 
Of the 146 participants who had their 10-year CVD risk calculated at the initial 
assessment, 90 participants completed the study (that is, attended the twelve-
month follow-up). Five could not have their risk calculated because of the 
exclusion criteria; three exceeded the age limit (older than 74 years), one had 
had a myocardial infarction during the past year and one had started 
Initial tests: 1.29 
mmol/L (SD ±0.39) 
Follow-up: 1.37 
mmol/L (SD ±0.45) 
Chapter 2: A longitudinal study of a community pharmacy based VRA service 
114 
 
antihypertensive pharmacotherapy and a statin. Therefore, only 85 participants 
had their CVD risk recalculated at this follow-up and the results show that their 
mean Framingham score was significantly reduced (Figure 2-11). The 
difference was -1.07 (95% CI -1.9 to -0.2). When data were adjusted for age, 
that is, using the age at initial assessment the difference was even greater; -1.5 
(95% CI -2.4 to -0.6).  
 
Figure 2 - 11 The mean of Framingham scores at initial assessment and twelve month 
follow-up. * Scores adjusted for age. 
 
Table 2-28 shows the number of participants in each category of the 
Framingham CVD risks. No age adjustment was made to the results, that is, 
Table 2-28 shows the Framingham scores exactly as they were communicated 
to the participants.  
Initial tests: 
13.1 (SD 
±9.6) 
Follow-
up*: 11.6 
(SD ±9.6) 
Follow-up: 
12.0 (SD 
±9.9) 
Chapter 2: A longitudinal study of a community pharmacy based VRA service 
115 
 
 
Table 2 - 28 Framingham scores as communicated to participants at initial assessment and 
at twelve month follow-up 
  Follow-up 
  <10% 10-20% >20% 
Initial 
assessment 
<10% 40 1↑ 0 
10-20% 6↓ 18 3↑ 
>20% 0 3↓ 14 
At follow-up ↓ 9 their CVD risk decreased to a lower 
category and ↑ 4 increased 
 
Of the four participants who had their CVD risk increased, three accessed the 
service at Boots Porthcawl and one at Boots Merthyr Tydfil. On the other hand, 
six participants from the Porthcawl cohort and three participants from the 
Merthyr Tydfil cohort had their risk decreased.     
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2.4 Discussion 
2.4.1 Overview 
This was the first study in the UK to follow-up participants who had a VRA in 
a community pharmacy after a period of twelve months. The study was 
successful in recruiting 172 participants (146 had a full VRA and 26 had a brief 
assessment) and it was successful in following up 61% (n = 105) of these 
participants to the end of the study.  
2.4.2 Methodological considerations 
This study was a longitudinal pre- and post test cohort study. The main 
outcomes were either objective, such as changes to Framingham scores, 
changes to blood pressure, lipid profiles and BMI or subjective, such as self-
reported lifestyle changes. Blood pressure measurement, however, is less 
objective than blood tests and it can be a source of bias (Vera-Cala et al. 2011). 
The VRA service was affected by some limitations including the use of a 
Framingham based risk assessment tool (Chapter 7) instead of the more 
accurate QRISK2 and also the questionnaire used allowed for obtaining limited 
information on lifestyle (Section 8.4). Although these limitations were 
identified prior to the start of the study, it was decided that no changes would 
be made as, for indemnity reasons, the relevant Boots SOPs had to be followed 
thoroughly. Also when the study began the Framingham tool was the 
recommended tool by NICE (NICE 2008b) and this recommendation was only 
changed in March 2010 (NICE 2010a).  
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The service provided was similar to that being provided by other Boots 
pharmacies and the relevant Boots SOP was followed thoroughly. The 
pharmacist attended the same training session other pharmacists had before 
providing the service. There is, however, a major difference between the 
service in this study and in other Boots pharmacies as the pharmacist in this 
study conducted the tests and the consultations whereas in other Boots 
pharmacies pharmacy technicians usually involved in the tests. This was 
identified as a limitation and it is discussed further in Chapter 8.  
The venues for providing the service were selected with different factors being 
taken into consideration. Boots at Porthcawl was chosen first because of 
convenience principally as the research pharmacist had worked at that 
pharmacy in the past and undertook occasional weekend locum work and 
because of the level of support that was offered by the store manager and 
pharmacy staff. Boots at Merthyr Tydfil, however, was chosen because 
Merthyr Tydfil  had the highest proportion of the most deprived areas in Wales 
(WAG 2008). Choosing a pharmacy surrounded by areas with high deprivation 
for evaluating the VRA service was in line with the aims of the Heart MOT 
pilot (Horgan et al. 2010). However, in our study fewer participants were 
recruited in the pharmacy with high deprivation. Reasons for this were 
unknown. The availability of the service may have had an effect in that the 
recruitment period for Merthyr Tydfil was six weeks on only two days each 
week compared with approximately eight months at Porthcawl.  
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The literature review (Chapter 1) revealed that most of the identified studies (n 
= 6) were descriptive studies (Carter et al. 2009; Chambers et al. 2005b; 
Horgan et al. 2010; Kaczorowski et al. 2010; Liu et al. 2009; Peterson et al. 
2010). However, one study (Yamada et al. 2005) followed up participants six 
months after an intervention. Also another paper (Mc Namara et al. 2010) was 
identified which was a study protocol with a primary outcome of changes in 
the modified Framingham scores between baseline and at six month follow-up. 
There were also secondary health outcomes mentioned in the study protocol 
including change to blood pressure, lipid profile, random blood glucose, waist, 
BMI, and depression score. The shorter follow-up time of these studies was 
considered a limitation and the twelve-month period was considered more 
appropriate for the present study. The duration of the PhD programme 
prevented an even longer follow-up period being used.  
The proportion of participants (61%) who completed the study, that is, those 
who attended the twelve-month follow-up assessment, was relatively high 
when compared to other pre- and post cohort studies in pharmacy practice. For 
example, in the study conducted by Yamada et al. only 45% returned to the 
pharmacy. In this study patients who had an assessment and education by 
community pharmacists were invited to revisit the pharmacy to have an LDL test as 
the main outcome was changes to LDL level (Yamada et al. 2005). However, in 
another study evaluating the role of pharmacist in diabetes care, the first 
follow-up, at six months, succeeded to recruit 72% but in the second follow-up, 
at twelve months, only 43% were recruited (Cranor et al. 2003). 
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2.4.3 Characteristics of the participants  
The characteristics of participants were similar in some respects to other 
studies involving the community pharmacy in the primary prevention of CVD, 
in that the majority were Caucasians and the average age was over 50 years old 
(Amariles et al. 2008; Sancar et al. 2011; Thornley et al. 2009b).  
There were more female participants in this present study than males and this 
was the case in most studies which were identified in the literature review 
except for two studies and they are as follows: Horgan et al. (2010) which had 
60% and Boyle et al. (2004) which had 100% men. However, Horgan et al. 
(2010) evaluated a service used marketing strategies to target men and this was 
the reason for succeeding in attracting more men than women and Boyle et al. 
(2004) being male was one of the inclusion criteria. Men have been identified 
as one of the hard-to-engage groups (World Health Organization 2007). In one 
study men were only 29% of the sample (Peterson et al. 2010), other studies 
had also low proportions, including 30% (Thornley et al. 2009b), 32% 
(O'Donovan et al. 2010), 33% (Fernandez-Pinilla and Chaves 2008a), and 36% 
(Amariles et al. 2008).  
Participants’ ages ranged from 19 to 87 years in the present study. The 
forthcoming national VRA service in Wales is expected to be available free of 
charge for those who are between 40 and 74 years of age (WAG 2010), which 
is in line with the NHS Health Check in England (DOH 2008c). Six 
participants would have been ineligible to the expected national service 
because of their age; two under 40 years old and four over 74 years old. Also 
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individuals who were already diagnosed with a CVD or known to be at high 
risk of developing CVD are very likely to be ineligible for the expected 
national service. Twenty-three participants were in this category and they 
would be unlikely to receive a free of charge service. The reason this study 
included this number (n = 26) of participants in this category (ineligible for the 
expected national VRA service in Wales) because the first advert (Appendix 
7a) was similar to the standard Boots advert for this private, non-NHS service 
which did not have these exclusion criteria. The proportion may have been 
higher if the advert had not been amended to list all the inclusion and exclusion 
criteria (Appendix 7b).  
Participants from the most deprived areas were less represented in this study as 
7% only were from this group whereas this group makes up 10% of the general 
population (WAG 2008). The percentages of those who resided in the most 
deprived areas and used the two pharmacies in this study could not be 
determined because of technical and confidentiality issues. Therefore, no 
comparisons could be made at the local level.  
2.4.4 Lifestyle of the participants 
Promoting a healthy lifestyle is one of the priorities in Wales as unhealthy 
behaviours are not uncommon (BHF 2011b; Wales Centre for Health 2009). 
For example 25% of adults reported as current smokers (WAG 2007), the 
proportion of those who exceed the recommended weekly alcohol consumption 
is just above 40% for men and about 34% for women (Wales Centre for Health 
2009) and the proportion of people who do not have an acceptable level of 
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physical activity is about 70% (NHS Wales 2006). However, those who 
attended the VRA service self reported a healthier lifestyle than the general 
population as only 6% of participants reported that they were smokers, 9% had 
unhealthy drinking habits and 5% were physically inactive. A higher 
proportion, about a quarter, of participants admitted that their diet did not 
always include vegetables and fruits. One explanation that our study attracted 
mainly the “worried well”, which is a similar outcome of a study evaluating a 
web-based health risk assessment (Colkesen et al. 2011).  
Another, explanation is that as lifestyle information was captured by self-
completing the service questionnaire which could be a source of social 
desirability bias. Social desirability bias affects the validity of lifestyle surveys 
where participants have the tendency to provide a more positive image of 
themselves (van de Mortel 2008). van de Mortel (2008) argues that social 
desirability bias was more likely to occur when reporting a socially sensitive 
behaviour such dietary/alcohol intake or physical activity in this study. It 
cannot be determined whether it was social desirability bias behind the 
relatively high percentage of participants who stated that they were leading a 
healthy lifestyle or the study sample was healthier than the general population 
because participants were not evaluated, for example by using Marlowe-
Crowne Social Desirability Scale, to check if they were more likely to give a 
positive image about themselves (van de Mortel 2008). However, as it was not 
reflected on their body weight (76% were overweight or obese) the risk of 
social desirability bias cannot be overlooked.   
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2.4.5 Initial assessment 
There were 40% of participants who had a systolic BP of more than 140 
mmHg. This is double the proportion of people who have raised blood pressure 
in Wales as suggested by that the British Heart Foundation (BHF 2011b). Liu 
et al. (2009) reported that 45% of their study sample had a systolic BP of more 
than 140 mmHg whereas Peterson et al. (2010) reported a lower proportion of 
30%. Other studies which were identified in the literature review reported the 
mean systolic BP rather than the proportion of individuals with high BP. 
Reasons for this high proportion in the present study could include the fact that 
BP measurements were not repeated over a period of time and that there may 
have been some anxiety in participants leading to a community pharmacy 
variant of white coat syndrome.   
About two-fifths of participants (39%) had a total cholesterol level of more 
than 5 mmol/L. Cholesterol levels are not collected routinely in Wales (BHF 
2011b). Therefore, no comparison with the general population can be made. 
However, it is expected that the prevalence of those with a total cholesterol 
level of more than 5 mmol/L is similar to England which is higher than the 
study population, that is, 58% for men and 61% for women (BHF 2010). 
Although the level of more than 5 mmol/L is considered high, according to the 
guidelines in place, by itself a high total cholesterol level is not a cause for 
referral as long as it is less than 7.5 mmol/L (Appendix 6b). 
 Low HDL levels to a point that could increase the risk of CHD significantly 
(Wilson et al. 1998) was seen in 39% of participants. Also 12 participants had a 
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total cholesterol: HDL ratio of more than 6 which required an intervention 
(BNF 2011), therefore they were referred to their GP.  
A diabetes risk assessment tool was developed by University of Leicester, 
University Hospitals of Leicester and Diabetes UK and adopted by Community 
Pharmacy Wales for a health promotion campaign in Wales (Brennan 2011). 
According to this assessment tool only 14% of all participants had a low risk of 
developing diabetes in the next 10 years. The remaining participants were at 
increased (37%), moderate (37%) or high risk (12%). Mostly, participants’ 
diabetes risk was elevated because of their age, BMI and/or waist 
circumference. 
In the present study, one third were referred to their GP because of their CVD 
risk (n = 33) and/or because of having a significant risk factor (n = 47), for 
example a high cholesterol level. High blood pressure was the most common 
risk factor as it was found to be present in 44 participants who had been 
referred. As was expected, male or older participants were statistically 
significant more likely to be referred, but there was no significant difference 
between participants from areas with different levels of deprivation.  
Despite the fact that it is more likely that large numbers of individuals with 
high risk will be identified in deprived areas (Soljak et al. 2009), in this study 
31% of those who came from the least deprived areas were estimated, using the 
Framingham charts, to be at high risk of CVD while only 25% of those who 
came from the most deprived areas were at high risk. One explanation is that 
those who came from the most deprived areas were not representative of their 
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communities. This could be a disadvantage of relying on the deprivation 
indices to determine the socio-economic status as a geographic area of high 
deprivation sometimes consists of wealthy individuals. On the other hand, an 
area with low deprivation sometimes consists of a pocket of deprivation (NHS 
Westminster 2011).  
2.4.6 Twelve-month follow-up 
By the time of the twelve-month follow-up, a total of 67 participants had 
withdrawn from the study. However, the demographics of the study 
participants at the twelve-month follow-up were not statistically different to 
those at the initial assessment.  
The main outcome of the referral to GP has shown that most participants have 
made a visit to the GP as advised by the pharmacist, 35 participants confirmed 
their visit versus two who stated that they did not. This is a 95% achievement 
compared to 64% of that reported by Boyle et al. (2004) who combined the 
figures of those who made their visit and those who were waiting for an 
appointment. Although this suggests a success of the service in that service 
users who needed to see the GP were convinced to make the visit, we could not 
obtain an accurate outcome of their visit to the GP. Most of the referred 
participants stated that GPs recommended lifestyle changes as opposed to 
pharmacological intervention. 
There were some inconsistencies seen in some participants’ answers to lifestyle 
questions. Some participants indicated that they modified lifestyle in one 
question but no change could be identified when comparing their answers with 
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the information they provided at the initial assessment. This may be due to that 
participants were estimating on both occasions rather than keeping a diary for a 
period of time prior to the assessments.  
More than a third of participants self-reported an improvement in lifestyle and 
of those who had been identified to be at high risk of CVD at the initial 
assessment, 80% (n = 16) reported a lifestyle improvement. This was a higher 
proportion than that reported by Peterson et al. (2010) (46%). However, as 
discussed above a limitation to the present study is relying on self-reporting of 
lifestyle modifications. For example, there were four participants who claimed 
that they had decreased their alcohol consumption but their self-reported 
weekly units of alcohol had increased at 12 months when compared with the 
initial assessment. This could suggest that some responses were subject to 
social desirability bias as some individuals prefer to portray a more positive 
image of themselves, for example, to health professionals (van de Mortel 
2008).  
It was not expected that a single interaction with the pharmacist would result in 
a successful, maintained behavioural change, indeed this was not a study aim. 
Participants were expected to have different personal and family circumstances 
which would support or hinder any change. Personal and family circumstances 
were not evaluated in this study, thus the effect of this on the study results was 
unknown.  
Theories on health behaviour have been developed and applied to understand 
the nature of behavioural change (Nutbeam and Harris 2004). According to the 
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transtheoretical model (Stages of Change model) which was developed by 
Prochaska and DiClemente (1984) change would occur depending on the 
readiness of the individual. The model consists of five stages which help to 
determine how close the individual to the behavioural change: 
1- Precontemplation: person not intending to make any decision results in 
healthy behavioural change. 
2- Contemplation: person considers the change but not ready to act on. 
3- Determination: person committed at this stage to take action. 
4- Action: person starts the action that is a behavioural change. 
5- Maintenance/Relapse: depending on whether or not the behavioural 
change is sustained this stage can be a mark for success or failure.  
Therefore, it was expected that participants who were at the determination 
stage would be closer to change than those who were at the precontemplation 
stage. This would be recommended as a further area of research. 
A recently published report by NHS Health Scotland shows that there is a gap 
between understanding messages that promoting a healthy lifestyle and 
attitudes toward health (Bromley et al. 2011). For example, 87% of adults in 
Scotland knew that eating five portions of fruit and vegetables a day is good for 
their health. However, only 22% ate at least five portions of fruit and 
vegetables a day. This confirms what behavioural change theories are 
suggesting that providing the information by itself is not always enough when 
helping people to adopt a healthier lifestyle. 
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There was a statistically significant reduction in mean BMI but not in mean 
waist circumference. The reduction was a small but the number of participants 
who moved to a BMI and waist circumference categories of a lower risk were 
more than those who moved to a higher risk category. Although changing from 
a higher BMI category to a lower category was important and encouraging for 
the participants concerned, there was not always a large reduction in weight. 
For example, of those who were overweight at the initial assessment but their 
weight was normal at the twelve-month follow-up, the BMI of one person 
changed from 25.2 kg/m
2 
to 24.7 kg/m
2 
while another person changed from 
27.1 kg/m
2
 to 22.2 kg/m
2
.   
The mean systolic and diastolic blood pressures decreased significantly and 
about a half of participants their blood pressure changed from a category of a 
higher risk to a lower risk, for example eight participants (including Subject 
116 who was prescribed felodipine 2.5mg) their systolic blood pressure was 
between 140 and 199 mmHg to less than 130 mmHg. In comparison Yamada et 
al. (2005) reported more individuals with hypertension at the follow-up than 
the baseline (73% versus 61% respectively).  
Although it was hoped that the improvement in lifestyle would be reflected on 
the lipid profile, there was a small increase in the mean total cholesterol. This 
increase was not statistically significant.  One participant, a 55 year old man, 
who had a decrease in waist circumference from 109 cm (high risk) to 96 cm 
that is, a lower risk category than before, had an increase in his total cholesterol 
level from 5.75 mmol/L to 8.11 mmol/L. This case contradicted the evidence 
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that reduction in abdominal obesity is associated with improvement in 
dyslipidaemia (Ferland and Eckel 2011). In contrast, there was a significant 
increase in mean HDL and 14 participants improved their levels from low to an 
acceptable level versus seven participants who had their HDL levels 
deteriorated.   
The average Framingham score decreased from 13.1% to 12.0% (11.6% with 
adjusted age) and this reduction was statistically significant. The risk (as 
communicated by the pharmacist without any age adjustment) of six 
participants decreased from moderate to low risk and three from high to 
moderate risk. However, the extent of the change in Framingham scores varied, 
for instance, one participant (Subject 70) had a reduction from 32% to 18% 
whereas the risk was increased from low to moderate risk for one participant; 
from 8% to 10%. Also it was increased from moderate to high risk for three 
participants; from 19% to 22%, 14% to 26% and 17% to 26%. Therefore, this 
study reported the change in the mean Framingham score and not only the 
changes in categories, even though they are important as they determine the 
intervention the clinician should make. 
Most participants who were referred to the GP stated that they made such a 
visit. It was noticeable that a statin was not prescribed in almost all those who 
had been referred because of their CVD risk, only two participants out of 33 
confirmed that they had been prescribed a statin. For primary prevention of 
CVD, NICE recommends that statin should be offered for those who have risk 
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of ≥ 20% in the next 10 years, as estimated using an appropriate CVD risk 
assessment tool (NICE 2008c).  
Recommending lifestyle changes over pharmacological intervention was seen 
in certain situations (Tocci et al. 2011). However, in this study it was not 
possible to know whether recommending lifestyle changes was the preferred 
approach by GPs in the management of those who were identified at high risk 
of CVD after they had been referred by the pharmacist. It was not clear 
whether or not GPs agreed with the results of the tests the participants had in 
the pharmacy.  
NICE emphasises that before making a decision on whether to prescribe statin, 
the risks and benefits of statin treatment should be discussed with the patient in 
the light of other factors such as other health issues and life expectancy (NICE 
2008c). Therefore, it was possibly the patient who preferred the lifestyle 
changes over taking the statin. 
There are a number of factors which might have affected the participants’ 
response to the advice. All participants who attended the twelve-month follow-
up assessment had had a telephone interview approximately two weeks after 
the initial assessment which could have been a reminder for them to follow the 
advice. Also, most of those who had been referred to the GP made their visit. 
The GP could have succeeded in helping the participants to make the lifestyle 
changes as those who made their visit were more likely to have reported a 
lifestyle improvement. Other possible explanations are discussed in the 
limitations in Chapter 8. 
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2.4.7  Limitations and future research 
The limitations of this study and suggestions for future research are discussed 
in Chapter 8. 
2.4.8 Conclusion 
This was an exploratory longitudinal pre- post study which assessed 
participants initially and twelve months later. The study explored the 
demographic characteristics of the participants and presented the tests results of 
the initial assessment and also results of the twelve-month follow-up 
assessment. No significant difference in CVD risk was seen in participants who 
came from areas of different levels of deprivation. The study showed a 
statistically significant change in the mean blood pressure, HDL and 
Framingham scores.  
 131 
 
Chapter 3: Access to, and patient satisfaction with, 
the VRA service - anonymous survey 
Chapter 3: Access to and patient satisfaction with the VRA service 
132 
 
3.1 Introduction 
 
This chapter presents a study conducted to evaluate the accessibility of the 
VRA service and the level of satisfaction of the service users. 
As part of clinical governance which is highlighted in the community 
pharmacy contract with the NHS, pharmacists in England and Wales are 
required to give patients the opportunity to feedback on the their level of 
satisfaction for the services they provide (RPS 2011a). This is usually done 
internally as part of an audit process which means the results of such surveys 
are not necessarily published. Particularly, satisfaction with VRA services has 
not been reported to a significant extent.  
For the VRA service to achieve its objectives as a prevention strategy the 
service should be highly accessible by the public. Therefore, there was an 
emphasis by the government in England on the suitability of the venue for the 
provision of the service (DOH 2008c).  
Pharmacy is readily accessed by the general public, for example a pharmacy-
based smoking cessation service was found to be more readily accessible when 
compared to another setting (Bauld et al. 2011). In a Needs Assessment Study 
for community pharmacy travel medicine services, the results suggested that 
travellers would be prepared to use the community pharmacy to receive both 
travel advice and immunisations (Hind et al. 2008). Long opening hours of 
some community pharmacies have improved patient access to services 
(Bellingham 2008). Taking advantage of the pharmacy’s unique position in the 
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community and delivering more local services would make healthcare more 
accessible (Richards 2009).  
Even though the community pharmacy as a location for delivering the VRA 
service was considered by the government as suitable, an appropriate private 
consultation room would also be considered as important. The consultation 
room was introduced to the community pharmacy setting as a requirement for 
certain services, such as the Medicine Use Review (MUR) and the supervised 
administration of controlled drugs, under the Community Pharmacy Contract 
with the NHS (PSNC 2004). For this study the consultation room for providing 
services under the pharmacy contract was used to provide the VRA service. 
Also,  the training and skills of the health professionals are essential to ensure 
the success of any programme involving screening and consulting the service 
users (DOH 2008c).  
The objectives of the present study were to: 
 identify reasons for requesting a free, non-NHS VRA service provided   
by two community pharmacies in Wales 
 evaluate patient satisfaction with the service. 
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3.2 Method 
A questionnaire (Appendix 10) was devised to measure the level of satisfaction 
of those who accessed the VRA service which was provided by two 
community pharmacies, at Porthcawl and Merthyr Tydfil, from November 
2009 to August 2010. Also the questionnaire was used to find out why service 
users chose to have the assessment in the community pharmacy.    
Although the questionnaire was developed specifically to help achieve the 
objectives of this study, other questionnaires from other studies (Horgan et al. 
2009; Knowsley PCT 2008; Stewart et al. 2008) were reviewed and questions 
used adapted, as appropriate, in consultation with academic supervisors. The 
questions and the tool were reviewed internally by academics within the 
School and independently reviewed and approved by the School Research 
Ethics Committee.  
The questionnaire was kept anonymous with only gender and age group being 
identified. Other questions were included to determine type of assessment they 
had, how they found out about the service and the reasons for having the check. 
Anonymous questionnaires are usually used to increase response rate and to 
encourage participants to report negative views unreservedly (Smith 2010).  
The questionnaire consisted of 16 statements where participants were asked to 
indicate their level of agreement to each statement using 5 point Likert scale. 
There was a mixture of positive and negative statements, therefore scores of 
negative statements were reversed in order to check the overall satisfaction. 
The questionnaire focused on acceptance of community pharmacy as a venue 
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for the service, and the satisfaction with the pharmacist as a service provider. 
The sixteen statements consisted of seven statements related to the experience 
in general of having the health assessment (statements a, b, c, d, n, o and p), 
and nine statements related to their interaction with the pharmacist (statements 
e to m). 
There were two open questions for participants to write what they thought 
would improve the service and what other comments they might have with 
regard to the service. 
Participants were given the questionnaire with a free-post envelope at the end 
of the consultation and were asked to post it back after completion at their 
convenience. As this survey was anonymous, non-responders could not be 
identified. Therefore, no follow-ups or reminders were sent to them. 
Data were analysed using descriptive statistics using the statistics programme 
PASW Statistics 18.   
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3.3 Results 
Of the 172 people who accessed the VRA service in the two community 
pharmacies, 127 returned the questionnaire giving a response rate of 74% 
(Table 3-1).  
Table 3 - 1 Demographics of satisfaction questionnaire respondents compared with all 
service users. * More people indicated they were over 74 than the actual number; this was 
probably because of confusion over which box to tick 
Demographics Satisfaction questionnaires 
returned (%) 
Service users 
(%) 
Females 74 (58) 101 (59) 
<40 years old 2 (2) 2 (1) 
40-49 years old 13 (10) 29 (17) 
50-59 years old 34 (27) 45 (26) 
60-74 years old 73 (57) 92 (53) 
>74 years old 6* (5) 4 (2) 
Total 127 (74) 172 (100) 
 
A total of 35 participants (28%) had had a similar check in the past. Most of 
these 35 (66%) indicated that they had it at GP surgery (Table 3-2).  
Table 3 - 2 Places where participants had a similar check before (total number = 35) 
Place Number (%) 
GP surgery 23 (66) 
Community pharmacy 8 (23) 
Workplace 4 (11) 
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Ten participants had such check three to six months prior to accessing the 
pharmacy VRA service (Table 3-3). 
Table 3 - 3 Time of the previous check (Total number = 35) 
Time Number (%) 
Three months 6 (17) 
Six months 4 (11) 
One year 8 (23) 
Two to four years 9 (26) 
Five or more years 8 (23) 
 
The numbers of respondents who had the full cardiovascular risk assessment 
was 116 (91.3%) and 11 (8.7%) had undertook a brief health check.  
About half of the respondents (n = 63) said that they found out about the 
service through an advert in a local newspaper. The remaining respondents 
found out about the service having seen a leaflet (n = 19, 15%), via Boots 
pharmacy staff (n = 19, 15%), from a friend or family member (n = 15, 11.8%), 
from seeing a notice at the pharmacy counter (n = 7, 5.5%) or from their GP (n 
= 1, 0.8%). 
Respondents reported varying reasons for accessing the VRA service (Table 3-
4). They had the option to choose more than one reason. Most of them (n = 
106, 83.5%) indicated that “it was an opportunity to have my health checked 
out”.  
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Table 3 - 4 The reasons why the participants had decided to have the assessment. 
Statements in descending order of responses, (for the right order see Appendix 10). 
Reason for having the health check Number (%) 
“It was an opportunity to have my health checked out” 106 (84) 
“I take care of my health”  48 (38) 
“It’s more convenient than making an appointment with my 
doctor”  
33 (26) 
“I was encouraged by a family member or friend”  17 (13) 
“I was worried about my health”  15 (12) 
“Pharmacy staff told me about it”  13 (10) 
“I don’t get to see my doctor” 6 (5) 
“To confirm the results of a similar check I had elsewhere” 3 (2) 
Other (people stated their reasons) 9 (7) 
 
Table 3-5 shows the responses to each statements of the questionnaire. About 
half (n = 63, 52%) of respondents indicated that their worrying about their 
health was the same before and after the assessment (in statements h and i). 
Twenty-two (18%) were more worried and 36 (30%) were less worried after 
having the assessment. The majority of respondents (n = 102, 81%) had trust in 
the pharmacist before the assessment and their trust remained the same after 
the assessment whereas 6 (5%) had less trust and 18 (14%) had more trust after 
the assessment.  
The medians for individual statements were; 5 (n = 7), 4 (n = 8) and 3 (n = 1). 
No respondent disagreed with the statement ‘I am totally satisfied with the 
cardiovascular risk assessment service’. Only two agreed with ‘I would rather 
have had this health check in my doctor’s surgery’.   
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Table 3 - 5 Patient satisfaction items and responses to each item.  
Questionnaire statements Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
Median 
a. I am totally satisfied with the cardiovascular risk assessment service. 
(m/r = 1) 
79 (62) 44 (35) 3 (2) 0 0 5 
b. The staff were friendly. (m/r = 1) 94 (74) 32 (25) 0 0 0 5 
c. The staff made me feel comfortable. (m/r = 1)  91 (72) 35 (28) 0 0 0 5 
d. There was sufficient privacy in the consultation room. (m/r = 1) 66 (52) 51 (40) 5 (4) 3 (2) 1 (1) 5 
e. I found it difficult to tell the pharmacist about some private things. (m/r 
= 8) 
5 (4) 2 (2) 20 (16) 55 (43) 37 (29) 4† 
f. The pharmacist explained everything to me in a way I could 
understand. (m/r = 1) 
71 (56) 55 (43) 0 0 0 5 
g. The pharmacist gave me sufficient opportunity to ask questions. (m/r = 
2) 
74 (58) 48 (38) 3 (2) 0 0 5 
h. I was worried about my health BEFORE having the cardiovascular 
risk assessment service. (m/r = 5) 
7 (6) 17 (13) 50 (39) 28 (22) 20 (16) 3† 
i. I am worried about my health AFTER having the cardiovascular risk 
assessment service. (m/r = 6) 
5 (4) 19 (15) 35 (28) 39 (31) 23 (18) 4† 
() the number inside brackets indicates the percentage. † Scores of negative statements are reversed. m/r = Missing response 
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Questionnaire statements Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
Median 
j. The consultation time with the pharmacist should have been a little 
longer. 
0 7 (6) 29 (23) 72 (57) 19 (15) 4† 
k. The pharmacist informed me about the results of the tests without 
making me worried. (m/r = 1) 
61 (48) 59 (47) 4 (3) 2 (2) 0 4 
l. I had trust in the pharmacist’s ability to perform the cardiovascular 
risk assessment service before I saw him for the check. 
45 (35) 65 (51) 15 (12) 1 (1) 1 (1) 4 
m. My trust in the pharmacist remains the same after the cardiovascular 
risk assessment service. (m/r = 1) 
56 (44) 62 (49) 4 (3) 4 (3) 0 4 
n. I would rather have had this health check in my doctor’s surgery. (m/r 
= 2) 
0 3 (2) 55 (43) 51 (40) 16 (13) 4† 
o. I would recommend the cardiovascular risk assessment service to other 
people. 
78 (61) 49 (39) 0 0 0 5 
p. Some things about the cardiovascular risk assessment service could 
have been better. (m/r = 7) 
1 (1) 10 (8) 38 (30) 46 (36) 25 (20) 4† 
Table 3 – 5 (Continued) Patient satisfaction items and responses to each item. 
() the number inside brackets indicates the percentage. † Scores of negative statements are reversed. m/r = Missing response 
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The number of those who ticked agree or strongly agree for statement p was 
eight. They provided their suggestions on how to improve the service by 
answering (table 3-6) the first open question.  
Table 3 - 6 Comments and suggestions made by respondents in their response to the first 
open question 
Identified theme Responses to open 
question 1 
Gender Age group  
(years) 
Critical of 
measurement/ 
assessment 
“Waist size was taken with 
my clothes on.” 
Male 50-59 
 “There was no question 
about stress.” 
Female 50-59 
Critical of the place 
of the BMI machine 
“The weight, height and 
BMI machine was in the 
middle of the shop. Not 
private enough for me.” 
Female 60-74 
 “The room we were in was 
rather small and had to go 
into shop for weighing.” 
Female 60-74 
 “Just the booth and 
weighing scales which were 
in the middle of the shop.” 
Female 50-59 
Critical of the 
booking system 
“I was not advised when 
booking app that the blood 
test could not be completed 
(on warfarin)” 
Male 60-74 
Suggesting 
additional elements 
to the service 
“Possibly immediate 
treatment if needed.” 
Male 60-74 
“ECG should be available if 
possible” 
Female 50-59 
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Thirty-nine respondents answered the second open question, of which more 
than half expressed their satisfaction. Table 3-7 provides the participants’ 
responses. 
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Table 3 - 7 Examples of the responses to the second open question. Some responses had more than one theme 
Identified theme  No of 
responses 
Examples 
 Quote Gender Age group 
(years) 
Satisfaction with service 22 “I was pleased to be able to have this service and look forward to year 
time to see if I have taken the advice given and it worked.” 
Female 60-74  
  “An excellent opportunity to receive information about my health and has 
had the effect of making me aware of certain actions I need to take to 
improve my health. Thank you.” 
Male 50-59 
  “Thank you very much that I was able to have this evaluation of 
cardiovascular risk assessment without having to go to GP surgery or 
hospital clinic.” 
Female 60-74 
  “I found the check far less stressful than having to attend one at my local 
GP's surgery” 
Female 50-59 
  “If the results of the consultation are not entirely positive its difficult for 
the pharmacist not to worry you! Apart from this it was a very satisfactory 
experience.” 
Male 50-59 
Satisfaction with pharmacist 7 “It was convenient for me, I had it during my lunch break hour. 
Pharmacist very helpful and gave me good advice.” 
Female 40-49 
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Identified theme  No of 
responses 
Examples 
 Quote Gender Age group 
(years) 
 
 “The pharmacist noted that my BP readings were high and recommended 
that I refer to my Doctor. This I have done, readings and blood tests are 
being undertaken at the present time. I am grateful to the pharmacist for 
his advice.” 
Female 60-74 
Satisfaction with information 
provided or advice 
3 “I am very grateful for [] Test and results and I am far better informed as 
to improve of my overall health!!” 
Male 40-49 
Too much information/ 
worry/ uncertainty  
3 “Too much information by way of page after page unfamiliar terminology 
is useless to the elderly & less-informed. 
1- the elderly will forget it, almost immediately and then worry about what 
they have forgotten. (Thank you very much for worrying me with too much 
information) 
2- lots of people do not understand unfamiliar terms. Truth is, when 
answering Yes or No they really mean don't know… Actually!” 
Male 60-74  
Critical of lack of privacy 3 “Scales are in a very public and busy area, obviously because of space. 
Also as the consulting area is at the side of the pharmacy, while ones are 
waiting for prescriptions, conversations can be heard, again possibly 
because space is limited.” 
Female 60-74  
Table 3 – 7 (Continued) Examples of the responses to the second open question. Some responses had more than one theme 
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Identified theme  No of 
responses 
Examples 
 Quote Gender Age group 
(years) 
Expressed desire for more 
often checks 
2 “I would like to have had the test for diabetes but had already had 
something to eat. When I phoned Boots I was told it was OK. The 
pharmacist explained that as all the other tests were OK he felt there 
probably was no need.” 
Female 50-59 
Critical of the booking 
system 
2 “When I made the appointment to have the risk assessment which my sister 
told me about I didn't realize it was for people up to the age of 74.” 
Female 75 or over 
Suggested that the 
government should fund this 
service 
2 “I would like to see everyone have this test done, if the government would 
fund this cardiovascular risk assessment.” 
Male 40-49 
Satisfaction with the time 
spent 
2 “It was a simple procedure and only took about 30 minutes of my time.” Male 60-74 
Critical of the measurement 2 “BP monitor varies in results” Male 60-74 
Prefer GP surgery over 
pharmacy 
1 “I would rather have had this check in GP surgery because I am familiar 
with my own GP.” (Patient stated that she had a similar test within 3 months at 
GP surgery) 
Female 75 or over 
Table 3 – 7 (Continued) Examples of the responses to the second open question. Some responses had more than one theme 
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Identified theme  No of 
responses 
Examples 
 Quote Gender Age group 
(years) 
Required written information 1 “I would have felt better if you had access to paperwork similar to this 
available, giving more information in layman’s terms of what to avoid and 
what would be beneficial. Having said that the pharmacist answered all my 
questions in my language, but as I said above if it was on paper at my 
hands I could always check with it for my use.” 
Male 60-74 
Critical of the questionnaire 1 “Statement L- Unable to inform opinion, such as trust, not having seen the 
person before. 
Statement M- Had improved, therefore question ambiguous. Was happy 
with treatment and pharmacist” 
Female 60-74 
Other 1 “I have trust and respect for the Welsh School of Pharmacy and in Boots.” Female 60-74 
 
Although respondents were mostly satisfied, some reported some dissatisfaction with the service. The perceived lack of privacy in the pharmacy, 
particularly with regard to location of the weighing scales, led to most of the criticisms made by respondents in their answers to either of the open 
questions. Also, three respondents expressed their dissatisfaction with regard to the information they received when they made the booking.  
Table 3 – 7 (Continued) Examples of the responses to the second open question. Some responses had more than one theme 
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3.4 Discussion 
This anonymous survey shows high respondent satisfaction with the 
community pharmacy-based VRA service. They were satisfied with the 
pharmacy in that it was convenient and with the pharmacist, whom they trusted 
as a healthcare professional. The survey also explored the reasons why 
respondents had requested the assessment. 
The method used in this survey was a self-complete questionnaire given to 
those who accessed the service provided in the two pharmacies, namely Boots 
in Porthcawl and in Merthyr Tydfil. The free post envelope was provided to 
assist in achieving as high a response rate as possible.   The survey was 
anonymous so that respondents could indicate their real opinions and such an 
approach is commonly used in social science research (Naik Panvelkar et al. 
2009). This service was free to users and the respondents were self-selecting 
and perhaps well-motivated and so these factors may contribute to the high 
satisfaction with the service. Also, as with all studies it may be that the non-
responders were not as satisfied and that may be one reason why they did not 
respond.  
 High level Satisfaction 
The high satisfaction level was similar to that seen in the Heart MOT, a pilot of 
a community pharmacy based VRA service which was taken place in 
Birmingham, England. This study took place in 14 pharmacies across the city 
from April 2007 to June 2008 (Horgan et al. 2009) and reported 98% agreeing 
or strongly agreeing that they were happy with the Heart MOT service; 
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equivalent to the 97% in the present study. Another study showed a high 
satisfaction with the VRA service was conducted in Australia as 71% of the 
respondents regarded the screening as worthwhile and 98% rated the 
consultation as good or excellent (Peterson et al. 2010). 
All respondents in the present study either agreed (39%) or strongly agreed 
(61%) with the statement “I would recommend the cardiovascular risk 
assessment service to other people.” Horgan et al. (2009) reported that 99% of 
respondents would recommend the service to others. It was not clear, however, 
if such a statement was constructed as a five-point Likert item or as a Yes/No 
question. 
The medians of seven statements were 5 indicating the very high overall level 
of satisfaction with the following elements of the service; total satisfaction, 
friendly staff, made to feel comfortable by staff, sufficient privacy, 
explanations were understandable, sufficient opportunity to ask questions and 
would recommend the service to others.  
 Response Rate 
Only 44% responded to the Heart MOT survey, the authors considered this as 
reasonable as only a single mailing was used. The response rate of the survey 
conducted by Peterson et al. (2010) was 53%. In contrast, the present study 
achieved a 74% response rate. This may have been due, at least in part, to the 
pharmacist providing the service being the person who provided the 
questionnaire to the subjects. However, more subjects were given the 
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questionnaire in both studies compared to the present study; 400 in the Heart 
MOT and 655 in the study conducted by Peterson et al. (2010). 
About half of the respondents (n = 63) in the present study found out about the 
service through an advert in the local newspaper. Horgan et al. (2009) reported 
that 64% of respondents found out about their service in the pharmacy. This 
may be due to the differences in recruiting strategies in each service.  
 Privacy and confidentiality at the pharmacy 
Privacy in the consultation room was seen as sufficient by 92% of respondents 
and that was also similar to what Horgan et al. (2009) reported (93%). 
However, both the privacy within and the size of the consultation room were 
criticised by one respondent in her response to the first open question. Also, a 
further five criticised the location of the weighing scales as these were located 
outside the consultation room and they believed this affected their privacy. 
Although these were small numbers this is an important issue and may prevent 
others from accessing pharmacy based services, as was found by others (Hirst 
et al. 1999) in a focus group study conducted prior to the pharmacy contract 
requirement for a private consulting room if providing advanced services. In 
the Heart MOT study, even though 93% of participants were happy with the 
consultation area about a quarter of the respondents rated the overall 
experience negatively and one of the reasons was the consultation facilities 
(size or privacy).  In a more recent  study, the size of the consultation room was 
considered by community pharmacists as one of the barriers for the success of 
the Medicines Use Review (MUR) service, which requires a private 
Chapter 3: Access to and patient satisfaction with the VRA service 
150 
 
consultation between pharmacist and patient (Latif et al. 2010). In a study 
using semi-structured interviews to explore patients’ opinions of MURs, 8 of 
23 patients criticised the size of the consultation room although  no-one raised 
the issue of lack of confidentiality or privacy (Iqbal and Wood 2010). 
 The Pharmacy as a place for the VRA service 
Peterson et al. (2010) reported that 97% of respondents regarded the 
community pharmacy as an appropriate place for such a service. In the present 
study survey the following statement was the third most commonly reason 
selected (by 26% of participants) as the reason for having the test in the 
pharmacy: “It’s more convenient than making an appointment with my 
doctor”. Only 2% agreed with the following statement: “I would rather have 
had this health check in my doctor’s surgery.” This may suggest that the 
pharmacy is seen as a convenient place to access and to receive services by at 
least some individuals. Of course, those accessing the service were self-
selecting and those who would prefer such a service from their doctor or nurse 
would be expected to be less likely to have participated. 
 Waiting time for the assessment 
Horgan et al. (2009) stated that respondents criticised the waiting time for the 
assessment. Horgan et al. (2009) stated, also, that most of respondents (128, 
73%) were able to access the service straightaway. The promptness of the 
service considered one of the advantages of the community pharmacy. 
However, the survey conducted by Horgan et al. (2009) did not prove that the 
service was available most of the time for walk in customers; it only showed 
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that most of the respondents had the assessment straight away. It would have 
been more useful to determine the proportion of people who were sent away 
because of the unavailability of the service. In the present study, however, this 
was not measured in this survey as the majority of participants had to book an 
appointment because the service was provided on a specific times/days of the 
week.   
 Information provided to the service users 
The clarity of information was criticised by one respondent to this survey. This 
issue was raised also by three respondents in the study conducted by Horgan et 
al. (2009). However, the vast majority of the respondents in the present study 
agreed (43%) or strongly agreed (56%) with the following statement “The 
pharmacist explained everything to me in a way I could understand”.  
 Reason for requesting the VRA service 
The majority of the respondents (84%) in this survey chose the following 
statement as their reason for requesting the assessment: “it was an opportunity 
to have my health checked out”. Only 2% indicated that they had the 
assessment to confirm the results of a similar check they had elsewhere. 
Although this is a small percentage, test duplication is a major issue and should 
not be overlooked as it can affect the cost-effectiveness of the service, for 
example, if the NHS were to pay.  
One respondent in the present study stated that they would have preferred to 
have the service at a GP surgery as she was known to the GP. Iqbal and Wood 
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(2010) reported that with regard to another service (the MUR) one patient was 
known to the pharmacy which made it the preferred place over the GP surgery. 
This emphasised the importance of engaging with pharmacy users.  
 The questionnaire and questions  
Thirty-five respondents stated that they had a similar check in the past. It is 
unclear whether or not they had a full VRA on a previous occasion or by 
similar check they meant any element of the assessment, for example, a 
cholesterol test. Therefore, this question was not as clear and should be 
changed if the survey is to be repeated. The instrument was not piloted, 
although it was subject to review by academic colleagues. The reason for not 
piloting was that this was a new service and that limited numbers would be 
recruited and we wanted the same questions asked of all respondents.    
Although the majority agreed (47%) or strongly agreed (48%) with the 
following statement: “The pharmacist informed me about the results of the 
tests without making me worried”, more respondents were worried after the 
service than before. One explanation that they were happy with the way the 
message was delivered even though the results were not as they hoped. One 
respondent stated a similar opinion: “If the results of the consultation are not 
entirely positive its difficult for the pharmacist not to worry you!...” 
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3.4.1 Limitations 
The questionnaire used in this survey was constructed through searching the 
literature and then the identified instruments were discussed with academic 
supervisors and used. Only one of the instruments found during the search 
(Stewart et al. 2008) was derived from rigorous qualitative work but it should 
be noted that it was not developed for evaluating a VRA service. Not having 
the instrument formally subject to a pilot is another limitation.  
Although the response rate was high, a limitation that may affect 
generalisability to the service users is that non-responders may have held 
different views. There is evidence to suggest that when people are less satisfied 
with the care provided they are less likely to respond to a satisfaction survey 
(Naik Panvelkar et al. 2009). 
The use of anonymous questionnaires prevented linking of responses to the 
questionnaire with the results of the VRA. There is a possibility that those who 
were identified at low risk were more satisfied than those who were at high 
risk. Also, those who were referred to their GP may have found the service 
more satisfactory. Peterson et al. (2010) coded the questionnaires so the results 
in their study were linked and therefore, these were confidential rather than 
anonymous questionnaires. We had decided, however, against any coding as 
this would involve a third party to handle/analyse the data. Also, it was hoped 
that by omitting the codes we would avoid preventing negative responses and 
would achieve a high response rate.  
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3.4.2 Further Work 
For future research it would be important to develop a validated instrument 
specific for the measurement of satisfaction of those who access the VRA 
service at the community pharmacy. Some of the questions may not have been 
as clear to the participants as we would have liked. For example, it was not 
clear whether respondents who indicated that they had a similar check in the 
past had a full VRA or cholesterol only. Also, one respondent stated that 
although her trust in the pharmacist improved as a result of the VRA she 
disagreed with the following statement: “My trust in the pharmacist remains 
the same after the cardiovascular risk assessment service.” 
Reasons why those who wanted to have the service at a GP surgery, although 
the numbers were small, selected to have it at the pharmacy are unknown. 
More work needed to investigate this. 
3.4.3 Conclusion 
The anonymous survey of those who accessed a community pharmacy based 
VRA service showed high satisfaction and acceptance with the service by those 
who returned the self-complete satisfaction questionnaire. Most service users 
were made aware of the VRA after having seen an advertisement in a local 
newspaper.  The venue was considered convenient in comparison to the 
doctor’s surgery to receive this service by one third of the respondents.
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4.1 Introduction 
This chapter presents a study reporting the short term outcomes through a 
semi-structure telephone interview with the VRA service users which was 
conducted approximately two weeks after accessing the service. 
Community pharmacy based services, including the VRA service, require more 
research in order to demonstrate the value of these services for the patients and 
healthcare system (Roberts and Kennington 2010b). Research on quality and 
outcome is essential to help the continuity of pharmacy practice to evolve in 
response to changing healthcare needs and marketplace competition (Roberts 
and Kennington 2010a). The effectiveness of a service has been determined by 
evaluating patients’ knowledge, skills, expectations and acceptance as well as 
by evaluating short and long term clinical outcomes (Bereznicki et al. 2011; 
Cranor and Christensen 2003; Naik Panvelkar et al. 2010). 
The time specified for the follow up to measure the short term outcomes 
depends on the type of the concerned outcomes. Improvement in clinical 
outcomes in a study evaluating pharmacist intervention was measured seven to 
nine months after the first intervention in one study (Cranor and Christensen 
2003). The final follow up in a study evaluating adherence to medication 
among diabetic patients was at six months after the initial pharmacist 
intervention (Clifford et al. 2006). However, the follow up was conducted 
straight after an educational campaign on public attitudes towards antibiotics in 
a study assessing the impact of such campaign (Radosevic et al. 2010). 
Similarly, in a study focusing on pharmaceutical care to hypertensive patients, 
Chapter 4: Views and experiences of those who accessed the VRA service – the two week 
follow-up telephone interview 
157 
 
the level of knowledge was assessed before and after the intervention but the 
final assessment was six months later (Oparah et al. 2006). 
Semi-structured interviews have been used as a method in pharmacy practice 
research to assess the level of knowledge of a specific condition, the ability to 
self-manage their condition and to determine patients’ expectations and 
acceptance to a service provided by the pharmacy. Also the semi-structured 
interview has been used to evaluate patient satisfaction (Bereznicki et al. 2011; 
Naik Panvelkar et al. 2010). 
In order to try to minimise interviewer bias, it is important to determine who 
should conduct research interviews and how much the interviewer should know 
about the research subject. Although it is advisable that the interviewers 
familiarise themselves with the aim and objectives of the research project, it is 
also important that some information which could bias the interviewers or 
compromise their objectivity should not be shared (Waltz et al. 2010). 
Although the improvement in clinical outcomes has been used by most 
research on patient commitment to change or adherence to the advice provided 
by a healthcare professional, there are certain research areas where self-
reporting is used as the main methodological strategy, for instance when 
assessing outcomes in smoking cessation studies (Velicer et al. 1992). 
Assessing patients’ knowledge, understanding of the advice and their attitude 
towards certain behaviours can be useful to predict the possibilities of 
following the advice provided by the pharmacist as there is a link between 
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patients’ beliefs and behavioural changes, according to research conducted on 
health behaviour change (Nutbeam and Harris 2004).  
The aim of this follow up was to explore the users’ views and experiences by a 
researcher who did not undertake VRA.  
The objectives of this study were to: 
 Explore participants’ views of the pharmacy as a place to provide the 
VRA service.  
 Identify reasons for undergoing the assessment.  
 Examine the participants’ recall of, and compliance with, the advice 
given by the pharmacist. 
 Determine the number of participants who reported taking action to 
reduce their CVD risk or made any changes to improve their lifestyle. 
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4.2 Method 
Individuals who accessed the VRA service (Section 2.2 for more details of the 
service) in Porthcawl and Merthyr Tydfil were invited to participate in a 
follow-up to explore their views and experiences. Those who agreed were 
asked to indicate in the consent form (Appendix 2) – the preferred method - 
whether they preferred to have a telephone interview with a researcher (other 
than the research pharmacist) or to complete a form they would receive in the 
post. 
The two-week follow-up interview was the first follow-up planned to take 
place approximately two weeks after accessing the VRA service. A 
methodology consisted of a semi-structured interview was chosen in order to 
cover specific issues with the regard to the VRA service and in the same time 
to provide the opportunity to the participants to elaborate on matters when they 
felt it was necessary. This approach was the most appropriate to answer the 
study objectives; studying both specific issues (identifying reasons for 
accessing the service) and broad issues (exploring participants’ views). Also, 
the telephone interview was used as opposed to face to face interview to 
maximise convenience to the participants and increase the response rate (Smith 
2010). An interview schedule (Appendix 11a) was developed and it consisted 
of two main parts; about the participant background and the assessment they 
had at the pharmacy. After an introduction and confirming the participant was 
on the telephone, the interview started with questions to gain a brief 
background about the participant including, how the participant was made 
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aware about the service, whether or not he/she had a similar check in the past 
and the reasons for deciding to have the assessment at the pharmacy this 
occasion and whether or not they knew anyone with CVD. Then there were 
questions about the tests and advice they had received.  
A researcher (DNJ) who did not provide the VRA service contacted the 
participants, who consented, to conduct a semi-structured interview over the 
telephone (Appendix 11a). Otherwise a form (Appendix 11c) was sent by post 
to those who did not consent to have the telephone interview and to those who 
could not be contacted by telephone. 
The interviewer was only provided with the contact details of the participant, 
date and time the assessment was undertaken and whether or not the 
Framingham based 10-year CVD risk was calculated (and communicated to 
participants). The interviewer was not provided with any other documentation 
or information prior to the interview in order to reduce potential bias.  
The telephone interview was audio-recorded. When participants filled in the 
consent form they indicated if they were happy for the interview to be audio- 
recorded. The interviewer confirmed that they were still happy with having the 
conversation audio taped before the start of the interview. If the participant did 
not want the interview to be recorded the interviewer did not record the 
interview and instead made brief written notes.  
All recorded interviews were transcribed ad verbatim by an independent 
transcriber. A code was given to each participant to ensure confidentiality. 
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Each code was double-checked to ensure that all transcripts were linked 
correctly to the same record in the data set collected during the VRA. All 
quotes used were double-checked by the researcher (SW) and confirmed to be 
ad verbatim, by listening to the tapes and reading the transcripts. The 
transcripts were anonymised during transcription. Data were subjected to 
descriptive content analysis, that is, transcripts were reviewed to identify 
responses to the questions in the schedule and were then categorised and coded 
systematically (Neuendorf 2002). Data are presented as frequencies. 
Qualitative excerpts from interviews have been used in the results section of 
this chapter to provide examples of responses under each theme.  
The satisfaction with the service was determined by the anonymous 
questionnaire that participants were asked to complete and send by post and is 
reported in Chapter 3. However, in this follow-up participants were asked 
whether or not they had recommended the service. This type of question 
usually is seen in satisfaction surveys as an indication of how well the service 
is perceived by the service user. Some participants also chose to express their 
satisfaction when they answered the open question at the end of the interview;  
 Is there anything that you would like to tell me about the test or the 
service at Boots that I have not asked you about, something that we 
have not covered? 
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Inclusion criteria 
All participants must have consented to have the follow-up and undergone an 
assessment at Boots, Porthcawl or Merthyr Tydfil during the period between 
4
th
 November 2009 and 5
th
 August 2010.  
Study population 
All participants of this study were invited to participate in the follow-up 
telephone interview.  
Ethical considerations 
Ethical approval was sought and obtained from the Welsh School of Pharmacy 
Research Ethics Committee (Section 2.2.1.2). The consent form included a 
section against which participants could indicate whether or not to participate 
in this stage of the research and if so, if they wished to be interviewed by 
telephone interview or to be sent a form in the post. Additional verbal consent 
was obtained by the interviewer at the beginning of the telephone interview for 
the interview to be recorded. The participants were reassured that no sensitive 
information would be discussed and they had the option to ask for the 
recording to be stopped whenever they felt it should stop. Transcriptions were 
anonymised to maintain confidentiality and a unique code was used for each 
participant. 
 
 
Chapter 4: Views and experiences of those who accessed the VRA service – the two week 
follow-up telephone interview 
163 
 
4.3 Results 
4.3.1 Overview 
Out of the 163 who consented to have the two week follow-up, a total of 153 
participants completed the telephone interview after undertaking the VRA at 
Boots and six completed the posted questionnaire. The remaining four could 
not be contacted. One-hundred and twenty four participants accessed the 
service at Boots, Porthcawl and 35 participants at Boots Merthyr Tydfil. Total 
response rate was 92% of all service users (159 out of 172) who had accessed 
the VRA service between 4 November 2009 and 5 August 2010.   
Participants had the follow up interview on average 23 days (SD = ±10.6) after 
they had accessed the VRA service (range from 14 to 91 days; mode = 19 
days). 
An example interview is included (Appendix 11b). 
4.3.2 Identified themes 
During the interview transcription and analysis process, themes and sub-themes 
were identified (Table 4-1). 
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Table 4 - 1 Identified themes and sub-themes 
Themes and subthemes 
1. Awareness of the service 
2. Similar test in the past: 
2.1. Setting of previous test 
3. Awareness of any relatives, friends or acquaintances with CVD  
4. Reasons for undertaking the tests 
5. Framingham risk communicated during consultation:  
5.1. Recall of Risk 
5.2. Referral to GP outcome  
5.3. Feelings when risk was communicated  
5.4. Usefulness of being told risk 
6. Attitudes towards lifestyle advice:  
6.1. Alcohol  
6.2. Diet  
6.3. Weight  
6.4. Smoking status  
6.5. Exercise 
7. Changes in lifestyle or medications as a result of the VRA 
8. Satisfaction with, and recommendation of, the VRA service: 
8.1. Satisfaction with the service 
8.2. Recommendations of the service 
 
4.3.3 Awareness of the service 
Most (n = 61) participants in the study were made aware of the service from an 
advert placed within the pharmacy (either a notice on the pharmacy counter or 
a leaflet) (Table 4-2). 
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Table 4 - 2 Participants were made aware of the service from different sources 
Source of information about the service Number (%) 
An advert placed within the pharmacy 61 (38) 
An advert in the local paper 60 (38) 
Informed by a family member or a friend 27 (17) 
Informed by pharmacy staff 8 (5) 
A leaflet from a local caravan site 3 (2) 
4.3.4 Similar tests in the past 
There were 34% (n = 54) of participants who had undergone a similar test to 
the VRA in the past. 
The most common setting where the participants had a similar test in the past 
was in a GP practice (n = 36): 
“Well I do have one with my surgery. Sometimes they go down, 
they take my, they cholesterol, and they take my blood pressure, 
and my sugar level well basically.” (Subject 117) 
Other participants that had undertaken similar tests in the past were at varying 
settings, included hospital (n = 1), insurance company (n = 1), workplace (n = 
8) and a community pharmacy (n = 1). Seven participants did not specify the 
place where they had the similar tests in the past. 
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4.3.5 Awareness of any relatives, friends or acquaintances with 
CVD  
Participants were asked whether they knew people, including family members, 
friends, colleagues or neighbours who were suffering from a CVD. About a 
quarter (n = 41) of participants mentioned one person only who was living or 
had lived with a CVD, 19% (n = 29) mentioned two people, and 35% (n = 54) 
mentioned three or more: 
Interviewer: is there anybody in your family who has or has had 
heart disease  
Subject 16: yes 
Interviewer: ok and if you don’t mind me asking who would that 
be... what relation? 
Subject 16: my father’s side is my father um all his brothers 
have had heart problems... his sister. 
 
 Twenty-five (16%) people said they did not know anyone suffering from 
CVD. 
4.3.6 Reasons for undertaking the tests 
Participants were asked about the reasons which prompted them to undertake 
the VRA. Just less than a third of participants (n = 48, 30%) gave a general 
reason such as: 
“I just thought it was good it was just a good opportunity to do a 
lot of things in one go really have a few tests in one go” (Subject 
28) 
“well it was for both uh myself and my husband uh really just to 
you know sort of check out on our health and um uh you know to 
see if um uh we need to change our lifestyle really” (Subject 85) 
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The service was considered by five participants as a good opportunity to 
double check the results of tests they had at GP surgery: 
“Basically um I’m coming up 75 I normally have them done fairly 
regular with the doctor... so I thought I’ll just double check type 
of thing you know” (Subject 1) 
Risk factors (Table 4-3) were mentioned by participants as reasons for 
requesting the VRA. Age was the most common risk factor mentioned:  
“I’m 60 next year and uh just to find out the lay of the land 
really” (Subject 4) 
“um it was just because I’m getting older now and uh thought I 
take the precaution you know it was offered as a free test so I 
went for it” (Subject 27) 
 
Table 4 - 3 Risk factors mentioned by participants as reasons to undertake a VRA 
Reason Number (%) 
Age 37 (23) 
To check cholesterol level 24 (15) 
Family history of CVD 21 (13) 
Being overweight or obese 13 (8) 
To check blood pressure 10 (6) 
Medical history of CVD 7 (4) 
To have a Diabetes test 4 (2) 
Poor diet 3 (2) 
Waist size 1 (1) 
 
BMI, diet, family history, cholesterol, blood pressure and diabetes were also 
mentioned by participants as reasons to access the VRA service: 
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 “um well just my wife and uh myself we I suppose were both 
concerned about our weight at the moment and uh had nothing to 
lose by going sort of thing” (Subject 60) 
“well I’m overweight” (Subject 8) 
“Basically, to kick start me going on a diet really, and trying to 
get a bit healthier, so yeah.” (Subject 126) 
“mainly because um my father died of um a stroke and I was a bit 
just concerned about sort of whether there were any factors that I 
could do to sort of prevent there’s a bit of a medical history of 
sort of heart attacks and things in the family I wanted to see 
whether or not if I was at risk of anything” (Subject 39)  
“I was keen to get my um to find out what my cholesterol was” 
(Subject 35) 
“Well I have been having problems with blood pressure, and I 
thought well have it checked up” (Subject 88) 
“I was a little concerned I think about um maybe diabetes 
because I’m a bit of a chocoholic” (Subject 78) 
Seventeen participants mentioned two or more risk factors which prompted 
them to request the VRA: 
“Well, you know, I’m nearly 50, and I thought, you know, that’s 
the sort of time you need to keep an eye on your health, I think. 
Probably, felt like I could lose a bit of weight, so I thought I 
better have a check and see what came up, you know? 
Cholesterol levels, that sort of thing.” (Subject 132) 
 Other reasons for accessing the VRA service, other than the classic risk 
factors, participants mentioned; convenience (n = 4) and being encouraged by a 
relative or a friend (n = 9).  
One participant added that finding out about CVD risk as one of the reasons 
which prompted to decide to have the tests: 
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“Well that’s partly why I went as well because it says that they 
will tell you that [the CVD risk]” (Subject 38) 
A further four participants mentioned other reasons which could not be linked 
to the nature of the tests or the risk factors 
“I’ve had quite a low period over the last few weeks at myself 
personally and um I was sort of trying to sort of um alleviate sort 
of and put myself back on a even keel so I thought well you know 
some good positive news or some bad news might motivate me to 
do something about it you know what I mean” (Subject 11) 
“because I haven’t been feeling good over the past months” 
(Subject 83) 
4.3.7 Recall of Framingham risk communicated during 
consultation 
Participants who had their risk calculated (n = 136) were asked during the 
interview if they could recall the pharmacist talking about the CVD risk, either 
in terms of high, moderate and low risk, or as a percentage.  
The majority (n = 96, 71%) of participants who had their risk calculated 
successfully recalled their individual risk in comparison with their record in the 
main study results (Chapter 2). 
However, 40 participants (29%) were unable to correctly recall their risk. Some 
participants discussed other results calculated during the VRA: 
“He said, with the problem I have, I tend to have blood pressure, 
which goes up and down...” (Subject 89) 
The participant went on further to discuss the results of their BMI: 
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“Quite pleased with the results, yes, you know, he said it was 
about 23% my body count (sic), it was about 23.” (Subject 89) 
As shown in Table 4-4, participants who were found to be at low risk were 
more likely to recall the CVD risk as communicated by the research pharmacist 
than those who were found to be at high risk (p < 0.001, Pearson Chi-square). 
Twenty-five (19%) participants understated their CVD risk: 
“Well he didn’t leave me with an impression that I was even a 
moderate risk, I think I’m low.” (Subject 33, moderate risk) 
On the other hand, five (8%) participants overstated their CVD risk: 
“I think I was a medium with the blood pressure. The blood 
pressure was up a bit.” (Subject 120, low risk) 
 
Table 4 - 4 The number (%) of participants who were able, or otherwise, to recall CVD risk as 
communicated by the research pharmacist. ‡ One participant said she had no risk. † 
Including those 8 participants who said their risk 20% instead of “more than” 20% 
Risk of 
CVD 
Recalled Understated Overstated Unable 
to recall/ 
unclear 
Low 50 (82) 1‡ (2) 5 (8) 5 (8) 
Moderate 34 (79) 6 (14) 0 3 (7) 
High 12 (38) 19† (59) 0 1 (3) 
 
A further six participants could not remember discussing specific risk with the 
pharmacist researcher: 
 “No, didn’t mention it.” (Subject 125) 
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Some participants did not fully understand how the Framingham risk 
percentage was interpreted in terms of high, moderate and low risk: 
“I think it was moderate to high I think, or 20%, I don’t know, 
that’s moderate is it? I’m not sure. It was about 20%.” (Subject 
132) 
“I think I’ve got it here; the risk was 10 to 20%. I don’t know if 
that is small, not sure to be honest with you.” (Subject 124) 
Some participants were not convinced that the risk score provided an accurate 
reflection of their risk. Participants believed they were at lower risk than that 
calculated by the pharmacist researcher: 
“Well, I’m not actually disputing, but I don’t agree, I disagree 
with a bit of what they said, they said I was at high risk, but I sort 
of exercise as I go out to work, he said I was overweight, but I 
don’t think I was that overweight...” (Subject 115) 
“20%, in his opinion, considering. Well, I don’t know how he can 
say that, you know, he sort of diagnosed that I was somewhat 
overweight, except that I personally know that I do things, 
regards exercise, daily for years no, which entitles me to believe 
that internally, regards cardio, and so on and so forth, I should 
be OK, like.” (Subject 139) 
However, one participant who was also at high risk was of the opinion that the 
score was an accurate reflection of their risk, taking into account individual 
risk factors: 
“Well, taking account of my age, and what-have-you, and you 
know, I suppose that’s a reasonable, and of course, I’m slightly 
overweight a bit. I thought I was fairly reasonable prognosis, you 
know?” (Subject 146) 
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4.3.8 Participants referred 
As a result of the VRA, 51 (32%) participants had been referred to GP for 
further investigation. By the time of the two week follow-up, 45% (n = 23) of 
all those who were referred visited their GP: 
“yes I took um the pharmacist suggested I go which and took the 
results with me and I went the following day” (Subject 47) 
Further 14 (27%) participants indicated that they intended to visit their GP to 
discuss the results:   
“I’ve arranged a follow up test in the doctors” (Subject 27) 
However, 12 (24%) participants (7 of them were identified at high risk) did not 
intend visiting their GP practice. One participant openly stated: 
“I don’t see any urgency; I haven’t been actually and don’t 
intend to…I don’t feel any urgency to go to the doctors if I’m 
honest” (Subject 146) 
 
One participant agreed to discuss the results with the doctor but admitted that 
he could not see the value of it: 
“Well yes... I’ll go and see what the doctors got to say now and... 
I think personally it’s a bit of a waste of time, but there we go 
we’ll go on his recommendation” (Subject 6) 
Two participants were referred but the issue of seeing the GP was not 
discussed during the interview. 
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4.3.9 Usefulness of participants being told individual risk 
Participants who had had their CVD risk calculated were asked if it was useful 
to be told of their individual risk (14 out of 136 were not asked this question). 
The majority (n = 118, 87%) believed it was of use: 
“Oh yes, yeah, yeah, yeah. You were just confirming what I knew 
already, yes.” (Subject 136) 
“uh yes... well I just think uh if it had been the other way and it 
had been high risk I could have done you know something to 
change my lifestyle really” (Subject 65) 
Only four participants thought it was not useful to be told the individual risk of 
developing a CVD. One participant believed it was not useful to be told of their 
risk of future CVD: 
 “Not for me no…” (Subject 126) 
The other believed it was not useful to her, but it was useful to her husband due 
to his weight: 
“Not for me personally, because I just felt that everything I do 
with my life is OK, but having said that my husband is two stone 
overweight and I know that, and I think him being told that by 
somebody else was useful.” (Subject 137) 
One participant who was found to be at high risk could not see the usefulness 
of being told the individual risk of CVD: 
“That’s a moot point, I was alright going in, I felt worse coming 
out.” (Subject 121) 
One participant thought it was not useful because it reminded her of losing her 
mother at a young age: 
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“no no and you know it was a pain I mean I was only 20 when my 
mother died and it was quite a painful thing always been a 
painful thing for me so it just brings that back really” (Subject 2) 
 
4.3.10 Attitudes towards lifestyle advice 
Advice on maintaining a healthy lifestyle was provided by the pharmacist 
researcher during the VRA. The results are discussed under five sub-themes: 
namely alcohol intake, diet, weight, smoking and exercise. The follow-up 
interview explored participant recall, compliance and barriers to advice 
provided by the pharmacist researcher, information to which the interviewer 
was unaware. 
Alcohol intake 
The Boots service questionnaire required participants to state how many units 
of alcohol they consumed on a weekly basis (Appendix 3a). The form provided 
examples of what beverages constituted to particular units of alcohol, thus 
enabling the participant to calculate their weekly intake. There was generally a 
lack of understanding of the interpretation of alcohol intake, particularly in 
terms of volume and concentration: 
“My alcohol intake is very moderate, I live on my own, so very 
cautious about not wanting to have alcohol, drinking on my own. 
So socially, when I have friends or family here, or when I’m with 
friends or family. But equally if I have a special Sunday roast, 
then I will open a bottle of wine, [unclear] you know. Then I’m 
quite happy to do it, but it would last, a bottle would last me 4 
days, so I don’t think to heavily.” (Subject 141 – 3 units weekly) 
“It was discussed, yes. And I drink moderately. Red wine twice a 
week, usually.” (Subject 143 – 2 units weekly) 
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Participants were sometimes vague in terms of the alcoholic beverages they 
consumed weekly, often unable to explain the full extent of their habits: 
“…he said what is your intake of alcohol? And I said, very little.” 
(Subject 120 – 0 units weekly) 
“…few bits and all that.” (Subject 139 – 20 units weekly). 
Furthermore, one participant alleged that individuals are untruthful when it 
comes to explaining their alcoholic habits, often underestimating their intake: 
“Yes, I give him my units and he said that was alright. Nobody 
tells the truth about alcohol units do they? They don’t do they, it’s 
one of those thing isn’t it, they always knock about 5 pints a week 
off, at least. But he said it was alright. I got a feeling he didn’t 
quite understand what I said so I didn’t push him on it.” (Subject 
121 – 12 units weekly) 
Two participants admitted to drinking in excess of their weekly allowance, 
both individuals accepted the pharmacist’s advice in attempting to reduce their 
intake in the future. Their comments came 20 and 19 days, respectively, 
following the VRA: 
“Yeah, we mentioned that [alcohol]…it can be decreased. It 
wasn’t excessive...” (Subject 125 – 24 units weekly) 
“I will reduce the amount of units of alcohol I drink in a week.” 
(Subject 123 – 18 units weekly) 
One participant was inconsistent in the number of units provided on the data 
collection form with the figure given during the follow-up interview: 
“I don’t think he was concerned about it [alcohol intake], I was 
quite truthful, I said 15 units a week.” (Subject 122 – 12 units 
weekly) 
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Diet 
Participants were given the options during the consultation of stating to the 
pharmacist researcher that they either ate at least five portions of fruit and 
vegetables everyday or whether they did not: 
“…we have a pretty good diet…the diet we’re on, we always have 
our 5 fruits and veg.” (Subject 131) 
Not all participants accepted the advice provided by the pharmacist, as they 
disliked the food type that was recommended: 
“I don’t particularly like fish to be honest.” (Subject 137) 
“…we do try to watch our food. My husband eats a lot of fruit, 
but I’m not a fruit lover. So I don’t eat so much fruit as I should.” 
(Subject 117) 
 
Weight 
About a fifth (22 out of 120) of participants who were informed that they were 
overweight and have been recommended to lose weight disregarded the 
information and advice provided: 
 “He said I was overweight, but I don’t think I was that 
overweight.” (Subject 115) 
One participant stated: 
“Now I’ll be honest with you, if I was 11 stone 10 or 8 stone 10, I 
would look seriously ill.” (Subject 124) 
One participant believed it was not an ideal time of the year to lose weight: 
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“It’s the wrong time of the year to diet.” (Subject 116) 
Two participants had concerns relating to the methods used in measuring 
individual weight. One issue related to confidentiality: 
“The discussion of my weight took place there [on the shop 
floor], rather than back in the consulting room…I mean I wasn’t 
unduly upset about it, but I don’t think it was, it would’ve been 
better to have kept it in the consulting room…the scales are in the 
middle of the store so I mean I was quite happy about that, but I 
think the discussion should’ve taken place in the consulting 
room.” (Subject 134) 
The other related to the methods used in measuring individual weight: 
“…when I was weighed and I said shall I take my shoes off and 
the pharmacist said it’s up to you, when I think if you’re looking 
at body mass index there should be a more consistent approach to 
weight. I know your shoes and your coat are only a relatively 
small amount but to somebody like me who was 3 or 4 pounds 
overweight, that could make quite a difference, you know what I 
mean? I did think it should be more consistent and that should 
everybody should be asked to take their shoes and coat off or 
nobody should.” (Subject 137) 
One participant noted that it would have been of use to have been put in 
contact with a dietician:  
“No, he weighed me and, what I have, on everyone of these tests 
that I have, including the one in Porthcawl, what’ll be a good 
idea at the end of them, if they say you’ve got to diet, or 
something like that, is to put you in touch with the dietician.” 
(Subject 128) 
One participant commented that it would have been useful if the annual 
consultation follow-up was sooner, therefore would be more likely to modify 
their lifestyle: 
“…when I discussed it with the lady who recommended, who told 
me about it, we agreed that it would have been more helpful to 
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use if we’ve been returning sooner, rather than in 12 months. We 
would’ve been more likely to modify our lifestyle, diet etcetera, if 
we’ve been say going back in 2 months or something, you’d see a 
difference in my weight.” (Subject 138) 
Smoking 
The data collection form gave the participants four options relating to smoking 
habit: ‘never smoked’, ‘quit over five years ago’, ‘quit within the last five 
years’ or ‘current smoker’ (Table 4-5). 
Table 4 - 5 Smoking status of participants who had the two week follow up interview (n = 
158) 
Smoking status Number (%) 
Never smoked 98 (62) 
Quit over five years ago 49 (31) 
Quit within the last five years 6 (4) 
Current smoker 5 (3) 
 One participant who had quit smoking over five years ago described his 
smoking habit prior to quitting: 
“I did yeah, but I used to smoke, I smoked a pipe for 30 but I 
haven’t smoked for 15 years at least.” (Subject 127) 
Some participants who had previously smoked did not expand on their past 
habit: 
 "Well he just asked if I smoked and I said no." (Subject 
130) 
One participant stated on the data collection form that they had never smoked, 
however somewhat inconsistent with their previous response to the data 
collection form: 
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“No, I don’t at the moment. I did smoke when I was in school, 
which is 30 years ago. I did smoke for about 4 or 5 years until the 
age of 28 or 29.” (Subject 122) 
There were five smokers in the study and the pharmacist signposted them to a 
helpline: 
“Yeah, he did actually say that, [cough] excuse me, there was a 
help line, I think, that I could get in touch with if I wanted to. So I, 
actually he wrote it down, for me. I haven’t done anything about 
it yet though, unfortunately.”(Subject 144) 
The difficulty of changing habits with regard to smoking was reflected during 
the interview with one participant: 
“Yeh so let’s hope I can achieve either both give up smoking or 
lose weight or at least one isn’t it.” (Subject 9) 
One participant was not clear about the advice he received with regard to 
smoking: 
Interviewer: did he talk about smoking with you? 
Subject 153: yeh he did yeh yeh 
Interviewer ok and is that did he advise you to try and cut down or... 
Subject 153: yes yeh 
Exercise 
The majority of participants interviewed who did not undertake regular 
exercise, and did not suffer from concurrent conditions were aware that they 
did not undertake enough exercise. They accepted the advice and were actively 
looking to increase levels of physical activity: 
“I have just retired, so hopefully I’m going to get a dog.” 
(Subject 128) 
“Yes, he said, I could do. Could do a bit more exercise, I’m 
determined to go swimming this year” (Subject 89) 
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Some of those who were advised to improve their exercise intensity and 
regularity provided at least one reason as to why they have not accepted the 
advice. There were three themes: injury and morbidity factors, time limitations 
and weather conditions. 
Injury or morbidity factors acted as a barrier to six participants in accepting the 
advice provided by the pharmacist: 
“I can’t do a lot of exercise, you know, training, because I’ve got 
two detached tendons in my ankle so I’m a bit limited” (Subject 
135) 
“I told him I do exercise. I walk down town every day, but my 
problem was I used to play a lot of golf and I got this arthritis in 
the back and the neck and I’ve had to pack up golf…” (Subject 
121) 
Being too busy was a reason for not undertaking regular exercise: 
“He asked me if I exercise and I said no not really, but I’m just a 
very, very busy woman anyway. I’m always on the go.” (Subject 
144) 
“…I’m extremely busy…” (Subject 143) 
One participant stated that he was unable to take part in more regular exercise 
due to the extreme weather conditions: 
“…I told him I exercise. I used [unclear] I don’t know, about 3, 3 
and a half miles from work, so usually cycle if the weather’s 
good, unlike this time of the year, where I do a lot less, 
obviously.” (Subject 115) 
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4.3.11 Changes in lifestyle or medications as a result of the VRA 
service 
In this section, the data about any initiation of change is presented while 
Section 4.3.10 presented the ability to remember the advice and whether or not 
they accepted the advice. Even though there was no direct question in the 
interview schedule to ask participants what changes they have made, some 
participants provided some information about this matter. About a third (n = 
52) mentioned at least one change in their lifestyle or medications. Only one 
person said he had been prescribed a medication by the GP: 
“yeh I took the referral letter from Boots over to the GP’s and the 
doctor did another test again, it was high... so she prescribed 
some medication” (Subject 17) 
A further person (Subject 34) who already was on blood pressure treatment 
said that the doctor had doubled the dose of his medication: 
“pharmacist said because I think it was my blood pressure was 
quite high it was reading um I did go back to the doctor although 
he found it a lot lower than the pharmacist found um he did uh 
double my dose of my medication” (Subject 34) 
 
Four participants said they started to take a fish oil supplement since they had 
the tests at the pharmacy. 
Most participants (n = 28) who mentioned the lifestyle changes said they have 
improved diet since they had the tests: 
“I don’t put salt on to anything but of course since I’ve been there 
actually I tend to look at things I buy and I have had quite a shock 
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as to the content of salt in various foods that I didn’t think you 
know were a high risk.” (Subject 5) 
Thirteen participants said they have been trying to lose weight, including one 
participant mentioned the waist size: 
“ he did say like 4 inches off my waist and since he told me I am 
more wary of it then” (Subject 40) 
Starting or doing more exercise was mentioned by 11 participants: 
“I’ve started swimming and everything and walking.” (Subject 
19) 
 Five participants said that they reduced alcohol consumption: 
“I told him how much how many years I’ve been drinking... and I 
know myself it’s far too much and since I’ve been there I’ve cut 
down I’ve cut down at least 25 units a week” (Subject 111)  
A further participant did not give the details of the change she had made: 
“I tend to take more notice now of what I’m doing and how it 
affects me.”(Subject 45) 
4.3.12 Satisfaction with, and recommendation of, the VRA 
service 
Recommendation of the service 
Participants were asked if they had recommended the service to anyone. 
Almost two third of participants (n = 103, 65%) had recommended the service 
to at least one person: 
Interviewer: Have you recommended the Boots service to 
anybody else, if you don’t mind me asking? 
Subject 141: I have, yes. Quite a few of my friends. I think about 
4 of have already, 3 of the have certainly had it and I think 
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there’s another one, who has an appointment made to come down 
some time fairly soon. 
A further 43 (27%) participants who had not recommended the service stated 
that they would in future if an opportunity to do so arose and it was appropriate 
for them to recommend the service: 
Interviewer: Have you recommended the service to anyone else 
that you can remember? 
Subject 117: No, I don’t think we have. No, I don’t think we 
have. The advert is, was on the counter in the pharmacy in 
Porthcawl, in Boots. 
Interviewer: Do you think you would recommend it, or make 
people aware of it, or is it something that you wouldn’t do? 
 Subject 117: Oh I would yeah, absolutely, not a problem at all. 
One participant has not recommended the service, however, this was mainly 
due to a family bereavement: 
Interviewer: Have you recommended the risk assessment to 
anybody else?  
Subject 145: Well I haven’t really, no… 
Interviewer: Because of the circumstances? 
Subject 145: Yeah. 
 
Those who did not, or would not, recommend the service gave reasons other 
than dissatisfaction: 
“Not really because most of my friends are ok I think... you 
know” (Subject 99) 
“No I haven’t... I don’t have many friends really” (Subject 93) 
“it was well advertised and it’s up to people to take advantage of 
it really” (Subject 1) 
“I don’t pressurise or recommend things to anybody really...[] 
because you know it’s really really personal” (Subject 76) 
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Satisfaction with the service 
Some participants expressed their satisfaction with the service and with the 
pharmacist: 
“...yes I enjoyed the experience with him” (Subject 4) 
“ well he [the pharmacist] did which I thought was very good he 
did actually explain the cholesterol result which I’ve which has 
never been explained to me before so I thought that was quite 
good because then I understood it better” (Subject 38) 
“He [the pharmacist] was ready which suits me because I’m not 
one that likes to hang around for half hour for people, everything 
was prompt everything was done as I would have expected it to be 
done” (Subject 52) 
However there were some participants who criticised certain elements of the 
service, such as the reaction of Subject 2 and Subject 121 when they were 
asked about the usefulness of being told individual risk (Section 4.3.9). Also 
Subject 134 was critical of the place of the weighing machine which was 
reported as being in the middle of shop. Another example of a criticism of the 
service was from one participant could not have the full range of tests because 
he was on warfarin: 
“It was only that factor I think because I travelled from 
Cowbridge down to Porthcawl I might have I might have thought 
twice if... if I’d known beforehand if somebody said to me there’s 
a limited amount you can ask beforehand because they are just 
booking the appointments at Porthcawl the girls do there you 
know... if somebody had asked me are you on any drugs such as 
warfrin something like that I would have then told them and they 
could have explained to me well we will be able to do these tests 
but we won’t be able to do the others” (Subject 28) 
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4.4 Discussion 
The two week follow-up interview was a useful method of gaining an insight in 
the participants’ views of the service. It also captured short-term self-reported 
outcomes including lifestyle changes or starting pharmacological therapy. The 
two week follow-up interviews gave participants the opportunity to comment 
on the service and to express their level of satisfaction to an individual who did 
not provide the service. It allowed the exploration of the views and perceptions 
of 92% of the service users. 
The general literature review presented in Chapter 1 was also relevant to this 
study. There is a gap identified in the literature for studies conducted in the UK 
that explored the views and experiences of individuals who have accessed 
community pharmacy based VRA service. As this study was an exploratory a 
qualitative method was the method of choice (Kairuz et al. 2007). A semi-
structured interview, rather than an in-depth interview, was chosen because of 
the intention of including all participants rather than a small sample in this 
follow-up. Semi-structured interviews have been widely used in pharmacy 
practice research as a data collection tool (Abu-Omar et al. 2000). Qualitative 
analysis of the collected data from interviews of varying depth including the 
semi-structured interviews can be helpful in exploring the reasons behind the 
decisions people make in certain situations (Kairuz et al. 2011). A method 
involving telephone interviews has been used in pharmacy practice research 
conducted in the UK particularly when the opinions and views of pharmacists 
and pharmacy staff were being explored (Cowley et al. 2010; Crabtree et al. 
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2010a; Paudyal et al. 2009). This study has shown that the telephone semi-
structured interview is useful with patients as well. It reduced the time 
constraints on both the participant and the researcher and helped to achieve a 
high response rate. 
Patient satisfaction with the VRA service was measured by an anonymous 
survey (Chapter 3) and also by giving the opportunity to participants during the 
two week follow-up interviews to comment on the service in general. Using 
two different methods approach to examine the same issue, that is, 
triangulation, is useful to increase reliability of the results (Kairuz et al. 2007). 
It is acknowledged that it was not possible to link response provided in the 
questionnaire immediately post-consultation (as these were anonymous) with 
individual responses at interview.  
The aim of having a researcher who did not provide the VRA service to 
conduct follow-up interviews was to provide a situation in which the 
participant could comment freely on all elements of the VRA service. Subjects 
were aware that the interviewer was from the Welsh School of Pharmacy 
although he was independent of the VRA service. The interviewer had the 
opportunity to examine short term outcomes including any changes made by 
the participants, their knowledge of CVD risk, and compliance with referrals to 
health professionals. There is a consensus among researchers that an 
independent evaluation is important to attempt to increase validity to the 
findings (Smith 1998). 
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More than two-thirds of participants had their follow-up interview between 14 
and 21 days following the tests at the pharmacy. While it was planned that the 
telephone interview should take place approximately two weeks following the 
VRA, it was acknowledged that it would be unrealistic for both the researcher 
and participant to be free at the same time. It was decided that having 
flexibility with the interview time would not affect the results providing it 
would take place within an acceptable timeframe; that is, after enough time so 
that participants had the chance to reflect on the information they received, but 
not too long after the VRA so that they could remember the details of the 
experience. However, there was a time when it was impossible to be as rigid as 
we would have liked with that timeframe because of participants’ 
circumstances, for example, a husband and wife asked to have the interview 
three months following the VRA because they were going on a holiday. Also 
some participants had their tests just before the busy period of Christmas 
holiday which meant the interview had to be after the New Year. 
About a third of participants had had a similar test in the past. The majority of 
those who had previous tests had them within a GP practice, followed by 
workplace. Duplication of VRAs would increase the cost of the service on the 
NHS if it was the funder. However, it is unknown whether those who had a 
similar test before were due for another test by the time they visited the 
pharmacy. It is recommended by the Department of Health that the testing is 
repeated every 5 years (DOH 2008c). The service was accessed by patients 
with pre-existing CVD conditions, five of whom said they chose to have the 
tests at the pharmacy to double-check the results they had with their GP.  
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The findings show that 43% of participants were made aware of the service 
after visiting the pharmacy, either from seeing an advert placed in the 
pharmacy or being informed by a member of staff. However, it was recognised 
that the most effective method of attracting individuals to the service was the 
advert which was placed in the local paper. This method attracted 38% of 
participants even though it was only used in the last three months whereas 
other recruitment methods continued over the nine months of providing the 
service. The findings of this study proved that the use of the local media was 
effective in attracting people to a screening service such as the VRA service. 
However, it could not show whether it is the best method to attract those living 
in the most deprived areas (Chapter 2) and/or those who did not access health 
services, for example, NHS primary care services or community pharmacies. 
More than half of participants mentioned at least one risk factor when they 
were asked about the reasons which prompted them to request an appointment 
for the VRA. This finding may indicate that people respond well to an advert if 
curries a meaningful message to them. As the Welsh Government pointed out, 
the marketing materials for the VRA service should be designed and piloted to 
confirm they deliver the message (WAG 2010). Service providers in the future 
may want to include key risk factors on the marketing materials if they want to 
attract people with potentially high risk or hard to reach. As the number of risk 
factors increases in a person the risk of developing a CVD increases. 
The literature search did not identify any relevant UK studies which evaluated 
people’s response to the risk when it is communicated by the pharmacist. Even 
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when the search was extended to other healthcare professionals and other 
settings there is a gap in the literature on what people do with particular pieces 
of information and whether or not they understand it or remember it. 
On the other hand, CVD risk perception in the general population has been 
investigated. Women tend to underestimate their CVD risk because until late 
1980s it was perceived, even among health professionals and researchers, that 
mainly men are affected by the disease (Hammond et al. 2007). This was the 
main reason for not recruiting women in large trials conducted in the past. 
However, in this study women represented only 27% (seven out of 26) of those 
who underestimated their risk. 
Although the majority were able to recall their CVD risk as communicated by 
the pharmacist, those who were identified at moderate or high risk were less 
likely to remember. Those people needed to recall more than the low risk 
group. However, there was no evidence to suggest that being able to remember 
the Framingham risk is linked to the way people would act on the issues which 
increases the risk. To confirm a link between the understanding of the CVD 
risk and the compliance with the advice provided by the pharmacist may 
require further research. 
Service providers in the future may need to provide tailored educational 
materials which explain the interpretation of the CVD risk in order to reduce 
the likelihood of having similar confusion as it was the case in 29% of 
participants in this study.  
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About one-third of participants was referred to GP for further investigations. 
This included patients who were referred because they were identified at high 
risk of CVD and those who were referred because of an issue with one of their 
risk factors, such as having a high blood pressure. Of those who were referred, 
it was established that 45% made their visit to their GP. If this percentage was 
combined with that for the participants who said they intended to go to their 
GP, it would reach 73%. In another study (Boyle et al. 2004) of patients who 
were referred, because they were found to be at risk of hypertension, 
hyperlipidaemia or diabetes, 64% made their visit or were waiting for an 
appointment. 
About a quarter of those who were referred said they did not want to see their 
GP, seven of those were found to be at high risk which means 22% of the high 
risk participants would not be seen by GP. It is important to find ways to 
increase compliance with referral as this could affect the cost-effectiveness of 
the service. One suggestion for consideration would be to require the 
pharmacist to provide relevant information directly to a patient’s GP so at least 
the GP was made aware of the results and could follow-up as appropriate. 
The majority of participants found that it was useful to be informed of CVD 
risk whether they were compliant with the referral or not. Only one person who 
was referred but did not go to the GP thought it was not useful as this was 
perceived as a painful reminder of the loss of her mother. There were a further 
three participants thought it was not useful to be informed about their 
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individual risk. These were not referred and all thought they had a low risk 
(one of them was identified at high risk). 
Participants were asked about the advice related to adapting to, and 
maintaining, a more healthy lifestyle which was provided by the pharmacist. 
Although the discussion generated interesting points regarding the difficulty of 
behavioural change, it was not possible to measure their accuracy in 
interpretation of the advice. This was because the advice provided was not 
documented in any detail. Examples of some inconsistencies, however, were 
evident between self-reporting of alcohol intake and what some participants 
said what their consumption actually was. 
Diet was the most common lifestyle change participants reported having made 
since they had the tests at the pharmacy. Improvements to diet were attempted 
by some participants either to help them in their weight loss effort, to reduce 
their blood pressure (by reducing salt intake) or improving their lipid profile 
(by eating more oily fish). Other changes reported included starting or doing 
more exercise or reducing alcohol intake. 
The service was recommended to others by 65% of those who had the tests and 
further 27% said they would recommend it if there was an opportunity to do so. 
Only a few people said they would not recommend the service for different 
reasons even though they expressed their satisfaction with the service. One 
participant said he would not recommend any health check and not only this 
one because “it is really personal”. 
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4.4.1 Limitations 
The time of the follow-up interview could not be kept within the original 
agreed timeframe of two weeks because of the circumstances some participants 
had. There were some participants (34%) had their follow-up interview in the 
fourth week, or later, following their tests even though the primary aim was to 
have it approximately two weeks following the test. Two participants had a 
period as long as three months following the VRA. This could have been an 
extra time to reflect on the results and make any changes but also this period 
could have been too long to remember the details of the tests and the advice 
provided. 
Although the interviewer who conducted the two-week follow-up interviews 
did not provide the VRA service, he was the principal supervisor and a member 
of the research team. There is a risk of researcher bias which could have been 
reduced by having an independent researcher. 
Not all patients had the telephone interview as one participant did not consent 
for receiving any phone call, and also those who could not be contacted were 
sent a questionnaire covering all the questions in the interview schedule. This 
resulted in six participants completing the questionnaire instead of having the 
full discussion with the researcher.  
Some participants were not asked all the questions in the interview schedule. 
For example, 14 participants were not asked whether or not they found it useful 
to be informed about their individual risk of developing CVD. It was clear that 
this question was omitted when the participant said they did not have the VRA. 
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However, this was not always the case, as the reasons for omitting this question 
was not clear in 11 of the cases which led to missing data. More missing data 
was a result of not including a direct question in the interview schedule to ask 
participants about lifestyle changes they have made. One way to overcome this, 
which itself has limitations, would be to conduct a structured interview. 
The documentation of the details of the advice provided by the pharmacist 
during the consultation was not possible because of time constraints. 
Consequently, participants’ understanding of the advice or their ability to 
remember the details of it could not be investigated.   If the consultation had 
been audio-recorded then this would have been possible following transcription 
but the subjects would need to consent and if they had been recorded this may 
have affected what they said to the pharmacist.  
4.4.2 Conclusion 
The two-week follow-up interviews were conducted by a researcher who did 
not provide the VRA service. The study achieved 92% response rate which 
means the study population was well-represented. Participants were given the 
opportunity to express their views about the VRA service in detail and 
provided some useful explanation and clarification. This was the first study in 
the UK that the short-term outcomes of a VRA service being evaluated.
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5.1 Introduction 
This chapter presents a retrospective analysis of data collected from a VRA 
service other than the service of the main study. A major difference between 
this service and that of the main study is that in order to access this service 
customers were required to pay a charge. 
Community pharmacy has an important role in helping tackle health 
inequalities (DOH 2003). A number of activities have been identified which 
may contribute to this agenda including the provision of screening services, 
particularly if they can reach out to the more deprived sectors of society or 
individuals who are more ‘hard to engage’ in healthcare (DOH 2005).  
To target the ‘hard to engage’, it is essential to have a basic understanding of 
the individuals themselves and how to attract them to the service. There is no 
single definition, however, for this term. The ‘hard to engage’ or the ‘hard to 
reach’ is a term often used differently and is context dependent. The 
Department of Health has issued a leaflet called ‘Addressing inequalities – 
reaching the hard-to-reach groups’ as part of the National Service Framework 
(DOH 2002). Although no definition of “hard to reach” is included therein, it is 
clear that it targets people from deprived areas, those with lower levels of 
education, insecure employment, disability or from a minor ethnic group. The 
following have been identified as ‘hard to reach’: culturally and linguistically 
diverse communities, young, elderly, disabled and homeless people. Other 
difficult to engage groups included drug users, sex workers, those on low 
incomes, high rise apartment dwellers, faith based communities, businesses 
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(traders), single parents, newly arrived residents, gay and lesbian people, 
problem gamblers and residents of hostels and boarding houses. Some rural 
populations may also be considered ‘hard to reach’ (Meredyth et al. 2008). 
In Wales the use of deprivation indices, such the Townsend Deprivation Index 
(TDI) and the Welsh Index of Multiple Deprivation (WIMD), is generally used 
to determine the socio-economic status. However, it is not a measure of wealth 
and it should not suggest that all individuals living in an area of high 
deprivation are poor (CDU 2010; WAG 2008). 
According to Hippisley-Cox et al. (2011) there is an association between 
deprivation and risk of CVD as those who live in most deprived areas are at 
high risk of CVD (Section 1.1.2.6). 
Recent work has indicated that if a VRA service is provided free of charge, 
recruitment across all socio-economic groups can be achieved (Horgan et al. 
2010).  
Whether a service that requires customer payment will attract such a broad 
range of individuals is unknown. The present study was undertaken to explore 
this. 
The aim of this study was: 
 To explore whether a VRA service that requires customer payment 
attracts individuals from areas of different levels of deprivation. 
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5.2 Method 
A retrospective analysis of data obtained from a private VRA service was 
conducted. The service was provided by a large, city centre Boots pharmacy 
with a catchment area from across South Wales and beyond. Individuals aged 
40 to 74 years were eligible and charged £10 to access the service.  
Records of those who accessed the service during the period between January 
2008 and September 2009 were retrieved to capture the data (Table 5-1) 
needed for the analysis by using a data collection tool (Appendix 16). As the 
data were already existed, a retrospective methodology was adopted. The data 
collected as part of the service included information as provided by the 
customer, results of tests and measurements performed by a trained pharmacy 
assistant and 10-year CVD risk as calculated by the pharmacist.  
Table 5 - 1 The data collected using the data collection tool (Appendix 15) 
Source Data 
Information provided by 
service users by self-
completion of a questionnaire 
 Postcode  
 demographic characteristics  
 lifestyle (smoking, alcohol and 
exercise) 
Results of tests and 
measurements performed by a 
trained pharmacy assistant 
 body mass index  
 waist circumference 
 systolic blood pressure 
 blood glucose 
 total cholesterol  
 HDL 
Results provided by the 
pharmacist 
 CVD risk estimated using 
Framingham based charts 
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The Welsh School of Pharmacy ethics committee granted ethics approval prior 
to accessing patients’ records held at the pharmacy. NHS Research Ethics 
Committee approval was not sought as this was a private service not part of the 
NHS.   
Residential postcodes for individuals were allocated to one of five deprivation 
quintiles (Q1 = least deprived; Q5 = most deprived) using the Townsend 
Deprivation Index (CDU 2010). The Townsend Deprivation Index was used in 
this study instead of the Welsh Index of Multiple Deprivation in order to 
include all individuals in the analysis whether they live in Wales or England. 
Table 5-2 shows the proportion of the Welsh population in each Townsend 
quintile. 
Table 5 - 2 Distribution of the Welsh population in the Townsend deprivation quintiles 
 Wales England and Wales 
 (Number of Census Area Statistics wards) 
Q1 (least deprived) 23% (198) 20% (1768) 
Q2 10% (86) 20% (1769) 
Q3 17% (143) 20% (1769) 
Q4 28% (245) 20% (1769) 
Q5 (most deprived) 22% (193) 20% (1769) 
The characteristics and results of those who came from the Q1 were compared 
to those of their counterparts who came from the Q5. Statistical tests used 
include Chi-squared test and Fisher’s exact test, for nominal data and Mann-
Whitney U test for interval data (non-parametric). Data were analysed using 
the statistics programme PASW Statistics 18.   
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5.3 Results 
A total of 132 adults had their CVD risk assessed. Table 5-3 shows the 
demographics and lifestyle characteristics of service users.  
Table 5 - 3 Demographics of all service users 
Demographics Results 
Age Mean = 60 years  
[range 41 to 74, SD = ±8.1]  
 
Number of patients (%) 
Females 95 (72) 
Males 37 (28) 
Family history of CVD 29 (22) 
Ethnicity- White 124 (94) 
Other  7 (5) 
Not provided 1 (0.8) 
Current smokers 16 (12) 
Alcohol  
None 32 (24) 
Within the weekly 
recommended level 
91 (69) 
Exceeding the weekly 
recommended level 
9 (7) 
Exercise  
None 11 (8) 
Some (1 or 2 days a week) 49 (37) 
Moderate (3 or 4 days a week) 48 (36) 
Regular (at least 5 days a week) 24 (18) 
 
 
Chapter 5: Deprivation status and utilization of a non-NHS community pharmacy based VRA 
service 
200 
 
About two thirds of service users were overweight and three-quarters had 
increased abdominal adiposity (Table 5-4). 
Table 5 - 4 BMI and waist circumference of all service users 
 Results (%) 
Mean BMI  26.9 kg/m
2 
[range 19 to 39, SD = ±3.9] 
Less than 25 43 (33) 
25 to 29.9 64 (48) 
30 to 34.9 22 (17) 
35 or above 3 (2) 
Waist circumference:  
OK (acceptable size) 31 (24) 
Increased risk 37 (28) 
High risk 62 (47) 
 
Results of systolic blood pressure measurements and cholesterol tests are 
summarised in Table 5-5. Also Table 5-6 shows the results of the 10-year CVD 
risk of all service users. 
Table 5 - 5 Systolic blood pressure and lipid profile of all service users 
 Results: mean 
Systolic BP 125 mmHg  
(range 90 to 174, SD = ±15.4) 
Total Cholesterol 4.91 mmol/L  
(range 3.05 to 8.78, SD = ±0.98) 
HDL cholesterol 1.27 mmol/L  
(range 0.64 to 2.26, SD = ±0.35) 
Total Cholesterol: HDL ratio 4.1 
(range 2.3 to 7.9, SD = ±1.1) 
 
 
Chapter 5: Deprivation status and utilization of a non-NHS community pharmacy based VRA 
service 
201 
 
Table 5 - 6 Results of 10-year CVD risk calculated using the Framingham based BNF charts 
 Number of patients (%) 
Low risk (< 10%) 85 (64) 
Moderate risk (10-20%) 35 (27) 
High risk (> 20%) 12 (9) 
 
Those who were identified at high risk were referred to their GP. Other reasons 
service users were referred to their GP include high blood pressure 15 (11%) 
and high fasting glucose 7 (5%).  
There were 124 (94%) service users who had a valid postcode and therefore 
could be allocated a deprivation quintile (Table 5-7). Of the 124 service users 
there were 33 (27%) males and 117 (94%) Caucasians.  
Table 5 - 7 Individuals within each quintile 
Townsend Deprivation Quintiles  No. (%)  
Q1 (Least deprived)  43 (35)  
Q2  13 (11)  
Q3  23 (19)  
Q4  19 (15)  
Q5 (Most deprived)  26 (21)  
 
There were no significant differences in demographic characteristics or 
lifestyle between Q1 and Q5 except the mean age of subjects in Q1 was higher 
and the proportion of smokers in Q5 was higher (Table 5-8).  
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Table 5 - 8 Comparison of lifestyle of individuals from Q1 and Q5. (%) 
 Q1 Q5  p value 
Mean age (years) 63 (±7.1) 56.9 (±7.9) 0.001
§
 
Smokers no. (%) 1 (2) 5 (19) 0.026† 
Alcohol consumption    0.428*  
None  9 (21)  7 (27)   
Low/moderate  32 (74)  16 (62)   
Unhealthy  2 (5)  3 (11)   
Exercise    0.657*  
None  2 (5)  2 (7)   
Low 17 (40)  9 (35)   
Moderate  17 (40)  8 (30)   
Regular  7 (16)  7 (27)   
§ Mann-Whitney U test. † Fisher’s exact test. * Chi-squared test  
± = standard deviation 
 
Also no significant difference was found in BMI or in waist circumference 
between Q1 and Q5 (Table 5-9). 
Table 5 - 9 Comparison of BMI and waist circumference of Q1 and Q5 patients 
 Q1  Q5  p value  
Mean BMI (SD)  26.1 (±3.4)  27.4 (±3.7)  0.105
§
  
Waist circumference    0.263**  
OK  14 (33)  4 (15)   
Increased risk  11 (26)  9 (35)   
High risk  17 (40)  13 (50)   
§ Mann-Whitney U test ** Fisher’s exact test 
The difference between the mean systolic blood pressure of those from the 
least deprived areas and the mean of the most deprived areas was not 
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significant. This was the case for the total cholesterol, the HDL and the total 
cholesterol: HDL ratio (Table 5-10). 
Table 5 - 10 Comparison of means (SD) of subjects in Q1 and Q5 patients. Statistics: Mann-
Whitney U test 
 Q1  Q5  p value  
Systolic BP 
129.4 mmHg (±14.7)  127.6 mmHg (±18.2)  0.488  
Total cholesterol  4.78 mmol/L (±0.89)  5.02 mmol/L (±0.98)  0.207  
HDL  1.21 mmol/L (±0.28)  1.30 mmol/L (±0.32)  0.334  
Total cholesterol 
to HDL ratio  
4.07 (±0.92)  4.07 (±1.27)  0.585  
Glucose  5.24 mmol/L (±0.85)  5.59 mmol/L (±1.40)  0.762  
Fasting glucose  5.21 mmol/L (±0.86)  5.36 mmol/L (±1.39)  0.892  
 
Although the percentage of those who were identified at high risk was higher 
for the Q5 individuals than the Q1 individuals, the difference was not 
statistically significant (Table 5-11). 
Table 5 - 11 Individuals at low, moderate and high CVD risk 
 Q1   Q5  
Low risk (<10%) 25 (58)  17 (65)  
Moderate risk (10-20%) 14 (33)  4 (15)  
High risk (>20%) 4 (9)* 5 (19)* 
* p = 0.282 Fisher’s exact test  
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5.4 Discussion 
The aim of this study was to explore whether a VRA service that requires 
customer payment attracts individuals from areas of different deprivation 
levels. Of the 132 individuals who had a VRA in the pharmacy, 124 (94%) had 
accurate postcodes so they were allocated to their deprivation quintiles. 
To date, no studies in the literature were found which evaluated the 
accessibility of a non-NHS VRA service according to deprivation. Horgan et 
al. (2010) suggested that if a VRA service is provided free of charge, 
recruitment across all socio-economic groups can be achieved. 
Of the service users (n = 124) who could be allocated a deprivation quintile, 
21% resided in the most deprived areas. This proportion was higher than other 
individuals from areas of less deprivation (Q2 and Q4). It was similar to the 
proportion (19%) of participants from Q3. However, the proportion of those 
living in the most deprived areas was lower than the proportion (35%) of those 
living in the least deprived areas (Q1).  
Although there was a levy of £10 to access the service, the proportion of those 
who were from the most deprived areas was similar to the ‘Heart MOT’ pilot 
(19%) which was free of charge and directed at the most deprived areas 
(Horgan et al. 2010). 
The present study compared the results of those from the most deprived areas 
with those from the least deprived areas. There was no significant difference in 
tests results nor referrals to GP between the two groups.   
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More effort is needed to be invested to increase access to services for deprived 
populations to tackle health inequalities (Richards 2009). However, some 
clusters of the society, for instance ethnic minorities, tend to utilise the health 
system including the pharmacy services less frequently (Jerrell and Sakarcan 
2009). This study originally aimed to see whether this VRA service was 
accessible by the “hard to engage” groups, including men, elderly, 
unemployed, those from low-income households and minor ethnic groups. 
However, as the study was conducted retrospectively only limited information 
was available to determine whether or not any of those who accessed the 
service were from a hard to engage group other than being male, elderly or 
from an ethnic minority. 
The service recruited fewer men (28%) than women. It is probably the location 
of the pharmacy, being in a large shopping centre.  Other studies showed also 
the proportion of male service users is quite low; for example, in one study 
conducted in Australia only 29% were males (Peterson et al. 2010) and in 
another study conducted in Northern Ireland males were just under one third 
(32%) of all participants (O'Donovan et al. 2010).  
Only 6% of the service users were from an ethnic minority background. It is 
estimated that in Cardiff, the capital city of Wales, 10% of the population are 
ethnic minorities (Welsh Goverment 2010). 
5.4.1 Limitations 
The data were obtained from a single pharmacy and only a small number of 
subjects had accessed the service over an 18 month period which means about 
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seven assessments every month. It was less likely to detect any difference in 
test results because of the small number of individuals at each deprivation 
quintile.  
The study was retrospective which limited the evaluation only to those who 
had a valid residential postcode in their records. Also, because of the limited 
information in records, the identification of the ‘hard to engage’ groups could 
only be limited to men, ethnic minorities and those living in the most deprived 
areas.   
Although deprivation indices are commonly used as an indicator for socio-
economic status, it does not provide sufficient information about the individual 
concerned, such as their income, wealth, education and occupation (CDU 
2010). There is a possibility that a wealthy person living in an area with higher 
deprivation access the service and he or she cannot be representative to the 
people with low socio-economic status. Poorer individuals living in 
communities with high deprivation are most likely to have the worst health 
outcomes (Stafford and Marmot 2003). Therefore, the use of deprivation 
indices in small sample size studies is probably less useful than in larger 
studies where the sample is more representative of the area of deprivation in 
general.    
These limitations prevent any generalisability of the results.  
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5.4.2 Conclusion 
This study has shown that a paid for community pharmacy VRA service was 
accessed by a group of individuals including those from the most deprived 
areas. There was no significant difference between the proportions of 
individuals from the least and most deprived areas referred to their GP because 
of CVD risk.  
Although, the service was not designed to target high deprivation or hard to 
reach groups, males and non-Caucasians were under represented in the study, 
suggesting that groups known to be more difficult to engage may be less likely 
to access and thereby benefit from a community pharmacy based screening 
service which levies a charge. 
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6.1 Introduction 
This chapter presents a retrospective analysis of data obtained from an MUR 
service in one of the venues where the main study (that is, the VRA service) 
was conducted. A comparison was made between the demographic 
characteristics of those who accessed the MUR service and those who accessed 
the VRA service. 
The Medicines Use Review (MUR) is an advanced service provided by 
accredited pharmacists as part of the current Community Pharmacy Contract 
with the NHS in England and Wales. The service is a consultation between the 
pharmacist and patient on medicines for chronic conditions (PSNC 2004).  
There is a fixed fee for every MUR that is completed (£23, 2011). The 
maximum number of MUR for any pharmacy to provide is 400 per year, unless 
an agreement with the Local Health Board was obtained (NHS Wales 2011). 
According to The Pharmaceutical Services Negotiating Committee (PSNC), 
the body representing pharmacy contractors for England, the aim of the MUR 
is to improve the use of medicines by helping patients understand the treatment 
they are on, identifying any issues with their treatment, and find possible 
solutions to solve the identified issues (Panel 6-1).  
Chapter 6: Analysis of the medicine use review data in a Boots pharmacies in Wales with a 
focus on cardiovascular diseases 
210 
 
Panel 6 - 1 The definition of the Medicines Use Review by the Department of Health 
(Blenkinsopp et al. 2007). 
A Medicines Use Review aims “with the patient’s agreement, to improve 
his knowledge and use of drugs by in particular: 
a- establishing the patient’s actual use, understanding and experience 
of taking drugs;  
b- identifying, discussing and resolving poor or ineffective use of 
drugs by the patient; 
c- identifying side effects and drug interactions that may affect the 
patient’s compliance with instructions given to him by a health care 
professional for the taking of drugs; and 
d- improving the clinical and cost effectiveness of drugs prescribed to 
patients thereby reducing the wastage of such drugs.” 
 
There have been several published studies evaluating the MUR service since it 
was introduced in April 2005 (Blenkinsopp et al. 2008; Blenkinsopp et al. 
2007; Latif and Boardman 2008; Latif and Boardman 2007; Latif et al. 2011; 
Portlock et al. 2009; van den Berg and Donyai 2010). The adoption of the 
MUR service was evaluated after the first year of implementation through a 
questionnaire sent to primary care organisations and structured telephone 
interviews of Strategic Health Authority in England and the Welsh 
Government in Wales. Payment for providing MURs in the first year of the 
service was claimed by 38% of community pharmacies. Pharmacies from 
multiples were the highest in implementing the service undertaking about 84% 
of all MURs. Views identified from the survey and the structured telephone 
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interview suggested that MURs had considerable potential but progress was 
slow. A number of barriers were identified by the study including lack of 
remuneration for the implementation of the new service and the suitability of 
the place for the service. Other barriers were more specific to the 
independently owned pharmacies such as lack of corporate system to share the 
work (Blenkinsopp et al. 2007). 
The progress in the provision of the MUR service in England and Wales in its 
second year was evaluated by Blenkinsopp et al. (2007). Community 
pharmacies from a stratified random sample (n = 733) of 31 primary care 
organisations in England and Wales were included in this study. Routinely 
collected data were analysed retrospectively. There was an increase (from 38 to 
67.2%) of community pharmacies providing the MUR service in the second 
year of implementation, a more than fourfold increase in the total number of 
MURs provided (n = 62,559), with the mean number of MURs increasing from 
36 to 85 MURs per pharmacy. The domination by multiples as providers of 
MURs (82%) continued in the second year of implementation with 78% of 
those not providing MURs being independents. Twenty-one independents had 
no MURs in the second year even though they were existing MUR providers in 
the first year. Only a small number of pharmacies (11 out of 733) provided the 
maximum number of 400 MURs for the year. The authors suggested the 
successful adoption of the MUR service was less likely to occur in 
independents when compared with the multiples (Blenkinsopp et al. 2008) 
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A prospective study using questionnaire feedback evaluated the outcome of 
MURs targeted at patients with asthma. A total of 965 individuals who 
received an MUR from community pharmacies (n = 46) in the Hampshire and 
Isle of Wight Local Pharmaceutical Committee area during July to December 
2007 were surveyed. The service identified more than a third of individuals as 
primarily non-adherent (prescriptions not dispensed) and about two thirds as 
secondary non-adherent (prescriptions dispensed but medication not used). 
Adherence issues identified included difficulty using the inhaler (281, 29%), 
incorrect beliefs about their medicines (236, 24%), and due to other medicines 
issues, e.g. side effects (141, 15%). The response rate to the questionnaire was 
24% (n = 230). A third of the respondents used the MUR service to gain more 
confidence. The authors reported high satisfaction with the service among 
respondents. Feedback from the small number of GPs (15 out of 46) who 
responded to the questionnaire was positive as 12 agreed that community 
pharmacists have an important role to play in the management of asthma and 
11 agreed that the service is of benefit to asthmatic patients (Portlock et al. 
2009).  
Community pharmacists’ attitudes toward the MUR service were evaluated by 
a survey which identified a number of barriers that community pharmacists 
perceived (Latif and Boardman 2008). Barriers identified included the 
availability of an adequate consultation room, the time and trained pharmacy 
support staff. The number of MUR performed was affected by the number of 
hours the pharmacist worked per week with those working more than 20 hours 
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a week performed significantly more MURs than those who work less than 20 
hours. 
The consultation skills of community pharmacists were criticised by one study 
(Latif et al. 2011). The authors suggested that MUR sessions tended to be brief 
and closed questions used by the pharmacists which did not give patients the 
opportunity to ask questions. Also, the authors suggested that the MUR had 
limited effect on patient knowledge.  
A retrospective audit of MUR forms was conducted in August 2008 which 
included all community pharmacies of a large multiple chain within a specific 
district in South-East England (n = 33) (Donyai and van den Berg 2009). The 
audit aimed to evaluate MUR forms completed during a one month period, 
June 2008. A total of 464 MUR forms (46% male) from 17 (51.5%) 
pharmacies were received and included in the analysis. The mean of items per 
patient was 5.03 (range 1–17) and only 3% of patients were on one item. The 
most common type of medicines (45.1%) in all MUR forms were related to the 
cardiovascular system, but the proportion of patients on these medicines was 
not reported. Recommendations reported in 34% of the submitted MUR forms 
and they were as the following: lifestyle recommendations (24.7%), 
interactions and contraindications (23.4%), adherence (34.8%), synchronisation 
of repeats (3.2%) and patients advised to talk to their GP (32.9%). This audit 
which used a readily available tool (RPSGB 2009) did not seem to evaluate the 
quality of each recommendation in the submitted forms. 
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Patients’ satisfaction with the MUR service was discussed at the 2010 
conference of Health Services Research and Pharmacy Practice (Donyai and 
van den Berg 2009). The researchers pointed out the importance of measuring 
patients’ satisfaction. As there was a limited number of satisfaction 
questionnaires to evaluate pharmacy services the researchers were developing a 
specific questionnaire to be used in MUR satisfaction surveys. Interviews of 
those who received an MUR were being conducted to “identify relevant 
concepts and develop a conceptual framework to inform item development for 
a Patient Reported Outcome Measure questionnaire bespoke to the MUR”. 
Community pharmacy has been recognised as a crucial player in the healthcare 
system to tackle health inequality (DOH 2003). Many primary care 
organisations have commissioned services such as the provision of emergency 
hormonal contraception and quit smoking services through pharmacies. Some 
pharmacies have been chosen to take part in these schemes because they have 
been located in areas with higher deprivation in order to reduce health 
inequality (DOH 2005). However, any evidence to support the contribution of 
pharmacy in reducing health inequality is lacking. Ideally pharmacists should 
be encouraged to actively target the hard to engage groups when they promote 
healthy choices, signpost healthcare services and when they directly provide 
service. 
The government has stated that the MUR service should be targeted to those 
who would benefit the most from the service. This came after a criticism made 
by the DOH of the way pharmacists conduct MURs, which was highlighted in 
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the 2008 White Paper (DOH 2008b). It suggested that some MURs are of 
limited quality and patients on a single prescribed medicine being selected as 
an easy way to reach their targets (McDonald et al. 2010). The surge in 
conducting high number of MURs in the last financial month of the year was 
also thought to affect the quality of MURs (DOH 2008b). The DOH 
emphasised that primary healthcare organisations should prioritise MURs to 
meet local health needs. It has been suggested MURs be targeted at individuals 
who have been discharged from hospital and those taking medicines associated 
with high hospital readmission rate, e.g. diuretics, non-steroidal anti-
inflammatory drugs and antiplatelet drugs (Livingstone 2010). Other groups 
with possible adherence issues could also be targeted and include those who 
receive polypharmacy and/or treatment with complex regimens (Bangalore et 
al. 2007). 
Community Pharmacy Wales is the body responsible for liaising with the 
Welsh Government and for negotiating the contractual terms for the provision 
of the NHS community pharmacy services including the MUR service 
(CPWales 2011a). Up to now most of the English National Pharmacy Contract 
negotiated by PSNC has been adopted by the Welsh Government (PSNC 
2011). However, this is expected to change as Welsh contractual arrangements 
continue to differ from those in England. 
In Wales, two new relevant services have been introduced recently. The 
targeted MUR service was introduced on 1
st
 December 2011 which required 
community pharmacists to provide half of MURs to patients from selected 
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groups and they include those taking antihypertensive medicines, with 
respiratory diseases, those taking high risk medicines such as lithium, NSAIDs 
and warfarin, and those being prescribed a medication they no longer require 
(RPS 2011b). A second service introduced in Wales on 1
st
 November 2011 is 
the Discharge Medicine Review Service which requires the pharmacists, in 
addition to ensuring patients have the maximum benefits from their treatments, 
also to check for discrepancies in medications between prescriptions issued by 
the hospital and the GP (CPWales 2011b). 
No published study to date has evaluated the accessibility of the service 
according to the socio-economic status of the patient or focussed on MURs 
relating to medicines used in CVD.  
The aim of this study was to explore these issues using MUR records from a 
Boots pharmacy. 
Aim 
The aim of this study was to retrospectively analyse the MUR data obtained 
from the forms completed in Boots pharmacy, Porthcawl, South Wales.  
Objectives 
- Identify the proportion of MURs completed for those who were 
receiving cardiovascular medications. 
- Determine the number of issues identified in the MUR. 
- Determine the proportion of issues to be resolved by the pharmacist, GP 
and patient. 
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- Explore whether the MUR service has been accessed by a range of 
individuals living in areas of different levels of deprivation. 
- Compare the deprivation status of patients who have received the MUR 
service with those who have accessed the VRA service. 
- Determine whether those considered hard-to-reach were likely to be 
recruited for the service. 
- Determine whether the demographical characteristics of individuals 
who had MURs at the start of the year would be different when 
compared with those who had MURs at the end of the financial year. 
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6.2 Method 
Although anonymous data were collected, the Welsh School of Pharmacy 
ethics committee was approached to have the protocol to be reviewed. Ethics 
committee approval was obtained in September 2010 prior to the collection of 
data. 
As the data was previously available in the pharmacy, a retrospective design 
was chosen for this study. The research pharmacist was a Boots employee. As 
a consequence, and as part of the normal provision of NHS care, access was 
possible to the patient data stored in the pharmacy. The anonymous data 
required for the study were acquired from the MUR forms (Appendix 17) 
completed during the period from April 2009 to March 2010. The data were 
entered into two Microsoft Access files using a password protected notebook 
computer. The first file was used to enter a unique identification code for each 
patient and their postcode. The second file was used to enter the same 
identification code and the remainder of the data collected. Each file was 
protected by a different password from the other file and from the computer’s 
main password. A screenshot showing the data collection form within Access 
is provided (Appendix 18). The analysis of the anonymous data was then 
carried out at the Welsh School of Pharmacy. The data were mainly obtained 
from the hard copies of the completed MUR forms, however, occasionally 
when information was missing, for example postcode or age, the Patient 
Medication Record (PMR) within the pharmacy was used to access this 
information.  
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The expected number of MURs was 400 which was the maximum number of 
MURs any pharmacy can claim for per year. The collected information 
included date of review, gender, age, postcode, number of medicines, number 
of identified issues, type of CVD medicine as classified by the BNF (2011) if 
used and the person responsible for any action recommended.  
The issues counted from the MUR forms were anything raised by the 
pharmacist which could include a counselling point, an issue with compliance, 
a suspected adverse effect, a drug-drug interaction, or provision of life-style 
advice. 
The demographics of those who accessed the MUR service at the start of the 
year were compared with those who received an MUR at the end of the 
financial year. This analysis was undertaken to see if pharmacy staff were more 
or less likely to approach certain groups of clients towards the end of the year. 
Postcodes for individuals were allocated to one of five deprivation ranks using 
the Welsh Index of Multiple Deprivation (WIMD). Rank 1 being the most 
deprived areas and Rank 5 the least deprived (WAG 2008). Townsend 
Deprivation Index (TDI) (CDU 2010) was also used in the analysis to 
overcome some of the disadvantages associated with WIMD. 
Descriptive data and frequencies were calculated using PASW Statistics 18. 
The socio-economic status of those who received an MUR was compared to 
those who had a VRA using Pearson Chi square test. 
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A request to Boots head office was made for a list of postcodes of those who 
received prescriptions from the pharmacy to compare their socio economic 
status with the MUR service users. Permission to access the full postcode of 
each patient was not forthcoming because of technical difficulties and 
confidentiality concerns. However, a list of incomplete postcodes, only the 
postcode sector (e.g. PO16 7), was provided for the period 1
st
 February 2009 to 
31
st
 January 2010. 
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6.3 Results 
Four hundred and five MURs were undertaken in 2009/10; the pharmacy was 
remunerated for the first 400 MURs only. One hundred and fifty (37%) of 
recipients were male, mean age was 60.5 years and almost half of service users 
were elderly, that is, 65 year old and over. Only 15 patients (4%) were on a 
single prescribed medicine. The majority of patients (71%) were on CVD 
medicines (Table 6-1).  
Table 6 - 1 Summary of characteristics of all MUR users 
Characteristic Number (%) 
Gender: Male 150 (37) 
Female 255 (63) 
Mean age 60.5 years (ranged from 18 to 88 years 
and SD = ±15) 
Elderly 186 (46) 
Median number of items 4 (Range 1 to 12 items) 
Patients on CVD medicines 289 (71) (Range 1 to 6, median 2 items) 
 
The majority of the service users were from the least deprived areas whether 
their socio-economic status was determined by WIMD or TDI (Table 6-2).  
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Table 6 - 2 Socio-economic status according to WIMD and TDI determined by postcode of 
residence 
  WIMD  
Number (%) 
TDI 
Number (%) 
Most deprived Rank 1 = 1 (0.3) Q5 = 10 (3) 
 Rank 2 = 3 (1) Q4 = 162 (40) 
 Rank 3 = 50 (13) Q3 = 1 (0.2) 
 Rank 4 = 97 (25) Q2 = 0 
The least deprived Rank 5 = 243 (62) Q1 = 231 (57) 
Total  391 (missing* = 11) 404 (missing* = 1) 
* missing = patients who could not be allocated to a deprivation area 
 
When using TDI, more patients were considered from the most deprived areas. 
This could not be compared with the socio-economic status of users of the 
pharmacy in general because of the limited information received from Boots 
head office. However, the list of the postal sectors received from the head 
office showed that 77% of pharmacy users who dispensed their prescription 
from 1st February 2009 to 31st January 2010 were from the surrounding 13 
Lower Layer Super Output Areas (LSOA). According to WIMD eight out of 
these 13 LSOAs were in rank 5 (the least deprived), three LSOAs were in rank 
4 and two were in rank 3 (non of these LSOAs were in rank 2 or 1). The 
remaining 23% of patients came from different areas with different levels of 
deprivation, and some of them were from the most deprived areas. With the 
limited information received from the Boots head office, however, it was not 
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possible to determine exactly what the proportion was for those who resided 
the most deprived areas. 
According to TDI, 77% of patients came from 9 Census Area Statistics (CAS) 
wards, four CAS wards were categorised as Q1 (least deprived), four CAS 
wards as Q4, and one CAS ward as Q5 (most deprived). 
There was no significant difference (p > 0.05, Pearson chi-square test) in the 
socio-economic status between those who received an MUR and those who 
accessed the VRA service in Porthcawl (Table 6-3). On the other hand, when 
TDI was used the difference was significant (p < 0.001, Pearson chi-squire 
test) between the proportions of users living in the most deprived areas in each 
service (Table 6-4). 
Table 6 - 3 Comparison of socio-economic status of VRA clients versus MUR clients 
according to WIMD (p > 0.05, chi-square test) 
WIMD 
 VRA  
Number (%) 
MUR 
Number (%) 
Rank 1 (Most deprived) 0 1 (0.3) 
Rank 2  3 (2) 3 (1) 
Rank 3  12 (9) 50 (13) 
Rank 4  25 (19) 97 (25) 
Rank 5 (Least deprived) 89 (69) 243 (62) 
Total 129 (4 missing) 394 (11 missing) 
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Table 6 - 4 Comparison of socio-economic status of VRA clients versus MUR clients 
according to TDI (p < 0.001, chi-square test) 
TDI 
VRA  
Number (%) 
MUR 
Number (%) 
Q5 (Most deprived) 14 (11) 10 (2) 
Q4  37 (29) 162 (40) 
Q3  7 (5) 1 (0.2) 
Q2  6 (5) 0 
Q1 (Least deprived) 65 (50) 231 (57) 
Total 129 (4 missing) 404 (1 missing) 
 
The majority of treatment regimens were once daily doses with 87% of 
patients’ medicines being prescribed as such (Table 6-5). A third of patients 
were on medication with “As directed by the prescriber” as the directions for 
use on the label.  
Table 6 - 5 Treatment regimen frequencies for patients who received an MUR. Some 
patients had different treatment regimen frequencies for different drugs (so %s add up to 
>100%) 
Dose frequency Number (%)  
Once daily 354 (87) 
At night 156 (39) 
Twice daily 143 (35) 
Three times a day 78 (19) 
Four times a day 84 (21) 
When required 58 (14) 
As directed 124 (31) 
Weekly 22 (5) 
Monthly 3 (1) 
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About a third of patients (34%) who received an MUR were on lipid regulating 
drugs. Table 6-6 shows the proportion of patients on each class of CVD 
medicines.   
Table 6 - 6 Class of CVD medicine by BNF Chapter 2 subheadings (Number of patients = 289) 
Class of CVD medicine Number (%)  
Positive inotropic drugs 2 (1)  
Diuretics 52 (18) 
Anti-arrhythmic drugs 3 (1) 
Angiotensin-converting enzyme inhibitors 85 (29) 
Angiotensin-II receptor antagonists 27 (9) 
Nitrates 15 (5) 
Calcium-channel blockers 46 (16) 
Anticoagulants 17 (6) 
Antiplatelet drugs 79 (27) 
Lipid regulating drugs 137 (47) 
 
Most MURs (n = 396, 98%) identified at least one issue and a few identified up 
to four issues (Table 6-7). According to the MUR forms, not all issues required 
an action by any person and some issues were required more than one person to 
resolve (Table 6-8). Only eight patients were referred to other healthcare 
professionals. 
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Table 6 - 7 Number of issues per MUR (total number of issues = 672) 
Number of issues Number of 
patients (%) 
No issues 9 (2) 
One issue 158 (39) 
Two issues 203 (50) 
Three issues 32 (8) 
Four issues 3 (1) 
 
 
Table 6 - 8 Person who was asked by pharmacist to action the issue. Some forms had > 1 
selection (n = 31 forms) 
Issue(s) to be 
actioned by 
Number (%) 
Pharmacist 26 (7) 
Patient 14 (4) 
GP 6 (2) 
Practice nurse 2 (1) 
 
Characteristics including age, gender and deprivation status of the first 50 
patients who received an MUR were similar when compared to the last 50 
patients who had an MUR in the financial year 2009-2010 (Table 6-9). 
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Table 6 - 9 Comparison between characteristics of the first 50 patients and the last 50 
patients (p > 0.05, chi-square test) 
 First 50 
patients 
Last 50 patients P value 
Elderly 29 (7%) 21 (5%) > 0.05 
Male 18 (4%) 21 (5%) > 0.05 
WIMD rank 3 6 (2%) 6 (2%) > 0.05 
rank 4 13 (3%) 15 (4%)  
rank 5 29 (7%) 28 (7%)  
TDI Q 5 0 1 (0.2%) > 0.05 
       Q 4 23 (6%) 24 (6%)  
       Q 1 27 (7%) 25 (6%)  
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6.4 Discussion 
6.4.1 Overview 
The MURs were undertaken mainly by individuals who were from the least 
deprived areas. When compared with the VRA service, significantly fewer 
people from the most deprived areas (TDI) accessed the MUR service. The 
recruitment strategies were different for each service. but it would be helpful to 
investigate further whether the different types of services attract people from 
different areas of deprivation. 
6.4.2 Major findings 
The data was obtained for a full financial year (from 1
st 
April 2009 to 31
st
 
March 2010). This was important because anecdotal reports suggested that the 
recruitment was different during the financial year as more patients were 
recruited at the end of year which means pharmacies focus on quantity rather 
than quality of MURs.  
The MUR service at Boots Porthcawl was accessed by 405 patients over a 
whole financial year. Female patients accounted for 63% of patients and the 
average age was 60.5 years (with a range from 18 to 88 years). Ethnicity was 
not recorded in the MUR form. For future research and auditing purposes the 
ethnicity should be included to monitor how ethnic minorities are utilising 
these services. 
Although pharmacists were aware of, through training and the briefings they 
received from their managers, the maximum number of MURs that the 
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pharmacy would be remunerated for the pharmacy exceeded the 400 MURs in 
the year. It was unknown whether these extra MURs were done as a tool of 
recording an intervention or to refer to other healthcare professionals as the 
reason behind this was not explored. 
 Proportion of MURs for patients with CVD 
More than two thirds of those who had an MUR were on one or more CVD 
medicines. It was not clear whether the pharmacist was actively targeting 
patients on CVD medicines. Since 1
st
 December 2011 patients with CVD 
became one of the groups to be targeted to receive an MUR in Wales (RPS 
2011b). The proportion of medicines for the cardiovascular system was 
reported as the highest (45%) by a retrospective audit (Donyai and van den 
Berg 2009), but the proportion of patients on CVD medicines was not reported. 
 Number of issues identified in the MUR 
The majority of MURs raised at least one or two issues. Most of these issues 
did not specify who was the person responsible to deal with them, with only 
eight patients being referred to other healthcare professionals. Mostly the 
pharmacist was required to action the identified issues.  
Many of the patients were on a treatment with a complex regimen and there 
was a number of patients who were receiving polypharmacy. These would 
benefit from such a service to identify any compliance issues. However, the 
types of issues were not explored by this study and it was not recorded how 
many of the issues identified were compliance issues. 
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The demographic characteristics of service users confirmed others’ work to 
suggest that men are less likely to take advantage of health services available. 
The study confirms also the work by van den Berg and Donyai (2010) that 
pharmacists did not target easy patients to perform MURs as only few MURs 
were provided to patients with a single medication treatment. 
 The proportion of issues to be resolved by the pharmacist, other 
healthcare professionals and patient 
Out of 405 MUR forms conducted in this pharmacy, only 31 MURs (48 issues) 
specified the person who should action the recommendations. It was unclear if 
this means the majority of the issues raised (total number = 672) did not 
require any action or there were incomplete forms included. The pharmacist, 
according to the MUR forms, had to deal with 26 issues whereas eight patients 
were referred to other healthcare professionals. 
 The socio-economic status of the service users 
The majority of the Boots pharmacy users in Porthcawl come from the less 
deprived areas. Also, the surrounding residential areas are mostly of lower 
deprivation. However, this does not fully explain why the MUR service was 
accessed by a low proportion of those living in the most deprived areas. In 
order to address health inequalities, the pharmacy should adopt a new strategy 
to encourage those from the most deprived areas to receive the MUR. 
The demographic characteristics of the first and the last 50 MURs were similar 
which suggest that patients were not recruited differently on the basis of these 
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characteristics in the beginning and at the end of the financial year. 
Furthermore, it is not possible to generalise as the data were collected from one 
pharmacy and only for one year. 
When comparing with other services, the number of men was expected to be 
low. They need to be targeted and encouraged to have the review. 
 The deprivation status of patients who received the MUR service 
compared with that of those who accessed the VRA service 
The proportion of the MUR patients with low deprivation status was 
significantly lower than those who accessed the VRA service at the same 
pharmacy, that is, 2% versus 11% respectively (p < 0.001, Pearson chi-squire 
test). However, the proportions of both services were lower than the general 
population (20%) (CDU 2010).  
6.4.3 Limitations 
Although the focusing on one pharmacy allowed looking into the data in more 
detail, the evaluation of such data from a single pharmacy was not enough to 
provide a complete picture of what is going on in pharmacy with regard to the 
MUR service. The results of this study cannot be generalised across the UK. 
In this study deprivation as a surrogate marker for socio-economic status of the 
service users was determined by using two different indices. The WIMD was 
used because it was the index recommended by the Welsh Government when 
assessing local needs. However, when using WIMD 50% of the Welsh 
population are considered as being from the least deprived areas and only 10% 
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from the most deprived areas. This division was a problematic in the present 
study as the sample size was small and that limited the statistical tests which 
could be used to compare the two services. 
As this was a retrospective study, it was limited by the extent of the availability 
of information in the MUR forms. Some forms were not complete in term of 
demographic data and other data. Also as no clinical data was acquired to go in 
the MUR forms, the indication of some CVD medications could not be 
confirmed whether they were for a CVD or for another condition.  
In addition, other ‘hard to engage’ groups, for example ethnic minorities, could 
not be confirmed if they were received the service as ethnicity was missing 
from the MUR form. 
The results would have been more meaningful if it was possible to compare the 
demographics of those who received an MUR with the average pharmacy users 
in general. The deprivation status of the pharmacy users was estimated by a list 
of incomplete postcodes obtained from Boots head office because, for technical 
problems and concerns over confidentiality, the complete postcode of each 
patient was not provided. However, even with a complete list there will be a 
limitation in using this method as postcodes of the pharmacy users include all 
those who have their prescriptions dispensed at the pharmacy, that is, those 
who have their medicines delivered are not excluded. In other words, even if 
the list provided was complete there is still uncertainty about who actually 
visits the pharmacy and being offered an MUR and who have other means to 
collect their medications. Even if the pharmacy is offering the service to all 
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those who visit the pharmacy, it is expected that some of the pharmacy users 
will be missed by the current recruitment strategy.   
The evaluation of the quality of the MURs was not one of the objectives of the 
study. Therefore, even though the number of issues was high, it was unknown 
whether these MURs were all of good quality. 
No follow-up was made with regard to any outcomes of the MUR service. It 
could not be determined whether those who were referred to other healthcare 
professionals actually went to see their GP or nurse as recommended by the 
pharmacist. It was unknown whether or not any of the issues identified by the 
pharmacist through the MUR sessions were resolved. However, it is important 
to note that this was not an aim of the study. Future work is warranted to 
address these issues.  
6.4.4 Conclusion 
This retrospective study analysed 405 MUR forms conducted over 12 months 
in one community pharmacy in South Wales. A total of 672 drug-related issues 
were identified by the pharmacists. The median number of items per patient 
was 4 and only 3.7% of patients were on a single item. More than two thirds 
(71%) of patients were on one or more CVD medications. 
This study helped to identify the demographic characteristics of the MUR 
service users at Boots Porthcawl which allowed the comparison with the 
participants of the main study (the VRA service). This comparison failed to 
show a clear difference between the two groups.   
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7.1 Introduction 
This chapter compares the results obtained from two CVD risk assessment 
tools available in the UK when used in the same population. The main study 
population (Chapter 2) was used to calculate the risk using both the 
Framingham based BNF charts and the QRISK2 calculator. 
The estimate of an individual’s 10-year risk of CVD is the first step currently 
used in the Wales government’s preventative strategy to combat the increase in 
CVD morbidity (WAG 2010). The prediction of CVD must be as accurate as 
possible in order for the preventative measures to be appropriate and in line 
with the national guidelines (SIGN 2007). 
A number of tools have been developed to calculate risk, including charts, 
tables, computer software and website tools, which are based on algorithms 
such as Framingham risk score (Shindler 2011), ASSIGN (SIGN 2007) and 
QRISK2 (Hippisley-Cox et al. 2008). 
When estimating an individual’s risk of CVD there is consensus that a 
combination of risk factors needs to be taken into account rather than the extent 
or severity of any single factor (Hippisley-Cox et al. 2007).  
The BNF charts (BNF 2011) are based on the American Framingham study 
although the relevance of this to the current UK population is unclear. The 
Framingham Heart Study was conceived in 1948, at a time when there was 
insufficient knowledge about the causes of CVD. At the time CVD was 
increasing in prevalence and becoming the leading cause of morbidity and 
mortality in developed countries as infectious diseases came under control. The 
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Framingham Heart Study was set up to identify the risk factors that contribute 
to CVD. More than 14,000 participants over five decades and representing 
three generations have been recruited and monitored for the development of 
CVD. The Framingham Heart Study has successfully identified that high blood 
pressure, high blood cholesterol, smoking, obesity, diabetes, and physical 
inactivity are risk factors for CVD (Shindler 2011). As a result, the concept of 
CVD risk factors has become the cornerstone of advancing prevention and 
treatment of CVD. Based on the Framingham population a risk assessment tool 
for estimating 10-year CVD risk has been developed.  
Until March 2010, NICE had followed the recommendation of the Joint British 
Societies’ guidelines in using the modified Framingham equation (NICE 
2010a). The Joint British Societies’ guidelines acknowledged the fact that 
Framingham was not derived from similar populations particularly with 
regards to ethnic minorities. Therefore, results obtained using the modified 
Framingham equation would be 1.4 times higher for people originating from 
the Indian subcontinent (JBS2 2005). 
The Scottish cohort based risk assessment tool, ASSIGN, is the first tool to 
include social deprivation and family history of cardiovascular disease in the 
equation as well as the classic risk factors (Table 7-1) (Tunstall-Pedoe and 
Woodward 2006). 
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Table 7 - 1 Risk factors taken into account in CVD risk assessment tools 
Modified Framingham ASSIGN QRISK2 
Age Age Age 
Gender Gender Gender 
Current smoker Current smoker Current smoker 
Systolic blood pressure Systolic blood pressure Systolic blood pressure 
Angina or heart attack in 
a 1st degree relative < 
60 years 
Angina or heart attack in 
a 1st degree relative < 
60 years 
Angina or heart attack in 
a 1st degree relative < 
60 years 
Diabetes  Diabetes Diabetes 
 Total Cholesterol: HDL 
ratio 
Total Cholesterol: HDL 
ratio 
Total Cholesterol: HDL 
ratio 
   
On blood pressure 
treatment 
   BMI 
  Deprivation  Deprivation 
Ethnicity   Ethnicity 
    Atrial fibrillation 
    Chronic kidney disease 
    Rheumatoid arthritis 
Researchers from the University of Nottingham have developed QRISK, a 
cardiovascular disease risk algorithm specifically for use in the UK (Hippisley-
Cox et al. 2007). The modified version of QRISK, QRISK2, was launched in 
2008. By entering more information, including ethnicity, presence/absence of a 
diagnosis of rheumatoid arthritis and chronic kidney disease and atrial 
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fibrillation, the QRISK2 is more accurate in predicting the risk than the 
original QRISK (Hippisley-Cox et al. 2008). In contrast to the USA based 
Framingham model, QRISK2 is based on data derived from primary care 
records in the UK. The original validation of QRISK2 did not require 
recruitment and monitoring of participants and this contributed to a much 
larger study population than obtained in the Framingham study (Jackson 2008). 
The QRISK2 model is based on data from 531 practices (2.3 million patients; 
aged 35-74) studied from 1 January 1993 to 31 March 2008 (Hippisley-Cox et 
al. 2008). In addition to the standard risk factors for CVD taken into account by 
Framingham, QRISK2 also takes account of variables relating to 
socioeconomic status and ethnicity (Hippisley-Cox et al. 2007).  
Unlike Framingham which overestimates CVD risk in lower risk populations 
and underestimates CVD risk in higher risk populations, the QRISK2 score is 
more accurate in predicting CVD risk (Jackson 2008). The claimed accuracy of 
QRISK2 is due to the increased size of the data base, the type of population 
from which the data were derived and validated, and the inclusion of other 
variables.  
Furthermore, an independent and external validation of the QRISK2 has 
provided evidence to support the use of QRISK in favour of the modified 
Framingham equation (Collins and Altman 2010). Individuals are either 
classified at low (<10%), moderate (10-20%) or high (>20%) risk of suffering 
from a CVD event within the next 10 years. However, its relevance has been 
somewhat questioned for the use on Northern Europeans’ demographies 
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(Hippisley-Cox et al. 2007). Although Framingham has been modified to 
accommodate UK populations, it over-predicted 35% of individuals at low risk 
of CVD over the next 10 years, as well as over-predicting those at moderate 
risk. Framingham also under-predicted 13% of individuals found to be at a 
high risk of CVD. Researchers from University of Nottingham have developed 
a CVD risk algorithm for the use in the UK demography, QRISK (Hippisley-
Cox et al. 2007).  
The accuracy of Framingham compared with that of QRISK2 in one study 
(Collins and Altman 2010) is shown in Figure 7-1. Patients who had their CVD 
risk underestimated by the modified Framingham when compared with 
QRISK2 tended to be older, have been treated for hypertension, have a family 
history of coronary heart disease, and have a diagnosis of type 2 diabetes, 
rheumatoid arthritis, or atrial fibrillation (Collins and Altman 2010). 
 
Figure 7 - 1 Comparison of Framingham and QRISK2 with the observed CVD events among 
those who were reclassified by QRISK2 as high risk from low/moderate. Data obtained from 
Collins and Altman (2010) 
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Another feature is available when using the QRISK2 calculator which is a heart 
age tool (QHeartAge) to communicate the CVD risk in more meaningful way. 
QHeartAge works out the typical age of a person of the same sex and ethnicity 
that normally has the same 10-year QRISK2 score (Hippisley-Cox 2011). For 
example, it could provide a false reassurance if a 50 year old woman was just 
told she had a low risk if it was 9% as a woman of this age her typical risk 
would be 3%. Therefore, by communicating the QHeartAge (which is in this 
case is 64) will help the clinician to highlight the danger if risk factors are 
ignored. If the subject has a CVD risk estimate that is typical for his/her age, 
the QHeartAge will be equal his/her chronological age.   
Aim 
To compare the cardiovascular risk estimates of those who accessed a 
community pharmacy based VRA service using the Framingham based BNF 
charts and the QRISK2 algorithm 
Objectives 
 Determine the proportion of individuals who had their CVD risk 
underestimated by Framingham algorithm when compared with the risk 
calculated using QRISK2. 
 Determine the proportion of individuals who had their CVD risk 
overestimated by Framingham algorithm when compared with the risk 
calculated using QRISK2.   
 Explore the differences in the CVD risk factors between those who had 
their risk calculated similarly by Framingham and QRISK2 algorithms, 
those who had their risk underestimated and those who had their risk 
overestimated. 
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7.2 Method 
The VRA service was provided free of charge by Boots pharmacies in Merthyr 
Tydfil and Porthcawl, Wales, from November 2009 to August 2010 (Chapter 
2). Individuals who had their Framingham risk estimated were included in this 
analysis. All test results were used anonymously to calculate the CVD risk 
using QRISK2. This was done to permit comparison of the Framingham based 
CVD risk assessment with that of QRISK2. This was a desktop exercise and 
the results were not communicated to the service user. 
Information collected through the VRA service, obtained by a questionnaire 
and measurements, was sufficient to calculate the Framingham score. That 
included; age, gender, smoking status, family history of CVD, diabetes status, 
total cholesterol, HDL cholesterol and systolic blood pressure.  
However, another data collection form was devised to capture the other 
parameters required to calculate cardiovascular risk using QRISK2. 
Information collected by this form included; ethnicity (Appendix 3b) based on 
the 16+1 classification, and whether the patient suffered from atrial fibrillation, 
chronic kidney disease or rheumatoid arthritis. 
Deprivation was determined by the patient’s residential postcode. Townsend 
Deprivation Index is used in this analysis for the reason that it is the same 
deprivation index used by QRISK2 algorithm. Each quintile represents 20% of 
the population: the first quintile (Q1) comprises the 20% least deprived areas in 
England and Wales. While the last quintile (Q5) represents the 20% most 
deprived areas. 
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The QRISK batch processor, version 2.1, software was used to obtain the 
estimates of the individuals’ CVD risk based on QRISK2 algorithm. 
PASW Statistics 18 was used for analysing the data. Chi-square test was used 
when comparing variables with nominal values, for example, gender and 
smoking status, or ordinal values, e.g. deprivation status. Mann-Whitney U test 
was used when comparing variables (two samples) with continuous data, for 
example, age, blood pressure, and cholesterol levels. The Kruskal Wallis test 
was used when comparing three or more groups with ranked data for example, 
when comparing age in each group of CVD risks (low, moderate and high). 
Patients’ ages were compared with their QHeartAge, that is, the typical age 
determined by their QRISK2 score, by using paired-sampled student t-test.  
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7.3 Results 
A total of 146 people had their CVD risk assessed, 107 (73%) from Porthcawl 
and 39 (27%) from Merthyr Tydfil. Table 7-2 shows the results required in the 
calculating CVD risk by both Framingham and QRISK2 algorithms.  
Table 7 - 2 Risk factors required in calculating CVD risk by both Framingham and QRISK2 
algorithms of service users who had their CVD risk estimated 
Risk factor Results 
Age 59 years  
(range 38 to 74, SD = ±9.3)  
Females 87 (60%) 
Males 59 (40%) 
Family history of CVD 44 (30%) 
Current smokers 10 (7%) 
Quit smoking ≤ 5 years 6 (4%) 
Systolic BP 135 mmHg  
(range 82 to 194, SD = ±18.3) 
Total Cholesterol 4.87 mmol/L  
(range 2.75 to 7.28, SD = ±0.87) 
HDL cholesterol 1.29 mmol/L  
(range 0.62 to 2.47, SD = ±0.42) 
Total Cholesterol: HDL 
ratio 
4.1 mmol/L  
(range 1.9 to 7.8, SD = ±1.3) 
Ethnicity- White 144 (99%) 
Pakistani  1 (0.7%) 
Indian 1 (0.7%) 
 
Table 7-3 shows risk factors required in calculating CVD risk by QRISK2 
algorithm only. All service users were non-diabetic and no one was on blood 
pressure treatment nor suffered from chronic kidney disease. 
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Table 7 - 3 Risk factors required to calculate CVD risk by only the QRISK2 algorithm 
Risk factor Results 
BMI mean = 27.7 kg/m
2
  
(range 18.4 to 44.9, SD = ±4.3) 
< 25 kg/m
2
 37 (25%) 
≥ 25 and < 30 kg/m2 68 (47%) 
> 30 kg/m
2
 41 (28%) 
Deprivation 5 (3%) could not be allocated to a 
deprivation quintile. 
Q1 (Least deprived) 53 (36%) 
Q2 6 (4%) 
Q3 7 (5%) 
Q4 48 (33%) 
Q5 (Most deprived) 27 (18%) 
Atrial fibrillation 2 (1%) 
Rheumatoid arthritis  6 (4%) 
 
Table 7-4 lists other characteristics related to the cardiovascular system but not 
taken into account by either of the algorithms, such as alcohol intake, the level 
of physical activity and whether the user had daily intake of fruits and 
vegetables. 
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Table 7 - 4 Lifestyle factors that could affect the cardiovascular system but not taken into 
account by either Framingham or QRISK2 
Lifestyle factor Results 
Alcohol-  
No alcohol intake 25 (17%) 
Alcohol intake within the recommended 
weekly limits  
111 (76%) 
Alcohol intake exceeding the recommended 
weekly limits 
10 (7%) 
Daily intake of vegetables and fruits 110 (75%) 
Exercise-  
No exercise 8 (6%) 
Exercise- some (1-2 days a week) 33 (23%) 
Exercise- moderate or regular (3 days or 
more per week) 
105 (72%) 
Waist circumference  92.7 cm (range 65 to 
124, SD = ±12.6) 
OK (acceptable size) 42 (29%) 
Increased risk 39 (27%) 
High risk 60 (41%) 
 
By using Framingham CVD risk algorithm, a total of 63 (43%) individuals 
were at low risk, 46 (32%) moderate and 37 (25%) high risk of developing 
CVD in the next 10 years. However, 44 of the cases (30%) had their risk 
overestimated (n = 25; 17%) or underestimated (n = 19; 13%) when compared 
with results calculated by QRISK2 algorithm (Table 7-5). This was a 
statistically significant difference (p < 0.001, Chi Squared test). 
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Table 7 - 5 Estimates of CVD risk compared between Framingham and QRISK2 algorithms.  
   QRISK2 
   Low Moderate High 
F
ra
m
in
g
h
a
m
   Total 66 46 34 
Low 63 54 (86)* 9 (14)‡ 0 
Moderate 46 12 (26)† 24 (52)* 10 (22)‡ 
High 37 0 13 (35)† 24 (65)* 
(%), * estimates similar by both algorithms, ‡ risk underestimated 
by Framingham, † risk overestimated by Framingham 
The differences in estimates derived from Framingham and QRISK2 were 
similar (p > 0.05, Chi Square test) for both pharmacies in Porthcawl and 
Merthyr Tydfil (Figure 7-2).  
 
Figure 7 - 2 The differences in estimates of Framingham and QRISK2 algorithms between 
Porthcawl and Merthyr Tydfil 
No significant difference was found (p > 0.05, Chi Square test) between 
different deprivation areas (Figure 7-3). 
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Figure 7 - 3 The differences in estimates of Framingham and QRISK2 algorithms between the 
5 deprivation quintiles 
 
People who had their CVD risk underestimated by Framingham tended to be 
older (p < 0.001, Kruskal Wallis test) (Figure 7-4).  
 
 
Figure 7 - 4 Differences in estimates of Framingham and QRISK2 compared with age 
 
 
Higher (p < 0.05, Kruskal Wallis test) systolic blood pressure measurements 
were seen in those who had their risk overestimated (Figure 7-5).  
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Figure 7 - 5 Differences in estimates of Framingham and QRISK2 compared with systolic BP 
measurements 
Lower levels (p < 0.05, Kruskal Wallis test) of total cholesterol to HDL ratio 
were seen in those who had their risk underestimated (Figure 7-6). No other 
significant difference in any of the other risk factors were found between the 
three groups of estimates. 
 
Figure 7 - 6 Differences in estimates of Framingham and QRISK2 compared with 
measurements of total cholesterol: HDL ratio. 
A total of 53 subjects (36%) were referred to their GP for further investigation. 
Reasons for referral (Chapter 2 for more details) included a score of >20% 
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using the modified Framingham algorithm, high blood pressure and/or high 
total cholesterol. 
The typical age (mean 61, SD ± 10.7) determined by the QRISK2, QHeartAge, 
was significantly different (p < 0.001, paired-sampled student t-test) from the 
actual age (mean 59, SD ± 9.3) of the service users (Figure 7-7). 
 
Figure 7 - 7 Actual age of individuals compared with the age (QHeartAge) determined by 
their QRISK score. 
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7.4 Discussion 
The estimates derived from the modified Framingham algorithm and QRISK2 
were significantly different when applied to data obtained in this present study 
sample. About a third of service users had their risk underestimated or 
overestimated by the modified Framingham algorithm when compared with 
those obtained using QRISK2. 
The BNF charts, which are based on Framingham, overestimated the risk of 
17% (n = 25) of participants (12 were identified at moderate risk instead of low 
risk and 13 were identified at high risk instead of moderate risk). On the other 
hand, the BNF charts underestimated the risk of 13% (n= 19) of the 
participants (9 were identified low instead of moderate and 10 were identified 
moderate instead of high). 
The evidence is mounting to support the notion that QRISK2 is more accurate 
than Framingham for use in England and Wales (Collins and Altman 2010). 
Therefore, by using the BNF charts 13 participants were referred unnecessarily 
and 19 were given a false reassurance. If a generalisation can be made, this 
means by using the less accurate modified Framingham tool even in a 
Caucasian population, there will be a number of people being unnecessary 
referred and possibly prescribed medication not proven to be cost-effective for 
them, and perhaps exposing them to unwanted side-effects of prescribed 
medication. Similarly, by using this less accurate tool, a number of people are 
given a false reassurance where they actually need to be referred and helped to 
reduce their risk of developing CVD. 
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In addition to the accuracy of QRISK2, other advantages it has including the 
availability of features which could help clinicians to interpret the data to the 
layman, such as QHeartAge. For example, when someone is in his/her early 
40s the chance that the CVD risk would be less than 10% even though their 
parameters are higher than the way they should be at. Therefore, these 
individuals could have their QHeartAge in late 50s or even 60s. Knowing the 
typical age for the person of same sex and ethnicity who would have this 
QRISK2 score, may be more encouraging and/or meaningful for the patient to 
make lifestyle changes. In the same way, healthy men over the age of 60 years 
would be always at moderate or high CVD risk. They would be reassured if 
they found their QHeartAge is lower than their actual age.   
Having clear objectives prior to the start of the study allowed for the design of 
an appropriate data collection form to capture all the data needed. Knowing 
whether the service user suffered from rheumatoid arthritis, for example, was 
required for calculating CVD risk when using QRISK2 algorithm but not 
required when using the Framingham algorithm. Even though QRISK2 was not 
used as part of the service, the data collection form captured this information 
for later use. Similarly, QRISK2 uses different classification of ethnicity than 
the one used by the modified Framingham. The data collection form captured 
ethnicity using the 16+1 classification which was important to have an accurate 
calculating of risk. 
The estimates derived from QRISK2 were not communicated to participants. 
The main reason for communicating Framingham estimates only was the fact 
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that the Boots SOP specified that the Framingham based BNF charts are to be 
used when estimating the 10-year CVD risk. Also, the local GP surgeries were 
expected to follow NICE guidelines which had recommended the modified 
Framingham, that is the BNF charts until March 2010 (NICE 2010a).  It is very 
important that pharmacists use the same tool used by the GPs otherwise 
patients might receive conflicting information about their risk management.  
7.4.1 Limitations 
The VRA service was accessed by a relative small number of subjects. Also, 
the number of venues for providing the service was limited to two pharmacies 
only, at Porthcawl and Merthyr Tydfil. Most individuals (73%) had their CVD 
risk estimates done in Porthcawl. 
The demographic characteristics of the study subjects were not representative 
of the general population. There were only two non-Caucasian people included 
in the study. Most participants came from the least deprived areas (Q1), 
followed by Q4 which means there was no appropriate spread between all 
deprivation quintiles. The genders were not equally represented with only 40% 
being males. 
7.4.2 Conclusion 
All participants (n = 146) who had their CVD risks estimated using the 
Framingham based BNF charts in the main study (Chapter 2) were included in 
this analysis to calculate their CVD risk again using QRISK2. 
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The BNF charts overestimated the risk of 17% (n = 25) of participants and 
underestimated the risk of 13% (n= 19) of the participants. Those who had 
their risk overestimated might have been put through unnecessary anxiety and 
were possibly subject to a pharmacological intervention. On the other hand, 
those who had their risk underestimated were given a false reassurance and 
may have missed out on opportunity to have the necessary interventions. 
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8.1 Introduction 
This chapter discusses the main findings in relation to the overall aim and 
objectives. The limitations are also discussed with the possible implications the 
findings might have for the practice and future research regarding the provision 
of cardiovascular risk assessment (VRA) services from the community 
pharmacy. 
8.2 General findings 
The aim of the thesis was to evaluate a community pharmacy based VRA 
service.  
Since April 2009 the VRA service became part of the pharmacy enhanced 
services in England, that is, pharmacies being remunerated if they provide it for 
their local population (PSNC 2011). However, in Wales it was privately 
available at pharmacies on a limited scale. 
The following objectives were determined to help to achieve the aim of this 
PhD thesis: 
1. Examine the feasibility of establishing a VRA service in Welsh 
community pharmacies similar to that available in England, that is 
free of charge. 
2. Determine how different people, including those who may be “hard-
to-engage”, respond to the service.  
3. Examine patients’ acceptance of the community pharmacy based 
VRA service. 
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4. Examine the short-term outcomes of those who accessed the VRA 
service. 
5. Examine the longer term outcomes of those who accessed the VRA 
service. 
6. To examine the differences, and the impact these difference could 
have on the service users, between the common tools available in 
the UK to estimate CVD risk. 
The VRA service was established and was provided free of charge in two 
community pharmacies in South Wales. This was the first objective achieved. 
The VRA service was accessed by 172 individuals who provided their 
demographic details and some information about their lifestyle through self-
completing a questionnaire. Then they had tests and measurements of blood 
pressure, total cholesterol, HDL, BMI and waist circumference. A total of 146 
(85%) participants had their Framingham 10-year CVD risk calculated. All 
participants then had a consultation with the pharmacist where they had an 
advice tailored to their needs and if necessary they were signposted to the 
relevant services and/or referred to their GP. It is estimated that using the 
Framingham risk assessment tool would identify about 15% of those who aged 
35 to 74 years in England and Wales as being at high risk (Collins and Altman 
2010). The results of this study, however, showed that 25% of participants 
were at high risk. One explanation is that the present study included a higher 
proportion of older people, who are at greater risk (Hippisley-Cox et al. 2007). 
The method and the results are discussed in more detail in Chapter 2. 
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The second objective, that is, determining how different people respond to the 
service was also discussed in Chapter 2. However, two different, smaller 
studies were designed in order to understand this issue further and they are 
discussed in Chapters 5 and 6. Chapter 5 analysed the demographic 
characteristics of users of another service provided privately by a different 
Boots pharmacy. The aim of this study was to determine the effect that socio-
economic status could have on the accessibility of the service when a charge 
was applied to the service users. This service was chosen because it was 
considered, with the exception of the charge, similar to that of the main study, 
however, there were other differences identified and they are discussed in the 
limitations in this chapter.  
A comparison was made between the characteristics of the participants who 
had an assessment at Boots Porthcawl and those who had an MUR at the same 
pharmacy and this comparison is discussed in Chapter 6. This comparison was 
made to see if either of the two services was more likely to attract those who 
live in the most deprived communities. 
Patients’ acceptance of the VRA service was the third objective of this thesis 
and it was evaluated by two different methods which are an anonymous survey 
(Chapter 3) and a telephone interview (Chapter 4). The results from the 
anonymous survey show a high satisfaction among respondents with the VRA 
service they received at a community pharmacy. This was similar to other 
satisfaction surveys of those who accessed a VRA service (Horgan et al. 2009; 
Knowsley PCT 2008). The two week follow-up interview was conducted by a 
researcher, who did not provide the VRA service, in order to gain an insight in 
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the participants’ views after having the assessment. The response rate was 
higher than the anonymous survey (92% versus 74% respectively). The two 
week follow-up interviews gave participants the opportunity to comment on the 
service and to express their degree of satisfaction. 
The two-week follow-up interview was more in depth in contrast to the 
anonymous survey. It was timed to give participants a chance to reflect on the 
advice they had in the pharmacy and implement any changes. Also, the results 
were linked to the main study findings whereas in the anonymous survey the 
results were analysed separately. This follow-up helped to achieve the fourth 
objective as the short-term outcomes, as they were communicated by the 
participants, were evaluated.  
The reported short term outcomes were identified as an initiation of lifestyle 
changes, a visit to their GP or nurse if they were referred and starting a 
pharmacological treatment if they were prescribed by their GP. Fifty-two 
participants (34%) reported a change, mostly to lifestyle with only one person 
stating that he had been prescribed medication. There was no direct question in 
the interview schedule about these changes, therefore those who did not 
mention a change could also have made some changes. Of those who were 
referred to their GP 45% stated that they made their visit by the time they had 
the two-week follow-up. 
The evaluation of the longer-term outcomes of the VRA service was the fifth 
objective and they are discussed in Chapter 2. Participants (n = 105, 61%) who 
attended the twelve-month follow-up had the results of the two assessments 
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(pre- and post) compared using paired-samples Student’s t-test. There was a 
statistically significant reduction in mean systolic and diastolic blood pressures 
and the mean Framingham score. There was also a statistically significant 
increase in mean HDL.  
The improvement seen in the results collected at the twelve-month follow-up 
probably because those who were ready to make lifestyle changes participated 
in the study, that is, self-selection to participate in the study. Also participants 
knowing they were going to be tested again could have made them keen to put 
an extra effort to improve their lifestyle. Also it is unknown how many of those 
who declined the invitation to attend the twelve-month follow-up did not want 
to have the repeat tests because their lifestyle had worsened or had not 
improved over the previous year, that is self-selection as to continuation in the 
study could have been made in participation in the twelve-month follow-up. 
The sixth objective of this thesis was achieved by the analysis presented in 
Chapter 7 where the comparison between Framingham CVD risk tool and 
QRISK2 algorithm was made. Although the estimates of CVD risk calculated 
by QRISK2 were not communicated to the participants, it identified potential 
problems which could occur when the GP uses one tool and the pharmacist 
uses the other. The BNF charts which are based on Framingham overestimated 
the risk of 17% (n = 25) of participants and underestimated the risk of 13% (n= 
19) of the participants. There was an independent validation of QRISK2 which 
suggested a higher accuracy than Framingham (Collins and Altman 2010). 
Therefore, by using the BNF charts 13 participants were referred unnecessarily 
and 19 were given a false reassurance. 
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8.3 The future of the national VRA service  
The impact assessment of the national VRA in England (NHS Health Checks) 
concluded that the service is cost-effective with the most benefit if it was 
universal for those aged 40 to 74 years and repeated every five years (DOH 
2008a). However, Chamnan et al. (2010) estimated the population impact to be 
similar with a lower cost if the VRA service is available to those who aged 50 
to 74 years. The authors argued that the Department of Health modelling 
depended on an incomplete data set whereas they used data from a prospective 
cohort thus less missing data.  
Another strategy suggested, which may have a similar impact with a 
significantly lower cost, is stratification of people before they are invited for a 
VRA. Patients’ data collected routinely by GP practices is suggested for use to 
stratify people so that only individuals at certain risk will be invited for a VRA 
(Chamnan et al. 2010). The authors did not discuss whether only those who are 
registered with a GP surgery will benefit from this strategy. Horgan et al. 
(2010) in an analysis of a pilot VRA data identified four individuals who were 
not registered with a GP surgery. The authors stated that by targeting areas 
with higher deprivation more of those who are unregistered with a GP surgery 
will be identified and helped. Also, the response to an invitation needs to be 
evaluated as other screening services shown that this approach is less effective 
in lower socioeconomic groups (Thomas et al. 2005; Tseng et al. 2001) . As a 
consequence, there is a risk that by relying on invitation systems this will lead 
to the widening in the health inequalities gap.  
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Providing the service only in neighbourhoods with high deprivation will not 
reduce health inequalities to a desired level. However, “proportionate 
universalism”, that is, actions applied in an intensity proportionate to the level 
of deprivation is more effective in reducing the gap between the most deprived 
and the least deprived (Marmot 2010). 
Wald et al. (2011) suggested that prescribing a statin to all people aged 55 
years or over will be more cost-effective than either the use of Framingham or 
QRISK2. However, there were some concerns expressed in the media by 
healthcare professionals with regard to screening using age only instead of risk 
assessment tools. Those concerns were mainly about the adverse effects that 
many people who do not need any treatment will be at risk of. Also the issue of 
“over medicalisation” of the population was raised. The cost benefit analysis 
included only Framingham risk assessment which is less accurate than 
QRISK2 algorithm (NHS Choices 2011b).  
Evidence of postcode lotteries in the English NHS Health Checks has been 
found, that is, different geographical areas have different standards of the VRA 
service and the risk reduction services (Graley et al. 2011). For example, there 
are some Primary Care Trusts (PCT) which only provide the service to those 
who are registered with a GP surgery in the same trust whereas other PCTs 
provide it to all residence regardless whether or not they are registered with a 
GP surgery. Guidelines should be in place for service providers to ensure 
minimum standards are met.  
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8.4 Limitations 
This section discusses the limitations which are related to the main study in 
general terms whereas limitations related to specific elements are mentioned in 
the relevant chapters. 
The VRA service was established with the aim to examine the impact such a 
service would have on those who access it. It was important for the VRA 
service to be as similar as possible to those available at pharmacies elsewhere, 
such as Boots Healthy Heart service and the English NHS service. However, 
there were inherent differences which could not be overcome. A major 
difference is that the VRA service in the main study was provided solely by the 
research pharmacist. This included helping individuals in completing the 
service questionnaire, through conducting all the tests and measurements and 
finishing with the consultation and provision of advice. Also, the research 
pharmacist was not part of the pharmacy team which means we did not 
investigate the possible impact of this service on the workload of the 
pharmacy. 
The VRA service was available at two community pharmacies only. This is a 
small number compared to other studies conducted in the UK (Donyai and van 
den Berg 2009; Horgan et al. 2010; Thornley et al. 2009b). The sample size 
was also small in comparison to these descriptive studies. However, more 
participants in this study were recruited when compared to the sample size 
specified by Mc Namara et al. (2010) in their protocol for a longitudinal pre-
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post study, and more than the participants (n = 26) in the study conducted by 
Lalonde et al. (2006). 
Lack of blinding is an important limitation affecting the validity of results of 
pharmacy practice research (Charrois et al. 2009). Another limitation is the fact 
that the research pharmacist, who had had a major role in study design, was the 
provider of the service and also being the evaluator of its effectiveness. 
Researcher bias in qualitative research has been studied where the interviewer 
could be a source of potential bias to the results (Chenail 2011). Even though 
the role of the researcher in this study is different from the role of the 
interviewer in qualitative research, the potential researcher bias cannot be 
disregarded. Similarly the interviewer who conducted the two-week follow-up 
interviews was one of the research team which means there was a risk of bias. 
The research pharmacist took blood pressure measurements, which might be 
considered a subjective outcome (Vera-Cala et al. 2011), at the initial 
assessment as well as the twelve-month follow-up assessment. This possible 
bias could have been reduced if another person, for example a trained 
pharmacy assistant took these measurements. 
The absence of a control group, to compare the results with, means that the 
positive outcomes that were seen in the study cannot be confidently attributed 
to the VRA service. Participants were informed through the patient information 
sheet (Appendix 1) about the details of the study and they knew about the time 
of the twelve-month follow-up. The knowledge could have made them to take 
the opportunity as a challenge and they might have put an extra effort more 
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than they would have done if it was a one off assessment. At the initial 
assessment some participants had mentioned that they would make a great deal 
of effort to achieve the agreed goals by the time of the twelve-month follow-
up. The two-week follow-up also could have helped participants to follow the 
lifestyle advice they had at the initial assessment. The reminder letter 
participants received before the twelve-month follow-up could have been a 
reminder for a behavioural change. A methodology which includes a control 
group and randomises participants would be needed to study the real effect of 
the service. 
A limitation with regard to the recruitment strategy includes self-selection, a 
convenience sample, which means participants of the present study were likely 
to be particularly interested in their health. This would make them 
unrepresentative of the general population (Smith 2010).  
Lifestyle information was not collected through using a detailed questionnaire 
which is based on rigorous academic research. The Boots service questionnaire 
(Appendix 3a) helped to elicit brief information about participants’ lifestyle. 
Although more information was obtained during the consultation, it was not 
possible to use it in the data analysis, for example some participants stated that 
their weekly alcohol consumption was within the recommended level but 
during the consultation they admitted that this amount of alcohol tend to be on 
one or two nights (binge drinking). When comparing the self-reported lifestyle 
characteristics of the participants with the national statistics for Wales (NHS 
Wales 2006; WAG 2007; Wales Centre for Health 2009) it seems that a higher 
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proportion of the participants were leading a healthy lifestyle than the general 
public. This was not reflected, however, in terms of their body weight as 58% 
in the present study were either overweight or obese.  
One of the objectives of this study was to investigate whether the VRA service 
would be accessible to those who live in communities with the highest 
deprivation. The first venue (Boots at Porthcawl), however, was chosen 
because it was the most convenient. It was not located in a surrounding of the 
most deprived areas and it was not either located in an area with high 
proportion of ethnic minorities. Therefore, the second venue (Boots at Merthyr 
Tydfil) was chosen because it was located in a borough with the highest 
fraction of the most deprived areas in Wales (WAG 2008). Even though the 
second venue was added to evaluate the service in different venues, most of the 
data (77%) were collected from Porthcawl. 
Recruitment strategy was less effective in recruiting more of those who would 
be considered from the “hard-to-engage” groups, for example only 41% were 
men and only two participants were non-Caucasians. Also, those who were 
recruited in the study seemed to have a healthier lifestyle than the general 
population in Wales. This would make the study sample less representative 
which adds another reason against generalisability. 
The original advert (Appendix 7a) listed inclusion and exclusion criteria which 
were different from those for the forthcoming NHS VRA service. There were 
several participants who could not have their CVD risk calculated because of 
their medical history. Those participants would have been ineligible for an 
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NHS service if it was available in Wales. Eventually, in March 2010 the 
second version of the advert (Appendix 7b) was designed to ensure that only 
those who would be eligible for such a service were recruited. The first version 
was designed with the intention that it would be similar to the official Boots 
advert for the company private service. 
Certain groups of people could have been recruited if the service was available 
in places outside the pharmacy, such as churches, mosques, community 
centres, rugby clubs and caravan sites. This could have increased the range of 
demographics of the participants. 
The flexibility was limited in the times the service was available. Providing the 
service during normal office hours on one or two days a week might not be 
convenient for those who are in full time jobs. It would have been more 
attractive to those people if the service was available everyday or even at the 
weekends. Pharmacies opening long hours, such as those located at retail parks 
(edge of town pharmacies) or supermarket pharmacies could have been a 
suitable alternative. Also in comparison with where the service is normally 
provided the VRA service in this study probably less accessible as the service 
at other Boots pharmacies is usually provided every day including the 
weekends and more likely to be available without the need for an appointment. 
Although the twelve-month follow-up assessment examined the longer-term 
outcomes, this period is not long enough to examine whether or not the 
lifestyle change, if any, is maintained. There is lack of evidence that lifestyle 
improvement, such as an increase in physical activity, achieved by health-care 
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professional interventions is sustained for periods of more than one year 
(Lawton et al. 2009).  
Although the response rate (61%) for the twelve-month follow-up was not low 
when compared with other studies (Cranor et al. 2003; Yamada et al. 2005), 
other studies achieved higher response rate. Recruitment for follow-up 
appointments is challenging particularly when no incentive is available. 
Incentives can increase the follow-up recruitments up to 100% as in the case of 
another study evaluating diabetes care which was conducted in the USA this 
rate could have been improved by offering incentives to participants (Garrett 
and Bluml 2005). The use of technology, such as emails and text messages, to 
remind participants shortly before the appointment time could have helped to 
increase the response rate as a handful of participants booked an appointment 
to have the follow-up, but they did not show up. This could have increased the 
sample size of the whole study as there were some missing appointments at the 
initial assessments as well which resulted in loss of potential participants. 
There is a possibility that the Framingham VRA tool used in this study, the 
BNF charts, is going to be replaced by QRISK2 by the time the service is 
available nationally in Wales. As it is mentioned in Chapter 7 there are 
differences in the results, therefore by using another VRA tool some of the data 
would be less relevant to the future national service.      
8.5 Implications for practice 
This thesis confirmed what is already known that effective communication 
channels with GPs need to be established so that relevant information is shared 
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to prevent test duplication and to maximise the service’ benefits. Making the 
VRA service available in more than one place and delivered by different 
providers would encourage some individuals to access the same service several 
times (WAG 2010). Subsequently, there would be an increase in the cost and a 
loss of resources.  
If the Welsh Government decided to roll out the free-of-charge VRA service 
across Wales and community pharmacy is included, pharmacy staff should 
inform the service users that service is exactly the same regardless of where it 
is provided. Advertising materials should make it clear to the public that all 
VRA services are the same and there is no need to have the test more than 
once.  
Local GP surgeries and pharmacies should agree on which VRA tool to be 
used. It is important that the most accurate tool and relevant to the population 
is used. The QRISK2 was developed and validated in England and Wales and 
there is cumulative evidence to suggest that it is more accurate than the 
Framingham based tools when used in British population (Collins and Altman 
2010). Clinicians should abandon the use of less accurate tools to prevent 
overestimating or underestimating CVD risk of their patients, therefore 
preventing the unnecessary anxiety for some and false reassurance for the 
others.  
During the consultation, the time is limited to go through all the health changes 
which the service user might need to make if he/she has multiple risk factors. 
For example, a smoker who needs to lose weight and increase physical activity 
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will not have enough time to deal with each issue during a single consultation. 
The limited time of the consultation is dealt with currently by signposting the 
service user to the relevant services. However, other approaches may be useful 
to increase efficacy, such as posting reminder letters and written information 
after the consultation to encourage individuals to follow the advice that they 
had from the pharmacist. 
The VRA service was not as accessible as it was hoped to be for the “hard-to-
engage”. Health inequalities are increasing in Wales between the most 
deprived areas and the least deprived areas. People in the least deprived areas 
can expect to live in good health for 18 to 19 years longer than those in the 
most deprived areas (Public Health Wales 2011). The gap in the life 
expectancy is widening as well; the difference is now 9.2 years for men 
(previously 8.6) and 7.1 for women (previously 6.5). Taking into account 
health inequalities, such a service should target those who live in the most 
deprived areas. 
Although men and certain ethnic groups are at higher risk of CVD in general 
they were under-represented in this study. A report published by Heart UK, a 
charity which aims to raise awareness of the risks of high cholesterol and to 
decrease preventable premature deaths caused by CVD, criticised the uptake of 
the English NHS Health Checks as patchy and made a number of 
recommendations to overcome the obstacles to the progress the service facing 
including about the strategies which should be in place for the service to reach 
those who are less likely to respond to such services (Heart UK 2011). 
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Recruiting individuals from the hard-to-engage groups, such as men, ethnic 
minorities and those with a lower social-economic status will present a 
challenge for the service provider. Recruitment strategies that aimed to attract 
such groups should be developed and tested. Heart MOT, a pilot which was 
aimed at men was successful in attracting a higher percentage of men than it is 
the case in similar services (Horgan et al. 2010). The importance of attracting 
individuals from the most deprived communities in that the service would help 
to reduce the health inequality gap (Jain et al. 2011; Richards 2009).  
8.6 Future work 
In this study the outcomes of the referral were evaluated after being 
communicated by the participants during the two week follow-up interview and 
the twelve-month follow-up assessment. Further research is required to 
evaluate the outcomes of the referral using a method with more accuracy, for 
example requesting feedback directly from the GP surgery. 
Recently the universal cardiovascular risk screening, currently available in 
England and expected to be rolled out across Wales, was described as not 
evidence-based policy (Katikireddi et al. 2011). The authors suggested that 
evidence is in favour of the targeted risk screening. Whether this criticism will 
change health policy in England and Wales is still unknown. For community 
pharmacy to continue in this favourable position as a provider of the VRA 
service, it is essential that collaboration is maximised between GPs and 
pharmacists as targeted screening will depend on the routine data available at 
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GP practices. To find out the extent of how GPs are willing to work with 
pharmacists to drive this policy forward needs to be investigated. 
There are other approaches being developed and piloted in primary care 
settings (Cox et al. 2011) and in community pharmacy (Mc Namara et al. 
2010) where the intervention includes a novel programme to assess CVD risk 
and also several sessions to manage CVD risk factors. However, to date no 
studies have been published to describe similar approaches here in the UK.  
The uptake of invitations for the VRA service also requires investigation. 
Based on other screening services (Thomas et al. 2005; Tseng et al. 2001), 
different ethnic groups and socioeconomic groups are expected to respond 
differently to the invitations. Furthermore, more research is needed on different 
recruitment strategies including how to invite people, for example, whether the 
use of technology can be included, and what formats and languages should be 
used for promotional and recruitment materials, to address health inequalities. 
The provision of the VRA service by the pharmacy team in unconventional 
places, such as local caravan sites, churches, mosques and in community 
centres, needs to be evaluated. A similar service was provided in Hindu 
temples by other healthcare professionals was effective in identifying high 
prevalence of modifiable risk factors for CVD (Rao et al. 2011). 
The cost-effectiveness of a universal NHS VRA service will depend on the 
number of high risk people identified and the available risk reduction services 
(Dalton et al. 2011). Further work is needed to see if the community pharmacy 
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can target those who will mostly benefit from the screening and from any 
intervention the pharmacist can make to reduce the risk of developing CVD.  
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8.7 Conclusion 
The VRA was established in two community pharmacies in South Wales and 
evaluated in this PhD thesis. The study recruited 172 individuals who had their 
CVD risk factors evaluated and 85% (n = 146) had communicated to them their 
10-year CVD risk estimated by using the Framingham based BNF charts. 
All study participants had the opportunity to provide their feedback 
anonymously on the service they received. A response rate of 74% (n = 127) 
was achieved to this anonymous survey. The results show a high satisfaction 
among respondents with the VRA service they received at a community 
pharmacy. 
Participants’ recall and understanding of the pharmacist’s advice were explored 
during the two-week follow-up interview which was conducted by a researcher 
who did not provide the VRA service.  The response rate was 92%. Short-term 
self-reported outcomes reported include change to lifestyle (34%) and having 
made a GP visit if referred by the pharmacist (45%). 
The longer-term outcomes of those (n = 105, 61%) who attended at the twelve-
month follow-up assessment were investigated. There was a statistically 
significant reduction in mean systolic and diastolic blood pressures and in and 
the Framingham score. There was also an increase in the mean HDL. However, 
the improvement seen in the results could not be attributed to the VRA service 
because of the absence of the control group. 
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There were major differences in the estimates of the 10-year CVD risk of the 
same sample when QRISK2 was used instead of the Framingham based BNF 
charts. Community pharmacist providing the VRA service should open 
communication channels with GPs in order to use the same VRA tool the GPs 
are using. 
To date this is the first study to investigate short-term and longer-term 
outcomes of a limited community pharmacy-based VRA service in Wales.  
References 
275 
 
References 
Abu-Omar, SM. Weiss, MC. and Hassell, K. (2000). Pharmacists and their customers: 
a personal or anonymous service? International Journal of Pharmacy Practice 8(2), 
pp. 135-143. 
 
ACCORD (2008). The Action to Control Cardiovascular Risk in Diabetes Study 
Group: Effects of intensive glucose lowering in type 2 diabetes. New England Journal 
of Medicine 358, pp. 2545-2559. 
 
Ahmad, I. Zhan, M. and Miller, M. (2005). High prevalence of C-reactive protein 
elevation with normal triglycerides (100-149 mg/dL): are triglyceride levels below 
100 mg/dL more optimal in coronary heart disease risk assessment? The American 
Journal of the Medical Sciences 329(4), p. 173. 
 
Amariles, P. Baena, MI. Faus, MJ. Machuca, M. Tudela, J. Barris, D. et al. (2005). 
Knowledge and cardiovascular disease risk among patients are taking cardiovascular 
related medications. [Spanish, English]. ARS Pharmaceutica 46 (3), pp. 279-300. 
 
Amariles, P. Machuca, M. Faus, MJ. Baena, MI. Martinez-Martinez, F. and Jimenez-
Martin, J. (2008). Application of the SCORE and Wilson-Grundy methods for the 
assessment of cardiovascular risk in community pharmacies. Journal of Clinical 
Pharmacy & Therapeutics 33(5), pp. 475-481. 
 
Appel, LJ. Frohlich, ED. Hall, JE. Pearson, TA. Sacco, RL. Seals, DR. et al. (2011). 
The Importance of Population-Wide Sodium Reduction as a Means to Prevent 
Cardiovascular Disease and Stroke. Circulation 123(10), pp. 1138-1143. 
 
Archer, E. and Blair, SN. (2011). Physical Activity and the Prevention of 
Cardiovascular Disease: From Evolution to Epidemiology. Progress in 
Cardiovascular Diseases 53(6), pp. 387-396. 
 
Aronson, S. and Fontes, ML. (2006). Hypertension: A new look at an old problem. 
Current Opinion in Anaesthesiology 19(1), pp. 59-64. 
 
Assmann, G. Schulte, H. Funke, H. and Von Eckardstein, A. (1998). The emergence 
of triglycerides as a significant independent risk factor in coronary artery disease. 
European Heart Journal 19, pp. 8-14. 
 
Astin, F. and Atkin, K. (2010). Ethnicity and coronary heart disease: making sense of 
risk and improving care. [Online]. Available at: 
http://www.raceforhealth.org/storage/files/health_brief16.pdf [Accessed: 23/6/2011]. 
 
Astrup, A. Dyerberg, J. Elwood, P. Hermansen, K. Hu, FB. Jakobsen, MU. et al. 
(2011). The role of reducing intakes of saturated fat in the prevention of 
cardiovascular disease: where does the evidence stand in 2010? The American Journal 
of Clinical Nutrition 93(4), pp. 684-688. 
 
Baigent, C. Blackwell, L. Emberson, J.  Holland, LE.  Reith, C.  and Bhala, N. (2010). 
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of 
References 
276 
 
data from 170 000 participants in 26 randomised trials. Lancet 376 (9753), pp. 1670-
1681. 
 
Ballantyne, C. (2009). Dyslipidemia and Atherosclerosis Essentials. Fourth ed. Jones 
and Bartlett. 
 
Bangalore, S. Kamalakkannan, G. Parkar, S. and Messerli, FH. (2007). Fixed-Dose 
Combinations Improve Medication Compliance: A Meta-Analysis. The American 
Journal of Medicine 120(8), pp. 713-719. 
 
Bauld, L. Boyd, KA. Briggs, AH. Chesterman, J. Ferguson, J. Judge, K. and Hiscock, 
R. (2011). One-Year Outcomes and a Cost-Effectiveness Analysis for Smokers 
Accessing Group-Based and Pharmacy-Led Cessation Services. Nicotine & Tobacco 
Research 13(2), p. 135. 
 
Belch, J. MacCuish, A. Campbell, I. Cobbe, S. Taylor, R. Prescott, R. et al. (2008). 
The prevention of progression of arterial disease and diabetes (POPADAD) trial: 
factorial randomised placebo controlled trial of aspirin and antioxidants in patients 
with diabetes and asymptomatic peripheral arterial disease. British Medical Journal 
337. 
 
Bell, S. and Britton, A. (2011). Alcohol and men's health. Trends in Urology & Men's 
Health 2(4), pp. 9-12. 
 
Bellingham, C. (2008). Pharmacies work to improve access. Pharmaceutical Journal 
280(7505), pp. 684-684. 
 
Bensen, JT. Li, R. Hutchinson, RG. Province, MA. and Tyroler, HA. (1999). Family 
history of coronary heart disease and pre clinical carotid artery atherosclerosis in 
African Americans and whites: The ARIC study. Genetic Epidemiology 16(2), pp. 
165-178. 
 
Bereznicki, B. Peterson, G. Jackson, S. Haydn Walters, E. Deboos, I. and Hintz, P. 
(2011). Perceived feasibility of a community pharmacy-based asthma intervention: A 
qualitative follow-up study. Journal of Clinical Pharmacy and Therapeutics 36 (3), 
pp. 348-355. 
 
Berger, JS. Lala, A. Krantz, MJ. Baker, GS. and Hiatt, WR. (2011). Aspirin for the 
prevention of cardiovascular events in patients without clinical cardiovascular disease: 
A meta-analysis of randomized trials. American Heart Journal 162(1), pp. 115-124. 
e112. 
 
Bernstein, AM. and Willett, WC. (2010). Red Meat Intake and the Risk of 
Cardiovascular Disease. Current Cardiovascular Risk Reports, pp. 1-4. 
 
BHF. (2010). Coronary heart disease statistics 2010. [Online]. Available at: 
http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001546 [Accessed: 
21/6/2011]. 
 
BHF. (2011a). Trends in Coronary Heart Disease 1961-2011. [Online]. Available at: 
http://www.bhf.org.uk/idoc.ashx?docid=b700412d-f9fe-4a82-9926-
4667b104ac33&version=-1 [Accessed: 21/12/2011]. 
 
References 
277 
 
BHF. (2011b). Coronary heart disease statistics in Wales. [Online]. Available at: 
http://www.bhf.org.uk/plugins/PublicationsSearchResults/idoc.ashx?docid=8040f3f1-
0c16-4042-a7a0-90dda1cb65c2&version=-1 [Accessed: 12/12/2011]. 
 
Blenkinsopp, A. Bond, C. Celino, G. Inch, J. and Gray, N. (2008). Medicines use 
review: Adoption and spread of a service innovation. International Journal of 
Pharmacy Practice 16 (4), pp. 271-276. 
 
Blenkinsopp, A. Celino, G. Bond, C. and Inch, J. (2007). Medicines use reviews: The 
first year of a new community pharmacy service. Pharmaceutical Journal 278 (7440), 
pp. 218-223. 
 
BNF (2011). British National Formulary. 62 ed. BMJ Group and RPS Publishing. 
 
Bonita, R. Duncan, J. Truelsen, T. Jackson, RT. and Beaglehole, R. (1999). Passive 
smoking as well as active smoking increases the risk of acute stroke. Tobacco Control 
8(2), p. 156. 
 
Boyer, JF. Gourraud, PA. Cantagrel, A. Davignon, JL. and Constantin, A. (2011). 
Traditional cardiovascular risk factors in rheumatoid arthritis: A meta-analysis. Joint 
Bone Spine 78(2), pp. 179-183. 
 
Boyle, TC. Coffey, J. and Palmer, T. (2004). Men's health initiative risk assessment 
study: effect of community pharmacy-based screening. Journal of the American 
Pharmacists Association 44(5), pp. 569-577. 
 
Brennan, N. (2011). Community pharmacy diabetes risk health promotion campaign. 
[Online]. Available at: http://www.cpwales.org.uk/News/17,500-visit-Welsh-
pharmacies-for-Type-2-diabetes-.aspx [Accessed: 21/9/2011]. 
 
Bromley, C. Graham, H. and Sharp, C. (2011). Knowledge, Attitudes and Motivations 
to health. [Online]. Available at: http://www.scotpho.org.uk/kam2010/ [Accessed: 
30/12/2011]. 
 
Bruckert, E. and Rosenbaum, D. (2011). Lowering LDL-cholesterol through diet: 
potential role in the statin era. Current Opinion in Lipidology 22(1), p. 43. 
 
Bucova, M. Bernadic, M. and Buckingham, T. (2008). C-reactive protein, cytokines 
and inflammation in cardiovascular diseases. Bratislavské lekárske listy 109(8), p. 
333. 
 
Carter, M. Karwalajtys, T. Chambers, L. Kaczorowski, J. Dolovich, L. Gierman, T. et 
al. (2009). Implementing a standardized community-based cardiovascular risk 
assessment program in 20 Ontario communities. Health Promotion International 24 
(4), pp. 325-333. 
 
CDU. (2010). Census Dissemination Unit: Deprivation Scores. [Online]. Available at: 
http://cdu.mimas.ac.uk/related/deprivation.htm [Accessed: 5/5/2011]. 
 
Chambers, L. W. Kaczorowski, J. Dolovich, L. Karwalajtys, T. Hall, H. L. 
McDonough, B. et al. (2005a). A community-based program for cardiovascular health 
awareness. Canadian Journal of Public Health 96 (4), pp. 294-298. 
 
References 
278 
 
Chambers, LW. Kaczorowski, J. Dolovich, L. Karwalajtys, T. Hall, HL. McDonough, 
B. et al. (2005b). A community-based program for cardiovascular health awareness. 
Canadian Journal of Public Health 96 (4), pp. 294-298. 
 
Chamnan, P. Simmons, RK. Khaw, KT. Wareham, NJ. and Griffin, SJ. (2010). 
Estimating the population impact of screening strategies for identifying and treating 
people at high risk of cardiovascular disease: modelling study. British Medical 
Journal 340. 
 
Charrois, TL. Durec, T. and Tsuyuki, RT. (2009). Systematic reviews of pharmacy 
practice research: methodologic issues in searching, evaluating, interpreting, and 
disseminating results. The Annals of Pharmacotherapy 43(1), pp. 118-122. 
 
Chenail, RJ. (2011). Interviewing the investigator: Strategies for addressing 
instrumentation and researcher bias concerns in qualitative research. The Qualitative 
Report 16(1), pp. 255-262. 
 
Clifford, S. Barber, N. Elliott, R. Hartley, E. and Horne, R. (2006). Patient-centred 
advice is effective in improving adherence to medicines. Pharmacy World & Science 
28(3), pp. 165-170. 
 
Coleman, A.  Steel, S. Freeman, P.  de Greeff, A. and Shennan, A. (2008). Validation 
of the Omron M7 (HEM-780-E) oscillometric blood pressure monitoring device 
according to the British Hypertension Society protocol. Blood Pressure Monitoring. 
13(1), pp. 49-54. 
 
Colkesen, EB. Ferket, BS. Tijssen, JGP. Kraaijenhagen, RA. van Kalken, CK. and 
Peters, RJG. (2011). Effects on cardiovascular disease risk of a web-based health risk 
assessment with tailored health advice: a follow-up study. Vascular Health and Risk 
Management 7, p. 67. 
 
Collins, GS. and Altman, DG. (2010). An independent and external validation of 
QRISK2 cardiovascular disease risk score: A prospective open cohort study. British 
Medical Journal 340 (7758), p. 1231. 
 
Collins, R. Peto, R. Hennekens, C. Doll, R. Bubes, V. Buring, J. et al. (2009). Aspirin 
in the primary and secondary prevention of vascular disease: collaborative meta-
analysis of individual participant data from randomized trials. Lancet 373(9678), pp. 
1849-1860. 
 
Comuzzie, AG. and Allison, DB. (1998). The search for human obesity genes. Science 
280(5368), p. 1374. 
 
Cooper, A. Nherera, L. Calvert, N.  O’Flynn, N. Turnbull, N.  Robson, J.  et al. 
(2008). Clinical Guidelines and Evidence Review for Lipid Modification: 
cardiovascular risk assessment and the primary and secondary prevention of 
cardiovascular disease.London: National Collaborating Centre for Primary Care and 
Royal College of General Practitioners. 
 
Cowley, J. Gidman, W. McGregor, L. and Andoh, N. (2010). Exploring community 
pharmacists' experience and opinions of Medication Review services in England, 
Wales and Scotland. International Journal of Pharmacy Practice 18(S2), pp. 88-89. 
 
References 
279 
 
Cox, JL. Carr, B. Vallis, TM. Szpilfogel, C. and O'Neill, BJ. (2011). A Novel 
Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A 
Primary Prevention Initiative Examining the Impact of Health Risk Factor Assessment 
and Management on Cardiac Wellness. Canadian Journal of Cardiology 27(6), pp. 
809-817. 
 
CPWales. (2011a). Community Pharmacy Wales. [Online]. Available at: 
http://www.cpwales.org.uk [Accessed: 5/5/2011]. 
 
CPWales. (2011b). New NHS "Home From Hospital" Medicines Service Launched in 
Welsh Community Pharmacies. [Online]. Available at: 
http://www.cpwales.org.uk/News/PRESS-RELEASE.aspx [Accessed: 25/12/2011]. 
 
Crabtree, V. Hall, J. and Gandecha, M. (2010a). NHS health checks: The views of 
community pharmacists and support staff. International Journal of Pharmacy Practice 
18, pp. 35-36. 
 
Crabtree, V. Hall, J. and Gandecha, M. (2010b). NHS health checks: The views of 
community pharmacists and support staff. International Journal of Pharmacy Practice 
Conference: Health Services Research and Pharmacy Practice Conference 2010 
Manchester United Kingdom. Conference Start: 20100412 Conference End: 
20100413. Conference Publication: (var.pagings). 18(S1), pp. 35-36. 
 
Cranor, CW. Bunting, BA. and Christensen, DB. (2003). The Asheville Project: long-
term clinical and economic outcomes of a community pharmacy diabetes care 
program. Journal of the American Pharmaceutical Association 43(2), pp. 173-184. 
 
Cranor, CW. and Christensen, DB. (2003). The Asheville Project: short-term 
outcomes of a community pharmacy diabetes care program. Journal of the American 
Pharmaceutical Association 43(2), pp. 149-159. 
 
Critchley, JA. and Capewell, S. (2003). Mortality risk reduction associated with 
smoking cessation in patients with coronary heart disease. Journal of the American 
Medical Association 290(1), p. 86. 
 
Crowe, FL. Roddam, AW. Key, TJ. Appleby, PN. Overvad, K. Jakobsen, MU. et al. 
(2011). Fruit and vegetable intake and mortality from ischaemic heart disease: results 
from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart 
study. European Heart Journal 32(10), p. 1235. 
 
Cubbin, C. Sundquist, K. Ahlén, H. Johansson, SE. Winkleby, MA. and Sundquist, J. 
(2006). Neighborhood deprivation and cardiovascular disease risk factors: protective 
and harmful effects. Scandinavian Journal of Public Health 34(3), p. 228. 
 
Cubbin, C. and Winkleby, MA. (2005). Protective and harmful effects of 
neighborhood-level deprivation on individual-level health knowledge, behavior 
changes, and risk of coronary heart disease. American Journal of Epidemiology 
162(6), p. 559. 
 
Czernichow, S. Kengne, AP. Huxley, RR. Batty, GD. de Galan, B. Grobbee, D. et al. 
(2011). Comparison of waist-to-hip ratio and other obesity indices as predictors of 
cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study 
References 
280 
 
from ADVANCE. European Journal of Cardiovascular Prevention & Rehabilitation 
18(2), p. 312. 
 
Dalton, ARH. Soljak, M. Samarasundera, E. Millett, C. and Majeed, A. (2011). 
Prevalence of cardiovascular disease risk amongst the population eligible for the NHS 
Health Check Programme. European Journal of Cardiovascular Prevention & 
Rehabilitation Published online before print November 4, 2011, doi: 
10.1177/1741826711428797. 
 
Dawar, R. Singal, S. and Singh, R. (2011). Is cardiovascular risk more in diabetics 
because of lower apolipoprotein A1 levels rather than higher ApoB/ApoA1 ratio? 
International Journal of Biomedical Research 2(2), pp. 143-150. 
 
De Backer, G. Ambrosionie, E. Borch-Johnsen, K. Brotons, C. Cifkova, R. 
Dallongeville, J. et al. (2003). European guidelines on cardiovascular disease 
prevention in clinical practice: third joint task force of European and other societies on 
cardiovascular disease prevention in clinical practice (constituted by representatives of 
eight societies and by invited experts). European Journal of Cardiovascular 
Prevention & Rehabilitation 10(1 suppl), p. S1. 
 
Dent, THS. (2010). Predicting the risk of coronary heart disease. I. The use of 
conventional risk markers. Atherosclerosis 213 (2), pp. 345-351. 
 
Devaraj, S. Valleggi, S. Siegel, D. and Jialal, I. (2010). Role of C-reactive protein in 
contributing to increased cardiovascular risk in metabolic syndrome. Current 
Atherosclerosis Reports 12(2), pp. 110-118. 
 
di Angelantonio, E. Chowdhury, R. Sarwar, N. Aspelund, T. Danesh, J. and 
Gudnason, V. (2010). Chronic kidney disease and risk of major cardiovascular disease 
and non-vascular mortality: prospective population based cohort study. British 
Medical Journal 341, p. c4986. doi:4910.1136/bmj.c4986. 
 
di Castelnuovo, A. Costanzo, S. di Giuseppe, R. de Gaetano, G. and Iacoviello, L. 
(2009). Alcohol consumption and cardiovascular risk: mechanisms of action and 
epidemiologic perspectives. Future Cardiology 5(5), pp. 467-477. 
 
Didonato, K. and May, J. (2011). The impact of wellness screening and monitoring 
services provided in a community pharmacy. Journal of the American Pharmacists 
Association 51 (2), p. 281. 
 
DOH. (2000). Coronary heart disease: national service framework for coronary heart 
disease - modern standards and service models. [Online]. Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_4057526.pdf [Accessed: 9/7/2011]. 
 
DOH. (2002). Addressing inequalities – reaching the hard-to-reach groups. . [Online]. 
Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_4065397.pdf [Accessed: 30/12/2011]. 
 
DOH. (2003). Tackling Health Inequalities: A Programme for Action. [Online]. 
Available at: 
References 
281 
 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_4019362.pdf [Accessed: 21/4/2011]. 
 
DOH. (2005). Choosing health through pharmacy: A programme for pharmaceutical 
public health 2005-2015. [Online]. Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_4107496.pdf [Accessed: 20/4/2011]. 
 
DOH. (2008a). Options Stage Impact Assessment for Vascular Risk Assessments. 
[Online]. Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_083824.pdf [Accessed: 19/12/2011]. 
 
DOH. (2008b). Pharmacy in England: Building on Strengths – Delivering the Future. 
[Online]. Available at: www.official-
documents.gov.uk/document/cm73/7341/7341.pdf [Accessed: 2/5/2011]. 
 
DOH. (2008c). Putting prevention first: Vascular Checks: risk assessment and 
management. [Online]. Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_083823.pdf [Accessed: 9/6/2011]. 
 
Donyai, P. and van den Berg, M. (2009). Coronary heart disease risk screening: The 
community pharmacy Healthy Heart Assessment Service. Pharmacy World and 
Science 31 (6), pp. 643-647. 
 
Doughty, C. (2003). What is the value of a family history of premature cardiovascular 
disease in predicting increased risk of cardiovascular disease? [Online]. Available at: 
http://nzhta.chmeds.ac.nz/publications/family_history.pdf [Accessed: 8/7/2011]. 
 
Downs, JR. Clearfield, M. Weis, S. Whitney, E. Shapiro, DR. Beere, PA. et al. (1998). 
Primary prevention of acute coronary events with lovastatin in men and women with 
average cholesterol levels: Results of AFCAPS/TexCAPS. Journal of the American 
Medical Association 279 (20), pp. 1615-1622. 
 
DTB (2009). Aspirin for primary prevention of cardiovascular disease? Drug and 
Therapeutics Bulletin 47(11), pp. 122-125. 
 
Ekinci, EI. Clarke, S. Thomas, MC. Moran, JL. Cheong, K. MacIsaac, RJ. and Jerums, 
G. (2011). Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes 
Care 34(3), pp. 703-709. 
 
El Feghali, RN. Topouchian, JA.  Pannier, BM. El Assaad, HA.  and Asmar, RG. 
(2007). Validation of the OMRON M7 (HEM-780-E) blood pressure measuring 
device in a population requiring large cuff use according to the International Protocol 
of the European Society of Hypertension. Blood Pressure Monitoring. 12(3), pp. 173-
178. 
 
Ellison, RC. (2002). Balancing the risks and benefits of moderate drinking. Annals of 
the New York Academy of Sciences 957(1), pp. 1-6. 
 
References 
282 
 
Ergin, A. Muntner, P. Sherwin, R. and He, J. (2004). Secular trends in cardiovascular 
disease mortality, incidence, and case fatality rates in adults in the United States. 
American Journal of Medicine 117(4), pp. 219-227. 
 
Erhardt, L. (2009). Cigarette smoking: an undertreated risk factor for cardiovascular 
disease. Atherosclerosis 205(1), pp. 23-32. 
 
Feinleib, M. (1981). Seven Countries: A Multivariate Analysis of Death and Coronary 
Heart Disease. Journal of the American Medical Association 245(5), p. 511. 
 
Ferland, A. and Eckel, RH. (2011). Does Sustained Weight Loss Reverse the 
Metabolic Syndrome? Current Hypertension Reports 13(6), pp. 456-464. 
 
Fernandez-Pinilla, C. and Chaves, J. (2008a). Cardiovascular risk detection in general 
Spanish population pfarmacar study. Atencion Farmaceutica 10 (6), pp. 335-343. 
 
Fernandez-Pinilla, C. and Chaves, J. (2008b). Cardiovascular risk detection in general 
Spanish population pfarmacar study. [Spanish]. Atencion Farmaceutica 10 (6), pp. 
335-343. 
 
Folsom, AR. Chambless, LE. Duncan, BB. Gilbert, AC. and Pankow, JS. (2003). 
Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes 
Care 26(10), p. 2777. 
 
Fuller, TD. (2011). Moderate Alcohol Consumption and the Risk of Mortality. 
Demography, pp. 1-21. 
 
Furberg, CD. Wright Jr, JT. Davis, BR. Cutler, JA. Alderman, M. Black, H. et al. 
(2002). Major outcomes in moderately hypercholesterolemic, hypertensive patients 
randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering 
treatment to prevent heart attack trial (ALLHAT-LLT). Journal of the American 
Medical Association 288 (23), pp. 2998-3007. 
 
Garrett, DG. and Bluml, BM. (2005). Patient self-management program for diabetes: 
first-year clinical, humanistic, and economic outcomes. Journal of the American 
Pharmacists Association 45(2), pp. 130-137. 
 
George, SJ. and Johnson, J. (2010). Atherosclerosis: Molecular and Cellular 
Mechanisms. Weinheim: Wiley-VCH. 
 
Gholap, N. Davies, M. Patel, K. Sattar, N. and Khunti, K. (2011). Type 2 diabetes and 
cardiovascular disease in South Asians. Primary Care Diabetes 5(1), pp. 45-56. 
 
Goldberg, DM. and Soleas, GJ. (2011). Wine and Health: A Paradigm for Alcohol and 
Antioxidants. Journal of Medical Biochemistry 30(2), pp. 93-102. 
 
Gonzalez, A. Kremers, HM. Crowson, CS. Ballman, KV. Roger, VL. Jacobsen, SJ. et 
al. (2008). Do cardiovascular risk factors confer the same risk for cardiovascular 
outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? 
Annals of the Rheumatic Diseases 67(1), p. 64. 
 
References 
283 
 
Gordon, DJ. Probstfield, JL. Garrison, RJ. Neaton, JD. Castelli, WP. Knoke, JD. et al. 
(1989). High-density lipoprotein cholesterol and cardiovascular disease. Four 
prospective American studies. Circulation 79(1), p. 8. 
 
Graffagnino, C. Gasecki, AP. Doig, GS. and Hachinski, VC. (1994). The importance 
of family history in cerebrovascular disease. Stroke 25(8), p. 1599. 
 
Graley, C. May, K. and McCoy, D. (2011). Postcode Lotteries in Public Health-The 
NHS Health Checks Programme in North West London. BMC Public Health 11(1), p. 
738. 
 
Gray, LJ Taub, NA Khunti, K. Gardiner, E. Hiles, S. Webb, DR et al. (2010). The 
Leicester risk assessment score for detecting undiagnosed type 2 diabetes and 
impaired glucose regulation for use in a multiethnic UK setting. Diabetic Medicine 
27(8), pp. 887-895. 
 
Hammond, J. Salamonson, Y. Davidson, P. Everett, B. and Andrew, S. (2007). Why 
do women underestimate the risk of cardiac disease? A literature review. Australian 
Critical Care 20(2), pp. 53-59. 
 
Heart Protection Study Collaborative Group (2011). C-reactive protein concentration 
and the vascular benefits of statin therapy: an analysis of 20?536 patients in the Heart 
Protection Study. The Lancet 377(9764), pp. 469-476. 
 
Heart UK. (2011). Cholesterol and a healthier nation: shared responsibility for better 
public health. [Online]. Available at: 
http://www.heartuk.org.uk/pressroom/images/uploads/1312_HeartUK_CholesterolHea
lthReport2011_FINAL.pdf [Accessed: 16/12/2011]. 
 
Helmut Gohlke, H. Rauch, B. Schneider, S. Katus, H. and Senges, J. (2011). Lifestyle 
and age at a first acute coronary syndrome - An Omega-trial observational sub-study. 
European Journal of Cardiovascular Prevention and Rehabilitation 18 (1 SUPPL. 1), 
p. S60. 
 
Hind, CA. Bond, CM. Lee, AJ. and van Teijlingen, ER. (2008). Needs assessment 
study for community pharmacy travel medicine services. Journal of Travel Medicine 
15(5), pp. 328-334. 
 
Hippisley-Cox, J. (2011). The QRISK2 risk calculator [Online].  Available at: 
http://qrisk.org/index.php [Accessed: 16/6/2011  
 
Hippisley-Cox, J. Coupland, C. Robson, J. and Brindle, P. (2011). Derivation, 
validation, and evaluation of a new QRISK model to estimate lifetime risk of 
cardiovascular disease: Cohort study using QResearch database. British Medical 
Journal 342 (7788), p. 93. 
 
Hippisley-Cox, J. Coupland, C. Vinogradova, Y. Robson, J. May, M. and Brindle, P. 
(2007). Derivation and validation of QRISK, a new cardiovascular disease risk score 
for the United Kingdom: Prospective open cohort study. British Medical Journal 335 
(7611), pp. 136-141. 
 
Hippisley-Cox, J. Coupland, C. Vinogradova, Y. Robson, J. Minhas, R. Sheikh, A. 
and Brindle, P. (2008). Predicting cardiovascular risk in England and Wales: 
References 
284 
 
Prospective derivation and validation of QRISK2. British Medical Journal 336 (7659), 
pp. 1475-1482. 
 
Hirst, JE. John, DN. Bloor, MJ. and Walker, R. (1999). Analysis of focus group 
discussion on privacy in community pharmacies. Pharmaceutical Journal 263, pp. 38-
39. 
 
Hobbs, FD. and Erhardt, L. (2002). Acceptance of guideline recommendations and 
perceived implementation of coronary heart disease prevention among primary care 
physicians in five European countries: the Reassessing European Attitudes about 
Cardiovascular Treatment (REACT) survey. Family Practice 19(6), pp. 596-604. 
 
Holman, RR. Paul, SK. Bethel, MA. Matthews, DR. and Neil, HAW. (2008). 10-Year 
follow-up of intensive glucose control in type 2 diabetes. New England Journal of 
Medicine 359(15), pp. 1577-1589. 
 
Horgan, J. Blenkinsopp, A. and McManus, RJ. (2010). Evaluation of a cardiovascular 
disease opportunistic risk assessment pilot ('Heart MOT' service) in community 
pharmacies. Journal of Public Health 32(1), pp. 110-116. 
 
Horgan, J. Blenkinsopp, A. and Spencer-Jones, C. (2009). Patient feedback on the 
'Heart MOT': A community pharmacy cardiovascular risk assessment service. 
International Journal of Pharmacy Practice 17 (S2), p. B35. 
 
Hotchkiss, JW. Davies, C. Gray, L. Bromley, C. Capewell, S. and Leyland, AH. 
(2011). Trends in adult cardiovascular disease risk factors and their socio-economic 
patterning in the Scottish population 1995–2008: cross-sectional surveys. BMJ open 1 
(1):e000176. 
 
HPS (2002). MRC/BHF Heart Protection Study of cholesterol lowering with 
simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 
Heart Protection Study Collaborative Group. Lancet 360(9326), pp. 7-22. 
 
Humphries, SE. Drenos, F. Ken-Dror, G. and Talmud, PJ. (2010). Coronary heart 
disease risk prediction in the era of genome-wide association studies: current status 
and what the future holds. Circulation 121(20), p. 2235. 
 
Imhof, A. Frohlich, M. Loewel, H. Helbecque, N. Woodward, M. Amouyel, P. et al. 
(2003). Distributions of C-reactive protein measured by high-sensitivity assays in 
apparently healthy men and women from different populations in Europe. Clinical 
Chemistry 49(4), p. 669. 
 
Iqbal, S.  and Wood, K. (2010). Exploring patient opinions of MURs. International 
Journal of Pharmacy Practice 18(S2), p. 20. 
 
Jackson, R. (2008). Cardiovascular risk prediction: are we there yet? Heart 94(1), pp. 
1-3. 
 
Jain, A. Persaud, JW. Rao, N. Harvey, D. Robertson, L. Nirmal, L. et al. (2011). Point 
of care testing is appropriate for National Health Service health check. Annals of 
Clinical Biochemistry 48 (2), pp. 159-165. 
 
References 
285 
 
JBS2 (2005). Joint British Societies' guidelines on prevention of cardiovascular 
disease in clinical practice. Heart 91(SUPPL. 5), pp. vi-v52. 
 
Jerrell, JM. and Sakarcan, A. (2009). Primary health care access, continuity, and cost 
among pediatric patients with obesity hypertension. Journal of the National Medical 
Association 101(3), pp. 223-228. 
 
Jousilahti, P. Rastenyte, D. Tuomilehto, J. Sarti, C. and Vartiainen, E. (1997). Parental 
history of cardiovascular disease and risk of stroke: a prospective follow-up of 14 371 
middle-aged men and women in Finland. Stroke 28(7), p. 1361. 
 
Kaczorowski, J. Chambers, LW. Dolovich, L. Farrell, B. McDonough, B. Sebaldt, R. 
et al. (2010). Improving cardiovascular health at the population level: A 39 
community cluster-randomised trial of the cardiovascular health awareness program 
(CHAP). Journal of Hypertension 28, p. e602. 
 
Kairuz, T. Crump, K. and O'Brien, A. (2007). An overview of qualitative research. 
Pharmaceutical Journal 278(7443), pp. 312-314. 
 
Kairuz, TE Crump, K. and O'Brien, A. (2011). Perspectives on qualitative research. 
Part 2: Useful tools for data collection and analysis. The Pharmaceutical Journal 
278(7445), pp. 371-372. 
 
Kannel, WB. (2011). Sixty Years of Preventive Cardiology: A Framingham 
Perspective. Clinical cardiology 34(6), pp. 342-343. 
 
Kannel, WB. and Benjamin, EJ. (2008). Status of the epidemiology of atrial 
fibrillation. Medical Clinics of North America 92(1), pp. 17-40. 
 
Katikireddi, SV. Higgins, M. Bond, L. Bonell, C. and Macintyre, S. (2011). How 
evidence based is English public health policy? British Medical Journal 343:d7310. 
 
Keys, A. Menotti, A. Aravanis, C. Blackburn, H. Djordevic, BS. Buzina, R. et al. 
(1984). The seven countries study: 2,289 deaths in 15 years. Preventive Medicine 
13(2), pp. 141-154. 
 
Khera, A. McGuire, DK. Murphy, SA. Stanek, HG. Das, SR. Vongpatanasin, W. et al. 
(2005). Race and gender differences in C-reactive protein levels. Journal of the 
American College of Cardiology 46(3), pp. 464-469. 
 
Kilpeläinen, TO. Zillikens, MC. Stan ákova, A. Finucane, FM. Ried, JS. Langenberg, 
C. et al. (2011). Genetic variation near IRS1 associates with reduced adiposity and an 
impaired metabolic profile. Nature Genetics 43, pp. 753–760. 
 
Knowsley PCT. (2008). Vascular Checks Case Study: Community Health Checks, 
Knowsley. [Online]. Available at: 
http://www.improvement.nhs.uk/NHShealthcheck/casestudies/knowsley/NS_Case_St
udy_Knowsley_Final.pdf [Accessed: 24/5/2011]. 
 
Kones, R. (2010). Rosuvastatin, inflammation, C-reactive protein, JUPITER, and 
primary prevention of cardiovascular disease–a perspective. Drug Design, 
Development and Therapy 4, p. 383. 
 
References 
286 
 
Krska, J. (2010). Pharmacy in Public Health. Pharmaceutical Press. 
 
Lalonde, L. O'Connor, AM. Duguay, P. Brassard, J. Drake, E. and Grover, SA. (2006). 
Evaluation of a decision aid and a personal risk profile in community pharmacy for 
patients considering options to improve cardiovascular health: The OPTIONS pilot 
study. International Journal of Pharmacy Practice 14 (1), pp. 51-62. 
 
Latif, A.  Mahmood, K. and Boardman, H. (2010). Medicines Use Reviews - How 
have pharmacists' views changed? International Journal of Pharmacy Practice 
18((S2)), pp. 68-69. 
 
Latif, A. and Boardman, H. (2008). Community pharmacists’ attitudes towards 
medicines use reviews and factors affecting the numbers performed. Pharmacy World 
& Science 30(5), pp. 536-543. 
 
Latif, A. and Boardman, HF (2007). Pharmacists' attitudes and factors affecting the 
numbers of medicines use reviews (MURs) performed. International Journal of 
Pharmacy Practice 15, p. 4. 
 
Latif, A. Pollock, K. and Boardman, HF. (2011). The contribution of the Medicines 
Use Review (MUR) consultation to counseling practice in community pharmacies. 
Patient Education and Counseling 83(3), p. 336. 
 
Lawton, BA. Rose, SB. Elley, CR. Dowell, AC. Fenton, A. and Moyes, SA. (2009). 
Exercise on prescription for women aged 40-74 recruited through primary care: two 
year randomised controlled trial. British Journal of Sports Medicine 43(2), pp. 120-
123. 
 
Lean, MEJ. Han, TS. and Seidell, JC. (1998). Impairment of health and quality of life 
in people with large waist circumference. The Lancet 351(9106), pp. 853-856. 
 
Lewington, S. Whitlock, G. Clarke, R. Sherliker, P. Emberson, J. Halsey, J. et al. 
(2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a 
meta-analysis of individual data from 61 prospective studies with 55,000 vascular 
deaths. Lancet 370(9602), pp. 1829-1839. 
 
Liem, AH. van de Woestijne, AP. Roeters van Lennep, HWO. Zwinderman, AH. van 
der Steeg, WA. and Jukema, JW. (2007). ApoB/A1 and LDL-C/HDL-C and the 
prediction of cardiovascular risk in statin-treated patients. Current Medical Research 
and Opinion® 24(2), pp. 359-364. 
 
Lindschou Hansen, J. Tolstrup, JS. Jensen, MK. Grønbæk, M. Tjønneland, A. 
Schmidt, EB. and Overvad, K. (2011). Alcohol intake and risk of acute coronary 
syndrome and mortality in men and women with and without hypertension. European 
Journal of Epidemiology 26(6), pp. 439-447. 
 
LIPID (1998). Prevention of cardiovascular events and death with pravastatin in 
patients with coronary heart disease and a broad range of initial cholesterol levels. The 
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 
New England Journal of Medicine 339(19), pp. 1349-1357. 
 
Liu, Y. McDonough, RP. Carruthers, KM. and Doucette, WR. (2009). Identifying 
patients at risk of cardiovascular disease: a pharmacist-managed screening event for 
References 
287 
 
union workers and their dependents. Journal of the American Pharmacists Association 
49(4), pp. 549-553. 
 
Livingstone, C. (2010). Onwards and upwards with target MURs. Pharmaceutical 
Journal 284, p. 57. 
 
Longmore, M. Wilkinson, IB. and Rajagopalan, SR. (2004). Oxford Handbook of 
Clinical Medicine. Sixth ed. Oxford: Oxford University Press. 
 
Loo, RL. Diaper, C. Salami, OT. Kundu, M. Lalkia, M. Airhiavbere, E. and Shah, S. 
(2011). The NHS Health Check: The views of community pharmacists. International 
Journal of Pharmacy Practice 19, p. 13. 
 
Maes, HHM. Neale, MC. and Eaves, LJ. (1997). Genetic and environmental factors in 
relative body weight and human adiposity. Behavior Genetics 27(4), pp. 325-351. 
 
Maguire, T. and Haslam, D. (2009). The Obesity Epidemic and Its Management. 
London: Pharmaceutical Press. 
 
Marmot, M. (2010). Fair Society Healthy Lives: a strategic review of health 
inequalities in England post 2010. [Online]. Available at: 
http://www.instituteofhealthequity.org/projects/fair-society-healthy-lives-the-marmot-
review/fair-society-healthy-lives-full-report [Accessed: 25/12/2011]. 
 
Martindale (2011). Martindale: The Complete Drug Reference. 37th ed. London: 
Pharmaceutical Press. 
 
Maurer, MS. (2003). Age: a nonmodifiable risk factor? Journal of the American 
College of Cardiology 42(8), p. 1427. 
 
Mc Namara, KP. George, J. O'Reilly, SL. Jackson, SL. Peterson, GM. Howarth, H et 
al. (2010). Engaging community pharmacists in the primary prevention of 
cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk 
and Treatment in Cardiovascular Disease (PAART CVD) pilot study. BMC Health 
Services Research 10:264 doi:10.1186/1472-6963-10-264. 
 
McDermott, MM. (2007). The international pandemic of chronic cardiovascular 
disease. Journal of the American Medical Association 297(11), pp. 1253-1255. 
 
McDonald, R. Cheraghi-Sohi, S. Tickle, M. Roland, M. and Doran, T. (2010). The 
impact of incentives on the behaviour and performance of primary care professionals. 
National Institute for Health Research Service Delivery and Organisation Programme 
[Online]. Available at: http://www.politiquessociales.net/IMG/pdf/impact-2.pdf 
[Accessed: 30/12/2011]. 
 
Meng, L. Wilkens, L. Murphy, S. Henderson, B. and Kolonel, L. (2011). Association 
of fish consumption factors with stroke mortality in the multiethnic cohort study. 
Stroke 42 (3), p. e276. 
 
Meredyth, D. Zwart, I. Gorjanicyn, K. Sheil, H. Stone, W. and Goebel, L. (2008). 
Social inclusion of the hard to reach. [Online]. Available at: 
http://www.sisr.net/Flagships/democracy/docs/htr_final.pdf [Accessed: 30/12/2011]. 
 
References 
288 
 
MHRA (2009). Aspirin: not licensed for primary prevention of thrombotic vascular 
disease. Drug Safety Update 3(3), pp. 10-11. 
 
Mosca, L. Barrett-Connor, E. and Wenger, NK. (2011). Sex/Gender Differences in 
Cardiovascular Disease Prevention. Circulation 124(19), pp. 2145-2154. 
 
Mosca, L. Ferris, A. Fabunmi, R. and Robertson, RM. (2004). Tracking women's 
awareness of heart disease: an American Heart Association national study. Circulation 
109(5), p. 573. 
 
Mozaffarian, D. Appel, LJ. and Van Horn, L. (2011). Components of a 
cardioprotective diet: New insights. Circulation 123 (24), pp. 2870-2891. 
 
Naik Panvelkar, P. Armour, C. and Saini, B. (2010). Community pharmacy-based 
asthma services-what do patients prefer. Journal of Asthma 47 (10), pp. 1085-1093. 
 
Naik Panvelkar, P. Saini, B. and Armour, C. (2009). Measurement of patient 
satisfaction with community pharmacy services: a review. Pharmacy World & Science 
31(5), pp. 525-537. 
 
Nakamura, H. Arakawa, K. Itakura, H. Kitabatake, A. Goto, Y. Toyota, T. et al. 
(2006). Primary prevention of cardiovascular disease with pravastatin in Japan 
(MEGA Study): a prospective randomised controlled trial. Lancet 368 (9542), pp. 
1155-1163. 
 
National Institute of Health. (2002). Third Report of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final 
Report). [Online]. Available at: 
http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm [Accessed: 9/7/2011]. 
 
Neuendorf, KA. (2002). The content analysis guidebook. Chicago: Sage Publications, 
Inc. 
 
NHS Choices. (2011a). Alcohol Units. [Online]. Available at: 
http://www.nhs.uk/Livewell/alcohol/Pages/alcohol-units.aspx [Accessed: 25/12/2011]. 
 
NHS Choices. (2011b). Call for all to take statins after 55. [Online]. Available at: 
http://www.nhs.uk/news/2011/05May/Pages/statins-for-all-55-plus.aspx [Accessed: 
13/7/2011]. 
 
NHS Wales. (2006). Welsh Health Survey 2004/05. [Online]. Available at: 
http://www.wales.nhs.uk/news/5137 [Accessed: 11/12/2011]. 
 
NHS Wales. (2011). Community Pharmacy Contract: Advanced Services. [Online]. 
Available at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=498&pid=7551 
[Accessed: 25/12/2011]. 
 
NHS Westminster. (2011). NHS Westminster Pharmaceutical Needs Assessment. 
[Online]. Available at: http://www.northwestlondon.nhs.uk/_uploads/documents/all-
documents/public-health-reports/nhs-westminster-pna[1].pdf [Accessed: 25/12/2011]. 
 
NICE. (2006a). Clinical guideline 36 Atrial fibrillation: the management of atrial 
fibrillation. [Online]. Available at: 
References 
289 
 
http://www.nice.org.uk/nicemedia/pdf/CG036niceguideline.pdf [Accessed: 
24/6/2011]. 
 
NICE. (2006b). Clinical guideline 43 Obesity: guidance on the prevention, 
identification, assessment and management of overweight and obesity in adults and 
children. [Online]. Available at: 
http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf [Accessed: 
24/6/2011]. 
 
NICE. (2008a). Clinical guideline 66: Type 2 diabetes: national clinical guideline for 
management in primary and secondary care: update (full NICE guideline). [Online]. 
Available at: http://www.nice.org.uk/Guidance/CG66/Guidance/pdf/English 
[Accessed: 11/7/2011]. 
 
NICE. (2008b). Clinical guideline 67: Lipid modification. [Online]. Available at: 
http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf [Accessed: 9/7/2011]. 
 
NICE. (2008c). Technology Appraisal 94: Statins for the prevention of cardiovascular 
events. [Online]. Available at: www.nice.org.uk/TA094 [Accessed: 13/12/2011]. 
 
NICE. (2010a). Press Release: NICE changes recommendations on cardiovascular risk 
assessment in lipid modification guideline. [Online]. Available at: 
http://www.nice.org.uk/media/9A1/6D/2010039ChangeToLipidModificationGudielin
e.pdf [Accessed: 14/6/2011]. 
 
NICE. (2010b). Public health guidance 24. Alcohol-use disorders: preventing the 
development of hazardous and harmful drinking. [Online]. Available at: 
http://www.nice.org.uk/nicemedia/live/13001/48984/48984.pdf [Accessed: 
15/7/2011]. 
 
Nocon, M. Hiemann, T. Müller-Riemenschneider, F. Thalau, F. Roll, S. and Willich, 
SN. (2008). Association of physical activity with all-cause and cardiovascular 
mortality: a systematic review and meta-analysis. Journal of Cardiovascular Risk 
15(3), p. 239. 
 
NPC. (2010). Antiplatelets patient decision aid: aspirin for  primary prevention of 
cardiovascular disease. [Online]. Available at: 
http://www.npc.co.uk/therapeutics/cardio/antiplatelets/resources/antiplatelets_pda.pdf 
[Accessed: 12/7/2011]. 
 
Nutbeam, D. and Harris, E. (2004). Theory in a nutshell: a practical guide to health 
promotion theories. McGraw-Hill. 
 
O'Donovan, D. Byrne, S. McGillicuddy, A. Ledwidge, M. and Sahm, L. (2010). 
Development and administration of a screening tool for cardiovascular risk assessment 
in community pharmacy. Pharmacoepidemiology and Drug Safety, pp. 655-656. 
 
Oparah, AC. Adje, DU. and Enato, EFO. (2006). Outcomes of pharmaceutical care 
intervention to hypertensive patients in a Nigerian community pharmacy. 
International Journal of Pharmacy Practice 14(2), pp. 115-122. 
 
Panz, VR. Raal, FJ. Paiker, J. Immelman, R. and Miles, H. (2005). Performance of the 
CardioChek[trademark] PA and Cholestech LDX point-of-care analysers compared to 
References 
290 
 
clinical diagnostic laboratory methods for the measurement of lipids. Cardiovascular 
Journal of South Africa. 16(2), pp. 112-117. 
 
Paudyal, V. Hansford, D. Stewart, D. and Cunningham, I. (2009). Exploring 
innovations in scottish community pharmacy practice: Change theory and new 
nonprescription medicine services. International Journal of Pharmacy Practice 17 
(S2), p. B72. 
 
Peden, JF. Hopewell, JC. Saleheen, D. Chambers, JC. Hager, J. Soranzo, N. et al. 
(2011). A genome-wide association study in Europeans and South Asians identifies 
five new loci for coronary artery disease. Nature Genetics 43, pp. 339–344. 
 
Pedersen, TR. Kjekshus, J. Berg, K.  and Haghfelt, T. (2004). Randomised trial of 
cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian 
Simvastatin Survival Study (4S). Atheroscler Suppl. 5(3), pp. 81-87. 
 
Petersen, S. Peto, V. and Rayner, M. (2005). European Cardiovascular Disease 
Statistics. [Online]. Available at: 
http://www.heartstats.org/uploads/documents/PDF.pdf [Accessed: 13/10/2011]. 
 
Peterson, GM. Fitzmaurice, KD. Kruup, H. Jackson, SL. and Rasiah, RL. (2010). 
Cardiovascular risk screening program in Australian community pharmacies. 
Pharmacy World and Science 32 (3), pp. 373-380. 
 
Pieske, B. and Wachter, R. (2008). Impact of diabetes and hypertension on the heart. 
Current Opinion in Cardiology 23(4), pp. 340-349. 
 
Points, E. (2008). The ADVANCE Collaborative Group: Intensive blood glucose 
control and vascular outcomes in patients with type 2 diabetes. New England Journal 
of Medicine (358), pp. 2560-2572. 
 
Portlock, J. Holden, M. and Patel, S. (2009). A community pharmacy asthma MUR 
project in Hampshire and the Isle of Wight. Pharmaceutical Journal 282 (7537), pp. 
109-112. 
 
Prochaska, JO. and di Clemente, CC. (1984). Self change processes, self efficacy and 
decisional balance across five stages of smoking cessation. Progress in Clinical and 
Biological Research 156, p. 131. 
 
PSNC. (2004). Summary of new contract structure. [Online]. Available at: 
http://www.psnc.org.uk/data/files/PharmacyContract/pharmacy_contract_summary_de
c_2004.pdf [Accessed: 21/4/2011]. 
 
PSNC. (2011). Pharmaceutical Services Negotiating Committee. [Online]. Available 
at: http://www.psnc.org.uk/pages/about_psnc.html [Accessed: 5/5/2011]. 
 
Public Health Wales. (2011). Large differences in healthy life expectancy in Wales 
found. [Online]. Available at: http://www.wales.nhs.uk/sitesplus/888/news/21230 
[Accessed: 8/12/2011]. 
 
Radosevic, N. Popovic, B. Palcevski, G. and Vlahovic-Palcevski, V. (2010). The 
impact of educational campaign on public attitudes towards antibiotics. Clinical 
Microbiology and Infection 16, p. S434. 
References 
291 
 
 
Rao, N. Eastwood, SV. Jain, A. Shah, M. Leurent, B. Harvey, D. et al. (2011). 
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility 
study. International Journal of Clinical Practice 66(3), pp. 262-269. 
 
Richards, C. (2009). How pharmacy can help close the health inequality gap in 
Britain. Pharmaceutical Journal 282(7536), pp. 67-68. 
 
Ridker, PM. Danielson, E. Fonseca, FA. Genest, J. Gotto, AM. Jr. Kastelein, JJ. et al. 
(2008). Rosuvastatin to prevent vascular events in men and women with elevated C-
reactive protein. New England Journal of Medicine 359(21), pp. 2195-2207. 
 
Roberts, R. and Kennington, E. (2010a). Getting involved in pharmacy research. 
Pharmaceutical Journal 284(7597), pp. 365-367. 
 
Roberts, R. and Kennington, E. (2010b). Pharmacy practice research has an impact on 
each and every pharmacist. Pharmaceutical Journal 284(7593), pp. 267-268. 
 
RPS. (2011a). Clinical Governance. [Online]. Available at: 
http://www.rpharms.com/support-tools/clinical-governance.asp [Accessed: 
23/11/2011]. 
 
RPS. (2011b). NHS Community Pharmacy Contract Wales. [Online]. Available at: 
http://www.rpharms.com/nhs-community-pharmacy-contract-wales/targeted-
medicines-use-reviews.asp [Accessed: 25/12/2011]. 
 
RPSGB. (2009). Pharmacy Medicines Use Review – Community Pharmacy Audit. 
[Online]. Available at: 
http://www.qi4pd.org.uk/images/stories/PDFs/MURPharmacy.pdf [Accessed: 
2/5/2011]. 
 
Sacks, FM. Pfeffer, MA. Moye, LA. Rouleau, JL. Rutherford, JD. Cole, TG. et al. 
(1996). The effect of pravastatin on coronary events after myocardial infarction in 
patients with average cholesterol levels. Cholesterol and Recurrent Events Trial 
investigators. New England Journal of Medicine 335(14), pp. 1001-1009. 
 
Sancar, M. Akyildiz, E. Okuyan, B. Apikoglu Rabus, S. Soydeger Carli, B. Yilmaz, Z. 
and Izzettin, F. V. (2011). Cardiovascular disease risk assessment among patients with 
hyperlipidemia at a community pharmacy setting. International Journal of Clinical 
Pharmacy 33 (2), pp. 429-430. 
 
Satta, N. Packard, CJ. and Petrie, JR. (1998). The end of triglycerides in 
cardiovascular risk assessment? British Medical Journal 317(7158), p. 553. 
 
Schenck-Gustafsson, K. (2009). Risk factors for cardiovascular disease in women. 
Maturitas 63(3), pp. 186-190. 
 
Scott, R. Donoghoe, M. Watts, GF. O'Brien, R. Pardy, C. Taskinen, MR. et al. (2011). 
Impact of metabolic syndrome and its components on cardiovascular disease event 
rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD 
randomised trial. Cardiovascular Diabetology 10(1), p. 102. 
 
References 
292 
 
Segal, NL. and Allison, DB. (2002). Twins and virtual twins: bases of relative body 
weight revisited. International Journal of Obesity and Related Metabolic Disorders 
26(4), p. 437. 
 
Selvin, E. Marinopoulos, S. Berkenblit, G. Rami, T. Brancati, FL. Powe, NR. and 
Golden, SH. (2004). Meta-analysis: Glycosylated hemoglobin and cardiovascular 
disease in diabetes mellitus. Annals of Internal Medicine 141(6), pp. 421-431. 
 
Sever, PS. Dahlof, B. Poulter, NR. Wedel, H. Beevers, G. Caulfield, M. et al. (2004). 
Prevention of coronary and stroke events with atorvastatin in hypertensive patients 
who have average or lower-than-average cholesterol concentrations, in the Anglo-
Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A 
multicentre randomised controlled trial. Drugs 64 (SUPPL. 2), pp. 43-60. 
 
Shah, T. Newcombe, P. Smeeth, L. Addo, J. Casas, JP. Whittaker, J. et al. (2010). 
Ancestry as a determinant of mean population C-reactive protein values: implications 
for cardiovascular risk prediction. Circulation: Cardiovascular Genetics doi:10.1161/
CIRCGENETICS.110.957431. 
 
Shelton, N. and Savell, E. (2011). The geography of binge drinking: the role of 
alcohol-related knowledge, behaviours and attitudes. Results from the Health Survey 
for England 2007. Health & Place 17(3), pp. 784-792. 
 
Shepherd, J. Cobbe, SM. Ford, I. Isles, CG. Lorimer, AR. MacFarlane, PW. et al. 
(1995). Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New 
England Journal of Medicine 333(20), pp. 1301-1307. 
 
Shindler, E. (2011). The Framingham Heart Study official website. [Online].  
Available at: www.framinghamheartstudy.org [Accessed: 5/5/2011  
 
Shlipak, MG. Fried, LF. Cushman, M. Manolio, TA. Peterson, D. Stehman-Breen, C. 
et al. (2005). Cardiovascular mortality risk in chronic kidney disease. Journal of the 
American Medical Association 293(14), p. 1737. 
 
SIGN. (2007). Scottish Intercollegiate Guidelines Network No. 97: Risk estimation 
and the prevention of cardiovascular disease. [Online]. Available at: 
http://www.sign.ac.uk/pdf/sign97.pdf [Accessed: 10/5/2011]. 
 
Simpson, SH. Johnson, JA. and Tsuyuki, RT. (2001). Economic impact of community 
pharmacist intervention in cholesterol risk management: an evaluation of the study of 
cardiovascular risk intervention by pharmacists. Pharmacotherapy 21(5), pp. 627-635. 
 
Smith, FJ. (1998). HEALTH SERVICES RESEARCH METHODS IN PHARMACY: 
Qualitative interviews. International Journal of Pharmacy Practice 6(2), pp. 97-108. 
 
Smith, FJ. (2010). Conducting your pharmacy practice research project: a step-by-
step approach. London: Pharmaceutical Press. 
 
Soljak, M. Lonergan, K. and Hayward, J. (2009). Systematic review of methods of 
patient and public contact for screening programmes. Public Health Action Support 
Team [Online]. Available at: 
http://system.improvement.nhs.uk/ImprovementSystem/DocumentArchive/ViewDocu
References 
293 
 
ment.aspx?documentid=4070&nodeid=645&hideheader=true&email=true&ModuleTy
pe=Forum [Accessed: 13/11/2011]. 
 
Sposito, AC. Alvarenga, BF. Alexandre, AS. Araujo, ALR. Santos, SN. Andrade, JM. 
et al. (2011). Most of the patients presenting myocardial infarction would not be 
eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive 
protein. Atherosclerosis 214 (1), pp. 148-150. 
 
Stafford, M. and Marmot, M. (2003). Neighbourhood deprivation and health: does it 
affect us all equally? International Journal of Epidemiology 32(3), p. 357. 
 
Stewart, D. George, J.  Bond, CM. Cunningham, IT. Diack, HL. and McCaig, DJ. 
(2008). Exploring patients’ perspectives of pharmacist supplementary prescribing in 
Scotland. Pharmacy World & Science (30), pp. 892-897. 
 
Stranges, S. and Trevisan, M. (2011). Alcohol Intake, Dyslipidemia, and CVD. 
Nutritional and Metabolic Bases of Cardiovascular Disease, pp. 176-182. 
 
Svetkey, LP. Stevens, VJ. Brantley, PJ. Appel, LJ. Hollis, JF. Loria, CM. et al. (2008). 
Comparison of strategies for sustaining weight loss. Journal of the American Medical 
Association 299(10), p. 1139. 
 
Taylor, F. Ward, K. Moore, THM. Burke, M.  Davey Smith, G. Casas, JP. and 
Ebrahim, S. (2011a). Statins for the primary prevention of cardiovascular disease 
(Review). [Online]. Available at: 
http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD004816/frame.html 
[Accessed: 27/5/2011]. 
 
Taylor, RS. Ashton, KE. Moxham, T. Hooper, L. and Ebrahim, S. (2011b). Reduced 
dietary salt for the prevention of cardiovascular disease. Cochrane Database of 
Systematic Reviews 7. 
 
Thomas, VN. Saleem, T. and Abraham, R. (2005). Barriers to effective uptake of 
cancer screening among Black and minority ethnic groups. International Journal of 
Palliative Nursing 11(11), pp. 562-571. 
 
Thompson, D. Pepys, MB. and Wood, SP. (1999). The physiological structure of 
human C-reactive protein and its complex with phosphocholine. Structure 7(2), pp. 
169-177. 
 
Thornley, T. Blenkinsopp, A. and Chapman, S. (2009a). Consultation length for 
vascular risk assessment in a community pharmacy Healthy Heart service. 
International Journal of Pharmacy Practice 17 (S2), pp. B42-B43. 
 
Thornley, T. Blenkinsopp, A. and Chapman, S. (2009b). Demography and 
cardiovascular risk profile of clients of a community pharmacy Healthy Heart service. 
International Journal of Pharmacy Practice 17 (S2), pp. B41-B42. 
 
Tocci, G.  Ferrucci, A.  Guida, P.  and Avogaro, A. (2011). Impact of physicians’ age 
on the clinical management of global cardiovascular risk: analysis of the results of the 
Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation 
Educational Programme. The International Journal of Clinical Practice study 65(6), 
pp. 649–657. 
References 
294 
 
 
Tseng, DS. Cox, E. Plane, MB. and Hla, KM. (2001). Efficacy of patient letter 
reminders on cervical cancer screening. Journal of General Internal Medicine 16(8), 
pp. 563-568. 
 
Tsuyuki, RT. Johnson, JA. Teo, KK. Ackman, ML. Biggs, RS. Cave, A. et al. (1999). 
Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial 
design of the effect of a community pharmacist intervention program on serum 
cholesterol risk. The Annals of Pharmacotherapy 33(9), pp. 910-919. 
 
Tunstall-Pedoe, H. and Woodward, M. (2006). By neglecting deprivation, 
cardiovascular risk scoring will exacerbate social gradients in disease. Heart 92(3), p. 
307. 
 
Vachharajani, V. and Granger, DN. (2009). Adipose tissue: a motor for the 
inflammation associated with obesity. International Union of Biochemistry and 
Molecular Biology (IUBMB life) 61(4), pp. 424-430. 
 
van Bussel, BCT. Henry, RMA. Schalkwijk, CG. Ferreira, IF. Feskens, EJM. Streppel, 
MT. et al. (2011). Fish consumption in healthy adults is associated with decreased 
circulating biomarkers of endothelial dysfunction and inflammation during a 6-year 
follow-Up. Journal of Nutrition 141 (9), pp. 1719-1725. 
 
van de Mortel, TF. (2008). Faking it: Social desirability response bias in self-report 
research. Australian Journal of Advanced Nursing 25(4), p. 40. 
 
van den Berg, M. and Donyai, P. (2010). A retrospective audit of medicines use 
review forms. International Journal of Pharmacy Practice 18 (SUPPL. 1), pp. 33-34. 
 
Van Halm, VP. Peters, MJL. Voskuyl, AE. Boers, M. Lems, WF. Visser, M. et al. 
(2009). Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: 
a cross-sectional study, the CARRE Investigation. Annals of the Rheumatic Diseases 
68(9), p. 1395. 
 
Velicer, WF. Prochaska, JO. Rossi, JS. and Snow, MG. (1992). Assessing Outcome in 
Smoking Cessation Studies. [Review]. Psychological Bulletin January 111(1), pp. 23-
41. 
 
Vera-Cala, LM. Orostegui, M. Valencia-Angel, LI. López, N. and Bautista, LE. 
(2011). Accuracy of the Omron HEM-705 CP for blood pressure measurement in 
large epidemiologic studies. Abstract in English. Arquivos Brasileiros de Cardiologia 
96(5), pp. 393-398. 
 
WAG. (2001). Coronary Heart Disease NSF for Wales: Tackling CHD in Wales: 
Implementing Through Evidence. [Online]. Available at: 
http://www.wales.nhs.uk/sites3/home.cfm?orgid=442 [Accessed: 14/8/2011]. 
 
WAG. (2007). Smoking in Wales: current facts. [Online]. Available at: 
http://www.wales.nhs.uk/sitesplus/documents/888/WCH%20smoking%20ban%20rep
ort%20E%20final.pdf [Accessed: 11/12/2011]. 
 
WAG. (2008). Welsh Index of Multiple Deprivation 2008 Summary Report. [Online]. 
Available at: 
References 
295 
 
http://wales.gov.uk/docs/statistics/2010/100712wimd08summaryreviseden.pdf 
[Accessed: 19/3/2011]. 
 
WAG. (2010). Vascular Risk Management in Wales. A report from the Vascular 
Project Group. [Online]. Available at: 
http://www.wales.nhs.uk/sites3/Documents/338/100823vascularriskassesmentreporten
%5B1%5D.pdf [Accessed: 10/5/2011]. 
 
Waheedi, S. Donovan, M. Walker, R. and John, DN. (2011). Reasons for requesting 
and patient satisfaction with a free, non-NHS, community pharmacy-based vascular 
risk assessment (VRA) service. International Journal of Pharmacy Practice 19 (S2), 
pp. 39-40. 
 
Waheedi, S. John, DN. Donovan, M. and Walker, R. (2010). Deprivation status and 
utilization of a non-NHS community pharmacy based cardiovascular risk assessment 
service. International Journal of Pharmacy Practice 18, pp. 61-62. 
 
Wald, NJ. Simmonds, M. and Morris, JK. (2011). Screening for Future Cardiovascular 
Disease Using Age Alone Compared with Multiple Risk Factors and Age. PLoS ONE 
6(5), p. e18742. 
 
Wales Centre for Health. (2009). A profile of alcohol and health in Wales. [Online]. 
Available at: 
http://www.wales.nhs.uk/sites3/Documents/568/Alcohol%20and%20Health%20in%2
0Wales_WebFinal_E.pdf [Accessed: 11/12/2011]. 
 
Walker, R. and Whittlesea, C. (2012). Clinical pharmacy and therapeutics. London: 
Churchill Livingstone. 
 
Waltz, CF. Strickland, OL. and Lenz, ER. (2010). Measurement in nursing and health 
research. Springer Publishing Company. 
 
Weber, KT. (2002). Collaborative meta-analysis of randomized trials of antiplatelet 
therapy for prevention of death, myocardial infarction, and stroke in high risk patients. 
British Medical Journal 321, pp. 71-86. 
 
Weiner, DE. Tighiouart, H. Amin, MG. Stark, PC. MacLeod, B. Griffith, JL. et al. 
(2004). Chronic kidney disease as a risk factor for cardiovascular disease and all-cause 
mortality: a pooled analysis of community-based studies. Journal of the American 
Society of Nephrology 15(5), p. 1307. 
 
Welsh Goverment. (2010). Population Estimates by Ethnic Group, 2001-2007. 
[Online]. Available at: 
http://wales.gov.uk/topics/statistics/headlines/population2010/0205/?lang=en 
[Accessed: 27/11/2011]. 
 
Wensley, F. Gao, P. Burgess, S. Kaptoge, S. Di Angelantonio, E. Shah, T. et al. 
(2011). Association between C reactive protein and coronary heart disease: mendelian 
randomisation analysis based on individual participant data. British Medical Journal 
342. 
 
References 
296 
 
Williams, B. Poulter, NR. Brown, MJ. Davis, M. McInnes, GT. Potter, JF. et al. 
(2004). British hypertension society guidelines for hypertension management 2004 
(BHS-IV): Summary. British Medical Journal 328(7440), pp. 634-640. 
 
Wilson, PWF. Anderson, KM. Harri, T. Kannel, WB. and Castelli, WP. (1994). 
Determinants of change in total cholesterol and HDL-C with age: the Framingham 
Study. Journal of Gerontology 49(6), p. M252. 
 
Wilson, PWF. D'Agostino, RB. Levy, D. Belanger, AM. Silbershatz, H. and Kannel, 
WB. (1998). Prediction of coronary heart disease using risk factor categories. 
Circulation 97(18), pp. 1837-1847. 
 
Wolin, KY. and Colditz, GA. (2008). Can weight loss prevent cancer? British Journal 
of Cancer 99(7), pp. 995-999. 
 
Woodward, M. Brindle, P. and Tunstall-Pedoe, H. (2007). for the SIGN Group on 
Risk Estimation. Adding social deprivation and family history to cardiovascular risk 
assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort 
(SHHEC). Heart 93(2), pp. 172-176. 
 
World Health Organization. (2004). Global Status Report on Alcohol. [Online]. 
Available at: 
http://www.who.int/substance_abuse/publications/global_status_report_2004_overvie
w.pdf [Accessed: 15/7/2011]. 
 
World Health Organization. (2007). Achieving health equity: from root causes to fair 
outcomes. [Online]. Available at: 
http://www.who.int/social_determinants/resources/csdh_media/cdsh_interim_statemen
t_final_07.pdf [Accessed: 7/7/2011]. 
 
Yamada, C. Johnson, JA. Robertson, P. Pearson, G. and Tsuyuki, RT. (2005). Long-
term impact of a community pharmacist intervention on cholesterol levels in patients 
at high risk for cardiovascular events: extended follow-up of the second study of 
cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy 
25(1), pp. 110-115. 
 
Yusuf, S. (2010). Evidence-Based Cardiology. 3 ed. London: Wiley Blackwell. 
 
Yusuf, S. Hawken, S. and Ounpuu, S. (2004). Erratum: Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): Case-control study (Lancet (2004) 364 (937-952)). Lancet 
364(9450), p. 2020. 
 
Zhang, Y. Tuomilehto, J. Jousilahti, P. Wang, Y. Antikainen, R. and Hu, G. (2011). 
Lifestyle Factors on the Risks of Ischemic and Hemorrhagic Stroke. Archives of 
Internal Medicine 1, p. 443. 
 
 
 297 
 
List of publications 
Muir D, Waheedi S, Donovan M, Walker R and John DN. (2012). A non-NHS, 
free of charge, community pharmacy-based cardiovascular risk assessment 
service: the views and experiences of the service users. International Journal 
of Pharmacy Practice. Abstract accepted. In press 
 
Waheedi S, Walker R and John DN. (2012) An analysis of medicines use 
review documentation in one community pharmacy.  International Journal of 
Clinical Pharmacy 34, p. 184. 
 
Waheedi S, Donovan M, Walker R and John DN. (2011). Reasons for 
requesting and patient satisfaction with a free, non-NHS, community 
pharmacy-based vascular risk assessment (VRA) service. International Journal 
of Pharmacy Practice 19 (S2), pp. 39-40. 
 
Waheedi S, John DN and Walker R. (2011).Drugs related issues raised from a 
cardiovascular risk assessment service based in a community pharmacy. 3rd 
Kuwait International Pharmacy Conference KIPC 2011, February 14 - 16, 
2011. 
 
Waheedi S, John DN, Donovan M and Walker R. (2010). Deprivation status 
and utilization of a non-NHS community pharmacy based cardiovascular risk 
assessment service. International Journal of Pharmacy Practice 18, pp. 61-62. 
 
 298 
 
Appendices
Appendix 1: The participant journey through the VRA service 
 
299 
 
Appendix 1: The participant journey through 
the VRA service 
 
 
Appendix 2: Participant Information Sheet and Consent Form 
 
300 
 
 
Appendix 2a: Participant Information Sheet  
Evaluation of a cardiovascular risk assessment service 
 
You are invited to participate in a study. Before you decide whether or 
not to participate, please take the time to read the following information. 
It is important you understand what is involved and the reasons behind 
the study. You are free to discuss the information with others if you 
wish. Please do not hesitate to ask any questions. 
Thank you for reading this. 
 
What is the purpose of the study? 
We have started to provide a cardiovascular risk assessment service, 
free of charge, at Boots, Porthcawl. The aim of the study is to evaluate 
this service which consists of an assessment of your risk of developing 
cardiovascular disease (heart attack or stroke) in the next 10 years. As 
part of the service we will provide you with information and advice to 
help you make lifestyle changes to reduce your cardiovascular risk. We 
would like to follow-up people who use this service for 12 months. We 
are interested to find out how they deal with the information and advice 
we provide. Therefore, two follow-ups have been planned.  
 
Who are the researchers and who is funding the research? 
The research team is based at Welsh School of Pharmacy, Cardiff 
University and consists of Mr Salah Waheedi (a community 
pharmacist/research pharmacist), Dr Dai John and Professor Roger 
Walker. The data will be collected by Mr Waheedi. The research is 
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funded by Cardiff University and has been approved by South West 
Wales Local Research Ethics Committee (subject to approval). 
 
Why have I been invited to participate in this study? 
You have been invited to participate because you expressed an interest 
in undertaking a cardiovascular risk assessment at Boots, Porthcawl. 
 
What is expected of me? 
After you have had the cardiovascular risk assessment service we 
would like to contact you on two further occasions and I would like to 
ask for your consent to do this. Information about the cardiovascular 
risk assessment service is provided in the ‘Look after your hear’ flyer. 
The service usually takes between 25 to 40 minutes. You are not 
expected to agree to anything that you do not want to. The following 
sections will describe in more detail what is expected.   
 
1) Two-week follow-up interview 
This interview will be over the telephone and will take place 
approximately two weeks after the cardiovascular risk assessment 
service. It is expected that the interview will take about 10-15 minutes 
but it may be longer. A researcher will phone you to obtain your views 
and to see if you have any comments you want to share. The 
researcher will ask you about the advice you were given. The interview 
will be audio recorded, with your permission, or the researcher will take 
brief notes. If at any time you feel that the audio recording should be 
stopped then you are free to say so. 
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2) Twelve month follow-up 
Approximately 11 months after the cardiovascular risk assessment 
service you will receive a reminder letter about this study and then you 
will be contacted to make an appointment for an interview in the 
pharmacy. If appropriate we will repeat all the tests you initially had as 
part of the cardiovascular risk assessment service. The additional 
assessment you will have in this follow-up will allow comparison of your 
new results with the results from your initial assessment. With the 
reminder letter we will enclose a pre-paid envelope which you can send 
back in case you wish to withdraw from the study or do not want to be 
contacted by telephone. 
 
Do I have to take part? 
It is up to you to decide whether to consent. If you decide to consent 
please read and sign the consent form enclosed. Please bring along 
both signed copies of the form to the pharmacy or sign them in the 
pharmacy before you have the cardiovascular risk assessment service. 
One copy is for your own records. You can withdraw your consent at 
any time without giving a reason. If you require more information please 
feel free to contact myself (Mr Waheedi: contact details below) or my 
project supervisor (Dr Dai John: contact details below), this does not 
commit you to participating. 
 
How will my information be used? 
When collecting information and data we will ensure confidentiality at all 
times. Any published information will not identify your involvement in the 
study. A copy of the consent form, satisfaction questionnaire and result 
documents will be kept securely in the Welsh School of Pharmacy. The 
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information we retain on university computers, however, will contain no 
personal data, only a reference number. 
Your name and address will not be kept for any longer than is needed 
to complete the study. It is anticipated this will be no longer than three 
years. Your details will only be seen by the research team. 
 
Who can I contact for more information? 
We are more than happy to discuss any issues you may have regarding 
the research project. Our contact details are as follows:  
 
Research pharmacist: 
Mr Salah Waheedi, Welsh School of Pharmacy, Cardiff University, 
Redwood Building, King Edward VII Avenue, Cardiff. CF10 3NB 
Telephone: 0776559690                       E-mail: waheedis2@cf.ac.uk 
 
Research project supervisor and pharmacist: 
Dr Dai John, Welsh School of Pharmacy, Cardiff University, Redwood 
Building, King Edward VII Avenue, Cardiff. CF10 3NB 
Telephone: 029 208 75804                      E-mail: johndn@cf.ac.uk  
 
Thank you for taking the time to read this information.  
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Appendix 3b: Supplementary data collection form 
 
Evaluation of cardiovascular risk assessment service 
1. Participant’s reference number____________________ 
2. Is participant registered with a local GP:  □ Yes  □ No 
3. When was the last time the participant went to see the 
GP__________________ 
4. How many times in the past 12 months has the participants been 
to the GP__________ 
5. Does the participant suffer from Rheumatoid Arthritis □ or Atrial 
Fibrillation □ 
Duration of the assessment: 
Start time: Finish time: Performed by: 
   
 
Ethnicity: 
□ White or not stated 
□ Indian 
□ Pakistani 
□ Bangladeshi 
□ Other Asian 
□ Black Caribbean 
□ Black African 
□ Chinese 
□ Other ethnic group 
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Appendix 5: Services local to Porthcawl Boots 
Smoking cessation  
Stop Smoking Wales 
0800 085 2219 
www.stopsmokingwales.com 
 
Specially trained staff offer: 
 guidance 
 advice 
 information and  
 free access to counseling and support groups across Wales. 
 
 
Weight management 
Weight Watchers (Private*) 
Tel: 0845 0705116      WeightWatchers.co.uk 
* Other private services are available upon request. 
 
Alcohol advice and support 
Welsh Alcohol Helpline 
0800 6 33 55 88 
 
Healthy eating 
A food co-operative is a simple system through which you can access fresh 
fruit, salad and vegetables on a weekly basis at affordable prices.  Local 
produce is accessed as much as possible (quality and price permitting) and 
bought in bulk benefiting and encouraging local farmers.  Local sourcing 
means: 
  
·        money you spend is kept within the region 
·        food miles are reduced 
  
The savings from the bulk buying are then passed on to the members so that 
the fruit and vegetables are sold at reasonable prices. There are several co-
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operatives currently running in the County Borough of Bridgend and to find 
out where these co-op’s are please contact Catherine Webb/ Ann Davies on 
01656 754465 
The food cooperatives are run by volunteers who sort the produce, take orders 
for the following week and the money. 
For further information and assistance in setting up a Food Coop contact: 
  
Richard Reast on 01443 402317 or email: richard.reast@rru.org.uk 
 
 
Physical activity 
Healthy Living Department – Bridgend County Borough Council 
The Healthy Living Department currently provide a number of initiatives 
aimed at those people wanting to increase their levels of physical activity. 
These include an Exercise Referral Scheme, free swimming for the over 60’s 
and for under 16’s during the school holidays and the Bridge Card 
membership. For further information about any of these activities or to find out 
what’s on in your local leisure centre please click on the following link: 
 http://www.bridgend.gov.uk/Web1/groups/leisure/documents/services/004417.
hcsp   
 Walk your Way to Health 
A local walking group is currently being run by Groundwork Bridgend and 
Neath Port Talbot. These short walks take place every Thursday morning 
starting at 11am and take place at various venues throughout the Borough of 
Bridgend including Bryngarw Country Park, Park Slip Nature Reserve and 
along the Garw Valley Community Route. The walks are led by trained walk 
leaders and are graded to suit different levels of ability. To find out more about 
these walks or to request a timetable, please phone 01656 727800 
  
For those people who prefer longer walks the Ramblers Association have the 
following two groups within the County Borough of Bridgend. Please click on 
the appropriate link to find out more:    
  
Bridgend and District Ramblers     http://www.bridgendramblers.org.uk/    
Maesteg Ramblers   http://www.maestegramblers.org.uk/ 
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Mental Health 
HOW WE CAN IMPROVE AND MAINTAIN OUR MENTAL HEALTH 
Have you got the right balance between work, or other daytime occupation, 
social life and any other activities? 
With one in four adults likely to experience a mental health problem in the 
course of one year, we all need to take action to ensure that we can enjoy the 
best possible mental health we can. 
Good mental health is generally being able to 
 Develop emotionally, creatively intellectually and spiritually 
 Sustain satisfying personal relationships 
 Face problems, resolve them and learn from them 
 Be confident and assertive 
 Be aware of others and empathise with them 
 Use and enjoy special time on our own 
 Play and have fun 
 Laugh, both at ourselves and at the world about us 
Mental health problems can range from the worries and distress we all 
experience as part of everyday life; to a disabling anxiety disorder; from mild 
to severe depression; to desperation and suicide; or to a complete loss of touch 
with everyday reality.  Sometimes these problems can cause real and lasting 
damage, both to ourselves and to others about us.  Fortunately many of the 
people who experience mental health problems can get over them or learn to 
live with them, especially if they can get the right help early on. 
How can we help ourselves? 
There are many ways we can help ourselves, these include 
 Making time to do the things we enjoy 
 Taking moderate physical exercise 
 Cutting down on coffee, alcohol, nicotine and other addictive 
substances 
 Remembering and acknowledging the things we like about ourselves 
 Keeping things in perspective 
 Developing and keeping friendships 
 Listening to and respecting other people, even when we disagree with 
them! 
This does not guarantee a problem-free life but can lead to more self-awareness 
and being able to recognise when things are going wrong. 
Looking after yourself or even putting yourself first is not always being selfish 
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but about being realistic about our own mental health needs, and this can then 
help us to help others. 
Information about local voluntary or statutory mental health services can be 
found by contacting your local GP for one of the following Community Mental 
Health Teams (CMHT) – Bridgend, Porthcawl, Maesteg, Ogmore and Garw 
Valley, West Vale. 
Mental Health Matters Wales Tel: 01656-767 045  
BAVO Tel: 01656 810 400 
Gofal Cymru Tel: 01656-647722 
Hafal Tel: 01656-729191 
 
Other Services 
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Appendix 6c: Boots SOP, obtaining blood sample 
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Appendix 6d: Boots SOP, BMI calculation 
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Appendix 6e: Boots SOP, waist measurement  
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Appendix 6f: Boots SOP, blood pressure 
measurement 
 
 
Appendix 6: Boots Standard Operating Procedure 
321 
 
Appendix 6g: Boots SOP, monthly quality assurance 
 
 
Appendix 6: Boots Standard Operating Procedure 
322 
 
Appendix 6h: Boots SOP, daily quality assurance 
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Appendix 6i: Boots SOP, waste disposal 
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Appendix 6j: Boots SOP, fasting glucose test 
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Appendix 6k: Boots SOP, external quality assurance 
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Appendix 7a: Advert v1 
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Appendix 7b: Advert v2 
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Appendix 7c: The GEM advert (for Porthcawl) 
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Appendix 7d: Merthyr Tydfil Express Advert 
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Appendix 11a: Interview schedule for two-week 
follow-up 
Interview conducted over the phone by an independent researcher 
 
 Hello. May I speak to  ______________________________ please? 
  
o Hello my name is _________ from Cardiff University. I am 
phoning to see if it is convenient to ask some questions about 
the cardiovascular risk assessment service you had at Boots 
Porthcawl recently  
o Is now a good time to talk?  If they hesitate or aren’t sure then 
say ‘ If it is more convenient I can call back” and ask ‘what day 
and time suits you’ 
Date/Time___________________________________________ 
 
 Before we start we would like to record the interview so that we don’t 
miss anything you say. We won’t be asking sensitive questions. Is this 
OK? 
 
 
The interview 
 
 How did you find out about the cardiovascular risk assessment service 
at Boots, Porthcawl? 
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 Can you remember the reasons you decided to have the cardiovascular 
assessment service at Boots on this occasion? 
 
 
 
 Have you had any similar checks in the past either in the surgery or 
pharmacy or elsewhere?  
 
If YES, can you remember when it was and what the results were? 
 
 Is there anyone in your family who had or has heart disease? 
 
 
 Do you know any friends, neighbors or colleagues who have had heart 
disease? 
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I am now going to ask a few questions about what happened at Boots 
 Did the pharmacist say if you were at high, low or moderate risk of 
cardiovascular disease?    
The consent form will state if risk assessment performed If NO, go to 
next page 
 At that time what did being at ______* risk  mean to you?  [*they may 
give a %] 
 
 How was it useful to be told of your individual risk by the pharmacist? 
 
 How did you feel when the pharmacist told you what your risk was?  
(If they’re not sure, ask   Did the cardiovascular risk assessment service 
make you reassured, concerned or something else ? ) 
 
 Have you talked to your doctor or nurse about the results of the Boots 
check? 
Do you remember what they said? 
 
 
 Have you discussed the Boots results with anybody else? (Prompt only: 
spouse, friend, relatives) 
 
 
 How do you feel NOW that is today about your ______ * risk ?  *[they 
may give a %] 
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 I am now going to ask some questions about the advice you 
and the pharmacist discussed  
Did the pharmacist mention anything about ______? Do you remember what 
was discussed? Ask for each section one by one  
 
 
- diet,  
- weight,  
- exercise,  
- smoking,  
- alcohol 
- anything else  
 
 Have you recommended this Boots service to anyone else?  
  
If NO, have you mentioned it to anybody or would you? 
 
 Is there anything you would like to say about the actual cardiovascular 
risk assessment service you had at Boots, Porthcawl? 
 
 
Thank you very much for your time. 
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Appendix 11b: Example Interview Transcript (with 
subject 104) 
 
Subject 104: Hello 
Interviewer: oh hello can I speak to Mr [ ] please? 
Subject 104: Speaking 
Interviewer:  oh hello Mr [ ] my names Dai John from Cardiff University I was 
hoping to ask a few questions about your Boots health check 
Subject 104: Yes 
Interviewer: But I know it’s about tea time so you may be having your tea at the 
moment? 
Subject 104: Right if I just finish my mouthful I’ll be fine actually. 
Interviewer: Are you sure I tried to call in the day but of course I realised that people 
don’t sit at home waiting for me to ring. 
Subject 104: ah yeh no no its fine now  
Interviewer: ah right thank you I’m just wondering if it’s ok to record the 
conversation please there’s nothing... 
Subject 104: Yes that’s fine. 
Interviewer: Thank you thank you, so first of all Sir how did you find out about the 
service down at Boots? 
Subject 104: I saw it in the local paper 
Interviewer: ah right thank you and can you remember the reasons you decided to 
have the tests done at Boots on this occasion? 
Subject 104: Well just to see what my blood pressure and cholesterol was like really. 
Interviewer: OK thank you have you had similar checks in the past please sir? 
Subject 104: um I’ve had my blood pressure checked. 
Interviewer: OK 
Subject 104: Before 
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Interviewer: Right and do you remember what the results were? 
Subject 104: um not exactly no 
Interviewer: OK no that’s fine that’s fine is there anybody in your family who’s got 
heart disease? 
Subject 104: um no. 
Interviewer: OK and do you know any friends neighbours or colleagues who’ve got 
heart disease or may have had it? 
Subject 104: uh no not really no 
Interviewer: OK thank you now were going to take you to the actual visit that you 
had with the pharmacist.  
Subject 104: Yes sure. 
Interviewer: Do you remember if he said to you if you were a high low or moderate 
risk of cardiovascular disease? 
Subject 104: He said I was let me think moderate I think 
Interviewer: Moderate? 
Subject 104: Yes 
Interviewer: And at the time what did being at moderate risk mean to you do you 
remember? 
Subject 104: uh it was something like it was under 20% chance that I would have a 
heart attack or a stroke within the next 10 years I think 
Interviewer: OK thank you and was it useful for you to be told your individual risk 
do you think 
Subject 104: uh well it was useful to have uh to know the results of the blood 
pressure and uh cholesterol yes 
Interviewer: OK and what about the risk itself was it useful to know your individual 
risk or not useful 
Subject 104: um I suppose it was yes yes 
Interviewer: OK and how did you feel when the pharmacist told you what your risk 
was when he said to you are less than 20% 
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Subject 104: I suppose that was a bit disconcerting really obviously a low would 
have been a lot better 
Interviewer: Right, OK yeh have you spoke to your doctor or nurse about the results 
of the Boots check? 
Subject 104: No I haven’t no 
Interviewer: OK is it something that you might do you won’t do or have you not 
bothered about it? 
Subject 104: Well I rarely go to a doctor so um I probably wouldn’t mention it you 
know. 
Interviewer: Right, yeh... and have you talked to anybody else about the results of 
this test maybe friends or family? 
Subject 104: um friends yes yes 
Interviewer: OK thank you and finally it’s been two and a half weeks since you had 
the test.. 
Subject 104: Yes 
Interviewer: Nearly three weeks now how do you feel today about your moderate 
risk is there any change? 
Subject 104: um no I think what it’s made me do I think is think about the amount of 
exercise I have and what I’m eating you know. 
Interviewer: yeh...  
Subject 104: So I think it’ll probably um amend the way that I do things over the 
next year. 
Interviewer: OK did the pharmacist and you discuss the types of foods you eat when 
he met with you? 
Subject 104: Yes he did yes yes 
Interviewer: OK 
Subject 104: And he suggested that I eat less salt  
Interviewer: Yeh 
Subject 104: Well I’ve taken less salt  
Interviewer: Yeh.. anything else you can remember not the detail just broadly really 
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Subject 104: um no all he said was perhaps get a bit more exercise 
Interviewer: Yeh OK 
Subject 104: And be careful what I’m eating have lots of fresh fruit and veg you 
know. 
Interviewer: Yeh... thank you and what about weight I don’t need to know how much 
you are but did you discuss with the pharmacist?  
Subject 104: My weight was fine. 
Interviewer: OK thank you and about alcohol intake did you and the pharmacist 
discuss alcohol? 
Subject 104: We did and that was fine as well yeh. 
Interviewer: Fine OK and smoking did that come up? 
Subject 104: uh it did but I don’t smoke. 
Interviewer: You don’t smoke right? 
Subject 104: No 
Interviewer: Thank you and was there anything else you and the pharmacist talked 
about in terms of lifestyle advice if you like? 
Subject 104: uh no I don’t think so. I think the two things were exercise and diet 
really. 
Interviewer: OK thank you have you recommended the service to anybody else sir? 
Subject 104: uh I’ve mentioned it to some other people.  
Interviewer: Right 
Subject 104: Who for whatever reason didn’t seem that keen on going but yes 
Interviewer: OK thank you and finally I’ve been asking you questions for the past 5 
minutes is there anything you’d like to say about the risk assessment you 
had at Boots in Porthcawl that I’ve not asked you about this evening 
Subject 104: No not really it was fine it was yeh it was quite useful I think 
Interviewer: OK and I noticed you live in Pencoed so 
Subject 104: Yeh 
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Interviewer: Did you go all the way over to Porthcawl to have the test or do you go 
to Porthcawl? 
Subject 104: Yes we did go there although we often go to Porthcawl anyway 
Interviewer: ah right ok ok well thank you very much indeed for your time Mr [ ]   
Subject 104: OK that’s fine 
Interviewer: Sorry to have troubled you thank you 
Subject 104: No problem 
Interviewer: Bye bye 
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Appendix 11c: Questionnaire for two-week follow-
up 
Covering letter: 
 
Date 
  
 
Dear    
Evaluation of a cardiovascular risk assessment service 
 
We are writing to you as you had a health check at Boots pharmacy in 
Porthcawl recently.  We have tried contacting by telephone but we have 
not been able to speak to you.  Therefore, we are writing to you to ask if 
you would be kind enough to answer the questions enclosed and return 
to us in the next 5 days if possible. We have enclosed a Freepost 
envelope, so no stamp is required. 
If you have any questions please do contact me on  029 2087 5804, or 
if you prefer you can e-mail me  at  JohnDN@cardiff.ac.uk. 
 
Thank you very much in anticipation of your help. 
Yours sincerely  
 
 
Dr DN John 
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Questionnaire: 
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Appendix 12a: Reminder letter for twelve-month 
follow-up 
 
Evaluation of a cardiovascular risk assessment service 
Date 
Dear Mr [   ] 
It is about a year since we asked you to participate in a study to help us 
evaluate a cardiovascular risk assessment service. You received the 
cardiovascular risk assessment service on 5
th
 August 2010 at Boots, 5 New 
Market Walk, Merthyr Tydfil. At that time you gave permission for us to 
contact you to check out your progress. 
I am writing to invite you for a follow-up consultation with me as part of the 
study. This consultation may include a repeat of the tests you had about 11 
months ago. I will try to contact you in about a week to see if you are still 
interested in participating and to answer any questions you may have. If you 
are interested in participating then we can arrange a mutually convenient time 
for the follow-up consultation to take place in Boots.  
In addition to offering the follow-up at the New Market Walk branch we are 
also able to offer this service at Boots, Cyfartha Retail Park. When I speak with 
you I will ask you to specify whether you prefer to have this follow-up at: 
1- Boots, 5 New Market Walk, Merthyr Tydfil 
2- Boots, Cyfarthfa Retail Park, Merthyr Tydfil 
If you would prefer to contact me feel free to do so. You can contact me by 
telephone, email, or by return of the enclosed slip in the Freepost envelope 
provided. 
 
Thank you very much for your help with this study. 
Yours sincerely  
 
Salah Waheedi 
WaheediS2@cf.ac.uk 
07765596906 
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Appendix 12b: Withdrawal form to accompany 
reminder letter for twelve-month follow-up 
 
 
Name _____________ 
 
Please do not complete and return this form if you wish to be contacted by 
the research pharmacist to arrange the appointment.  
  
If applicable, please tick one of the following boxes and return in the Freepost 
envelope provided as soon as possible. 
 I would prefer NOT to be contacted by anyone from the 
research team for the follow up consultation.* 
 I do not want to be contacted but I may contact you to 
arrange for the appointment myself 
Please write the date of completing this form here:  ___________________ 
 
* If you do not wish to have a follow-up consultation it would be very helpful 
to us to hear any reasons you may have. Please note that you do not have to 
give any reasons, it is entirely up to you. If you are willing, please use the 
following box to provide any information you would like to share with us. 
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Appendix 13: Questionnaire for twelve-month 
follow-up 
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Appendix 14: List of subjects who accessed the VRA service 
 
P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
1 (P) 21 12.6 74 Male 26.9 26.3 109 106 138/91 131/80 4.3 4.87 1.05 1.32 4.1 3.7 25.8  
2 (P) 19   66 Female 23.9  77  162/95  5.8  1.83  3.2  19.5  
3 (P) 16   74 Female 25.6  80  184/98  3.93  1.56  2.5     
4 (P) 15   59 Male 25.5  101  122/88  4.27  0.91  4.7  21.0  
5 (MT) 25   62 Female 23.7  81.5  135/81  5.42  1.39  3.9  9.2  
6 (P) 20   67 Male 29  100  132/83  4.44  0.75  5.9  37.0  
7 (MT) 16 12.0 54 Female 26.7 27.1 95 87 116/77 106/71 5.23 5.56 1.43 2.09 3.7 2.7 4.4 2.3 
8 (MT) 14 11.7 55 Female 36.4 35.7 114 114 126/84 107/72 5.42 5.87 0.83 0.96 6.5 6.1 17.1 12.1 
9 (MT) 15 12.4 59 Female 26.6 26.7 100 100 125/80 112/69 4.18 4.56 1.19 1.41 3.5 3.2 10.9 8.1 
10 (P) 14 14.0 70 Male 27.8 27    161/104 138/87          
11 (P) 19 12.6 52 Female 23.7 24.2 85.5 81 116/85 109/77 5.88 5.32 1.71 1.73 3.4 3.1 3.6 2.7 
12 (P) 40   62 Female 26.7  88  132/89   5.52  1.31  4.2  9.5   
13 (MT) 14   41 Female 30.2  96.5  124/84  5.07  1.19  4.3  3.2  
14 (P) 20 12.1 68 Male 26.4 26.6 90 91 135/88 129/80 4.7 5.15 2.19 1.4 2.1 3.7 16.8 26.3 
15 (MT) 20 12.4 47 Female 30.1 31 94.5 94 121/87 129/87 5.27 6.59 2.41 2.59 2.2 2.5 4.3 3.4 
Appendix 14: List of subjects who accessed the VRA service 
353 
 
P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
16 (P) 20   49 Female 28.8  84.5  113/75   4.05  1.32  3  3.4  
17 (MT) 15 12.1 50 Male 28 28.5 102 101 170/100 139/87 4.57 5.98 0.97 1.11 4.7 5.4 16.1 13.3 
18 (P) 28 13.1 56 Female 31.5 31.9 107 99 125/84 113/77 4.93 5.2 1.07 1.18 4.6 4.4 7.7 6.1 
19 (MT) 22   47 Male 30.3  100.5  109/79   4.53  0.69  6.6  13.0   
20 (P) 20 12.8 71 Female 30.6 33.6  108 141/94 142/80 3.98 3.92 1.14 0.96 3.5 4.1 11.3 13.6 
21 (MT) 15 12.1 64 Female 25.1 23.8 78 79.5 118/87 118/79 5.44 5.38 1.21 1.25 4.5 4.3 12.7 12.4 
22 (P) 19 14.8 55 Male 26.9 26.7 108.5 96 132/80 131/80 5.75 8.11 1.41 1.82 4.1 4.5 11.0 12.5 
23 (P) 15   78 Male 27.6  99  143/83   3.43  1.06  3.2      
24 (P) 15   72 Female 26.9  79  120/85  3.62  1.78  2  6.7  
25 (P)  12.1 79 Female 26.7 26.5 97 90 113/68 104/68 4.97 3.26 1.27 1.09 3.9 3     
26 (MT) 21   61 Male 25  92  158/102  5.8  1.46  4  20.2  
27 (MT) 15 11.9 55 Female 23.4 23.5 82.5 81.5 160/104 145/93 4.01 6.32 0.9 0.96 4.5 6.6 11.9 15.3 
28 (P) 19 12.1 62 Male 30.8 29.7 108 102 141/90 117/76           
29 (P) 19 12.4 43 Female 23.9 22.6 74.5 73 126/85 116/81 4.34 4.51 2.34 2.18 1.9 2.1 0.8 0.8 
30 (MT) 24   72 Female 27.3  87  144/89   6.68  1.16  5.8  18.9   
31 (MT) 14   60 Female 36.9  106.5  161/104   3.84  0.8  4.8  15.6   
32 (MT) 17 12.1 57 Female 26.9 27.5 90 93 157/91 125/76 4.89 5.86 1.37 1.3 3.6 4.5 14.9 12.1 
33 (P) 19 13.8 69 Female 26.2 26.2 87 96 123/83 122/83 6.51 5.82 1.19 1.56 5.5 3.7 12.6 8.4 
34 (P) 15 13.8 65 Male 29.2 28 99 98 170/102 142/85 5.31 4.2 2.02 1.05 2.6 4     
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
35 (MT) 14 11.4 67 Female 28.8 27.7 94.5 80.5 123/80 109/74 4.92 5.93 1.04 1.19 4.7 5 10.5 8.8 
36 (MT) 15   40 Female 21  77  115/70   5.38  2.36  2.3  0.5   
37 (P) 16 11.9 66 Female 28.7 28 100 95 120/73 120/81 5.52 6.64 2.16 2 2.6 3.3 7.2 9.9 
38 (P) 19 13.3 59 Female 28.1 27.2 89.5 87 116/85 117/82 6.76 5.92 2.11 1.24 3.2 4.8 4.6 8.0 
39 (MT) 32 12.6 42 Female 26.4 29.7 85 89 105/68 122/61 4.97 5.15 1.29 1.29 3.8 4 1.3 2.3 
40 (MT) 15 11.7 49 Female 26 25.7 86 81 104/69 99/69 4.4 4.59 1.18 1.34 3.7 3.4 2.5 2.1 
41 (P) 23 14.7 56 Female 27 26.8 94.5 92 120/111 111/79 4.06 3.82 1.36 1.44 2.99 2.7 5.6 4.2 
42 (P) 14   59 Male 32.6  107  142/85   5.06  0.74  6.9  24.5  
43 (P) 19 13.5 56 Female 27.7 27 90 81 127/83 99/68 6.17 5.95 1.77 2.24 3.5 2.7 5.6 2.1 
44 (P) 19 12.1 46 Male 27.5 27.3 104.5 102 122/89 129/85 5.33 5.07 1.06 0.83 5 6.1 10.7 16.2 
45 (MT) 21 11.7 43 Female 28.8 28.1 91 92 128/80 114/70 5.34 6.94 1.3 1.37 4.1 5.1 7.9 9.0 
46 (P) 22 12.9 47 Male 30.7 29.6 107 108 114/84 109/71 4.27 4.37 1.04 1.09 4.1 4 5.0 4.7 
47 (MT) 16 11.7 65 Male 25.6 24 92 85 128/71 115/59 3.08 2.59 0.71 0.59 4.3 4.4 25.9  
48 (P) 50 11.4 66 Female 22.8 22.8 71 71 153/99 164/99 4.91 5.37 1.09 1.36 4.5 3.9 15.5 16.5 
49 (MT) 44  58 Female 31.4  103  177/121   5.29  1.26  4.2  15.8  
50 (MT) 16 12 50 Female 33.6 32.9 116 112 127/92 130/84 4.17 3.75 1.18 1.53 3.5 2.5 4.1 2.8 
51 (P) 19   70 Female 33.6  106  133/73  4.48  1.57  2.9  7.9  
52 (P) 33   71 Male 27.3  100.5  122/82   4.84  1.4  3.4  16.0   
53 (P) 41 13.9 61 Female 31.5 26.1 95.5 84 146/103 107/76 3.71 4.14 1.24 2.18 3 1.9 8.1 2.1 
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
54 (P) 21 13.1 64 Male 30 29.3 104 102 146/94 121/88 4.37 4.94 1.41 1.2 3.1 4.1 23.6 22.2 
55 (P) 21 13.1 63 Female 29.5 28.3 100 100 153/88 136/91 5.3 6.04 1.15 1.2 4.6 5 14.7 12.9 
56 (P) 27 12.6 62 Female 24.2 24.3 81.5 87 108/73 92/69 4.13 5.29 0.87 1.15 4.7 4.6 10.7 7.5 
57 (P) 20   55 Female 28.8  97.5  127/84   4.86  0.9  5.4  13.9   
58 (P) 26 12.8 56 Female 26.6 27.3 86.5 92 158/108 155/95 5.94 6.96 1.68 1.05 3.5 6.6 14.3 26.9 
59 (P) 16   72 Male 26.3  96  137/77  4.35  1.04  4.2  24.3  
60 (P) 22 13.1 57 Male 32.1 31.7 108.5 109 119/78 107/75 4.82 4.84 0.82 0.95 5.9 5.1 22.3 16.5 
61 (P) 28 13.6 72 Male 29.7 29.6 102 103 142/86 156/80 3.83 3.91 0.63 0.88 6 4.5   
62 (P) 19   58 Female 24.3  78.5  140/95   5.81  2.11  2.8  5.9  
63 (P) 22   61 Female 32.8    141/76  4.4  0.74  5.9     
64 (P) 20 12.1 67 Male 36.5 36.8 124 120 137/98 128/84 3.12 3.88 0.96 0.97 3.3 4 16.3 18.0 
65 (P) 20 12.1 50 Female 20.4 20.4 71 70 130/78 151/87 6.26 7.08 1.91 2.2 3.3 3.2 3.9 5.9 
66 (P) 20 12.6 52 Male 25.2 24.7 88 80 147/84 133/75 4.47 4.75 1.38 1.59 3.2 3 9.0 7.0 
67 (MT) 17 12.6 62 Male 30.5 30.4 111 113 161/94 132/88 4.52 4.2 0.71 0.69 6.4 6.5 31.3 23.0 
68 (MT) 16 12.7 65 Female 28.2 26 94 84 143/86 118/73 6.45 5.8 1.88 1.75 3.4 3.3 10.0 6.2 
69 (P) 16 11.7 67 Male 24.3 24.3 90.5 91 146/82 130/75 4.27 5.46 0.83 0.76 5.1 7.2 40.5 45.1 
70 (P) 16 11.7 65 Female 21.6 21.4 71.5 70 189/98 134/74 4.84 4.79 1.32 1.06 3.7 4.5 31.1 17.5 
71 (MT) 17 12.4 74 Female 27.8 28.1 89 86 142/79 119/71 5.78 5.07 1.32 1.37 4.4 3.7 14.9   
72 (P) 15 11.9 53 Female 22.8 22.5 77 71 100/69 111/71 4.93 4.81 1.51 1.63 3.3 3 3.6 4.3 
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
73 (P) 23 11.4 65 Male 24.1 23.6 91.5 88 125/81 109/73 3.55 4.15 0.82 1.12 4.4 3.7 24.8 17.0 
74 (P) 21 13.8 71 Female 29.9 28 89 87 153/97 135/86 7 5.53 1.49 1.75 4.7 3.2     
75 (MT) 28 12.3 68 Female 21.6 21.3 75 70 119/74 122/74 5.59 5.98 1.6 1.72 3.5 3.5 7.0 7.6 
76 (P) 23 12.7 67 Male 30.5 29.9 105 100 121/84 104/70 4.02 3.16 0.89 1.07 4.5 2.9 26.3 13.0 
77 (MT) 17 12.2 55 Female 28.9 28.2 86 84 112/74 122/77 5.52 4.63 0.98 0.76 5.6 6.1 7.6 10.3 
78 (P) 33 12.6 47 Female 26.5 26.4 93.5 93 126/63 108/77 4.54 5.08   2.11 0 2.4 1.2 1.3 
79 (MT) 16 12.9 48 Female 29.1 27.9 94 84 123/71 110/67 5.8 3.83 0.99 1.1 5.8 3.5 6.6 2.6 
80 (P) 17 12.8 62 Female 19.3 19.3 73 68 120/83 109/74 3.83 4.15 1.45 1.98 2.6 2.1 6.6 3.9 
81 (P) 20   57 Male 26.5  99  127/78   3.85  0.62  6.2  26.2   
82 (P) 19   61 Male 33    144/82  4.4  0.9  4.9  30.5  
83 (P) 15 13.1 56 Male 28.7 26.7 97 98 134/81 134/66 5.14 4.6 1.92 1.96 2.7 2.3 7.5 6.8 
84 (P) 34 13.5 45 Male 27.5 26.5 94 94 136/87 133/74 4.06 3.42 0.88 0.85 4.6 4 19.0 16.7 
85 (P) 14   51 Female 27.9  85  108/74  4.12  1.4  2.9  3.3  
86 (P) 30 13.3 53 Male 34.4 33.1 114 116 126/89 120/62 4.98 4.29 1.03 0.89 4.8 4.8 16.4 15.7 
87 (P) 34   56 Female 25.2  84  124/81  5.18  1.58  3.3  4.9  
88 (P) 91 17.5 72 Male 23.2 22.3   170/89 163/89 3.22 4.12 1.14 1.39 2.8 3 28.2 27.5 
89 (P) 91 17.5 67 Female 25.2 25.5 74 86 122/82 112/72 4.05 3.77 1.28 1.27 3.2 3 6.5 5.0 
90 (P) 16 13.8 67 Male 30 31.4 110 120 161/90 180/99 4.38 4.11 1.19 0.95 3.7 4.3    
91 (P) 20 13.5 69 Male 27 27.3 99 101 186/101 152/93 4.94 3.71 1.3 1.26 3.8 2.9     
Appendix 14: List of subjects who accessed the VRA service 
357 
 
P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
92 (P) 20   83 Female 24.9  85  149/84  3.77  1.73  2.2     
93 (P) 21   69 Female 22.6  85  130/80  5.48  1.13  4.8  12.5  
94 (P) 19   67 Female 24.1  69  123/75  3.34  1.69  2     
95 (MT) 16 12.9 48 Female 37.2 28.4 110 82 130/98 112/68 5.05 4.12 1.71 1.51 2.9 2.7 8.3 5.5 
96 (P) 20 12.8 42 Female 24.4 24 71.5 71 95/68 93/63 3.85 3.72 1.9 2.25 2 1.7 0.3 0.2 
97 (P) 15   57 Female 36.4  106  127/87   5.07  0.96  5.3  9.7   
98 (P) 28 12.8 65 Female 33 32 94 98 117/91 114/72 3.15 3.02 1.21 1.31 2.6 2.3     
99 (P) 20   71 Female 23.1  74  136/85   5.1  0.98  5.2  15.2   
100 (P) 20   63 Female 32  94  118/82   3.53  1.13  3.1  5.3  
101  (MT) 14 11.4 68 Male 24.2 22.8 88 83 129/93 110/72 5.22 5.05 1.17 1.14 4.5 4.4 20.1 15.7 
102 (P) 28 14.5 58 Male 18.9 17.7 79 76 120/76 118/72 3.15 3.32 1.18 1.64 2.7 2 6.4 4.7 
103 (P) 28 14.5 54 Female 27.9 26.9 88 86 131/98 109/76 4.64 5.92 1.71 1.91 2.7 3.1 7.4 3.1 
104 (P) 19 13.3 64 Male 23.3 22.8 83 80 136/92 136/84 6 5.84 1.34 1.14 4.5 5.1 19.1 22.3 
105 (MT)    48 Female 24.1  79  129/84   4.21  1.64  2.6  2.3   
106  (MT)  11.7 48 Male 24.5 25.6 82 89 122/69 115/73 4.42 5.88 1.26 1.34 3.5 4.4 5.0 6.4 
107 (P) 27Q   71 Female 29.3  95.5  128/76   6.05  0.81  7.4  18.9  
108 (P) 27Q 12.1 64 Female 21.5 21.1 79 78 135/93 125/85 5.14 6.76 1.2 1.66 4.3 4.1 16.1 13.2 
109 (P) 29Q   71 Female 25.9  72  194/113  5.58  1.51  3.7  26.2  
110 (P) 28 13.8 54 Male 33.9 34.5   120 123/84 147/88 2.86 2.73 1.21 1.05 2.4 2.6     
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
111 (P) 26   44 Male 24.4  78  116/80             
112 (P) 27   54 Female 23  89.5  115/80   4.97  2.06  2.4  2.4   
113 (P) 21 12.4 67 Male 32.9 32.7 117.5 116 151/97 144/90 4.31 4.74 0.89 1.11 4.8 4.3 27.3 23.6 
114 (P) 21   55 Male 32.6  111  153/93   5.25  0.83  6.4  22.1   
115 (P) 37 14.2 60 Male 27 26.5 89 94 148/95 146/99 5.35 5.13 0.9 0.78 5.9 6.6 36.3 39.9 
116 (P) 28 14.9 67 Female 28.1 27.6 89 89 150/98 128/81 6.28 5.77 1.23 1.68 5.1 3.4 17.0 8.2 
117 (P) 35 13.8 65 Female 35 36.3 103 107 114/79 113/77 4.84 3.54 1.12 0.89 4.3 4 7.7 7.0 
118 (P) 35 13.8 68 Male 23.6 24 87 92 150/83 144/85 4.53 3.83 1.2 1.26 3.8 3     
119 (P) 35 14.5 69 Male 27.5 27.7 96 98 147/85 136/75 3.69 4.39 0.75 0.75 4.9 5.8 28.2 29.2 
120 (P) 35 14.5 63 Female 24.5 24.1 79 76 124/82 128/84 4.7 4.91 1.52 2.59 3.1 1.9 5.9 3.9 
121 (P) 35 13.8 68 Male 28 27.5 99 105 150/97 158/98 5.18 5.79 1.56 1.46 3.3 4 20.8 27.4 
122 (P) 19   57 Male 25.8  90  174/100  4.74  1.31  3.6  19.0  
123 (P) 19   55 Female 19  74  137/79   5.64  2.17  2.6  4.5   
124 (P) 26 16.2 49 Male 30.1 29.6 94 99 141/87 133/85 7.28 6.45 0.98 1.03 7.5 6.3 17.3 13.8 
125 (P) 20 13.8 42 Male 24.8 25.3 92 92 147/93 143/91 4.66 4.2 1.08 1.01 4.3 3.9 6.5 6.3 
126 (P) 18 13.8 38 Female 30.3 30.2 91.5 101 120/89 109/82 4.47 3.68 1.41 1.51 3.2 2.4 0.7 0.4 
127 (P) 35  68 Male 28  104  141/95  5.06  2.47  2  18.0  
128 (P) 37 14.2 64 Male 29.2 27.7 110 102 138/83 119/78 2.75 2.81 0.66 0.71 4.1 4 27.5 20.7 
129 (P) 15  40 Male 30.3  105  128/63  3.93  0.98  4  3.6  
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
130 (P) 28 13.8 69 Female 26.3 29.6 86 94 153/91 162/107 5.56 6.41 1.47 1.5 3.8 4.3 21.3 27.6 
131 (P) 28 13.8 69 Male 25.9 24.9 91 95 150/88 150/89 6.89 5.83 1.11 0.99 6.2 5.9 34.3 34.1 
132 (P) 35   53 Male 31.8  104  159/98  6.11  0.94  6.5  22.1  
133 (P) 44   52 Female 19.4  65  82/59   3.48  1.38  2.5  0.8   
134 (P) 21   61 Female 27.4  79  150/97  5  1.97  2.5  7.4  
135 (P) 15 13.8 49 Male 27.6 26 95 93 155/90 145/80 3.91 3.24 1.63 1.49 2.4 2.2 6.1 4.9 
136 (P) 22 14.2 72 Male 29.1 29.5 107 114 135/85 117/82 5.25 4.94 1.14 1.01 4.6 4.9 25.5 21.8 
137 (P) 21 13.5 72 Female 26.6 27.5 79 80 130/83 123/76 4.92 6.08   2.27   2.7 5.4 6.4 
138 (P) 19 14.5 62 Female 25.3 25.4 81  129/78 119/77 4.15 5.06 1.22 1.91 3.4 2.7 7.1 4.4 
139 (P) 35 13.7 67 Male 30 30.4 106 107 168/93 168/91 4.56 3.93 1.4 1.24 3.3 3.2 37.5 38.3 
140 (P) 28 14.9 69 Male 29.7 29.8 100 105 139/90 129/78  3.55  1.38  2.6     
141 (P) 21 13.5 65 Female 29.1 28.4 82 83 122/86 119/76 6.41 4.52 1.8 2.1 3.6 2.2 7.1 3.9 
142 (P) 15   61 Female 34  98  143/98   6.21  1.49  4.2  16.3   
143 (P) 20 13.8 71 Female 23.2 24.4 79 84 153/95 146/88 3.93 3.92 0.91 1.44 4.3 2.7 16.6 10.2 
144 (P) 21   46 Female 20.9  71  123/82   4.41  1.09  4  9.3   
145 (P) 26   62 Female 40.4  116  143/109   6.19  1.12  5.6  14.9   
146 (P) 19   71 Male 29.9  97  148/79  4.62  0.8  5.8  33.9  
147 (P) 19   55 Female 44.9    125/83  4.51  1.31  3.5  5.1  
148 (P) 19 11.9 53 Male 23.9 22.2 89.5 83 173/112 152/101 3.95 4.59 2.04 2.22 1.9 2.1 8.7 6.9 
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
149 (P) 21 12.8 67 Female 31 33.2 88 98 135/88 123/75 5.97 5.91 1.41 1.35 4.2 4.4   9.8 
150 (P) 15 12.1 63 Female 27.1 22.2 89 78 137/93 126/78 5.71 3.64 1.61 1.44 3.5 2.5    
151  (MT)  15 11.8 56 Male 31.8 31 109.5 106 140/92 140/89 5.44 5.77 0.69 0.67 7.8 8.6 24.3 27.0 
152 (P) 14   70 Female 25.2  67  150/93  4.11  2.49  1.7     
153 (P) 20   43 Male 28.4  96.5  125/49  5.36  0.92  5.9  12.5  
154 (MT) 16 11.7 43 Male 29 29.9 99.5 103 137/86 127/72 7.15 7.28 1.3 1.33 5.5 5.5 8.3 7.6 
155 (P) 16 12.6 87 Male 23.9 21.3   135/71 154/98         
156 (P) 19   54 Female 48.5    131/97             
157 (P) 20 13.1 74 Female 18.4 18.1 67 66 167/74 171/77 4.9 5.71 1.82 2.06 2.7 2.8 15.6   
158 (MT) 14   51 Female 22.7  79  112/73  4.74  1.91  2.5  5.6  
159 (MT)    48 Female 26.7  89  114/80   6.17  1.29  4.8  11.4   
160 (MT)    49 Female 25.8  85.5  141/96   4.46  1.09  4.1  15.6   
161 (P)    71 Female 33.8    140/90   4.85  1.54  3.1  10.1   
162 (MT)    74 Male 31.5  115  155/91  4.56  0.78  5.9  40.0  
163 (P)    72 Male 27.9  101  165/94  4.7  1.24  3.8  32.1  
164 (P)    65 Male 34.6  122  134/79   4.6  0.73  6.3  55.7   
165 (P)    72 Male 35.8  119.5  142/88   3.73  0.95  3.9  24.7  
166 (P)    55 Female 31.2  97.5  137/98   4.53  1.82  2.5  4.3   
167 (P)    19 Female 38    108/83           
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P = Porthcawl. MT = Merthyr Tydfil.  ¥ data collected at 12 month follow-up. Q subject completed a questionnaire at the 2 week follow-up instead of a telephone interview 
Subject  Time to 
2wk 
follow-up 
(days) 
Time to 
12mnth 
follow-up 
(mnths) 
Age 
(yrs) 
Sex BMI BMI¥ Waist Waist¥ BP  BP¥ TC TC¥ HDL HDL¥ TC: 
HDL 
ratio 
TC: 
HDL 
ratio¥ 
Risk Risk¥ 
168 (P)    73 Female 29.3    125/75           
169 (P)    62 Female 20.8  72  156/82           
170 (P) 35 14.2 41 Female 31.2 27.1 86 86 117/79 124/76 4.24 4.4 1.07 1.83 4 2.4 1.6 1.0 
171 (P)    68 Male 25.2  101  134/89   4.72  0.83  5.7  38.0   
172 (MT) 21Q 12.0 63 Male 25.2 25.2 97 96 155/98 129/78 4.21 3.6 0.76 1.61 5.5 2.2 27.5  
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Appendix 16: Data collection tool used in the 
retrospective study of a non-NHS VRA service  
Patient:     Date of assessment:___________________________ 
 
Age: 
Sex: □ Male □ Female 
Ethnicity: □ White □ South Asian  □ Other___________ 
Postcode:  
 
 
Clinical information: 
□ Diabetic?  
□ Had a heart attack, angina, stroke or TIA?  
□ Angina or heart attack in a 1st degree relative < 60?  
□ Current smoker? 
□ Chronic kidney disease? 
□ Atrial fibrillation? 
□ On blood pressure treatment? 
□ Rheumatoid arthritis? 
 
Cholesterol/HDL ratio  
BMI  
Systolic BP 
Other info:_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Alcohol Exercise Waist TC HDL Glucose Fasting G Risk 
        
Referred to GP? □ Yes □ No  if yes the reason of referral is:__________ 
QRisk2 
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Appendix 17: The MUR form used in practice as 
per NHS Pharmacy Contract  
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Appendix 18: Microsoft Access files used to 
collect data for the MUR study 
 
 
 
 
